text,chunk_id,title,publication_date,authors,disease
Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis This case report presents a comprehensive evaluation of the complex balance of therapeutic benefits and potential risks associated with the cystic fibrosis transmembrane conductance regulator (CFTR) modulator elexacaftor/tezacaftor/ivacaftor (ETI) therapy in managing an eight-year-old male with cystic fibrosis (CF) and exocrine,0_0,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"male with cystic fibrosis (CF) and exocrine pancreatic insufficiency (EPI). While ETI therapy significantly enhanced exocrine pancreatic function, it led to hepatotoxicity, necessitating therapy discontinuation. Attempts to restart ETI at reduced doses were unsuccessful due to persistent hepatic dysfunction. Reduced ETI dosing frequency, implemented due to hepatic dysfunctions, did not result in substantial therapeutic benefits. Clinical markers showed a resurgence of severe EPI and sustained need for",0_1,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"a resurgence of severe EPI and sustained need for gastrostomy tube feeds, with only modest improvement in hepatic function compared to the period following ETI cessation or during prior use of CFTR modulator therapy with lumacaftor/ivacaftor. This case underscores the importance of personalized therapeutic approaches, biomarker-guided monitoring, and multidisciplinary insights to optimize CF management while also highlighting the ongoing need for research to mitigate hepatotoxicity risks and ensure",0_2,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"to mitigate hepatotoxicity risks and ensure long-term therapeutic efficacy. Cystic fibrosis (CF) is a prevalent autosomal-recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, affecting more than 30,000 individuals in the United States and over 160,000 globally, based on estimates (<xref rid=""B1"" ref-type=""bibr"">1</xref>). CF has multi-organ implications, particularly impacting the respiratory, digestive, and hepatic systems due to absent or",0_3,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"digestive, and hepatic systems due to absent or defective CFTR protein function (<xref rid=""B2"" ref-type=""bibr"">2</xref>). Approximately 85% of people with CF develop exocrine pancreatic insufficiency (EPI) at an early age, accounting for significant morbidity (<xref rid=""B3"" ref-type=""bibr"">3</xref>). Poorly controlled EPI leads to malnutrition with poor weight gain, impacting pulmonary function and overall health outcomes (<xref rid=""B4"" ref-type=""bibr"">4</xref>). Fecal pancreatic elastase-1 (FE-1)",0_4,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"Fecal pancreatic elastase-1 (FE-1) measurement is the most widely used indirect test to assess EPI, with values less than 200 µg/g of stool consistent with EPI (<xref rid=""B5"" ref-type=""bibr"">5</xref>). Recent advances in CF care have dramatically transformed both the diagnosis and treatment of the disease. Newborn screening has been crucial in revolutionizing CF diagnosis, allowing for pre-symptomatic early detection and alleviating the distressing diagnostic journeys that many patients and families",0_5,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"journeys that many patients and families previously experienced (<xref rid=""B6"" ref-type=""bibr"">6</xref>). Early diagnosis enables timely interventions that can mitigate disease progression from infancy, leading to improved clinical outcomes (<xref rid=""B6"" ref-type=""bibr"">6</xref>). On the treatment side, significant advancements have been the development of CFTR modulator therapies that directly target defective CFTR (<xref rid=""B7"" ref-type=""bibr"">7</xref>). These CFTR therapies enhance chloride ion",0_6,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"These CFTR therapies enhance chloride ion transport across epithelial surfaces, including in the pancreatic ducts, which may ameliorate EPI signs and symptoms (<xref rid=""B8"" ref-type=""bibr"">8</xref>). CFTR modulator therapy has made it possible for some people with CF to experience improvement in FE-1, suggesting an improvement in their exocrine pancreatic function. Recent studies have shown that the CFTR modulator elexacaftor/tezacaftor/ivacaftor (ETI) can enhance and restore exocrine pancreatic function",0_7,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"enhance and restore exocrine pancreatic function in children with CF, as evidenced by changes in FE-1 levels (<xref rid=""B9"" ref-type=""bibr"">9</xref>–<xref rid=""B12"" ref-type=""bibr"">12</xref>). While these modulators, such as ETI, show promise in restoring pancreatic function, they also carry risks of hepatotoxicity (<xref rid=""B13"" ref-type=""bibr"">13</xref>). This case report examines the complexities of ETI therapy in managing a pediatric patient with CF, focusing on the balance between improved",0_8,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"with CF, focusing on the balance between improved pancreatic function and hepatotoxicity. The findings highlight the need for patient-specific treatment strategies and provide insights into the complexities of CFTR modulators, emphasizing the careful balance between therapeutic benefits and potential risks. Our patient is an eight-year-old male with CF. At birth, the newborn screen revealed elevated immunoreactive trypsinogen and genetic testing confirmed two pathogenic CF mutations in the CFTR gene",0_9,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"two pathogenic CF mutations in the CFTR gene (F508del/F508del). Confirmatory sweat chloride testing revealed levels of 109 and 118 mmol/L (average 113.5 mmol/L), well above the diagnostic threshold for CF of ≥60 mmol/L. Pancreatic enzyme replacement therapy and fat-soluble vitamins were initiated at diagnosis. At two weeks of age, FE-1 testing showed EPI with a level of 55 µg/g stool (correlating with severe pancreatic insufficiency at <100 µg/g of stool). At seven months of age, FE-1 testing was repeated,",0_10,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"seven months of age, FE-1 testing was repeated, again revealing severe EPI (19 µg/g). At one year of age, gastrostomy tube (G-tube) feeds were initiated to improve the patient's nutritional status. At three years of age, the patient began the CFTR modulator lumacaftor/ivacaftor (LUM/IVA) therapy and continued to require G-tube feeds until six years of age. These feeds were discontinued following a significant increase in weight and BMI percentages. A few months later, the patient transitioned from LUM/IVA",0_11,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"later, the patient transitioned from LUM/IVA to ETI. Despite an initial subjective improvement in appetite, the patient experienced a sharp decline in weight and BMI percentiles after stopping G-tube feeds and initiating ETI, leading to reinitiation of G-tube feeds. This intervention was followed by subsequent weight gain of 2 kg over two months, which once again led to the discontinuation of G-tube feeds. Overall, fluctuations in weight and BMI were effectively managed through G-tube feeds. After nine",0_12,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"managed through G-tube feeds. After nine months of ETI therapy, FE-1 improved to 233 µg/g, correlating with exocrine pancreatic sufficiency (defined as a level >200 µg/g). This status was confirmed three months later, with a value of 288 µg/g. Concurrently, the patient had hepatic function abnormalities, with an elevation of alanine aminotransferase (ALT) of 110 U/L (>3× the upper limit of normal (ULN)) and total bilirubin of 1.4 mg/dl (>2× ULN), prompting discontinuation of ETI as per prescribing",0_13,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"discontinuation of ETI as per prescribing information guidelines. These guidelines state that if ALT or aspartate aminotransferase (AST) levels are >5× ULN, or if ALT or AST levels are >3× ULN with bilirubin levels >2× ULN, dosing should be interrupted and tests closely monitored until resolved (<xref rid=""B14"" ref-type=""bibr"">14</xref>). Of note, liver function tests were normal prior to the initiation of both CFTR modulator therapies. A hepatic ultrasound was performed following hepatic function",0_14,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"was performed following hepatic function abnormalities, and the results were normal. Three months after discontinuing ETI, FE-1 decreased to <10 µg/g, consistent with severe EPI. The full therapeutic ETI dose could not be restarted due to persistent hepatic function abnormalities. Instead, reduced dosing regimens of ETI were attempted with ongoing assessments of clinical outcomes and medication-induced adverse effects. Despite these changes, the hepatic function abnormalities persisted. As a result, ETI",0_15,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"abnormalities persisted. As a result, ETI was discontinued completely, leading to the normalization of hepatic function labs. The patient was then successfully restarted on LUM/IVA, a regimen previously well-tolerated without hepatic complications, and has since continued to tolerate that treatment without any issues. Throughout the patient's life, routine annual testing for fat-soluble vitamins has been conducted, with supplementation adjusted as needed to maintain levels within the normal range. The",0_16,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"to maintain levels within the normal range. The patient has a history of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> growth on CF throat cultures, first at one year of age and again at four years of age, both without significant clinical impact or need for hospitalization. Both instances were appropriately treated with inhaled tobramycin and there has been no recurrence. Typically, the patient's CF throat cultures, obtained approximately four times per year, are normal. The patient has had",0_17,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"times per year, are normal. The patient has had sporadic growth of methicillin-sensitive <italic toggle=""yes"">Staphylococcus aureus</italic> and <italic toggle=""yes"">Haemophilus influenzae</italic> in the past, but not while on ETI. Throughout life, the patient has had no significant pulmonary exacerbations requiring hospitalization or intravenous antibiotics. <xref rid=""F1"" ref-type=""fig"">Figure 1</xref> illustrates our patient's clinical course and management from age 4–8 years (expressed in months of",0_18,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"from age 4–8 years (expressed in months of age), highlighting key interventions and outcomes (clinical markers) related to CFTR modulator therapies. We monitored FE-1 levels, sweat chloride levels, spirometry [percentage predicted forced expiratory volume per second (ppFEV1)], anthropometric measurements, and the need for G-tube feeds. At the same time, hepatic function was evaluated to determine tolerance to the modified dosing regimen. Analysis of the patient data presented in <xref rid=""F1""",0_19,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"of the patient data presented in <xref rid=""F1"" ref-type=""fig"">Figure 1</xref> revealed that the reduced ETI dosing frequency, implemented in response to hepatic dysfunctions, was not associated with substantial therapeutic benefits. Clinical markers indicated a resurgence of severe EPI. Furthermore, the reduced ETI dosing frequency led to only a modest improvement in hepatic function, which was less significant compared to the cessation of ETI or the effects observed during prior therapy with LUM/IVA. The",0_20,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"observed during prior therapy with LUM/IVA. The anthropometric data and the need for G-tube feeds presented in <xref rid=""F1"" ref-type=""fig"">Figure 1</xref> suggest that G-tube feeds are closely linked to sustained weight and BMI percentiles rather than to CFTR modulator therapy. This is especially clear following the 76-month age mark, where the patient experienced a sharp decline in weight (from the 84th to the 54th percentile) and BMI percentiles (from the 95th to the 72nd percentile) after stopping",0_21,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"the 95th to the 72nd percentile) after stopping G-tube feeds, despite the initiation of full-dose ETI. This decline led to the reinitiation of G-tube feeds, which was followed by improvements in weight to the 70th percentile and BMI to the 87th percentile, which again led to the discontinuation of G-tube feeds. Sweat chloride testing revealed important information about how the patient responded to CFTR modulators. As seen in <xref rid=""F1"" ref-type=""fig"">Figure 1</xref>, both LUM/IVA and lower-dose ETI",0_22,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"both LUM/IVA and lower-dose ETI regimens showed improved sweat chloride levels (80 and 69.5 mmol/L, respectively), suggesting a degree of CFTR modulation. Unfortunately, sweat chloride levels were not obtained on full-dose ETI. The final clinical marker not yet mentioned in <xref rid=""F1"" ref-type=""fig"">Figure 1</xref> is ppFEV1, which showed mild fluctuations throughout all therapeutic interventions, with a generally stable and reassuring trend. The average lifetime ppFEV1 is 115%.  This case report sheds",0_23,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"lifetime ppFEV1 is 115%.  This case report sheds light on the delicate equilibrium of therapeutic benefits and potential risks of ETI therapy in CF management, showing its potential to restore pancreatic function while posing risks of hepatic complications. The findings emphasize the importance of careful monitoring and thoughtful application of ETI, especially regarding dose adjustments. The clinical course underscores the need for rigorous hepatic monitoring, establishing clear thresholds and optimal",0_24,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"establishing clear thresholds and optimal assessment duration to ensure patient safety and therapeutic effectiveness. Future research should focus on developing CFTR modulators with improved safety profiles to enhance CF care. Understanding the mechanisms of ETI-induced hepatotoxicity is crucial for enhancing treatment outcomes and minimizing adverse effects. This case contributes to the deeper understanding of CFTR therapies and encourages further investigation into their optimal use, balancing efficacy",0_25,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"into their optimal use, balancing efficacy and safety to improve the lives of those with CF.",0_26,Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis,23 10 2024,,Cystic_Fibrosis
"Complicated meconium ileus in a male neonate with cystic fibrosis: Case report In about 10%-15% of instances, meconium ileus (MI) is the first sign of cystic fibrosis (CF). If a newborn exhibits signs of intestinal obstruction and does not pass meconium within a short period of time after birth, MI is suspected. The cystic fibrosis transmembrane conductance regulator gene (CFTR), which is found on chromosome 7q31, is mutated in CF patients. A premature baby, 5 days old, with clinical signs that were typical",1_0,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"5 days old, with clinical signs that were typical of MI. These attempts failed in spite of conservative therapies, such as rectal injection of gastrografin. An ileostomy was made and meconium was manually evacuated after an exploratory laparotomy revealed the presence of a typical MI. At ≥1300 µg/L (reference value ≤1000 µg/L), immunoreactive trypsinogen (IRT) levels were increased, which prompted the start of oral pancreatic enzyme replacement treatment. Discharge at 65 days of age included referrals to",1_1,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"Discharge at 65 days of age included referrals to primary care and a specialized CF clinic. The baby has since shown normal growth and development. This case highlights the rapid onset of CF in a premature infant with complex MI as the initial clinical presentation. Genetic abnormalities on the long arm of chromosome 7 are the cause of the autosomal recessive illness known as cystic fibrosis (CF). It mostly affects the exocrine glands, which causes thick mucus to be produced and increased viscosity in",1_2,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"mucus to be produced and increased viscosity in secretions [<xref rid=""bib0001"" ref-type=""bibr"">1</xref>]. Consequently, malabsorption, abnormalities in pulmonary secretions, and electrolyte imbalances in sweat are linked to cystic fibrosis (CF). Numerous clinical symptoms, such as recurrent pneumonia, malabsorption resulting in chronic malnourishment, chronic pancreatitis, meconium ileus in neonates, and recurrent polyposis, are indicative of cystic fibrosis (CF). Furthermore, women tend to become less",1_3,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"(CF). Furthermore, women tend to become less fertile as they age, while men usually become infertile [<xref rid=""bib0002"" ref-type=""bibr"">2</xref>,<xref rid=""bib0003"" ref-type=""bibr"">3</xref>]. Meconium ileus (MI), which affects 15%-20% of CF patients, is defined as intestinal blockage with thick meconium during the neonatal stage [<xref rid=""bib0004"" ref-type=""bibr"">4</xref>,<xref rid=""bib0005"" ref-type=""bibr"">5</xref>]. There are 2 ways it manifests. Simple MI is characterized by dilatation with buildup",1_4,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"MI is characterized by dilatation with buildup of meconium, gas, and fluid due to viscid meconium physically obstructing the terminal ileum and proximal small intestine. Extra problems associated with complex MI include intestinal atresia in the meconium-distended regions of the ileum, ischemic necrosis, and prenatal volvulus [<xref rid=""bib0006"" ref-type=""bibr"">6</xref>]. In CF patients with meconium ileus, the clearance of ileal obstruction usually requires rigorous treatment, such as extra saline or",1_5,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"rigorous treatment, such as extra saline or acetylcysteine enemas, as well as rectal infusion of gastrografin and/or enema under fluoroscopy. When a newborn with cystic fibrosis (CF) presents with meconium ileus, surgical intervention is often necessary to remove the obstruction or treat related problems including intestinal atresia or perforation. Thankfully, survival rates for infants with CF and meconium ileus have now surpassed those of children without the condition, marking a major improvement in",1_6,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"the condition, marking a major improvement in their prognosis. A 5-day-old male baby born at 33+2 weeks gestation was referred to our hospital due to abdominal distension. Initially evaluated at a regional clinic, he underwent a simple X-ray of the abdomen which revealed distended loops of bowel. Upon arrival in the nursery, the infant was noted to be grunting, with severe abdominal distension. His measurements were as follows: body weight 2000 g (25-50 percentile), length 40 cm (25-50 percentile), and",1_7,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"percentile), length 40 cm (25-50 percentile), and head circumference 29 cm (10-25 percentile). Vital signs recorded were 140 beats/min for heart rate, 40 breaths/min for respiratory rate, and a body temperature of 37°C. The patient appeared acutely ill but alert. Both chest walls expanded symmetrically, and clear breathing sounds were heard bilaterally across both lung fields. His heart had a regular beat without murmurs. Abdominal examination revealed marked distension and increased bowel sounds. A",1_8,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"marked distension and increased bowel sounds. A nasogastric tube (NGT) was inserted, yielding aspirated yellow-colored fluid. No pitting edema was observed in the extremities, and the external genitalia appeared normal. Neurological examination did not reveal any specific findings. The infant was born via vaginal delivery at 33+2 weeks of gestation with Apgar scores of 6 and 9. His mother was a 19-year-old primigravida who had attended 5 prenatal consultations with negative serology for vertical infections",1_9,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"with negative serology for vertical infections and normal obstetrical ultrasound A plain abdominal radiograph revealed absence of air in the lower abdomen (<xref rid=""fig0001"" ref-type=""fig"">Fig. 1</xref>). The laboratory finding were as follows: the white blood cell count was 16,040/mm3, hemoglobin 16.5 g/dL(14-2g/dL), platelet count 401,000/mm3(150-450000/mm³), C-reactive protein 0.1 mg/dL(≤5mg/dL), sodium 136 mEq/L(135-145mEq/L), potassium 4.1 mEq/L(3.5-5.5mEq/l)., glucose 63 mg/dL, calcium 9.4",1_10,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"glucose 63 mg/dL, calcium 9.4 mg/dL(9-11mg/dL), phospate 6 mg/dL(2.4-6mg/dL), magnesium 3 mg/dL(2.6-6mg/dL). A barium enema at 7 days of age showed a large amount of meconium in the cecum and a functional microcolon with a normal rectum (<xref rid=""fig0002"" ref-type=""fig"">Fig. 2</xref>). Rectal infusion of gastrografin, was attempted without success. An emergency operation was done on the next day. Exploration revealed, typical MI findings.Of inspissated meconium pellets in distal ileum and colon,marked",1_11,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"meconium pellets in distal ileum and colon,marked dilatation of proximalileum, which was filled with thick, sticky meconium. Manual evacuation of abnormal meconium,assisted by Mucomist(NAcetyl cysteine) irrigation was done. Ileostomy were performed, followed by reconstruction of the bowel transit at 12 days of life.<fig id=""fig0001""><label>Fig. 1</label><caption><p>Plain radiograph of the abdomen view reveal dilated small bowel loops (<inline-graphic http://www.w3.org/1999/xlink",1_12,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"(<inline-graphic http://www.w3.org/1999/xlink href=""fx1.gif""></inline-graphic>) with absent gas in colon and distal bowel (<inline-graphic http://www.w3.org/1999/xlink href=""fx2.gif""></inline-graphic>).</p></caption><alt-text id=""alt0001"">Fig 1:</alt-text><graphic http://www.w3.org/1999/xlink href=""gr1"" id=""celink0003""></graphic></fig><fig id=""fig0002""><label>Fig. 2</label><caption><p>A barium enema showed a large amount of meconium in the cecum (A) and a functional microcolon (B) with a normal rectum",1_13,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"a functional microcolon (B) with a normal rectum (C).</p></caption><alt-text id=""alt0002"">Fig 2:</alt-text><graphic http://www.w3.org/1999/xlink href=""gr2"" id=""celink0004""></graphic></fig> Parenteral nutrition was gradually transitioned to infant formula, reaching a volume of 160 mL/kg/day. At 20 days of life, the initial immunoreactive trypsin (IRT) test result was ≥ 1300 µg/L, prompting the initiation of oral pancreatic enzyme replacement therapy (1000 U/kg/dose every 3 hours before feeding). Genetic",1_14,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"U/kg/dose every 3 hours before feeding). Genetic analysis revealed the patient to be a carrier, likely in the homozygous state, of a variant associated with the classic form of cystic fibrosis (C.1521_1523delCTT, p.Phe508del). By 40 days of age, the patient's weight had increased to 2500 g, and he was discharged with referrals to primary care and a specialized CF clinic. Approximately 13–27% of CF patients experience meconium ileus (MI), which is typically the first clinical symptom of the disease [<xref",1_15,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"the first clinical symptom of the disease [<xref rid=""bib0007"" ref-type=""bibr"">7</xref>,<xref rid=""bib0008"" ref-type=""bibr"">8</xref>]. The CF transmembrane conductance regulator (CFTR) protein is encoded by a single gene on chromosome 7′s long arm that is mutated in this syndrome [<xref rid=""bib0009"" ref-type=""bibr"">9</xref>]. Organs containing mucus-secreting glands exhibit pathogenic changes as a result of the CFTR mutation. Usually the intestines, pancreas, and lungs are impacted, which results in",1_16,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"and lungs are impacted, which results in decreased motility, absorption, and secretion. Through the CFTR membrane protein, the CFTR deficiency decreases fluid and chloride secretion in the gastrointestinal (GI) tract while increasing fluid and sodium absorption through epithelial sodium channels. Increased intraluminal viscosity is the result of these modifications [<xref rid=""bib0010"" ref-type=""bibr"">10</xref>]. Impaired GI motility is a result of leiomyositis of the gastrointestinal wall and myenteric",1_17,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"of the gastrointestinal wall and myenteric ganglionitis [<xref rid=""bib0011"" ref-type=""bibr"">11</xref>]. These deficiencies raise the risk of intestinal blockage, which typically manifests as distal intestinal obstruction syndrome (DIOS). A small proportion of patients develop liver cirrhosis as a result of CFTR failure, which also affects the bile ducts and causes chronic inflammation and periportal fibrosis in about one-third of individuals [<xref rid=""bib0009"" ref-type=""bibr"">9</xref>]. In male CF",1_18,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">9</xref>]. In male CF patients, infertility affects 98% of cases due to vas deferens obliteration [<xref rid=""bib0012"" ref-type=""bibr"">12</xref>]. Female fertility generally remains nearly normal, although cervical mucosa dehydration and impaired sperm activation from lacking HCO3 can be contributing factors [<xref rid=""bib0012"" ref-type=""bibr"">12</xref>]. When CF patients experience disimpaction of meconium, they frequently require rigorous treatment, such as saline or acetylcysteine",1_19,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"treatment, such as saline or acetylcysteine enemas and rectal infusion of gastrografin under fluoroscopy. When a newborn with cystic fibrosis (CF) presents with meconium ileus, surgical intervention is often necessary to relieve the obstruction and address related problems [<xref rid=""bib0013"" ref-type=""bibr"">13</xref>,<xref rid=""bib0014"" ref-type=""bibr"">14</xref>]. This was made clear in our case study when our patient required surgical intervention. Pancreatic insufficiency in neonates with MI should be",1_20,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"insufficiency in neonates with MI should be specifically treated since good management is essential for favorable outcomes, including weight gain while in the hospital [<xref rid=""bib0015"" ref-type=""bibr"">15</xref>]. According to recent data, when CF treatment is successful, MI is no longer regarded as a poor prognostic factor [<xref rid=""bib0016"" ref-type=""bibr"">16</xref>]. In our instance, the mother was given instructions to dissolve the pancreatic enzymes in water upon the patient's discharge. The",1_21,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"in water upon the patient's discharge. The treatment of pancreatic insufficiency entails the oral administration of intact microspheres containing pancreatic enzymes, usually in the range of 2,000 to 4,000 IU of lipase per 120 mL of feeding, right before nursing or formula feeding. This case report highlights a premature patient with cystic fibrosis (CF) whose first clinical presentation was complex meconium ileus (MI) without respiratory symptoms. In newborns with MI, distal intestinal blockage may",1_22,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"newborns with MI, distal intestinal blockage may result, requiring early surgical surgery for successful management. This clinical case was written based on clinical observation without any funding. I obtained a written informed consent from the patient for images or other clinical information relating to his case to be reported in a medical publication.",1_23,Complicated meconium ileus in a male neonate with cystic fibrosis: Case report,19 10 2024,,Cystic_Fibrosis
"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients This study aimed to conduct a retrospective Middle East systematic review and meta-analysis on the prevalence and antibiotic susceptibility pattern for this microorganism isolated from cystic fibrosis patients. We searched MEDLINE, the Cochrane Library, SCOPUS, and Web of Science (ISI) to identify studies that reported the",2_0,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"(ISI) to identify studies that reported the prevalence of <italic toggle=""yes"">Pseudomonas aeruginosa </italic>isolated from cystic fibrosis (CF) patients, and antibiotic resistance patterns. To assess the quality of publications was used of a checklist provided by the Joanna Briggs Institute. Finally, the data was analyzed by comprehensive meta-analysis software. The studied populations comprised children and young, and adult CF patients. Patients were aged between 3 months-65 years. A higher percentage",2_1,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"between 3 months-65 years. A higher percentage of CF patients were males. <italic toggle=""yes"">Pseudomonas aeruginosa </italic>frequency varied between 5.9 and 76.2% in the studies included. The combined prevalence of <italic toggle=""yes"">P. aeruginosa </italic>was reported 34.3%. The lowest level resistance of <italic toggle=""yes"">P. aeruginosa </italic>was toward colistin (0%-13.3%) and ticarcillin (3.9%-24%). Our study showed the prevalence of <italic toggle=""yes"">P. aeruginosa </italic>and antibiotic",2_2,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"aeruginosa </italic>and antibiotic resistance are almost high, while colistin and ticarcillin are the best antibiotics to decrease postantibiotic effects (PAEs) in CF patients from the Middle East. Therefore, physicians should pay more attention to therapeutic protocols to prevent further resistance. Cystic fibrosis (CF), an autosomal recessive progressive condition triggered by a mutation in the gene encoding the CF transmembrane (CFTR), is characterized as chronic obstructive pulmonary disease, exocrine",2_3,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"chronic obstructive pulmonary disease, exocrine pancreatic insufficiency, and elevated sodium and chloride concentrations in sweat.<sup><xref rid=""b1-eajm-56-3-189"" ref-type=""bibr"">1</xref></sup> Electrolyte imbalance on both sides of the membrane decreases the volume of water in the secretions of the apocrine glands, which are very viscous and result in the narrowing of the duct, blockage, and subsequent dissolution of these glands. So, the moisture on the surface of the main respiratory tract is greatly",2_4,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"surface of the main respiratory tract is greatly decreased, and the condition is primed for the invasion of pathogens.<sup><xref rid=""b2-eajm-56-3-189"" ref-type=""bibr"">2</xref></sup> Cystic fibrosis is more common in white people in Europe, North America, and Australia, although the disease affects people of all races.<sup><xref rid=""b3-eajm-56-3-189"" ref-type=""bibr"">3</xref></sup> In the United States, for example, about 30 000 individuals are estimated to have CF, and more than 1000 new cases are found",2_5,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"have CF, and more than 1000 new cases are found each year.<sup><xref rid=""b4-eajm-56-3-189"" ref-type=""bibr"">4</xref></sup> This disease is very rare in Arab cultures, but it is equally widespread in white populations.<sup><xref rid=""b5-eajm-56-3-189"" ref-type=""bibr"">5</xref></sup> Many CF patients will begin to experience chronic hypoxic and hypercapnic respiratory failure, as well as pulmonary exacerbations, atypical respiratory pathogen acquisition, pneumothorax, hemoptysis, pulmonary hypertension, and",2_6,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"hemoptysis, pulmonary hypertension, and pulmonary hypertension development.<sup><xref rid=""b6-eajm-56-3-189"" ref-type=""bibr"">6</xref></sup> The presence of elevated sweat chloride confirms the diagnosis of CF. The majority of CF cases are discovered by newborn screening.<sup><xref rid=""b7-eajm-56-3-189"" ref-type=""bibr"">7</xref></sup> Many bacterial species have been linked to CF respiratory tract infections, including <italic toggle=""yes"">Pseudomonas aeruginosa</italic>, <italic",2_7,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"aeruginosa</italic>, <italic toggle=""yes"">Stenotrophomonas</italic>, <italic toggle=""yes"">Maltophilia</italic>, <italic toggle=""yes"">Staphylococcus aureus</italic>, and <italic toggle=""yes"">Haemophilus influenza</italic>.<sup><xref rid=""b7-eajm-56-3-189"" ref-type=""bibr"">7</xref></sup>",2_8,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"<italic toggle=""yes"">Pseudomonas aeruginosa</italic> aggravates lung function loss and is linked to high morbidity and mortality in CF patients.<sup><xref rid=""b8-eajm-56-3-189"" ref-type=""bibr"">8</xref></sup>",2_9,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"<italic toggle=""yes"">P. aeruginosa</italic> has been found in 60.9% of CF patients with CFTR mutations’ lower respiratory samples,<sup><xref rid=""b9-eajm-56-3-189"" ref-type=""bibr"">9</xref></sup> and this mutation is one of the most frequent among Arabs in the Gulf region who belong to a large Arab tribe.<sup><xref rid=""b10-eajm-56-3-189"" ref-type=""bibr"">10</xref></sup> The prevalence of <italic toggle=""yes"">P. aeruginosa</italic> increases with age, making it the most common pathogen in the",2_10,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"age, making it the most common pathogen in the elderly.<sup><xref rid=""b11-eajm-56-3-189"" ref-type=""bibr"">11</xref>-<xref rid=""b16-eajm-56-3-189"" ref-type=""bibr"">16</xref></sup> Therapeutic advances, such as a greater emphasis on improving diet with multivitamins and pancreatic enzymes, airway clearing treatments, antibiotics, and highly efficient CFTR modulators, have resulted in improved clinical conditions and longevity for CF patients.<sup><xref rid=""b17-eajm-56-3-189"" ref-type=""bibr"">17</xref></sup>",2_11,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">17</xref></sup> Many times in the past, the life expectancy of CF patients has often improved due in part to appropriate antibiotic therapy in the procedure.<sup><xref rid=""b18-eajm-56-3-189"" ref-type=""bibr"">18</xref></sup>",2_12,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"<italic toggle=""yes"">P. aeruginosa</italic> is still not eradicated in such patients, and the emergence of different bacterial morphotypes during chronic infection has been identified globally.<sup><xref rid=""b19-eajm-56-3-189"" ref-type=""bibr"">19</xref>,<xref rid=""b20-eajm-56-3-189"" ref-type=""bibr"">20</xref></sup> This microorganism has acquired an intrinsic antibiotic resistance which severely limits effective therapeutic options, especially in patients with CF and who have been thermally burnt.<sup><xref",2_13,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"CF and who have been thermally burnt.<sup><xref rid=""b21-eajm-56-3-189"" ref-type=""bibr"">21</xref></sup> According to some reports, extended spectrum beta-lactamases (ESBLs) and metallo-β-lactamases (MBLs) are becoming more common among <italic toggle=""yes"">P. aeruginosa</italic> in Middle Eastern Arab countries, which may result in a longer hospital stay, higher costs, and a fatal outcome for patients.<sup><xref rid=""b22-eajm-56-3-189"" ref-type=""bibr"">22</xref>-<xref rid=""b24-eajm-56-3-189""",2_14,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"rid=""b24-eajm-56-3-189"" ref-type=""bibr"">24</xref></sup> The presence of an alginate-containing matrix in mucoid strains causes them to be more resistant to antibiotics. Eradication methods not only harm non-mucoid strains but can also hinder disease growth.<sup><xref rid=""b25-eajm-56-3-189"" ref-type=""bibr"">25</xref></sup> Because of the repeated and sometimes extended courses of nasal, intravenous, and aerosolized antibiotics used to treat chronic lung disease, CF patients are at extremely high risk of",2_15,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"CF patients are at extremely high risk of contracting infections with multidrug-resistant (MDR) pathogens, especially <italic toggle=""yes"">P. aeruginosa</italic>. Furthermore, the Arabic-speaking population in the Middle East has a high prevalence of CFTR gene mutation.<sup><xref rid=""b26-eajm-56-3-189"" ref-type=""bibr"">26</xref></sup> In the management of lung infection resulting from <italic toggle=""yes"">P. aeruginosa</italic>, inhaled antibiotics such as azithromycin, aztreonam, and tobramycin are used",2_16,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"azithromycin, aztreonam, and tobramycin are used as maintenance drugs.<sup><xref rid=""b27-eajm-56-3-189"" ref-type=""bibr"">27</xref></sup> According to guidelines, continuous use of these antibiotics improves pulmonary function in patients with CF.<sup><xref rid=""b28-eajm-56-3-189"" ref-type=""bibr"">28</xref></sup> They also reduce exacerbations in chronic infection caused by <italic toggle=""yes"">P. aeruginosa.</italic>",2_17,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"<sup><xref rid=""b28-eajm-56-3-189"" ref-type=""bibr"">28</xref></sup> Since the extent of antibiotic resistance of <italic toggle=""yes"">P. aeruginosa</italic> recovered from CF patients in the Middle East has not been comprehensively addressed, we decided to conduct a retrospective Middle East systematic review about resistance to key antibiotics used in the treatment of <italic toggle=""yes"">P. aeruginosa</italic> infection and the prevalence of <italic toggle=""yes"">P. aeruginosa</italic> isolated from CF",2_18,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"aeruginosa</italic> isolated from CF patients, too.   As listed in <xref rid=""t2-eajm-56-3-189"" ref-type=""table"">Table 2</xref>, some studies have used molecular methods, some used phenotypic methods, and some of them used both methods to detect <italic toggle=""yes"">P. aeruginosa </italic>isolates. Molecular techniques were polymerase chain reaction (PCR),<sup><xref rid=""b21-eajm-56-3-189"" ref-type=""bibr"">21</xref>,<xref rid=""b31-eajm-56-3-189"" ref-type=""bibr"">31</xref></sup> random amplified polymorphic",2_19,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"random amplified polymorphic DNA (RAPD)-PCR,<sup><xref rid=""b32-eajm-56-3-189"" ref-type=""bibr"">32</xref></sup> pulsed-field gel electrophoresis (PFGE),<sup><xref rid=""b33-eajm-56-3-189"" ref-type=""bibr"">33</xref></sup> repetitive intergenic consensus (ERIC)-PCR,<sup><xref rid=""b34-eajm-56-3-189"" ref-type=""bibr"">34</xref></sup> allele specific PCR (ASPCR),<sup><xref rid=""b3-eajm-56-3-189"" ref-type=""bibr"">3</xref></sup> sequencing.<sup><xref rid=""b5-eajm-56-3-189"" ref-type=""bibr"">5</xref></sup> Also,",2_20,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">5</xref></sup> Also, phenotypic methods included conventional microbiological tests (oxidase tests, arginine dehydrolase, citrate, OF glucose, catalase test, and sugar fermentation test); culture (blood agar, tryptic soy agar, brain–heart infusion, MacConkey agar, cetrimide agar, Columbia blood agar, Columbia chocolate agar, and chocolate agar); staining (ethidium bromide, Congo red staining, and Gram staining). <italic toggle=""yes"">Pseudomonas aeruginosa </italic>exacerbates the pulmonary",2_21,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"aeruginosa </italic>exacerbates the pulmonary disease that frequently occurs in CF patients. Based on the patient registry annual data report in 2019, the prevalence of <italic toggle=""yes"">P. aeruginosa </italic>continues to decline over time (57% in 2004 to 43% in 2019); this might connect partly to the extensive application of therapy to eliminate early acquisition.<sup><xref rid=""b17-eajm-56-3-189"" ref-type=""bibr"">17</xref>,<xref rid=""b41-eajm-56-3-189"" ref-type=""bibr"">41</xref></sup> As well, in",2_22,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">41</xref></sup> As well, in Europe, the overall prevalence of <italic toggle=""yes"">P. aeruginosa</italic> has meaningfully decreased.<sup><xref rid=""b42-eajm-56-3-189"" ref-type=""bibr"">42</xref></sup> On the contrary, according to our systematic review, the trend of prevalence of<italic toggle=""yes""> P. aeruginosa</italic> in CF patients. in Middle East countries from 2000 to the end of 2023 did not show any special change. In European countries, the prevalence of chronic Pseudomonas",2_23,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"countries, the prevalence of chronic Pseudomonas infection is between 14.29% to 62.16%, their results are compared to our findings, where we had a varied prevalence of about 5.9%- 76.2%, and also the combined prevalence of 34.3% for<italic toggle=""yes""> P. aeruginosa</italic> in Middle East countries. The rate of infection caused by MDR-PA strains in adults with CF is high, which is probably due to the high exposure of these people to antibiotics. These findings are approximately in accordance with 2",2_24,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"findings are approximately in accordance with 2 studies included in the present review (about 8%-9%). According to the data extracted in our review, a higher percentage of CF patients were male. In consistency with our data, the patient registry annual data report in 2019 reported the percentage of male patients with CF as follows: 52% in 2004, 51.8% in 2009, 51.6% in 2014, 51.8% in 2018, and 51.8% in 2019. Since in most cases, <italic toggle=""yes"">P. aeruginosa </italic>is isolated from chronic infection,",2_25,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"</italic>is isolated from chronic infection, most studies included in the current review showed that most patients had chronic colonization conditions with <italic toggle=""yes"">P. aeruginosa</italic>. A full analysis of chronically infected CF patients with<italic toggle=""yes""> P. aeruginosa</italic> is required because early colonization with this microorganism is connected with higher morbidity and mortality.<sup><xref rid=""b5-eajm-56-3-189"" ref-type=""bibr"">5</xref></sup> Antibiotic resistance is one of",2_26,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"Antibiotic resistance is one of the most important concerns of health systems because its presence makes the treatment of diseases more difficult, which increases the mortality rate, the medical costs, and the recovery time in hospitals (WHO, 2018). It also imposes more medical costs on both patients and health systems.<sup><xref rid=""b43-eajm-56-3-189"" ref-type=""bibr"">43</xref></sup> As mentioned in the results, there is a slightly high antibiotic resistance in Arabic countries (Jordan, Iraq, and Qatar).",2_27,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"in Arabic countries (Jordan, Iraq, and Qatar). This is referred to the fact that these studies included older children and adults who are exposed to more antibiotics, resulting in increased resistance. Additionally, studies conducted by H. Y. Al Dawodeyh et al,<sup><xref rid=""b40-eajm-56-3-189"" ref-type=""bibr"">40</xref></sup> M. S. Ahmed et al,<sup><xref rid=""b30-eajm-56-3-189"" ref-type=""bibr"">30</xref></sup> and A. Abdul Wahab et al<sup><xref rid=""b26-eajm-56-3-189"" ref-type=""bibr"">26</xref></sup>",2_28,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">26</xref></sup> reported some MDR strains, which naturally show more resistance to antibiotics.<sup><xref rid=""b44-eajm-56-3-189"" ref-type=""bibr"">44</xref></sup> As a result, we can conclude that there is no significant difference in antibiotic resistance among the countries included in the present review from the Middle East. Recently, there are 3 classes of inhaled antibiotics including tobramycin, aztreonam, and colistin that are used for the treatment of infection resulting from<italic",2_29,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"the treatment of infection resulting from<italic toggle=""yes""> P. aeruginosa </italic>in CF patients. Among them, tobramycin is used most commonly, followed by aztreonam and colistin.<sup><xref rid=""b45-eajm-56-3-189"" ref-type=""bibr"">45</xref></sup> This should be noted, their peak use for all 3 antibiotics is between youth and adulthood. As well, Dornase alfa and hypertonic saline both are widely used for patients with CF. In addition, people with <italic toggle=""yes"">P. aeruginosa</italic> are prescribed",2_30,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"aeruginosa</italic> are prescribed Azithromycin with its peak use at slightly older ages.<sup><xref rid=""b44-eajm-56-3-189"" ref-type=""bibr"">44</xref></sup> As shown in our results, the resistance to tobramycin and aztreonam antibiotics has increased over time.<sup><xref rid=""b30-eajm-56-3-189"" ref-type=""bibr"">30</xref>,<xref rid=""b38-eajm-56-3-189"" ref-type=""bibr"">38</xref>,<xref rid=""b39-eajm-56-3-189"" ref-type=""bibr"">39</xref></sup> The lowest antibiotic resistance was reported against colistin. We think",2_31,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"was reported against colistin. We think the low level of resistance to colistin in the present review is perhaps due to the fact that in 2013, the CF Foundation Pulmonary Guidelines Committee stated that there is not enough evidence for the role of colistin and some other medications in decreasing the severity of lung disease, improving lung function, or improving quality of life in people with cystic fibrosis, so the use of it in CF patients in the Middle East and other parts of the world has recently",2_32,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"East and other parts of the world has recently decreased.<sup><xref rid=""b46-eajm-56-3-189"" ref-type=""bibr"">46</xref></sup> However, tobramycin, aztreonam, and colistin are the therapeutic options recommended by the European Cystic Fibrosis Society for the treatment of chronic <italic toggle=""yes"">P. aeruginosa </italic>infection.<sup><xref rid=""b47-eajm-56-3-189"" ref-type=""bibr"">47</xref></sup> The antibiotic resistance pattern varies against different antibiotics in various studies conducted in the",2_33,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"antibiotics in various studies conducted in the Middle East. It should be taken into consideration that the study conducted by M. S. Ahmed et al<sup><xref rid=""b30-eajm-56-3-189"" ref-type=""bibr"">30</xref></sup> from Qatar reported a high prevalence against all antibiotics tested. M. S. Ahmed et al<sup><xref rid=""b30-eajm-56-3-189"" ref-type=""bibr"">30</xref></sup> reported high resistance of 96.6%, 91.2%, 90.7%, 90.2%, 73.2%, 58%, and 54.6% to cefepime, ciprofloxacin, piperacillin–tazobactam, meropenem,",2_34,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"piperacillin–tazobactam, meropenem, gentamycin, amikacin, and tobramycin, respectively,<sup><xref rid=""b3-eajm-56-3-189"" ref-type=""bibr"">3</xref></sup> in contrast, studies conducted by Bozkurt-Güzel et al<sup><xref rid=""b35-eajm-56-3-189"" ref-type=""bibr"">35 </xref></sup>from Türkiye S. Mamishi et al<sup><xref rid=""b48-eajm-56-3-189"" ref-type=""bibr"">48</xref></sup> and Kodori et al<sup><xref rid=""b36-eajm-56-3-189"" ref-type=""bibr"">36</xref></sup> both from Iran, reported low resistance between 0% and 11%",2_35,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"Iran, reported low resistance between 0% and 11% against all antibiotics tested. This is likely is because of the source of bacterial isolates, year of study, location, and infection control measures in each country or region.<sup><xref rid=""b39-eajm-56-3-189"" ref-type=""bibr"">39</xref></sup> Also, an important note is that CF patients from years ago weren’t the same as those in 2022, owing to advances in pharmacotherapy and the care they have taken over time.<sup><xref rid=""b49-eajm-56-3-189""",2_36,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"over time.<sup><xref rid=""b49-eajm-56-3-189"" ref-type=""bibr"">49</xref></sup> Cystic Fibrosis Foundation, alongside tobramycin, aztronam, and colistin, makes a list of commonly prescribed intravenous antibiotics to encounter infections caused by <italic toggle=""yes"">P. aeruginosa </italic>in CF patients. Those are penicillin (piperacillin), cephalosporins (ceftazidime, cefepime, ceftolozane), carbapenems (meropenem, imipenem, doripenem), aminoglycosides (amikacin, gentamycin), a macrolide (azithromycin),",2_37,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"gentamycin), a macrolide (azithromycin), and fluoroquinolones (ciprofloxacin, levofloxacin) (<ext-link http://www.w3.org/1999/xlink href=""https://www.cff.org/Life-With-CF/Treatments-and"" ext-link-type=""uri"">https://www.cff.org/Life-With-CF/Treatments-and</ext-link> Therapies/Medications/Antibiotics/). Ceftazidime is commonly the best cephalosporin used to reduce acute pulmonary exacerbations in CF patients, chiefly owing to known bactericidal activity against <italic toggle=""yes"">P. aeruginosa",2_38,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"against <italic toggle=""yes"">P. aeruginosa </italic>compared to other cephalosporins,<sup><xref rid=""b50-eajm-56-3-189"" ref-type=""bibr"">50</xref>,<xref rid=""b51-eajm-56-3-189"" ref-type=""bibr"">51</xref></sup> similarly, piperacillin has the same sufficient activity against <italic toggle=""yes"">P. aeruginosa</italic> as ceftazidime is.<sup><xref rid=""b52-eajm-56-3-189"" ref-type=""bibr"">52</xref></sup> Amikacin is an alternative antibiotic used in cases where CF patients are unable to tolerate tobramycin or",2_39,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"CF patients are unable to tolerate tobramycin or who are infected by <italic toggle=""yes"">P. aeruginosa</italic> strains resistant to tobramycin.<sup><xref rid=""b53-eajm-56-3-189"" ref-type=""bibr"">53</xref></sup> According to our findings, half of the studies reported high resistance to ceftazidime (β-lactam) compared to all studies except one<sup><xref rid=""b39-eajm-56-3-189"" ref-type=""bibr"">39</xref></sup> reported low resistance to piperacillin (β-lactam). Regarding amikacin, most studies, resistance was",2_40,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"Regarding amikacin, most studies, resistance was low to moderate resistance, but some studies included here reported a high rate.<sup><xref rid=""b30-eajm-56-3-189"" ref-type=""bibr"">30</xref>,<xref rid=""b39-eajm-56-3-189"" ref-type=""bibr"">39</xref>,<xref rid=""b40-eajm-56-3-189"" ref-type=""bibr"">40</xref></sup> Our study showed that the pattern of antibiotic resistance is almost the same in the countries included from the Middle East. In some studies, the resistance pattern was higher; it depends on the site of",2_41,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"pattern was higher; it depends on the site of study, year of study, infection control policies, socioeconomic status, and type of isolates. Resistance against inhaled first-choice antibiotics, including tobramycin and aztreonam, and intravenous antibiotic (amikacin), has increased gradually over time. Of course, colistin, piperacillin, and ticarcillin are the most effective antibiotics for treating<italic toggle=""yes""> P. aeruginosa </italic>infection in CF patients according to our findings. It can be",2_42,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"CF patients according to our findings. It can be concluded from our study that the prevalence of<italic toggle=""yes""> P. aeruginosa </italic>and antibiotic resistance is high. However, it should be noted that some studies are small and there were no studies from some countries in the region included in this review, so in light of these points the interpretation of the results must be carefully considered. Our study showed that colistin and ticarcillin were found to be the best antibiotics for decreasing",2_43,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"found to be the best antibiotics for decreasing postantibiotic effects (PAEs) in CF patients from the Middle East. Therefore, physicians should pay more attention to therapeutic protocols to prevent further resistance, and antibiotic prescriptions must be based on the results of antibiotic susceptibility testing. The data that support the findings of this study are available on request from the corresponding author.",2_44,"Systematic Review and Meta-Analysis on the Prevalence and Antibiotic Susceptibility Pattern in <italic toggle=""yes"">Pseudomonas aeruginosa </italic>Isolated from Cystic Fibrosis Patients",10 2024,,Cystic_Fibrosis
"New guidelines for screening, evaluation and management of hepatobiliary disease in cystic fibrosis The treatment recommendations are not very prescriptive. This is understandable as there are no treatments proven to alter the natural history of CF liver disease. The guidelines recommend against routine treatment with ursodeoxycholic acid in all patients with CF to prevent the development of advanced liver disease. The use of CF transmembrane conductance regulator (CFTR) modulators in CFLD is a hot topic.",3_0,"New guidelines for screening, evaluation and management of hepatobiliary disease in cystic fibrosis",26 9 2024,,Cystic_Fibrosis
"(CFTR) modulators in CFLD is a hot topic. The committee recommends treatment, with close monitoring, for CFHBI or patients who have received a liver transplant, advise against treatment in patients with decompensated liver disease and make no recommendation for patients with advanced compensated liver disease. No doubt these recommendations will be re-visited as new information becomes available. Hopefully, with the move to starting modulator treatment at an earlier age, the evolution of liver disease may",3_1,"New guidelines for screening, evaluation and management of hepatobiliary disease in cystic fibrosis",26 9 2024,,Cystic_Fibrosis
"earlier age, the evolution of liver disease may be slowed or halted. The recommendations for management of portal hypertension and variceal bleeding are to follow established international guidelines, e.g., AASLD, Baveno and EASL as there is insufficient evidence to guide specific recommendations for CF. Due to a dearth of evidence, the committee could not recommend for or against beta blocker use for primary or secondary prophylaxis for varices. Given the requirement for general anaesthesia for endoscopy",3_2,"New guidelines for screening, evaluation and management of hepatobiliary disease in cystic fibrosis",26 9 2024,,Cystic_Fibrosis
"requirement for general anaesthesia for endoscopy in children the committee could not recommend for or against screening gastroscopy for varices or banding for primary prophylaxis. Portal systemic shunts and liver transplant are endorsed as treatments for appropriate candidates. Transjugular intrahepatic portosystemic shunts (TIPS) are not mentioned, which is surprising as surgical portal systemic shunts are rarely performed now. TIPS is an excellent treatment for uncontrolled or refractory variceal",3_3,"New guidelines for screening, evaluation and management of hepatobiliary disease in cystic fibrosis",26 9 2024,,Cystic_Fibrosis
"treatment for uncontrolled or refractory variceal bleeding. If and when elective TIPS should be used is not clear. The decision when to consider liver transplant can be difficult. As clinicians we try to avoid being too early or too late and some guidance would be appreciated, but perhaps this is not possible. The guidelines seem to suggest an international normalized ratio (INR) >1.5 as a threshold, although this seems a bit low. As the authors recognise, the guideline evaluation process highlighted many",3_4,"New guidelines for screening, evaluation and management of hepatobiliary disease in cystic fibrosis",26 9 2024,,Cystic_Fibrosis
"the guideline evaluation process highlighted many areas where clinical studies are needed to provide evidence-based advice. In particular, given the benefits of CFTR modulator therapy, it may be appropriate to look again at the safety of non-selective beta blockers. In summary, these guidelines are a welcome update. The new classification of CF liver disease will hopefully be very useful. The use of elastography and fibrosis markers should facilitate screening and monitoring, with the caveats about",3_5,"New guidelines for screening, evaluation and management of hepatobiliary disease in cystic fibrosis",26 9 2024,,Cystic_Fibrosis
"screening and monitoring, with the caveats about non-cirrhotic portal hypertension. The guidelines identify a number of areas where there is a lack of evidence to guide recommendations and hopefully this will stimulate further research.",3_6,"New guidelines for screening, evaluation and management of hepatobiliary disease in cystic fibrosis",26 9 2024,,Cystic_Fibrosis
"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients Cystic fibrosis (CF) is a genetic disorder primarily affecting the respiratory and digestive systems, caused by mutations in the CFTR (Cystic fibrosis transmembrane conductance regulator) gene. Globally, CF affects approximately 70,000 to 100,000 individuals, with prevalence rates",4_0,"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients",10 2024,,Cystic_Fibrosis
"to 100,000 individuals, with prevalence rates varying significantly across regions. In Europe, the incidence ranges from 1 in 2,000 to 1 in 3,500 live births, while in the United States, it is about 1 in 3,500 live births [<xref rid=""b1-cm-97-429"" ref-type=""bibr"">1</xref>,<xref rid=""b2-cm-97-429"" ref-type=""bibr"">2</xref>]. Similar prevalence rates are observed in other parts of the world, including Australia and Canada. CF is typically diagnosed in infancy or early childhood. Thanks to advancements in",4_1,"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients",10 2024,,Cystic_Fibrosis
"or early childhood. Thanks to advancements in treatment, life expectancy has improved significantly, with many patients now living into their 40’s and beyond [<xref rid=""b3-cm-97-429"" ref-type=""bibr"">3</xref>]. Despite these improvements, CF continues to impose a substantial disease burden, characterized by frequent hospitalizations, intensive treatments, and significant healthcare costs [<xref rid=""b4-cm-97-429"" ref-type=""bibr"">4</xref>]. The importance of studying CF, particularly in children, lies in",4_2,"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients",10 2024,,Cystic_Fibrosis
"of studying CF, particularly in children, lies in its significant morbidity and mortality. Complications related to CF, such as lung infections and pancreatic insufficiency, contribute heavily to this burden. Furthermore, CF-associated liver disease (CFLD) is emerging as a notable cause of morbidity and mortality, affecting approximately 23% of CF patients [<xref rid=""b5-cm-97-429"" ref-type=""bibr"">5</xref>]. CFLD can manifest as hepatic steatosis, fibrosis, and cirrhosis, and it is the third leading cause",4_3,"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients",10 2024,,Cystic_Fibrosis
"and cirrhosis, and it is the third leading cause of death in CF patients [<xref rid=""b6-cm-97-429"" ref-type=""bibr"">6</xref>]. Understanding the genetic and clinical factors associated with CFLD is crucial for improving patient outcomes and developing targeted therapies. CFLD is a significant complication in CF, with prevalence increasing with age. The pathophysiology of CFLD is complex and multifactorial, involving both genetic predispositions, such as mutations in the <italic toggle=""yes"">CFTR</italic>",4_4,"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients",10 2024,,Cystic_Fibrosis
"in the <italic toggle=""yes"">CFTR</italic> gene, and environmental factors [<xref rid=""b7-cm-97-429"" ref-type=""bibr"">7</xref>]. Hepatic steatosis is one of the most common forms of CFLD, affecting 15% to 60% of CF patients [<xref rid=""b8-cm-97-429"" ref-type=""bibr"">8</xref>]. The presence of liver disease in CF patients is associated with increased morbidity, including the risk of liver transplantation in severe cases [<xref rid=""b5-cm-97-429"" ref-type=""bibr"">5</xref>]. Therefore, identifying patients at",4_5,"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients",10 2024,,Cystic_Fibrosis
"Therefore, identifying patients at risk for CFLD and understanding the underlying mechanisms are essential for early intervention and management. The <italic toggle=""yes"">SERPINA1</italic> gene encodes alpha-1 antitrypsin, a protein that protects tissues from enzyme damage. Variants in this gene, specifically the S and Z alleles, have been associated with liver disease. The Z allele, in particular, is a well-known risk factor due to its role in protein misfolding and accumulation in the liver [<xref",4_6,"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients",10 2024,,Cystic_Fibrosis
"misfolding and accumulation in the liver [<xref rid=""b9-cm-97-429"" ref-type=""bibr"">9</xref>]. In the context of CF, the presence of the <italic toggle=""yes"">SERPINA1</italic> Z allele has been linked to an increased risk of developing CFLD [<xref rid=""b10-cm-97-429"" ref-type=""bibr"">10</xref>]. Understanding the role of these genetic variants in CF patients can provide insights into the pathogenesis of liver disease and suggest potential therapeutic targets. Several studies have explored the association",4_7,"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients",10 2024,,Cystic_Fibrosis
"Several studies have explored the association between the <italic toggle=""yes"">SERPINA1</italic> alleles and CFLD in CF patients. Research indicates that the presence of the <italic toggle=""yes"">SERPINA1</italic> Z allele is significantly associated with an increased risk of CFLD [<xref rid=""b8-cm-97-429"" ref-type=""bibr"">8</xref>,<xref rid=""b11-cm-97-429"" ref-type=""bibr"">11</xref>]. Comparative studies have shown that CF patients with the Z allele are more likely to develop liver disease compared to those",4_8,"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients",10 2024,,Cystic_Fibrosis
"likely to develop liver disease compared to those without this genetic variant [<xref rid=""b10-cm-97-429"" ref-type=""bibr"">10</xref>]. Additionally, the S allele, although less studied, may also contribute to liver disease risk in CF patients [<xref rid=""b9-cm-97-429"" ref-type=""bibr"">9</xref>]. These findings underscore the importance of genetic screening in CF patients to identify those at higher risk for liver complications. This study aims to compare children with CF who have hepatic disease to those",4_9,"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients",10 2024,,Cystic_Fibrosis
"with CF who have hepatic disease to those without hepatic disease, focusing on the presence of <italic toggle=""yes"">SERPINA1</italic> S and <italic toggle=""yes"">SERPINA1</italic> Z alleles, as well as other clinical characteristics. By identifying genetic and clinical differences between these two groups, the study seeks to enhance the understanding of CFLD pathogenesis in CF and inform strategies for early diagnosis and targeted interventions.  A total of 71 participants were enrolled in the study. The",4_10,"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients",10 2024,,Cystic_Fibrosis
"71 participants were enrolled in the study. The median age of the participants was 9 years (interquartile range: 5 to 13), with ages ranging from 0 to 17 years. Comprehensive patient evaluations are detailed in <xref rid=""tI-cm-97-429"" ref-type=""table"">table I</xref>. The analysis revealed that children with CF who developed hepatic disease were generally older and exhibited a higher prevalence of specific hepatic complications, such as biliary lithiasis, periportal fibrosis, and hepatomegaly, compared to",4_11,"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients",10 2024,,Cystic_Fibrosis
"fibrosis, and hepatomegaly, compared to those without hepatic disease. Additionally, these children had higher scores on fibrosis markers (APRI and FIB-4), indicating more advanced liver involvement. The observed difference in the use of UDCA between the two groups underscores the tailored clinical management approach for hepatic disease in this population. The genetic results were independently interpreted by two researchers, both of whom arrived at the same conclusions: We compared the cumulative",4_12,"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients",10 2024,,Cystic_Fibrosis
"the same conclusions: We compared the cumulative incidence of CF diagnosis based on the presence of hepatic disease (<xref rid=""f1-cm-97-429"" ref-type=""fig"">Figure 1</xref>). Both groups exhibited a rapid increase in cumulative incidence at a very early age, indicating that most children with CF are diagnosed within the first few months of life, irrespective of whether they develop hepatic disease. However, the group with hepatic disease showed a slightly lower cumulative incidence compared to the group",4_13,"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients",10 2024,,Cystic_Fibrosis
"lower cumulative incidence compared to the group without hepatic disease, suggesting that children who develop hepatic disease are diagnosed with CF marginally later. Despite this observation, the difference was not statistically significant (p = 0.300). By approximately 50 months of age (about 4 years), the cumulative incidence of CF diagnosis approached 100% in both groups, indicating that nearly all children in both cohorts are diagnosed by this age. In this prospective cross-sectional study, we found",4_14,"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients",10 2024,,Cystic_Fibrosis
"this prospective cross-sectional study, we found that hepatic disease in children with CF was not significantly associated with major CFTR genotypes, including the DF508/DF508 mutation, which was the most prevalent genotype in our cohort. The cumulative incidence analysis suggested a slight delay in CF diagnosis among patients who developed hepatic disease. This observation highlights the genetic heterogeneity within our CF population, with a predominance of the DF508 mutation but also a notable presence",4_15,"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients",10 2024,,Cystic_Fibrosis
"of the DF508 mutation but also a notable presence of less common or unclassified mutations. Our findings contribute to the ongoing debate regarding the relationship between CFTR genotypes and hepatic disease in CF patients. While severe CFTR mutations, such as DF508/DF508, are traditionally associated with more severe clinical manifestations including pancreatic insufficiency and respiratory complications, their link to liver disease remains less definitive [<xref rid=""b14-cm-97-429""",4_16,"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients",10 2024,,Cystic_Fibrosis
"less definitive [<xref rid=""b14-cm-97-429"" ref-type=""bibr"">14</xref>–<xref rid=""b17-cm-97-429"" ref-type=""bibr"">17</xref>]. Several studies have investigated this relationship with varying results. For example, research involving Turkish children with CF indicated that while severe CFTR mutations were linked to markers of disease severity such as pancreatic insufficiency and chronic lung infections, a direct connection to liver disease was not clearly established [<xref rid=""b17-cm-97-429""",4_17,"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients",10 2024,,Cystic_Fibrosis
"clearly established [<xref rid=""b17-cm-97-429"" ref-type=""bibr"">17</xref>]. Similarly, studies focusing on CF patients with severe liver disease who were ineligible for CFTR modulators did not find a direct correlation between specific CFTR mutations and liver disease severity [<xref rid=""b18-cm-97-429"" ref-type=""bibr"">18</xref>]. These findings suggest that factors beyond the CFTR genotype, such as environmental influences or other genetic modifiers, may play a more critical role in the development of",4_18,"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients",10 2024,,Cystic_Fibrosis
"play a more critical role in the development of liver disease in CF patients. Additionally, reviews of CF-related liver disease have underscored the complexity of its pathophysiology, proposing that while CFTR mutations contribute to the condition, other mechanisms, such as biliary obstruction and immune modulation, are also involved [<xref rid=""b19-cm-97-429"" ref-type=""bibr"">19</xref>–<xref rid=""b21-cm-97-429"" ref-type=""bibr"">21</xref>]. This complexity may explain the lack of significant association",4_19,"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients",10 2024,,Cystic_Fibrosis
"may explain the lack of significant association between major CFTR genotypes and hepatic disease in our study. Our results underscore the need for further research to elucidate additional genetic and environmental factors that may contribute to liver disease in CF. This study offers valuable insights into the interplay between CFTR genotypes, SERPINA1 alleles, and hepatic disease in children with CF, representing the first investigation of its kind in Romania. Although no significant association was found",4_20,"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients",10 2024,,Cystic_Fibrosis
"Although no significant association was found between specific CFTR genotypes and hepatic complications, our findings underscore the critical importance of early diagnosis and the use of fibrosis markers to identify children at risk for liver involvement. The study highlights the necessity for vigilant monitoring of liver function in CF patients and suggests that a personalized approach to treatment, taking into account the observed genetic diversity, may enhance patient care. Continued research is",4_21,"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients",10 2024,,Cystic_Fibrosis
"may enhance patient care. Continued research is essential to further elucidate the genetic and environmental factors contributing to hepatic disease in CF, aiming to refine management strategies and improve patient outcomes.",4_22,"Genetic and clinical factors influencing CF-associated liver disease: the impact of <italic toggle=""yes"">SERPINA1</italic> variants and <italic toggle=""yes"">CFTR</italic> genotypes in Romanian pediatric cystic fibrosis patients",10 2024,,Cystic_Fibrosis
"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic> <italic toggle=""yes"">Achromobacter xylosoxidans</italic> is an emerging pathogen that causes airway infections in patients with cystic fibrosis. Knowledge of virulence factors and protein secretion systems in this bacterium is limited. Twin arginine translocation (Tat) is a protein secretion system that transports folded proteins across",5_0,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"system that transports folded proteins across the inner cell membranes of gram-negative bacteria. Tat has been shown to be important for virulence and cellular processes in many different bacterial species. This study aimed to investigate the role of Tat in iron metabolism and host cell adhesion in <italic toggle=""yes"">A. xylosoxidans</italic>. Putative Tat substrates in <italic toggle=""yes"">A.</italic>",5_1,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"<italic toggle=""yes"">xylosoxidans</italic> were identified using the TatFind, TatP, and PRED-Tat prediction tools. An isogenic <italic toggle=""yes"">tatC</italic> deletion mutant (ΔtatC) was generated and phenotypically characterized. The wild-type and ΔtatC <italic toggle=""yes"">A.</italic>",5_2,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"<italic toggle=""yes"">xylosoxidans</italic> were fractionated into cytosolic, membrane, and periplasmic fractions, and the expressed proteome of the different fractions was analysed using liquid chromatography-mass spectrometry (LC-MS/MS). A total of 128 putative Tat substrates were identified in the <italic toggle=""yes"">A.</italic>",5_3,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"<italic toggle=""yes"">xylosoxidans</italic> proteome. The ΔtatC mutant showed attenuated host cell adhesion, growth rate, and iron acquisition. Twenty predicted Tat substrates were identified as expressed proteins in the periplasmic compartment, nine of which were associated with the wild type. The data indicate that Tat secretion is important for iron acquisition and host cell adhesion in <italic toggle=""yes"">A.</italic>",5_4,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"<italic toggle=""yes"">xylosoxidans</italic>. Cystic fibrosis (CF) is a monogenetic disease characterized by persistent microbial infection of the airways, leading to a progressive decline in lung function [<xref rid=""cit0001"" ref-type=""bibr"">1</xref>]. The gram-negative rod <italic toggle=""yes"">Achromobacter xylosoxidans</italic> is an emerging CF pathogen that infects approximately 5% of individuals with CF [<xref rid=""cit0002"" ref-type=""bibr"">2–4</xref>]. Persistent <italic",5_5,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"ref-type=""bibr"">2–4</xref>]. Persistent <italic toggle=""yes"">Achromobacter</italic> infections are associated with poor lung function [<xref rid=""cit0002"" ref-type=""bibr"">2</xref>,<xref rid=""cit0005"" ref-type=""bibr"">5</xref>], but very little is known about the virulence factors of this opportunistic pathogen. During persistent infection, CF pathogens, such as <italic toggle=""yes"">Pseudomonas aeruginosa</italic> and <italic toggle=""yes"">A. xylosoxidans</italic> adapt to the host environment via genetic",5_6,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"adapt to the host environment via genetic evolution to promote chronic colonization [<xref rid=""cit0006"" ref-type=""bibr"">6</xref>,<xref rid=""cit0007"" ref-type=""bibr"">7</xref>]. Bacteria utilize various protein secretion systems that are important for bacterial virulence [<xref rid=""cit0008"" ref-type=""bibr"">8</xref>], and different secretion systems are likely to be involved at different stages of infection. While Type 3 secretion is believed to be important for the early phase of <italic toggle=""yes"">P.",5_7,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"for the early phase of <italic toggle=""yes"">P. aeruginosa</italic> infection in CF lungs [<xref rid=""cit0009"" ref-type=""bibr"">9</xref>,<xref rid=""cit0010"" ref-type=""bibr"">10</xref>], the twin-arginine translocation system (Tat) has been implicated in cellular processes relevant to persistent infection, such as iron acquisition [<xref rid=""cit0011"" ref-type=""bibr"">11</xref>]. In gram-negative bacteria, the Tat system transports proteins across the inner membrane to the periplasmic space. Proteins are",5_8,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"membrane to the periplasmic space. Proteins are translocated in a fully folded state, which allows them to be transported together with co-factors or as hetero-oligomeric complexes [<xref rid=""cit0012"" ref-type=""bibr"">12</xref>]. The Tat complex consists of three membrane-bound subunits: TatA, B, and C. Tat substrates are targeted to the Tat complex by an N-terminal signal peptide containing a conserved twin-arginine motif [<xref rid=""cit0013"" ref-type=""bibr"">13</xref>]. Tat secretion is vital for",5_9,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"Tat secretion is vital for bacterial virulence in many different human pathogens [<xref rid=""cit0014"" ref-type=""bibr"">14–18</xref>], including the CF pathogen <italic toggle=""yes"">P. aeruginosa</italic> [<xref rid=""cit0019"" ref-type=""bibr"">19</xref>]. As the Tat system is involved in the secretion of proteins with diverse functions, the role of Tat depends on the nature of the transported Tat substrates. Consequently, Tat secretion has been implicated in various cellular processes such as cell growth,",5_10,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"various cellular processes such as cell growth, motility, and iron acquisition [<xref rid=""cit0011"" ref-type=""bibr"">11</xref>]. Both Type 3 secretion and Tat are present in <italic toggle=""yes"">A. xylosoxidans</italic> based on data from published genomes [<xref rid=""cit0020"" ref-type=""bibr"">20</xref>,<xref rid=""cit0021"" ref-type=""bibr"">21</xref>]. The aim of this study was to characterize the role of Tat secretion in <italic toggle=""yes"">A. xylosoxidans</italic> and to establish whether the system is",5_11,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
and to establish whether the system is important for the establishment and persistence of infection. This was done by generating a mutant deficient in Tat secretion and characterizing the proteomes of the wild type and mutant to elucidate the mechanistic backbone of important phenotypes related to Tat secretion.   Tat secretion of folded proteins is used to varying extents by different bacterial species. While over 100 suggested Tat substrates have been identified in <italic,5_12,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"Tat substrates have been identified in <italic toggle=""yes"">Streptomyces</italic> spp., important pathogens such as <italic toggle=""yes"">Escherichia coli</italic>, <italic toggle=""yes"">Salmonella enterica</italic> and <italic toggle=""yes"">Campylobacter jejuni</italic> express 15–30 predicted Tat substrates [<xref rid=""cit0012"" ref-type=""bibr"">12</xref>]. In this study, we identified 128 putative Tat substrates in the emerging CF pathogen <italic toggle=""yes"">A. xylosoxidans</italic> using three different",5_13,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"xylosoxidans</italic> using three different prediction tools. In comparison, only 44 putative Tat substrates were identified in the <italic toggle=""yes"">P. aeruginosa</italic> PA14 proteome using the same prediction algorithms [<xref rid=""cit0022"" ref-type=""bibr"">22</xref>], suggesting that Tat secretion plays an important role in <italic toggle=""yes"">A. xylosoxidans</italic>. In this study, we demonstrated that Tat secretion in <italic toggle=""yes"">A. xylosoxidans</italic> appears to be involved in cell",5_14,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"appears to be involved in cell growth, iron acquisition and adhesion to the host lung epithelium. In agreement with our findings, functional Tat secretion has been demonstrated to be required for iron acquisition in various pathogens [<xref rid=""cit0019"" ref-type=""bibr"">19</xref>,<xref rid=""cit0033"" ref-type=""bibr"">33</xref>,<xref rid=""cit0034"" ref-type=""bibr"">34</xref>]. The effects of Tat secretion on cell adhesion have not been previously described. However, it has been demonstrated to affect bacterial",5_15,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"it has been demonstrated to affect bacterial motility through the secretion of flagellar proteins [<xref rid=""cit0014"" ref-type=""bibr"">14</xref>,<xref rid=""cit0035"" ref-type=""bibr"">35</xref>], and flagella have also been implicated in cell adhesion [<xref rid=""cit0036"" ref-type=""bibr"">36</xref>]. To identify the Tat substrates involved in the phenotypic traits of the ΔtatC mutant, we performed extensive characterization of the expressed proteome of <italic toggle=""yes"">A. xylosoxidans</italic> wild-type",5_16,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"toggle=""yes"">A. xylosoxidans</italic> wild-type and ΔtatC mutants grown with and without iron. Under these growth conditions, 20 putative Tat substrates were identified as proteins expressed in the periplasmic compartment. The only predicted Tat substrate that was upregulated during iron starvation was a ferripyoverdine receptor (FpvA) (<xref rid=""f0005"" ref-type=""fig"">Figure 5</xref>). In <italic toggle=""yes"">P. aeruginosa</italic>, FpvA is required for iron acquisition via the siderophore pyoverdine",5_17,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"iron acquisition via the siderophore pyoverdine [<xref rid=""cit0037"" ref-type=""bibr"">37</xref>]. While Ochsner et al. described that the translocation of FpvA to the outer membrane is Tat-dependent [<xref rid=""cit0019"" ref-type=""bibr"">19</xref>], Voulhoux et al. found that FpvA was correctly located and functional in the cytoplasmic membrane of a Tat-mutant despite a Tat signal [<xref rid=""cit0038"" ref-type=""bibr"">38</xref>]. In the present study, FpvA was not expressed in the <italic toggle=""yes"">A.",5_18,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"was not expressed in the <italic toggle=""yes"">A. xylosoxidans</italic> wild type in the presence of iron, but was upregulated during iron limitation. In contrast, the protein was equally expressed under both growth conditions in the ΔtatC mutant, and there was no difference between the wild type and ΔtatC mutants during iron starvation (<xref rid=""f0005"" ref-type=""fig"">Figure 5</xref>). This finding supports previous reports that FpvA is not a true Tat substrate. Alternatively, the results may be affected",5_19,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"Alternatively, the results may be affected by the fractionation method, leading to leakage of FpvA from the cytoplasmic compartment in the ΔtatC mutant. If so, it could be speculated that the ΔtatC mutant experiences iron starvation, despite the presence of iron in the growth medium. Consequently, the bacterium upregulates the expression of FpvA, which then becomes trapped in the cytosol due to defective Tat translocation. We observed substantial contamination of cytosolic proteins in all periplasmic",5_20,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"of cytosolic proteins in all periplasmic fractions, and leakage was more pronounced in the ΔtatC mutant (Supplementary Figure S1). This is an important limitation that may interfere with the results, and the data must therefore be interpreted with caution. Interestingly, Tat is important for the outer membrane integrity in <italic toggle=""yes"">E. coli</italic> [<xref rid=""cit0039"" ref-type=""bibr"">39</xref>]. Similarly, tat mutants of <italic toggle=""yes"">Salmonella</italic> are attenuated due to envelope",5_21,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"are attenuated due to envelope effects and failure to translocate the N-acetylmuramoyl-L-alanine amidases AmiA and AmiC and the cell division protein SufI [<xref rid=""cit0040"" ref-type=""bibr"">40</xref>]. Thus, the increased cytosolic leakage observed in the ΔtatC mutant might be caused by impaired membrane integrity due to a defect in the Tat system. None of the nine putative Tat substrates associated with the wild type (<xref rid=""f0004"" ref-type=""fig"">Figure 4</xref>) could be linked to cell adhesion or",5_22,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"4</xref>) could be linked to cell adhesion or iron acquisition. Even so, many of the proteins are involved in key cellular processes and may contribute to the attenuated phenotype of the ΔtatC mutant. For example, argininosuccinate lyases are key enzymes in the biosynthesis of arginine in both eukaryotic and prokaryotic organisms [<xref rid=""cit0041"" ref-type=""bibr"">41</xref>], and ATP-binding cassette (ABC) transporters are important for the uptake of a broad range of substrates, including iron, in",5_23,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"a broad range of substrates, including iron, in bacteria [<xref rid=""cit0042"" ref-type=""bibr"">42</xref>]. However, none of the ABC transporters with a Tat signal peptide was affected in their expression by iron limitation. Importantly, it should be noted that phenotypes previously ascribed to Tat secretion seem to involve complex cellular processes, and no particular Tat substrate has often been linked to the observed phenotype [<xref rid=""cit0011"" ref-type=""bibr"">11</xref>]. In general, the annotation and",5_24,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"In general, the annotation and knowledge of <italic toggle=""yes"">Achromobacter</italic> proteins is poor, and it is possible that some of these proteins are involved in processes that we currently have no knowledge of. In addition, it cannot be ruled out that other proteins important for iron acquisition require Tat secretion, even in the absence of a Tat signal. For example, proteins lacking the Tat signal peptide can co-translocate with Tat substrates and be transported through the Tat system as",5_25,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"and be transported through the Tat system as heterooligomeric complexes [<xref rid=""cit0012"" ref-type=""bibr"">12</xref>]. Moreover, it has been demonstrated that atypical Tat substrates can utilize the Sec machinery for the initial insertion, followed by an internal Tat signal to direct the remaining peptide via the Tat system [<xref rid=""cit0043"" ref-type=""bibr"">43</xref>,<xref rid=""cit0044"" ref-type=""bibr"">44</xref>]. An example of such a protein is the ferric citrate regulator FecR in <italic",5_26,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"is the ferric citrate regulator FecR in <italic toggle=""yes"">E. coli</italic>, which is involved in iron acquisition [<xref rid=""cit0045"" ref-type=""bibr"">45</xref>]. Tat substrates with internal signal peptides were not detected using the prediction algorithms used in this study. In conclusion, we demonstrated that the CF pathogen <italic toggle=""yes"">A. xylosoxidans</italic> expresses a large number of predicted Tat substrates and that Tat secretion may be important for cell growth, iron acquisition, and",5_27,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"important for cell growth, iron acquisition, and cell adhesion. Given the diversity of substrates secreted by the Tat system, <italic toggle=""yes"">A. xylosoxidans</italic> may utilize this secretion system to facilitate persistence under the stressful conditions of the CF airway, where bacteria are exposed to a myriad of environmental stressors, including immunological host factors, nutrient limitation, and varying oxygen availability [<xref rid=""cit0006"" ref-type=""bibr"">6</xref>]. Importantly, this first",5_28,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
"Importantly, this first study involving a clinical isolate of <italic toggle=""yes"">A. xylosoxidans</italic> together with genetic tools and relevant infection models, has laid the foundation for future studies on the mechanisms underlying the establishment of persistent <italic toggle=""yes"">A. xylosoxidans</italic> lung infections in people with CF.",5_29,"The twin-arginine translocation system is vital for cell adhesion and uptake of iron in the cystic fibrosis pathogen <italic toggle=""yes"">Achromobacter xylosoxidans</italic>",16 11 2023,,Cystic_Fibrosis
An evaluation of the first ten years of Newborn Screening for cystic fibrosis in Ireland Full text not available in PMC,6_0,An evaluation of the first ten years of Newborn Screening for cystic fibrosis in Ireland,11 2024,,Cystic_Fibrosis
"Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs Insulin secretion is impaired in individuals with cystic fibrosis (CF), contributing to high rates of CF-related diabetes (CFRD) and substantially increasing disease burden. To develop improved therapies for CFRD, better knowledge of pancreatic pathology in CF is needed. Glucagon like peptide-1 (GLP-1) from islet α cells potentiates insulin",7_0,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"(GLP-1) from islet α cells potentiates insulin secretion by binding GLP-1 receptors (GLP-1Rs) on β cells. We determined whether expression of GLP-1 and/or its signaling components are reduced in CFRD, thereby contributing to impaired insulin secretion. Immunohistochemistry of pancreas from humans with CFRD versus no-CF/no-diabetes revealed no difference in GLP-1 immunoreactivity per islet area, whereas GLP-1R immunoreactivity per islet area or per insulin-positive islet area was reduced in CFRD. Using",7_1,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"islet area was reduced in CFRD. Using spatial transcriptomics, we observed several differentially expressed α- and/or β-cell genes between CFRD and control pancreas. In CFRD, we found upregulation of α-cell <italic toggle=""yes"">PCSK1</italic> which encodes the enzyme (PC1/3) that generates GLP-1, and downregulation of α-cell <italic toggle=""yes"">PCSK1N</italic> which inhibits PC1/3. Gene set enrichment analysis also revealed α and β cell-specific pathway dysregulation in CFRD. Together, our data suggest",7_2,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"dysregulation in CFRD. Together, our data suggest intra-islet GLP-1 is not limiting in CFRD, but its action may be restricted due to reduced GLP-1R protein levels. Thus, restoring β-cell GLP-1R protein expression may improve β-cell function in CFRD. Rates of diabetes in individuals with the life-limiting genetic disease, cystic fibrosis (CF), are incredibly high, i.e., ~ 20% of adolescents and 40–50% of adults<sup><xref ref-type=""bibr"" rid=""CR1"">1</xref>,<xref ref-type=""bibr"" rid=""CR2"">2</xref></sup>. As",7_3,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"ref-type=""bibr"" rid=""CR2"">2</xref></sup>. As highly effective modulator therapies (HEMT) are increasingly used in this population, lung and nutritional aspects of this multi-organ disease are much improved, resulting in a greater life expectancy. As the CF population ages, however, age-related components are expected to become even more prevalent, including CF-related diabetes (CFRD) where rates are approaching 100% in individuals with common severe <italic toggle=""yes"">CFTR</italic> mutations<sup><xref",7_4,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"toggle=""yes"">CFTR</italic> mutations<sup><xref ref-type=""bibr"" rid=""CR3"">3</xref></sup>. Current data, albeit limited, suggest HEMT do not significantly improve glucose metabolism or pancreatic endocrine function<sup><xref ref-type=""bibr"" rid=""CR4"">4</xref></sup>. Also, mortality for individuals with CFRD > 30 years remains higher than for individuals with CF without diabetes<sup><xref ref-type=""bibr"" rid=""CR3"">3</xref></sup>. Therefore, additional therapies are urgently needed, and for these to be",7_5,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"are urgently needed, and for these to be developed, fundamental knowledge of pancreas pathology in CF must be improved. Clinical data suggest that incretin-based therapies, widely used for treatment of type 2 diabetes, may also be of benefit in CFRD<sup><xref ref-type=""bibr"" rid=""CR5"">5</xref>–<xref ref-type=""bibr"" rid=""CR7"">7</xref></sup>, but the literature remains inconclusive. The incretin hormone, glucagon-like peptide-1 (GLP-1), is an alternate product of the proglucagon gene generated by the",7_6,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"product of the proglucagon gene generated by the enzymatic action of prohormone convertase (PC) 1/3 on proglucagon. GLP-1 is a well-known insulin secretagogue whose insulinotropic action has classically been linked to its production and secretion from intestinal L cells. Once released from L cells, circulating GLP-1 exerts its insulinotropic effects via the GLP-1 receptor (GLP-1R), which is predominantly expressed on the β cell<sup><xref ref-type=""bibr"" rid=""CR8"">8</xref></sup>. GLP-1Rs are also present on",7_7,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"GLP-1Rs are also present on afferent neurons within submucosal and myenteric nervous plexi, which transmit signals to the brain and pancreas through the vagus nerve<sup><xref ref-type=""bibr"" rid=""CR9"">9</xref>,<xref ref-type=""bibr"" rid=""CR10"">10</xref></sup>. Since GLP-1 is rapidly degraded by the proteases dipeptidyl peptidase-4 (DPP-4) and neprilysin<sup><xref ref-type=""bibr"" rid=""CR11"">11</xref>–<xref ref-type=""bibr"" rid=""CR15"">15</xref></sup>, it is thought that gut-derived GLP-1 mediates its",7_8,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"it is thought that gut-derived GLP-1 mediates its insulinotropic action mainly via neuronal, rather than hormonal, pathways. However, emerging evidence from studies of mice deficient in pancreas or gut proglucagon-derived peptides suggests that GLP-1 produced in the gut minimally contributes to insulin secretion<sup><xref ref-type=""bibr"" rid=""CR16"">16</xref></sup>. Maintenance of normal insulin secretion by β cells is dependent, in part, on paracrine signaling from islet α cells. This is supported by",7_9,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"from islet α cells. This is supported by observations that glucagon can stimulate insulin release<sup><xref ref-type=""bibr"" rid=""CR17"">17</xref>–<xref ref-type=""bibr"" rid=""CR20"">20</xref></sup>, and that α cells also produce glucagon-like peptide-1 (GLP-1)<sup><xref ref-type=""bibr"" rid=""CR21"">21</xref>–<xref ref-type=""bibr"" rid=""CR25"">25</xref></sup>. Thus GLP-1’s local effects within the islet are likely to impact insulin release to a greater extent than GLP-1 coming from the intestine via the peripheral",7_10,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"coming from the intestine via the peripheral circulation. To date, levels of GLP-1 within α cells have not been examined in CF, and it is unknown whether diabetes affects islet GLP-1 levels in CF subjects. Indeed, whether α-cell production of GLP-1 and/or GLP-1R signaling is impaired in CFRD is an important gap in our knowledge. If such impairments do exist, strategies to enhance levels of GLP-1 and/or GLP-1R signaling could be effective in increasing insulin release in CFRD. Thus, in the present study, we",7_11,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"release in CFRD. Thus, in the present study, we utilized paraffin-embedded pancreas sections from humans with CF or CFRD and age-matched non-CF/non-diabetic controls to quantify immunoreactivity of GLP-1 and GLP-1R via immunohistochemistry. One aim of this analysis was to identify differences between CF subjects with versus without diabetes. Another aim of our study was to better understand CFRD pathogenesis, focusing on the islet since it is thought to play a critical role yet very little is known about",7_12,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"a critical role yet very little is known about underlying mechanisms. To this end, we also performed the first spatial transcriptomics analysis of CFRD pancreas. In an exploratory analysis, we identified genes and pathways that may be dysregulated in α and β cells from CFRD pancreas. We also examined differentially expressed α- and/or β-cell genes involved in GLP-1 production and signaling, when compared to control pancreas. Together, new knowledge gained from our study has the potential to illuminate",7_13,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"from our study has the potential to illuminate avenues for improved therapies that restore pancreatic endocrine function in individuals with CFRD.  Signaling from islet α-cell secretory products, including GLP-1, is required for maintenance of normal insulin secretion<sup><xref ref-type=""bibr"" rid=""CR17"">17</xref>–<xref ref-type=""bibr"" rid=""CR21"">21</xref></sup>. To our knowledge, no studies have examined whether this paracrine signaling from islet α-to-β cells is defective in CFRD, a disease in which",7_14,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"cells is defective in CFRD, a disease in which impaired insulin secretion is a critical component. Here we show for the first time that in pancreas from humans with CFRD, intra-islet GLP-1 protein levels do not differ significantly whereas GLP-1R protein levels are reduced, when compared to pancreas from humans without CF or diabetes. Further, in a transcriptomics analysis of CFRD pancreas, we find that changes in α-cell gene expression favor increased GLP-1 production/levels, and that β-cell genes",7_15,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"GLP-1 production/levels, and that β-cell genes mediating GLP-1 action downstream of GLP-1R are unchanged. Together, these data suggest that although intra-islet GLP-1 levels are not reduced in CFRD, α-to-β cell signaling of GLP-1 (and its ability to enhance insulin secretion) may be impaired as a result of reduced GLP-1R availability. Our study focused on the pancreas, as loss of β-cell secretory function is known to be important in the development of diabetes. In CF in particular, several studies have",7_16,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"In CF in particular, several studies have demonstrated that impaired insulin secretion, rather than insulin resistance, is likely the major contributor to progression to CFRD. As an example, in CF subjects with normal glucose tolerance, β-cell function is substantially reduced compared to non-CF controls, even when measured as the disposition index, which normalizes the insulin response to the prevailing insulin sensitivity<sup><xref ref-type=""bibr"" rid=""CR27"">27</xref>,<xref ref-type=""bibr""",7_17,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"rid=""CR27"">27</xref>,<xref ref-type=""bibr"" rid=""CR28"">28</xref></sup>. Indeed, insulin secretory defects are present very early in the development of abnormal glucose tolerance in CF, and it has been shown that amongst CF subjects with normal glucose tolerance vs. impaired glucose tolerance vs. CFRD, there is no difference in insulin sensitivity<sup><xref ref-type=""bibr"" rid=""CR29"">29</xref></sup>. Several studies have demonstrated that α-cell mass is increased in CF and CFRD<sup><xref ref-type=""bibr""",7_18,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"in CF and CFRD<sup><xref ref-type=""bibr"" rid=""CR30"">30</xref>–<xref ref-type=""bibr"" rid=""CR33"">33</xref></sup>, including in our Cohort 1 population<sup><xref ref-type=""bibr"" rid=""CR31"">31</xref></sup>. Based on this, we expected that α-cell derived GLP-1 levels would be similarly increased. Moreover, we anticipated that α-cell GLP-1 levels would be greatest in CFRD because the diabetic state would be expected to increase GLP-1-positive α cells, as in human type 2 diabetes<sup><xref ref-type=""bibr""",7_19,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"human type 2 diabetes<sup><xref ref-type=""bibr"" rid=""CR34"">34</xref></sup>, as well as levels of the proglucagon processing enzyme PC1/3 that generates GLP-1, as documented in other hyperglycemic models<sup><xref ref-type=""bibr"" rid=""CR35"">35</xref>–<xref ref-type=""bibr"" rid=""CR39"">39</xref></sup>. Our data show that there are no statistically significant changes in GLP-1 immunoreactivity in CF or CFRD pancreas relative to non-CF/non-diabetic control pancreas. In CFRD pancreas from Cohort 2, islet GLP-1",7_20,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"In CFRD pancreas from Cohort 2, islet GLP-1 levels tend to be increased (<italic toggle=""yes"">p</italic> = 0.05), though this is seen only when expressed relative to total islet area and not glucagon-positive islet area. The latter suggests the trend for increased GLP-1 in CFRD pancreas is driven by an increase in glucagon-expressing cells. Of note, islet area was unchanged in CFRD pancreas, which is consistent with some but not all literature that report islet area in CF/CFRD pancreas. For example, in one",7_21,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"area in CF/CFRD pancreas. For example, in one study, islet area was comparable in pancreas from age-matched CF/CFRD and control subjects<sup><xref ref-type=""bibr"" rid=""CR30"">30</xref></sup>. However, when assessed by presence of diabetes or “lipoatrophic” pattern in CF pancreas, islet area was decreased<sup><xref ref-type=""bibr"" rid=""CR30"">30</xref></sup>. In another study, islets of both diabetic and non-diabetic subjects with CF were found to be hypertrophic<sup><xref ref-type=""bibr""",7_22,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"to be hypertrophic<sup><xref ref-type=""bibr"" rid=""CR40"">40</xref></sup>. These two examples indicate that reports of islet area in CF/CFRD are mixed, which is likely due to several factors such as differences in subject age, BMI and severity of disease amongst studies. Related to GLP-1, our transcriptomics data indicate that expression of the gene encoding PC1/3 (<italic toggle=""yes"">PCSK1</italic>) is significantly increased in α cells from CFRD pancreas. Given that upregulation of GLP-1 production has",7_23,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"Given that upregulation of GLP-1 production has been suggested to be a compensatory mechanism aimed at enhancing β-cell function and survival under diabetic conditions<sup><xref ref-type=""bibr"" rid=""CR34"">34</xref>,<xref ref-type=""bibr"" rid=""CR38"">38</xref>,<xref ref-type=""bibr"" rid=""CR39"">39</xref>,<xref ref-type=""bibr"" rid=""CR41"">41</xref>,<xref ref-type=""bibr"" rid=""CR42"">42</xref></sup>, we postulate the lack of reduced GLP-1 combined with enhanced <italic toggle=""yes"">PCSK1</italic> expression",7_24,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"<italic toggle=""yes"">PCSK1</italic> expression represent an attempt to compensate for defective β-cell function in CFRD. In contrast to our data on islet GLP-1 levels in CFRD pancreas, we observed a significant reduction in islet GLP-1R protein levels in CFRD pancreas, regardless of whether we expressed GLP-1R area relative to total islet area or insulin-positive islet area. This is consistent with data from human type 2 diabetes where islet GLP-1R protein expression also appeared to be decreased<sup><xref",7_25,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"also appeared to be decreased<sup><xref ref-type=""bibr"" rid=""CR43"">43</xref></sup>, though immunostaining was not quantified in that study and it is unclear whether a validated anti-GLP-1R antibody was utilized. In another study utilizing the same validated antibody we used<sup><xref ref-type=""bibr"" rid=""CR44"">44</xref></sup>, islet GLP-1R protein levels were reduced in human type 1 diabetes, but not type 2 diabetes<sup><xref ref-type=""bibr"" rid=""CR45"">45</xref></sup>. Together with our data from CFRD",7_26,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"Together with our data from CFRD pancreas, these differences in islet GLP-1R protein expression amongst various forms of diabetes suggest underlying mechanisms may differ. In addition to GLP-1, glucagon can bind GLP-1R to elicit an increase in insulin secretion<sup><xref ref-type=""bibr"" rid=""CR46"">46</xref></sup>. In CFRD, glucagon area per islet area is increased<sup><xref ref-type=""bibr"" rid=""CR30"">30</xref>–<xref ref-type=""bibr"" rid=""CR33"">33</xref></sup>. Thus, although there are no deficits in islet",7_27,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"Thus, although there are no deficits in islet levels of either GLP-1 or glucagon in CFRD, their action to potentiate insulin secretion may be limited due to insufficient expression of islet GLP-1R. Of note, glucagon can also potentiate insulin secretion by binding glucagon receptors on β cells<sup><xref ref-type=""bibr"" rid=""CR20"">20</xref>,<xref ref-type=""bibr"" rid=""CR47"">47</xref>–<xref ref-type=""bibr"" rid=""CR49"">49</xref></sup>. We observed no change in β-cell <italic toggle=""yes"">GCGR</italic>",7_28,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"in β-cell <italic toggle=""yes"">GCGR</italic> transcript levels between CFRD and control pancreas, but we cannot rule out that protein levels may be reduced in CFRD. That said, studies have shown that α- to β-cell communication is largely mediated by the GLP-1R, with significantly less contribution from the glucagon receptor<sup><xref ref-type=""bibr"" rid=""CR17"">17</xref>,<xref ref-type=""bibr"" rid=""CR20"">20</xref></sup>. Importantly, reduced islet GLP-1R levels may also impact the insulinotropic action of",7_29,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"may also impact the insulinotropic action of systemically circulating GLP-1. For example, in a study of humans with pancreatic insufficient CF (including CFRD), treatment with a dipeptidyl peptidase-4 inhibitor for 6 months increased circulating active GLP-1 levels without changing insulin secretory rates during a mixed-meal tolerance test<sup><xref ref-type=""bibr"" rid=""CR5"">5</xref></sup>. The latter may be explained by reduced islet GLP-1R expression; however, it is important to acknowledge other data",7_30,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"it is important to acknowledge other data that suggest GLP-1R remains functional to a degree in CF/CFRD. For example, GLP-1 infusion increased second-phase insulin concentrations during a hyperglycemic clamp in pancreatic insufficient CF humans with abnormal glucose tolerance<sup><xref ref-type=""bibr"" rid=""CR6"">6</xref></sup>. Also, the GLP-1R agonist semaglutide increased baseline plasma C-peptide and decreased HbA1c levels over time in a case report of a CFRD subject<sup><xref ref-type=""bibr""",7_31,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"of a CFRD subject<sup><xref ref-type=""bibr"" rid=""CR7"">7</xref></sup>. To further explore potential defects in GLP-1R signaling components in CFRD, we performed spatial transcriptomics on islet cells from paraffin-embedded human pancreas sections. This technique enabled an analysis of gene expression in adjacent α and β cells within any given islet. In an analysis focused on a subset of genes known to regulate GLP-1 levels and GLP-1R signaling in α and β cells, we found that <italic",7_32,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"signaling in α and β cells, we found that <italic toggle=""yes"">PCSK1</italic> was increased whereas <italic toggle=""yes"">PCSK2</italic> and <italic toggle=""yes"">PCSK1N</italic> were decreased in α cells from CFRD pancreas. These changes would be expected to promote production of GLP-1 and thus, may explain the lack of decrease in GLP-1 expression we observed by immunohistochemistry. Interestingly, we found no changes in the subset of GLP-1R signaling genes expressed in β cells, besides a decrease in",7_33,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"genes expressed in β cells, besides a decrease in <italic toggle=""yes"">INS</italic>. In a separate gene subset analysis (ROAST) better suited to our small sample size, we found similar results. Specifically, expression of genes involved in regulating GLP-1 levels in α cells was changed in CFRD; however, genes involved in GLP-1R signaling in β cells were unaltered. Importantly, these analyses revealed that β-cell expression of GLP-1R itself was unchanged in CFRD. A lack of change in GLP-1R gene expression",7_34,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"CFRD. A lack of change in GLP-1R gene expression has previously been reported in an RNA sequencing analysis of whole islets isolated from humans with CF/CFRD<sup><xref ref-type=""bibr"" rid=""CR32"">32</xref></sup>. Together, these data would suggest that reductions in GLP-1R are not occurring at the level of gene transcription, but rather that there may be defects in translation, processing or even degradation of GLP-1R. Previously, it was shown that exposure of rodent insulinoma cell lines and isolated mouse",7_35,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"rodent insulinoma cell lines and isolated mouse islets to palmitate caused a reduction in GLP-1R protein expression<sup><xref ref-type=""bibr"" rid=""CR50"">50</xref></sup>. Thus, we speculate that the fatty infiltration of the pancreas with CFTR mutation(s) in CFRD may similarly result in reduced GLP-1R protein levels. Additionally, lipids/cholesterol have been shown to modulate G protein-coupled receptors, including GLP-1R<sup><xref ref-type=""bibr"" rid=""CR51"">51</xref></sup>. Given that our transcriptomics",7_36,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"Given that our transcriptomics data revealed dysregulation of islet cell cholesterol homeostasis (discussed below), this may be a contributing factor to reduced GLP-1R protein levels. Aside from genes involved in GLP-1R signaling, we found several other differentially expressed genes between CFRD and control pancreas. For example, <italic toggle=""yes"">SCG5</italic> was downregulated in both α and β cells in CFRD pancreas. <italic toggle=""yes"">SCG5</italic> encodes neuroendocrine protein 7B2, which",7_37,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"encodes neuroendocrine protein 7B2, which functions as a chaperone of proprotein convertase 2 (PC2)<sup><xref ref-type=""bibr"" rid=""CR52"">52</xref></sup>. The enzymatic action of PC2 is important for cleavage of proglucagon to glucagon in α cells<sup><xref ref-type=""bibr"" rid=""CR53"">53</xref></sup>, as well as processing of pro-islet amyloid polypeptide in β cells<sup><xref ref-type=""bibr"" rid=""CR54"">54</xref></sup>. Thus, decreased expression of α- and β-cell <italic toggle=""yes"">SCG5</italic> in CFRD may",7_38,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"<italic toggle=""yes"">SCG5</italic> in CFRD may suggest defects in glucagon and islet amyloid polypeptide processing. In α cells, it may also be related to a switch from PC2- to PC1/3-mediated cleavage of proglucagon in an attempt to increase GLP-1 production. Another gene found to be downregulated in α cells of CFRD pancreas was <italic toggle=""yes"">GC</italic>, which encodes a vitamin D binding protein shown to be essential for α-cell morphology, electrical activity and glucagon secretion<sup><xref",7_39,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"activity and glucagon secretion<sup><xref ref-type=""bibr"" rid=""CR55"">55</xref></sup>. Further, we also observed downregulation of ER-associated genes, including <italic toggle=""yes"">PDIA4</italic> and <italic toggle=""yes"">HSPA5</italic> in α cells, and <italic toggle=""yes"">GRINA</italic> and <italic toggle=""yes"">HSP90AA1</italic> in β cells, some of which are involved in the unfolded protein response. This suggests there may be inadequate adaptation to accumulation of unfolded or misfolded proteins, such",7_40,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"of unfolded or misfolded proteins, such as islet amyloid polypeptide<sup><xref ref-type=""bibr"" rid=""CR31"">31</xref></sup>, which could lead to ER stress and cell death in CFRD. All differentially expressed genes between CFRD and control pancreas are presented in Supplemental Tables <xref rid=""MOESM2"" ref-type=""media"">S2</xref> and <xref rid=""MOESM3"" ref-type=""media"">S3</xref>. Additional analysis of our spatial transcriptomics data was performed using GSEA. In general, our findings are in keeping with",7_41,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"In general, our findings are in keeping with previously published pathway analysis of data from whole islets isolated from humans with CF/CFRD<sup><xref ref-type=""bibr"" rid=""CR32"">32</xref></sup>; however, we report for the first time to our knowledge, α and β cell-specific pathway dysregulation in CFRD. For example, we observed downregulation of pathways for cholesterol homeostasis (biosynthesis, metabolism, transport, etc.) in α cells, and mitochondrial processes (TCA cycle, oxidative phosphorylation) in",7_42,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"(TCA cycle, oxidative phosphorylation) in β cells from CFRD pancreas. Also, there was upregulation of immune, inflammatory and complement pathways in α cells, and extracellular matrix remodeling (integrins, proteoglycans, cell adhesion, etc.) pathways in β cells. Common to both α and β cells in CFRD was a downregulation of multiple gene sets for ER stress and proteasome pathways. Many of these enriched pathways align with data showing that in CF/CFRD, protein misfolding (e.g., islet amyloid), inflammation",7_43,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"misfolding (e.g., islet amyloid), inflammation and immune cell infiltration in islets is common, as is pancreatic remodeling with adipose and fibrotic tissue deposition<sup><xref ref-type=""bibr"" rid=""CR31"">31</xref>,<xref ref-type=""bibr"" rid=""CR32"">32</xref></sup>. Regarding dysregulation of α-cell/islet cholesterol homeostasis, this has not been studied in cystic fibrosis; however, accumulation of free cholesterol has been described in human CF lung tissue and non-islet cell models of CF<sup><xref",7_44,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"tissue and non-islet cell models of CF<sup><xref ref-type=""bibr"" rid=""CR56"">56</xref>,<xref ref-type=""bibr"" rid=""CR57"">57</xref></sup>. Whether cholesterol also accumulates in the islet in CF warrants further investigation, especially since prior studies have shown elevated islet cholesterol to contribute to islet dysfunction and death<sup><xref ref-type=""bibr"" rid=""CR58"">58</xref></sup>. The present study was greatly facilitated by access to pancreatic tissue from humans with CF/CFRD; however, there are",7_45,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"from humans with CF/CFRD; however, there are some limitations in utilizing this tissue. First, lack of availability or poor quality of tissue meant that the sample size was relatively small for some outcomes measures. Specifically, use of autopsy pancreas was not ideal, and better-quality donor pancreas from nPOD was limited to <italic toggle=""yes"">n</italic> of 5 for the CFRD group. This made it difficult to account for potentially confounding factors, such as sex or BMI in Cohort 2 or medication usage in",7_46,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"as sex or BMI in Cohort 2 or medication usage in all subjects, as well as reducing power for differential gene and pathway enrichment analysis. Furthermore, it limited our ability to make comparisons regarding islet GLP-1R protein levels and α or β cell gene expression between non-diabetic subjects with CF versus those without CF. Despite these shortcomings, in CFRD pancreas we demonstrated perturbations in GLP-1R signaling components and several other important genes and processes involved in islet",7_47,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"important genes and processes involved in islet function/survival, which will help guide future studies to better understand the pathogenesis of CFRD. Second, we cannot exclude the possibility that some genes identified in the transcriptomics analysis were derived from ‘contaminating’ cell types collected alongside the glucagon- and insulin-positive cells. For example, acinar cell contamination was particularly problematic since genes within this cell type were so strongly up- or down-regulated in CFRD",7_48,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"were so strongly up- or down-regulated in CFRD pancreas due to pancreatic insufficiency. To minimize the impact of these contaminating cells, we filtered the entire transcriptomics dataset to exclude genes known to be expressed in acinar cells but not α or β cells. This resulted in populations that were enriched for α or β cells, though we acknowledge it is unlikely these populations were entirely pure. Third, the CFRD pancreas was obtained from humans with diabetes duration of approximately 4 years. Thus,",7_49,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"diabetes duration of approximately 4 years. Thus, it is unknown whether the changes we observed in islets from these subjects also manifest in CF with shorter or longer diabetes duration – such knowledge could impact treatment strategies in CFRD. Additionally, we had no information on glucose tolerance status of non-diabetic CF subjects; specifically, it is unknown whether these subjects had impaired glucose tolerance, which may have affected our findings. Similarly, we had no information on whether these",7_50,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"Similarly, we had no information on whether these subjects had suppression of GLP-1R-mediated amplification of insulin release – this may inform on the degree to which GLP-1R signaling is involved in development of CFRD. Finally, while immunohistochemical and gene expression data are informative, additional studies are necessary to discern the functional impact of our findings on insulin secretion in CF/CFRD. In order to perform such studies, better models of the β-cell defects in CFRD than those currently",7_51,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"the β-cell defects in CFRD than those currently available are required. In conclusion, this is the first study to investigate intra-islet GLP-1R signaling in CFRD using both immunohistochemical and spatial transcriptomics approaches. Our findings suggest that intra-islet GLP-1R signaling may be impaired in humans with CFRD due to a reduction in β-cell GLP-1R protein expression. Further, using spatial transcriptomics, we identify several differentially expressed genes in α and β cells between CFRD and",7_52,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"expressed genes in α and β cells between CFRD and control pancreas, and uncover α and β cell-specific pathway dysregulation in CFRD. These novel findings illuminate potential targets for therapeutic intervention to improve islet function in CFRD, including strategies to restore islet protein levels of GLP-1R and/or promote intracellular signaling beyond GLP-1R.  Below is the link to the electronic supplementary material.",7_53,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"<supplementary-material content-type=""local-data"" id=""MOESM1""><media http://www.w3.org/1999/xlink href=""41598_2024_76722_MOESM1_ESM.docx""><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
 
<supplementary-material content-type=""local-data"" id=""MOESM2""><media http://www.w3.org/1999/xlink href=""41598_2024_76722_MOESM2_ESM.xlsx""><caption><p>Supplementary Material 2</p></caption></media></supplementary-material>",7_54,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"<supplementary-material content-type=""local-data"" id=""MOESM3""><media http://www.w3.org/1999/xlink href=""41598_2024_76722_MOESM3_ESM.xlsx""><caption><p>Supplementary Material 3</p></caption></media></supplementary-material>
 
<supplementary-material content-type=""local-data"" id=""MOESM4""><media http://www.w3.org/1999/xlink href=""41598_2024_76722_MOESM4_ESM.xlsx""><caption><p>Supplementary Material 4</p></caption></media></supplementary-material>",7_55,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"<supplementary-material content-type=""local-data"" id=""MOESM5""><media http://www.w3.org/1999/xlink href=""41598_2024_76722_MOESM5_ESM.xlsx""><caption><p>Supplementary Material 5</p></caption></media></supplementary-material>
 
<supplementary-material content-type=""local-data"" id=""MOESM6""><media http://www.w3.org/1999/xlink href=""41598_2024_76722_MOESM6_ESM.xlsx""><caption><p>Supplementary Material 6</p></caption></media></supplementary-material>",7_56,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"<supplementary-material content-type=""local-data"" id=""MOESM7""><media http://www.w3.org/1999/xlink href=""41598_2024_76722_MOESM7_ESM.xlsx""><caption><p>Supplementary Material 7</p></caption></media></supplementary-material>
 
<supplementary-material content-type=""local-data"" id=""MOESM8""><media http://www.w3.org/1999/xlink href=""41598_2024_76722_MOESM8_ESM.xlsx""><caption><p>Supplementary Material 8</p></caption></media></supplementary-material>",7_57,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"<supplementary-material content-type=""local-data"" id=""MOESM9""><media http://www.w3.org/1999/xlink href=""41598_2024_76722_MOESM9_ESM.docx""><caption><p>Supplementary Material 9</p></caption></media></supplementary-material>",7_58,Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs,28 10 2024,,Cystic_Fibrosis
"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum <italic toggle=""yes"">Aspergillus fumigatus</italic> (Af) and <italic toggle=""yes"">Pseudomonas aeruginosa</italic> (Pa) are pathogens inhabiting the lungs of persons with cystic fibrosis (CF), or immune-compromised patients, causing or aggravating disease. We previously investigated their microbial interaction as well as susceptibility to",8_0,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"interaction as well as susceptibility to anti-fungal drugs using RPMI medium (contains undetectable iron concentrations), as is standard for susceptibility testing. Here we investigated microbial interaction in synthetic sputum medium (SSPM), a complex mixture designed to mimic the milieu in CF lungs. SSPM contains Fe<sup>2+</sup>. Pa laboratory strain PA14 or PA14 siderophore mutant planktonic culture filtrate, prepared in RPMI or SSPM, were compared for inhibition of Af biofilm formation. SSPM enhanced",8_1,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"inhibition of Af biofilm formation. SSPM enhanced bacterial and fungal growth and the production of the Pa molecules pyoverdine, phenazines, and rhamnolipids. Af was more susceptible to these molecules in SSPM (with the exception of pyoverdine). SSPM interfered with fungal susceptibility to pyoverdine. Studies with the mutant helped to reveal that the reduced anti-fungal activity of pyoverdine in SSPM appears to be compensated by higher production of other anti-fungal molecules, e.g., rhamnolipids,",8_2,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"other anti-fungal molecules, e.g., rhamnolipids, phenazines, and PQS, and higher Af sensitivity to these molecules. In summary, SSPM better defines Pa–Af intermicrobial competition in the milieu of CF lungs. Microorganisms interact, affect each other, and are affected by the microenvironment in their hosts. An example for such a microenvironment are the lungs of persons with cystic fibrosis (CF), a hereditary disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), a",8_3,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"transmembrane conductance regulator (CFTR), a chloride channel on epithelial cells, with the loss or under-function leading to mucoid plaques in several organs [<xref rid=""B1-pathogens-13-00875"" ref-type=""bibr"">1</xref>,<xref rid=""B2-pathogens-13-00875"" ref-type=""bibr"">2</xref>,<xref rid=""B3-pathogens-13-00875"" ref-type=""bibr"">3</xref>]. In consequence, the lungs of persons with CF have a reduced ability to clear, e.g., pathogens and are therefore more susceptible to chronic infection. Prominent bacterial",8_4,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"to chronic infection. Prominent bacterial and fungal pathogens in the lungs of persons with CF are <italic toggle=""yes"">P. aeruginosa</italic> and <italic toggle=""yes"">A. fumigatus</italic>, respectively, which impair lung function, especially in co-infections [<xref rid=""B4-pathogens-13-00875"" ref-type=""bibr"">4</xref>,<xref rid=""B5-pathogens-13-00875"" ref-type=""bibr"">5</xref>]. Both pathogens compete for resources in their microenvironment, most notably for iron, which is rare in mucoid plaques and",8_5,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"for iron, which is rare in mucoid plaques and abundant in micro-hemorrhages, with both being present in CF lungs [<xref rid=""B6-pathogens-13-00875"" ref-type=""bibr"">6</xref>]. CF lungs tend to have a higher iron content than non-CF or healthy lungs [<xref rid=""B7-pathogens-13-00875"" ref-type=""bibr"">7</xref>]. Low-iron conditions trigger the production of siderophores by both <italic toggle=""yes"">P. aeruginosa</italic> and <italic toggle=""yes"">A. fumigatus</italic> and lead to competition [<xref",8_6,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"fumigatus</italic> and lead to competition [<xref rid=""B8-pathogens-13-00875"" ref-type=""bibr"">8</xref>]. RPMI-1640 medium (“RPMI”), a medium that does not contain detectable amounts of iron, has been extensively used in vitro to study bacteria, fungi, and microbial combinations, likely because it is fully defined (allowing controlled modifications of constituent contents for metabolic studies), and moreover, mammalian cells will grow in it, facilitating concurrent studies of such cells with microbes. RPMI",8_7,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"studies of such cells with microbes. RPMI medium is also used to determine fungal drug susceptibility in clinical tests, using the CLSI method [<xref rid=""B9-pathogens-13-00875"" ref-type=""bibr"">9</xref>]. The <italic toggle=""yes"">P. aeruginosa</italic> siderophore pyoverdine has been shown to possess anti-fungal activity in vitro [<xref rid=""B8-pathogens-13-00875"" ref-type=""bibr"">8</xref>], investigated in RPMI medium. Pyoverdine is not produced in RPMI medium complemented with ferric iron [<xref",8_8,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"RPMI medium complemented with ferric iron [<xref rid=""B10-pathogens-13-00875"" ref-type=""bibr"">10</xref>]. In iron-enriched RPMI medium, anti-fungal activity is partially taken over by the phenazine pyocyanin [<xref rid=""B10-pathogens-13-00875"" ref-type=""bibr"">10</xref>]. The relevance of pyoverdine or pyocyanin in intermicrobial competition in vivo is not yet fully understood. Other anti-fungal molecules in <italic toggle=""yes"">P. aeruginosa</italic> filtrates encompass PQS [<xref",8_9,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"filtrates encompass PQS [<xref rid=""B11-pathogens-13-00875"" ref-type=""bibr"">11</xref>,<xref rid=""B12-pathogens-13-00875"" ref-type=""bibr"">12</xref>,<xref rid=""B13-pathogens-13-00875"" ref-type=""bibr"">13</xref>], rhamnolipids [<xref rid=""B12-pathogens-13-00875"" ref-type=""bibr"">12</xref>], 1-hydroxyphenazine [<xref rid=""B14-pathogens-13-00875"" ref-type=""bibr"">14</xref>,<xref rid=""B15-pathogens-13-00875"" ref-type=""bibr"">15</xref>,<xref rid=""B16-pathogens-13-00875"" ref-type=""bibr"">16</xref>,<xref",8_10,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">16</xref>,<xref rid=""B17-pathogens-13-00875"" ref-type=""bibr"">17</xref>], phenazine-1-carboxamide [<xref rid=""B15-pathogens-13-00875"" ref-type=""bibr"">15</xref>,<xref rid=""B16-pathogens-13-00875"" ref-type=""bibr"">16</xref>,<xref rid=""B17-pathogens-13-00875"" ref-type=""bibr"">17</xref>], and phenazine-1-carboxylic acid [<xref rid=""B17-pathogens-13-00875"" ref-type=""bibr"">17</xref>]. In CF lungs, the growth milieu for pathogens is complex, containing multiple amino acids and factors that RPMI does",8_11,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"multiple amino acids and factors that RPMI does not provide. To investigate relevant microbes in CF in a milieu closer to that encountered in lungs in vivo, synthetic sputum media were developed [<xref rid=""B18-pathogens-13-00875"" ref-type=""bibr"">18</xref>,<xref rid=""B19-pathogens-13-00875"" ref-type=""bibr"">19</xref>,<xref rid=""B20-pathogens-13-00875"" ref-type=""bibr"">20</xref>,<xref rid=""B21-pathogens-13-00875"" ref-type=""bibr"">21</xref>,<xref rid=""B22-pathogens-13-00875"" ref-type=""bibr"">22</xref>,<xref",8_12,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">22</xref>,<xref rid=""B23-pathogens-13-00875"" ref-type=""bibr"">23</xref>,<xref rid=""B24-pathogens-13-00875"" ref-type=""bibr"">24</xref>]. It has been shown that such media affect the physiology of microbes differently than would be seen in RPMI [<xref rid=""B22-pathogens-13-00875"" ref-type=""bibr"">22</xref>,<xref rid=""B23-pathogens-13-00875"" ref-type=""bibr"">23</xref>]. Using one such medium, SSPM, in which <italic toggle=""yes"">P. aeruginosa</italic> can grow, we showed that <italic",8_13,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"can grow, we showed that <italic toggle=""yes"">A. fumigatus</italic> could grow, and in a cohort of CF and non-CF <italic toggle=""yes"">A. fumigatus</italic> isolates, there were differences in susceptibility to voriconazole, a widely used azole anti-fungal drug, when planktonic testing was compared to RPMI medium [<xref rid=""B24-pathogens-13-00875"" ref-type=""bibr"">24</xref>]. Here, we compare the bacterial growth as well as composition and anti-fungal activity of <italic toggle=""yes"">P. aeruginosa</italic>",8_14,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"of <italic toggle=""yes"">P. aeruginosa</italic> filtrates, prepared in SSPM or RPMI on <italic toggle=""yes"">A. fumigatus</italic> growing and forming biofilm.   Various studies have indicated that certain regions of the CF lung, e.g., where micro-hemorrhages occur, are rich in iron, whereas others, e.g., mucus plugs, may be iron-depleted [<xref rid=""B7-pathogens-13-00875"" ref-type=""bibr"">7</xref>]. RPMI, used in clinical testing as per the CLSI, is iron-poor and therefore does not fully reflect the",8_15,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"and therefore does not fully reflect the situation in CF lungs. In our present studies, we compared microbial interaction in RPMI to interaction in SSPM in an effort to more closely approximate the situation in the overall milieu in CF lungs. We observed that both Pa and Af grow more (<xref rid=""pathogens-13-00875-f002"" ref-type=""fig"">Figure 2</xref>A) and quicker (<xref rid=""pathogens-13-00875-f003"" ref-type=""fig"">Figure 3</xref>) in SSPM than in RPMI. Both organisms utilize iron via their respective",8_16,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"Both organisms utilize iron via their respective siderophores, foremost pyoverdine for Pa and SidA for Af [<xref rid=""B36-pathogens-13-00875"" ref-type=""bibr"">36</xref>,<xref rid=""B37-pathogens-13-00875"" ref-type=""bibr"">37</xref>]. In Pa filtrates produced in SSPM, more pyoverdine was detected compared to RPMI filtrates (<xref rid=""pathogens-13-00875-f002"" ref-type=""fig"">Figure 2</xref>B), but when normalized to bacterial growth, Pa produced less pyoverdine per bacterium in SSPM (<xref",8_17,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"less pyoverdine per bacterium in SSPM (<xref rid=""pathogens-13-00875-t002"" ref-type=""table"">Table 2</xref>). This can be explained by the depressing effect of Fe<sup>2+</sup> in SSPM on the production of iron-acquiring siderophores [<xref rid=""B10-pathogens-13-00875"" ref-type=""bibr"">10</xref>]. When the production by Pa of molecules in Pa filtrates was performed in the same medium as in the assay for inhibition of Af (both RPMI or both SSPM), the Pa filtrates in RPMI were more anti-fungal than the",8_18,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"filtrates in RPMI were more anti-fungal than the filtrates prepared in SSPM (<xref rid=""pathogens-13-00875-f004"" ref-type=""fig"">Figure 4</xref>B), despite the RPMI filtrates having less pyoverdine (<xref rid=""pathogens-13-00875-f002"" ref-type=""fig"">Figure 2</xref>B). This suggested that SSPM dampens the anti-fungal activity of Pa filtrates or protects the fungus from pyoverdine. To unravel this further, we equalized the medium used for the inhibition assay by studying Pa filtrates prepared in RPMI against",8_19,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"by studying Pa filtrates prepared in RPMI against conidia suspended in SPPM, and the assay was performed in SPPM; conversely, we studied filtrates prepared in SSPM against conidia suspended in RPMI, with the assay performed in RPMI. Thus, there were now equal quantities of RPMI and SSPM in all the assays (standardized, mixed media assay (SMMa)). The SMMa allowed for fungal growth comparable to fungal growth in SSPM (<xref rid=""pathogens-13-00875-f004"" ref-type=""fig"">Figure 4</xref>A). Under these",8_20,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"ref-type=""fig"">Figure 4</xref>A). Under these conditions, the Pa filtrates prepared in SSPM were more anti-fungal than the filtrates prepared in RPMI (<xref rid=""pathogens-13-00875-f004"" ref-type=""fig"">Figure 4</xref>C). However, with these assays now uniformly in 50% SSPM, anti-fungal activity was dampened, compared to the previous studies, whether the Pa filtrates were prepared in RPMI or SSPM (<xref rid=""pathogens-13-00875-f004"" ref-type=""fig"">Figure 4</xref>B vs. <xref rid=""pathogens-13-00875-f004""",8_21,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"4</xref>B vs. <xref rid=""pathogens-13-00875-f004"" ref-type=""fig"">Figure 4</xref>C). This suggests that SSPM decreases pyoverdine activity rather than protecting the fungus, which grew equally in SSPM vs. SMMa (<xref rid=""pathogens-13-00875-f004"" ref-type=""fig"">Figure 4</xref>A). We then tested pure pyoverdine and found it to indeed be less anti-fungal in SSPM than in RPMI (<xref rid=""pathogens-13-00875-f005"" ref-type=""fig"">Figure 5</xref>A), supporting our conclusion that pyoverdine in SSPM filtrates must",8_22,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"conclusion that pyoverdine in SSPM filtrates must be dampened in its activity. Since pyoverdine was less anti-fungal in SSPM, despite the Pa filtrates prepared in SSPM being more anti-fungal in the SMMa studies (as just described), this suggested that Pa must produce anti-fungal molecules other than pyoverdine in SSPM, and/or the other anti-fungals produced are more potent inhibitors in SSPM. We further confirmed that Fe<sup>2+</sup> at concentrations found in SSPM enhances the growth of Af in RPMI (<xref",8_23,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"in SSPM enhances the growth of Af in RPMI (<xref rid=""pathogens-13-00875-f005"" ref-type=""fig"">Figure 5</xref>B). However, if the increased Af growth in Fe<sup>2+</sup>-supplemented RPMI was normalized compared to growth in standard RPMI, the added Fe<sup>2+</sup> decreased the anti-fungal activity of pyoverdine in RPMI (<xref rid=""pathogens-13-00875-f005"" ref-type=""fig"">Figure 5</xref>C). This can explain why pyoverdine and Pa filtrates are less anti-fungal when prepared in SSPM, since SSPM contains",8_24,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"when prepared in SSPM, since SSPM contains Fe<sup>2+</sup>. Iron attaching to pyoverdine would decrease pyoverdine’s ability to inhibit a fungal competitor by denying iron to the fungus. Filtrates of a Pa mutant lacking the ability to generate the two principal Pa siderophores, pyoverdine and pyochelin (both of which are anti-fungal [<xref rid=""B8-pathogens-13-00875"" ref-type=""bibr"">8</xref>])<italic toggle=""yes"">,</italic> were studied to gain insight into the mechanisms at play. The mutant was less",8_25,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"into the mechanisms at play. The mutant was less anti-fungal than filtrates of wild-type Pa when the filtrates were prepared in RPMI (<xref rid=""pathogens-13-00875-f006"" ref-type=""fig"">Figure 6</xref>A) or SSPM (<xref rid=""pathogens-13-00875-f006"" ref-type=""fig"">Figure 6</xref>B) and studied in the assay in the same medium in which the filtrates were prepared. We noted that the mutant’s filtrates appeared more anti-fungal when these studies were performed in SSPM compared to RPMI (<xref",8_26,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"were performed in SSPM compared to RPMI (<xref rid=""pathogens-13-00875-f006"" ref-type=""fig"">Figure 6</xref>A vs. <xref rid=""pathogens-13-00875-f006"" ref-type=""fig"">Figure 6</xref>B). We also tested mutants lacking either pyoverdine (PA14 <italic toggle=""yes"">pvdD-</italic>) or pyochelin (PA14 <italic toggle=""yes"">pchE-)</italic> and could confirm that the lack of pyoverdine (<xref rid=""pathogens-13-00875-f0A2"" ref-type=""fig"">Figure A2</xref>, part A), but not pyochelin (<xref rid=""pathogens-13-00875-f0A2""",8_27,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"pyochelin (<xref rid=""pathogens-13-00875-f0A2"" ref-type=""fig"">Figure A2</xref>, part B), was responsible for the loss in anti-fungal activity of the double mutant compared to the wild type (<xref rid=""pathogens-13-00875-f006"" ref-type=""fig"">Figure 6</xref>B). When these studies were performed in an “SMMa” fashion, so that the assay conditions were the same for the different filtrates as described above, the mutant’s filtrates prepared in SSPM were anti-fungal, but not when prepared in RPMI (<xref",8_28,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"anti-fungal, but not when prepared in RPMI (<xref rid=""pathogens-13-00875-f006"" ref-type=""fig"">Figure 6</xref>C). Therefore, we concluded that, lacking siderophore production, the mutant must produce anti-fungals other than pyoverdine in SSPM. We then confirmed the absence of pyoverdine content in double (pyoverdine + pyochelin) mutant filtrates (<xref rid=""pathogens-13-00875-f007"" ref-type=""fig"">Figure 7</xref>A) and found the mutant’s increased growth (<xref rid=""pathogens-13-00875-f007""",8_29,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"growth (<xref rid=""pathogens-13-00875-f007"" ref-type=""fig"">Figure 7</xref>B) and increased production of phenazines (<xref rid=""pathogens-13-00875-f007"" ref-type=""fig"">Figure 7</xref>C), biosurfactants (<xref rid=""pathogens-13-00875-f007"" ref-type=""fig"">Figure 7</xref>D), and pyocyanin (<xref rid=""pathogens-13-00875-f007"" ref-type=""fig"">Figure 7</xref>E) in SSPM compared to RPMI. This reasoning would also apply to the wild type, as suggested in the SMMa experiments with the wild type described above, where",8_30,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"with the wild type described above, where wild-type Pa filtrates were more anti-fungal when prepared in SSPM, despite the lessened potency of pyoverdine in SSPM. An anti-fungal molecule overrepresented in SSPM filtrates could be responsible for the observed increased anti-fungal activity of SSPM filtrates in the absence of pyoverdine. We also found that pure rhamnolipids (<xref rid=""pathogens-13-00875-f008"" ref-type=""fig"">Figure 8</xref>A) or pyocyanin (<xref rid=""pathogens-13-00875-f008""",8_31,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"or pyocyanin (<xref rid=""pathogens-13-00875-f008"" ref-type=""fig"">Figure 8</xref>B) were more anti-fungal when presented in SSPM than in RPMI. These Pa products could contribute to a greater anti-fungal activity of Pa in iron-rich parts of CF lungs. It also has to be kept in mind that such anti-fungals are over-produced in iron-rich SSPM and, hence, possibly in iron-rich parts of CF lungs where pyoverdine activity is dampened. It has already been shown that bacteria in SSPM also produce large amounts of PQS",8_32,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"in SSPM also produce large amounts of PQS [<xref rid=""B20-pathogens-13-00875"" ref-type=""bibr"">20</xref>], another Pa molecule that, at certain concentrations, is anti-fungal but, as we have shown, can also deliver iron to the fungus [<xref rid=""B11-pathogens-13-00875"" ref-type=""bibr"">11</xref>]. PQS showed reduced activity in SSPM (<xref rid=""pathogens-13-00875-f008"" ref-type=""fig"">Figure 8</xref>C), resembling the siderophore pyoverdine (<xref rid=""pathogens-13-00875-f005"" ref-type=""fig"">Figure",8_33,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"ref-type=""fig"">Figure 5</xref>A), but to a lesser degree. Possible limitations to our study are as follows: (a) there may be molecules important for microbial competition present in CF sputum that are not represented in SSPM; (b) as mentioned, there are variations in the molecular contents in different portions of CF lung, so the ratio of microbial molecules present could vary from site to site; (c) what is relevant to CF sputum may not be relevant to sputum in other clinical situations where these two",8_34,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"in other clinical situations where these two pathogens also co-exist (e.g., lungs of cancer patients or transplant patients); (d) CF sputum content may be changing in the era of CFTR-manipulating drugs; and (e) CF sputum content may change in the wake of antimicrobial use in a patient. Pa in SSPM (and presumably in the airways milieu which SSPM mimics) produces higher amounts of anti-fungal molecules other than pyoverdine, compensating for reduced pyoverdine activity; moreover, Af is also more sensitive to",8_35,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"activity; moreover, Af is also more sensitive to these other molecules in that milieu. Thus, SSPM appears to help illuminate the complexities of Pa–Af intermicrobial competition in the milieu of CF lungs.",8_36,"Anti-Fungal (<italic toggle=""yes"">Aspergillus fumigatus</italic>) Activity of <italic toggle=""yes"">Pseudomonas aeruginosa</italic> in Cystic Fibrosis Synthetic Sputum",07 10 2024,,Cystic_Fibrosis
"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report <italic toggle=""yes"">Clostridioides difficile</italic> infection (CDI) is generally treated with vancomycin, metronidazole or fidaxomicin, although fecal microbiota transplantation (FMT) represents a promising therapeutic option for antibiotic-resistant recurrent <italic toggle=""yes"">C.",9_0,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"recurrent <italic toggle=""yes"">C. difficile</italic> infections (rCDIs) in adults. In pediatric cystic fibrosis (CF) patients, CDIs are generally asymptomatic and respond to treatment. Here, we present the case of an 8-year-old female, initially diagnosed as “CFTR-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis” (CMRS/CFSPID), who then progressed to CF at 12 months. In the absence of CF-related symptoms, she presented multiple and disabling episodes of bloody diarrhoea",9_1,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"and disabling episodes of bloody diarrhoea with positive tests for <italic toggle=""yes"">C. difficile</italic> antigen and A/B toxin. After conventional treatments failed and several CDI relapses, FMT was proposed. Donor screening and GM donor–receiver matching identified her mother as a donor. Metataxonomy and targeted metabolomics provided, through a pre- and post-FMT time course, gut microbiota (GM) profiling to assess GM engraftment. At first, the GM map revealed severe dysbiosis, with a prevalence of",9_2,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"revealed severe dysbiosis, with a prevalence of Bacteroidetes and Proteobacteria (i.e., <italic toggle=""yes"">Klebsiella</italic> spp., <italic toggle=""yes"">Escherichia coli</italic>), a reduction in Firmicutes, a GM nearly entirely composed of Enterococcaceae (i.e., <italic toggle=""yes"">Enterococcus</italic>) and an almost complete depletion of Verrucomicrobia and Actinobacteria, mostly represented by <italic toggle=""yes"">Veillonella dispar</italic>. Post FMT, an increment in <italic",9_3,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"Post FMT, an increment in <italic toggle=""yes"">Bifidobacterium</italic> spp. and <italic toggle=""yes"">Collinsella</italic> spp. with a decrease in <italic toggle=""yes"">V. dispar</italic> restored intestinal eubiosis. Consistently, four weeks after FMT treatment, the child’s gut symptoms cleared, without CDI recurrence. Cystic fibrosis (CF) is a multi-organ disease, primarily affecting the respiratory, digestive and reproductive systems and the sweat glands. The primary clinical manifestation of CF are",9_4,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"The primary clinical manifestation of CF are exocrine pancreatic insufficiency and progressive pulmonary and gastrointestinal tract dysfunctions [<xref rid=""B1-microorganisms-12-02059"" ref-type=""bibr"">1</xref>]. Moreover, patients with CF experience multiple bacterial infections throughout their lives [<xref rid=""B2-microorganisms-12-02059"" ref-type=""bibr"">2</xref>,<xref rid=""B3-microorganisms-12-02059"" ref-type=""bibr"">3</xref>]. Thus, antibiotic therapies in these patients are directed at preventing,",9_5,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"in these patients are directed at preventing, eradicating or controlling respiratory infections [<xref rid=""B4-microorganisms-12-02059"" ref-type=""bibr"">4</xref>]. However, these treatments also alter the gut microbiota (GM) composition and metabolic function, leading to a loss of commensal <italic toggle=""yes"">Clostridioides</italic> spp. and the onset of <italic toggle=""yes"">Clostridioides difficile</italic> infections (CDIs) [<xref rid=""B5-microorganisms-12-02059"" ref-type=""bibr"">5</xref>]. <italic",9_6,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">5</xref>]. <italic toggle=""yes"">C. difficile</italic> is a Gram-positive spore-forming bacterium. Its spores can spread by the fecal–oral pathway, pass the stomach barrier and germinate into vegetative forms [<xref rid=""B5-microorganisms-12-02059"" ref-type=""bibr"">5</xref>], producing toxins that can damage the intestinal mucosa, causing various symptoms from inflammation, diarrhoea, fever, abdominal pain and nausea to severe complications, such as toxic megacolon and colonic perforation",9_7,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"such as toxic megacolon and colonic perforation [<xref rid=""B6-microorganisms-12-02059"" ref-type=""bibr"">6</xref>,<xref rid=""B7-microorganisms-12-02059"" ref-type=""bibr"">7</xref>]. Normally, the GM protects the intestine against this pathogen by the production of short-chain fatty acids (SCFA) and secondary bile acids [<xref rid=""B8-microorganisms-12-02059"" ref-type=""bibr"">8</xref>] and by stimulating the immune system [<xref rid=""B9-microorganisms-12-02059"" ref-type=""bibr"">9</xref>]. The disruption of",9_8,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">9</xref>]. The disruption of intestinal eubiosis may cause an overgrowth of the vegetative forms, leading to toxinogenic <italic toggle=""yes"">C. difficile</italic> colonization [<xref rid=""B10-microorganisms-12-02059"" ref-type=""bibr"">10</xref>,<xref rid=""B11-microorganisms-12-02059"" ref-type=""bibr"">11</xref>]. In this case, two different kinds of clostridial exotoxins are produced, specifically TcdA and TcdB, responsible for inflammation and intestinal damage [<xref",9_9,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"for inflammation and intestinal damage [<xref rid=""B12-microorganisms-12-02059"" ref-type=""bibr"">12</xref>]. After a first episode of CDI, a symptomatic recurrence, namely recurrent CDI (rCDI), can develop [<xref rid=""B13-microorganisms-12-02059"" ref-type=""bibr"">13</xref>]. Spores are involved in the pathophysiology of rCDI, when the patient may become re-infected with the same or different <italic toggle=""yes"">C. difficile</italic> strains, causing a recurring inflammation [<xref",9_10,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"strains, causing a recurring inflammation [<xref rid=""B14-microorganisms-12-02059"" ref-type=""bibr"">14</xref>], especially in the case of an inappropriate immune response [<xref rid=""B15-microorganisms-12-02059"" ref-type=""bibr"">15</xref>]. In clinical practice, CDI is normally treated with antibiotic therapy, i.e., vancomycin, metronidazole or fidaxomicin [<xref rid=""B16-microorganisms-12-02059"" ref-type=""bibr"">16</xref>]. However, fecal microbiota transplantation (FMT) is a therapeutic option for rCDIs in",9_11,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"(FMT) is a therapeutic option for rCDIs in adults [<xref rid=""B17-microorganisms-12-02059"" ref-type=""bibr"">17</xref>,<xref rid=""B18-microorganisms-12-02059"" ref-type=""bibr"">18</xref>,<xref rid=""B19-microorganisms-12-02059"" ref-type=""bibr"">19</xref>] and is still an experimental treatment in children, despite support from the American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology and Nutrition [<xref",9_12,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"Gastroenterology, Hepatology and Nutrition [<xref rid=""B20-microorganisms-12-02059"" ref-type=""bibr"">20</xref>]. In the last few years, the use of FMT in children under different disease conditions has significantly increased and has progressively taken advantages from the growing knowledge on the ecology and function of the gut microbiota, including its degree of dysbiosis, as thoroughly reported in the literature (<xref rid=""app1-microorganisms-12-02059"" ref-type=""app"">Supplementary Table S1</xref>). FMT",9_13,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"Table S1</xref>). FMT is the process of transplanting feces from healthy donors to recipients to introduce a healthy GM [<xref rid=""B21-microorganisms-12-02059"" ref-type=""bibr"">21</xref>]. It can mitigate the negative effects of antibiotics by disrupting the receiver’s GM and restoring eubiosis [<xref rid=""B17-microorganisms-12-02059"" ref-type=""bibr"">17</xref>]. FMT is considered a safe and affordable treatment to correct GM imbalance after CDI and restore normal bowel function [<xref",9_14,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"CDI and restore normal bowel function [<xref rid=""B14-microorganisms-12-02059"" ref-type=""bibr"">14</xref>]. This is the case of an 8-year-old female followed at the Cystic Fibrosis Regional Reference Centre of Florence, Italy (Meyer Children’s Hospital IRCCS), initially diagnosed as CF transmembrane conductance regulator (CFTR)-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CMRS/CFSPID) [<xref rid=""B22-microorganisms-12-02059"" ref-type=""bibr"">22</xref>] in the presence",9_15,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">22</xref>] in the presence of positive CF newborn screening, sweat chloride in the intermediate range (49–42 mmol/L) and <italic toggle=""yes"">CFTR</italic> genotype: F508del/S737F (less than two <italic toggle=""yes"">CFTR</italic>-causing variants) [<xref rid=""B23-microorganisms-12-02059"" ref-type=""bibr"">23</xref>,<xref rid=""B24-microorganisms-12-02059"" ref-type=""bibr"">24</xref>]. The patient then progressed to CF with pancreatic sufficiency at 12 months for pathological (63–68 mmol/L) sweat",9_16,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"12 months for pathological (63–68 mmol/L) sweat tests. During follow-up, no CF-related symptoms appeared, nor did lung disease or the need for antibiotic therapies. The child presented multiple episodes of bloody diarrhoea between May 2022 and October 2023, with positive tests for <italic toggle=""yes"">C. difficile</italic> antigen and toxin A/B. Different antibiotic therapies, including metronidazole, vancomycin and fidaxomicin, were administered, but only with temporary clinical response. In fact,",9_17,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"only with temporary clinical response. In fact, constant relapse was observed after treatment discontinuation. Interestingly, the first CDI episode occurred in May 2022 after treatment of group A beta-haemolytic <italic toggle=""yes"">Streptococcus</italic> (SBEGA) infection with amoxicillin. At that time, after failure of metronidazole, the infection was successfully treated with vancomycin (<xref rid=""microorganisms-12-02059-t001"" ref-type=""table"">Table 1</xref>). However, in May 2023, CDI relapsed after a",9_18,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"However, in May 2023, CDI relapsed after a new episode of SBEGA infection, treated with cefixime. After that, vancomycin was also only temporarily beneficial, as was fidaxomicin, with different regimens (<xref rid=""microorganisms-12-02059-t001"" ref-type=""table"">Table 1</xref>) and with a persistent CDI outcome. Therefore, the medical staff of Meyer Children’s Hospital IRCCS asked for second opinion and possible FMT at Bambino Gesù Children’s Hospital, IRCCS (OPBG), a referral centre for this treatment in",9_19,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"(OPBG), a referral centre for this treatment in Italy. The first evaluation at OPBG was in November 2023 after the VI episode of rCDI. The infectious diseases team reviewed the patient’s infectious and pharmacological history. At that time, two weeks after the last fidaxomicin discontinuation, the Microbiomics Unit performed the first GM map by 16S rRNA analysis of three stool samples and produced a GM diagnostic report (<xref rid=""microorganisms-12-02059-f001"" ref-type=""fig"">Figure 1</xref>). Briefly,",9_20,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"ref-type=""fig"">Figure 1</xref>). Briefly, using the metataxonomy method for diagnosis of gut dysbiosis (OPBG patent N° WO2017216820A1, <uri http://www.w3.org/1999/xlink href=""https://patents.google.com/patent/WO2017216820A1/en"">https://patents.google.com/patent/WO2017216820A1/en</uri>, accessed on 8 October 2024), a degree of gut dysbiosis, expressed as per the microbial dysbiosis index (MDI), was assigned to the CF patient’s GM through comparison of the GM profile to that of healthy age-matched subjects,",9_21,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"profile to that of healthy age-matched subjects, or controls (CTRLs). The method characterized the GM profiles of the CF patient, describing operational taxonomic units (OTUs) at three taxonomic levels, i.e., phylum, family and genus. The MDI was computed by exploiting the quadratic dissimilarity index, Z = (½ × Σ(f<sub>case</sub> − f<sub>controls</sub>)<sup>2</sup>)<sup>1/2</sup> × 100 [<xref rid=""B25-microorganisms-12-02059"" ref-type=""bibr"">25</xref>], where f<sub>case</sub> represents the median value",9_22,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"f<sub>case</sub> represents the median value of the OTU distributions at the phylum, family and genus levels of the fecal GM of the CF patient, and f<sub>controls</sub> describes the median value of OTU distributions at the same taxonomic levels of the fecal GM of CTRLs. A value of MDI = 0 indicates no dissimilarity, while MDI = 1 represents maximum dissimilarity, hence representing a measure of dysbiosis. The MDI was classified as mild (<25%), moderate (25–35%) and high (>35%), accordingly to a study on",9_23,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"and high (>35%), accordingly to a study on pediatric IBD [<xref rid=""B26-microorganisms-12-02059"" ref-type=""bibr"">26</xref>]. The GM profile of the patient presented a high level of dysbiosis (35%), with a high prevalence at the phylum level of Bacteroidetes and Proteobacteria and a reduction in Firmicutes compared to the healthy age-matched control group (CTRL). Moreover, almost a complete depletion of both Actinobacteria and Verrucomicrobia was observed (<xref rid=""microorganisms-12-02059-f001""",9_24,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"(<xref rid=""microorganisms-12-02059-f001"" ref-type=""fig"">Figure 1</xref>A). Concerning OTU distributions at the family level, Ruminococcaceae was reduced by 5.5 times, while Enterobacteriaceae increased by 780 times, compared to CTRLs (<xref rid=""microorganisms-12-02059-f001"" ref-type=""fig"">Figure 1</xref>B). At the genus level, an increase in <italic toggle=""yes"">Veillonella, Enterococcus</italic> and <italic toggle=""yes"">Clostridium</italic> (Firmicutes) as well as an overabundance of <italic",9_25,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"as well as an overabundance of <italic toggle=""yes"">Sutterella</italic> and <italic toggle=""yes"">Klebsiella</italic> (Proteobacteria) (<xref rid=""microorganisms-12-02059-f002"" ref-type=""fig"">Figure 2</xref>A) were observed, while at the species level, <italic toggle=""yes"">Veillonella dispar</italic> and <italic toggle=""yes"">Escherichia coli</italic> were increased (<xref rid=""microorganisms-12-02059-f002"" ref-type=""fig"">Figure 2</xref>B). Based on rCDI episodes, absent or limited responsiveness to multiple",9_26,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"absent or limited responsiveness to multiple rounds of antibiotic therapy and evidence of dysbosis, the multidisciplinary team of clinicians and microbiologists from OPBG and the Meyer Children’s Hospital decided to proceed with compassionate use of FMT. The medical history report and treatment proposal for this single case was submitted to the National Transplant Center (Centro Nazionale Trapianti—CNT) and to the OPBG Ethics Committees (Prot. n. 977, 20 December 2023, Rome), finally obtaining",9_27,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"977, 20 December 2023, Rome), finally obtaining authorization to proceed. In order to identify the best donor for FMT, parents were selected following the FMT screening procedures in use in OPBG. Donor selection was based on anamnestic and clinical interviews, biohumoral and microbiological tests, GM profiles, MDI value and recipient–donor GM map matching (<xref rid=""microorganisms-12-02059-f003"" ref-type=""fig"">Figure 3</xref>) (The gut microbiome precision medicine and the fecal microbiota transplantation",9_28,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"medicine and the fecal microbiota transplantation in children, Putignani L and OPBG Multidisciplinary Study Group for FMT, Giornale SIGENP, n.1, 2024, <uri http://www.w3.org/1999/xlink href=""https://sigenp.org/giornale-sigenp/"">https://sigenp.org/giornale-sigenp/</uri>, accessed on 8 October 2024). Following the donor screening results, the mother was considered as an eligible donor (<xref rid=""app1-microorganisms-12-02059"" ref-type=""app"">Figure S1</xref>). During FMT authorization and donor selection, the",9_29,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"During FMT authorization and donor selection, the girl experienced her VII (last) rCDI episode. According to the infectious disease unit, another course of fidaxomicin was administered, with plans to continue the therapy until FMT approval. The child was admitted to the Gastroenterology Unit, asymptomatic, after suspending antibiotic treatment 48 h prior to admission. Stool samples were collected for a new baseline GM analysis immediately before FMT (T<sub>0</sub>). In parallel, a fecal emulsion from the",9_30,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"In parallel, a fecal emulsion from the mother’s stool was obtained and frozen, in order to be ready and available for the procedure [<xref rid=""B19-microorganisms-12-02059"" ref-type=""bibr"">19</xref>,<xref rid=""B27-microorganisms-12-02059"" ref-type=""bibr"">27</xref>]. Then, endoscopic FMT was performed by esophagogastroduodenoscopy (EGD). The post-procedure course was uneventful, and the child was discharged after three days of observation. Successful treatment outcomes included both the resolution of rCDI",9_31,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"outcomes included both the resolution of rCDI and the restoration of intestinal eubiosis. GM profiling was repeated at different post-FMT time points in order to observe the microbiological “engraftment”: T<sub>+1</sub> (1 day after transplant), T<sub>+5</sub>, T<sub>+9</sub>, T<sub>+15</sub> and T<sub>+31</sub> (<xref rid=""microorganisms-12-02059-f004"" ref-type=""fig"">Figure 4</xref>). The follow-up analysis after the FMT procedure showed, regarding Actinobacteria, an increase in <italic",9_32,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"regarding Actinobacteria, an increase in <italic toggle=""yes"">Bifidobacterium</italic> and <italic toggle=""yes"">Collinsella</italic>. Moreover, an increase in Bacteroidetes and a decrease in Firmicutes, in particular <italic toggle=""yes"">V. dispar</italic>, were observed (<xref rid=""microorganisms-12-02059-t002"" ref-type=""table"">Table 2</xref>). Furthermore, to corroborate the amelioration of intestinal dysbiosis after FMT, SCFAs were detected in fecal samples. The concentration of SCFAs was measured by a",9_33,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"The concentration of SCFAs was measured by a gas chromatograph (GC) coupled to a mass spectrometer (MS) [<xref rid=""B28-microorganisms-12-02059"" ref-type=""bibr"">28</xref>]. Firstly, the patient showed lower levels of SCFAs at the pre-FMT time point compared to the concentrations detected during the time course. In particular, immediately after FMT, higher quantities of acetic, propionic and butyric acids were observed; then, an expected concentration reduction was reported until a constancy of values",9_34,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"was reported until a constancy of values occurred during follow-up (<xref rid=""microorganisms-12-02059-t003"" ref-type=""table"">Table 3</xref>), coupled to low level of the dysbiosis index and, especially, to the clearance of gut symptoms. FMT is a method of changing the GM composition of a subject in order to gain a therapeutic benefit. FMT in children is still used as a potential, experimental therapy to treat or ameliorate different conditions or symptoms. Amongst the different pathological conditions,",9_35,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"Amongst the different pathological conditions, FMT has been tested in children with IBD and has been shown to be safe and effective in managing symptoms [<xref rid=""B29-microorganisms-12-02059"" ref-type=""bibr"">29</xref>,<xref rid=""B30-microorganisms-12-02059"" ref-type=""bibr"">30</xref>]. Currently, most clinical experience with FMT has originated from the treatment of recurrent or refractory CD in adulthood. However, it has also been tested in pediatric patients with recurrent <italic",9_36,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"in pediatric patients with recurrent <italic toggle=""yes"">Clostridium difficile</italic> infection [<xref rid=""B31-microorganisms-12-02059"" ref-type=""bibr"">31</xref>], with an optimal response in terms of <italic toggle=""yes"">Clostridioides</italic> eradication. However, the safety and efficacy of using FMT to treat rCDI in children with other pathologies is still largely unexplored. As observed for other FC-related models characterized by the F508del variant [<xref rid=""B32-microorganisms-12-02059""",9_37,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"variant [<xref rid=""B32-microorganisms-12-02059"" ref-type=""bibr"">32</xref>], it has been shown that defects in the gene encoding for the cystic fibrosis transmembrane conductance regulator (CFTR) lead to the malfunction of this protein, specifically exerting a block in the transport of chloride and bicarbonate ions and water at the level of the intestinal epithelial tissues [<xref rid=""B33-microorganisms-12-02059"" ref-type=""bibr"">33</xref>]. This new GI balance causes, within the GM, a reduction in pH and",9_38,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"causes, within the GM, a reduction in pH and an anaerobic environment, creating a microenvironment suitable for the growth of microbial species such as <italic toggle=""yes"">C. difficile</italic>. Normally, commensal bacteria, including Clostridia species such as <italic toggle=""yes"">Clostridium scindens</italic>, are capable of converting primary bile acids into secondary bile acids in the intestinal lumen, which inhibit the growth of <italic toggle=""yes"">C. difficile</italic> [<xref",9_39,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"<italic toggle=""yes"">C. difficile</italic> [<xref rid=""B34-microorganisms-12-02059"" ref-type=""bibr"">34</xref>]. However, antibiotic treatment can deplete competing commensal species, including <italic toggle=""yes"">C. scindens</italic> [<xref rid=""B35-microorganisms-12-02059"" ref-type=""bibr"">35</xref>], leading to the accumulation of primary bile acids and an increase in <italic toggle=""yes"">C. difficile</italic> spore germination [<xref rid=""B36-microorganisms-12-02059"" ref-type=""bibr"">36</xref>]. CDI is",9_40,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">36</xref>]. CDI is underestimated in CF because it is typically asymptomatic or displays minimal symptoms and, in any case, there is usually a rapid resolution after vancomycin or metronidazole treatment [<xref rid=""B37-microorganisms-12-02059"" ref-type=""bibr"">37</xref>]. Moreover, <italic toggle=""yes"">C. difficile</italic> in CF patients is not common, and generally diarrhea or other GI symptoms are primarily attributed to reasons different from CDI, such as reduced dosage of pancreatic",9_41,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"from CDI, such as reduced dosage of pancreatic extracts [<xref rid=""B38-microorganisms-12-02059"" ref-type=""bibr"">38</xref>,<xref rid=""B39-microorganisms-12-02059"" ref-type=""bibr"">39</xref>]. Surprisingly, in the present case, the <italic toggle=""yes"">Clostridium</italic> infection developed in absence of CF-related symptoms and after the first antibiotic treatment (amoxicillin) for <italic toggle=""yes"">Streptococcus</italic> infection. Both ampicillin and amoxicillin have been recognized as potent inducers",9_42,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"have been recognized as potent inducers of <italic toggle=""yes"">C. difficile</italic> infection [<xref rid=""B40-microorganisms-12-02059"" ref-type=""bibr"">40</xref>], and amoxicillin use is usually particularly identified as the highest risk factor for <italic toggle=""yes"">C. difficile</italic> diarrhea [<xref rid=""B41-microorganisms-12-02059"" ref-type=""bibr"">41</xref>]. Alterations in GM composition with signatures of CDI were reported for CF children, including lower species richness and microbial",9_43,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"including lower species richness and microbial diversity, with a predominance of Firmicutes [<xref rid=""B42-microorganisms-12-02059"" ref-type=""bibr"">42</xref>] and Proteobacteria [<xref rid=""B43-microorganisms-12-02059"" ref-type=""bibr"">43</xref>], compared to healthy individuals. In particular, <italic toggle=""yes"">Escherichia</italic> and <italic toggle=""yes"">Streptococcus</italic> were associated with CDI, while a reduction in microbial taxa linked to gut protection, such as Porphyromonadaceae [<xref",9_44,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"gut protection, such as Porphyromonadaceae [<xref rid=""B44-microorganisms-12-02059"" ref-type=""bibr"">44</xref>], Ruminococcaceae and Lachnospiraceae, well known as butyric acid producers [<xref rid=""B45-microorganisms-12-02059"" ref-type=""bibr"">45</xref>], was reported. Furthermore, increases in <italic toggle=""yes"">Enterococcus</italic>, <italic toggle=""yes"">Veillonella</italic>, <italic toggle=""yes"">Lactobacillus</italic> and Gammaproteobacteria have been reported in the literature [<xref",9_45,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"have been reported in the literature [<xref rid=""B45-microorganisms-12-02059"" ref-type=""bibr"">45</xref>]. In particular, in rCDIs, a statistically significant increase in <italic toggle=""yes"">Veillonella</italic>, Enterobacteriaceae, Streptococci and <italic toggle=""yes"">Parabacteroides</italic> [<xref rid=""B46-microorganisms-12-02059"" ref-type=""bibr"">46</xref>] was observed, consistent with the findings presented in this case report. The prevalence of <italic toggle=""yes"">Enterococcus</italic> and <italic",9_46,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"toggle=""yes"">Enterococcus</italic> and <italic toggle=""yes"">Veillonella</italic> is also a specific signature in CF patients, as is the depletion of <italic toggle=""yes"">Roseburia</italic> and <italic toggle=""yes"">Ruminococcus</italic>, as reported in the literature [<xref rid=""B32-microorganisms-12-02059"" ref-type=""bibr"">32</xref>]. Moreover, a large increase in <italic toggle=""yes"">Eubacterium dolichum</italic> and a depletion of <italic toggle=""yes"">Bifidobacterium longum</italic> are typically observed",9_47,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"longum</italic> are typically observed in CF patients’ GM profile [<xref rid=""B47-microorganisms-12-02059"" ref-type=""bibr"">47</xref>]. Moreover, beyond GM dysbiosis, a significant reduction in gut microbial metabolites, such as secondary bile acids and SCFAs, are also observed in CDI patients [<xref rid=""B48-microorganisms-12-02059"" ref-type=""bibr"">48</xref>]. In particular, a decrease in butyric acid-producing bacteria such as Ruminococcaceae, Lachnospiraceae and <italic toggle=""yes"">Clostridium</italic>",9_48,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"and <italic toggle=""yes"">Clostridium</italic> cluster IV e XIVa has been reported [<xref rid=""B45-microorganisms-12-02059"" ref-type=""bibr"">45</xref>]. In this case, a decrease in Ruminococcaceae and Lachnospira and metabolites, such as butyrric acid during CD colonization, was also observed, consistent with the literature. In order to obtain the best possible engraftment of transplanted GM, a donor with ideal characteristics was selected. In this case, the GM profile of the donor showed a beneficial",9_49,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"the GM profile of the donor showed a beneficial prevalence of Bacteroidetes and Actinobacteria, with particular reference to <italic toggle=""yes"">Bifidobacterium longum</italic> (relative abundance of 1.318)<italic toggle=""yes"">,</italic> which has been thoroughly described to have positive effects for CDI [<xref rid=""B49-microorganisms-12-02059"" ref-type=""bibr"">49</xref>]. Moreover, the donor presented a specific strain of <italic toggle=""yes"">Clostridium hiranonis</italic>, which has been reported to",9_50,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"hiranonis</italic>, which has been reported to impact the metabolism, growth and toxin production of <italic toggle=""yes"">C. difficile</italic> [<xref rid=""B50-microorganisms-12-02059"" ref-type=""bibr"">50</xref>]. After FMT, the recovery of Bacteroidetes and a decrease in <italic toggle=""yes"">V. dispar</italic> [<xref rid=""B51-microorganisms-12-02059"" ref-type=""bibr"">51</xref>] were observed, confirming the regression of the CDI and the restoration of GM eubiosis. Finally, a restoration of metabolic and",9_51,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"eubiosis. Finally, a restoration of metabolic and ecological activities was observed after FMT. In particular, in the patient, the regression of the CDI was associated with an increase in Ruminococcaceae and <italic toggle=""yes"">Collinsella</italic>, producers of butyrate and bile salts, metabolites that typically decrease in CDI, as also observed for pediatric FMT used to treat pediatric IBD [<xref rid=""B52-microorganisms-12-02059"" ref-type=""bibr"">52</xref>]. Additionally, SCFAs and secondary bile acid",9_52,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"Additionally, SCFAs and secondary bile acid production may increase resistance against CDI by improving the intestinal barrier, the anti-inflammatory response and through the direct inhibition of <italic toggle=""yes"">C. difficile</italic> [<xref rid=""B53-microorganisms-12-02059"" ref-type=""bibr"">53</xref>]. From an ecological point of view, at T<sub>+1</sub>, an increase in facultative anaerobes, including Proteobacteria, was observed, which could have been a transient result of the O<sub>2</sub> conditions",9_53,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"transient result of the O<sub>2</sub> conditions created during the FMT procedures. Afterward, the gradual increase in only anaerobes from the donor (e.g., Bacteroidetes, Firmicutes and Verrucomicrobia) reduced the O<sub>2</sub> conditions, suppressing the relative amount of Proteobacteria. Interestingly, Actinobacteria maintained low concentrations, probably due to their low kinetics of growth. A high growth rate of SCFA-producing microbes was also confirmed. In fact, compared to other the time points, we",9_54,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"In fact, compared to other the time points, we showed a peak increase in all SCFAs at T<sub>+1</sub> and a decrement at T<sub>+5</sub> with a stable, beneficial concentration level during the entire following time course. The high rate of beneficial bacteria after the FMT procedure could be explained by the donor’s GM composition, with a high presence of Ruminococcaceae and <italic toggle=""yes"">B. longum</italic>, both SCFA producers [<xref rid=""B54-microorganisms-12-02059"" ref-type=""bibr"">54</xref>]. FMT",9_55,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">54</xref>]. FMT is considered a standard treatment for the resolution of recurrent <italic toggle=""yes"">C. difficile</italic> infection in adults, compared to alternative treatments such as antibiotic treatment. Today, FMT is still an experimental treatment in children; hence, more studies are required to assess its safety and efficacy. However, for the current case, FMT actually represented an eradication solution for rCDI treatment in CFSPID, generating CD clearance and GM wellness, as",9_56,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
"generating CD clearance and GM wellness, as reported by the restoration of intestinal eubiosis and the increase in SCFAs. In the future, the use of personalized FMT for different pediatric patients and conditions, including CF, is expected to act as a clinical treatment.",9_57,"Fecal Microbiota Transplantation for Recurrent <italic toggle=""yes"">Clostridioides difficile</italic> Infections in a Cystic Fibrosis Child Previously Screen Positive, Inconclusive Diagnosis (CFSPID): A Case Report",12 10 2024,,Cystic_Fibrosis
One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study Introduction: The impact of ETI therapy on pulmonary function and nutritional status has been widely studied; the literature on the possible outcomes on glycemic control and insulin requirement in patients affected by CFRD is controversial. Aim: The main objective of our study was to evaluate HbA1c levels,10_0,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"of our study was to evaluate HbA1c levels in patients with cystic fibrosis-related diabetes (CFRD) after one year of therapy with elexacaftor/tezacaftor/ivacaftor (ETI). The secondary objective was to study the changes in the total daily insulin dose (TDD), pulmonary function and metabolism in this population. Materials and methods: A retrospective single-center observational study was conducted at the Regional Cystic Fibrosis Centre and Diabetology Centre of IRCCS Istituto Giannina Gaslini. The",10_1,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"Centre of IRCCS Istituto Giannina Gaslini. The observation period was divided into four different time points: initiation (T0), 3 months (T<sub>3mo</sub>), 6 months (T<sub>6mo</sub>) and 12 months (T<sub>12mo</sub>) of ETI therapy. Demographic and clinical data were collected. The results were then stratified by genotype (homozygous or heterozygous F508del). Results: Twenty-eight patients with CFRD undergoing insulin therapy were included. TDD (IU) significantly decreased at T<sub>3mo</sub> and",10_2,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"significantly decreased at T<sub>3mo</sub> and T<sub>6mo</sub>, but not at T<sub>12mo</sub>, whereas HbA1c decreased significantly at all three times. The number of hospitalizations and pulmonary exacerbations decreased significantly. Conclusion: We demonstrated both improvement in glycemic control (by means of HbA1c) and insulin requirement in insulin-dependent CFRD patients after one year of ETI treatment. Cystic fibrosis-related diabetes (CFRD) is a specific extra-pulmonary complication associated with",10_3,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"extra-pulmonary complication associated with increased morbidity and mortality in the cystic fibrosis (CF) population. Among the extrapulmonary complications of patients with CF, CFRD is by far the most common [<xref rid=""B1-life-14-01309"" ref-type=""bibr"">1</xref>]. CFRD is a unique form of diabetes, most frequently diagnosed in young adults and the prevalence increases with age [<xref rid=""B2-life-14-01309"" ref-type=""bibr"">2</xref>]. The etiology of CFRD seems to be linked to the partial loss or",10_4,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"of CFRD seems to be linked to the partial loss or dysfunction of pancreatic islets, leading to insulin deficiency and to insulin resistance [<xref rid=""B3-life-14-01309"" ref-type=""bibr"">3</xref>]. The etiology of insulin secretion impairment is also linked to a direct effect of the CF transmembrane conductance regulator (CFTR) protein [<xref rid=""B4-life-14-01309"" ref-type=""bibr"">4</xref>]. A decline in the patient’s pulmonary function and nutritional status begins about 2–4 years prior to the diagnosis of",10_5,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"begins about 2–4 years prior to the diagnosis of CFRD [<xref rid=""B5-life-14-01309"" ref-type=""bibr"">5</xref>]. This deterioration is believed to be associated with protein catabolism due to insulin insufficiency; the worsening of pulmonary function is directly associated with the severity of insulin insufficiency [<xref rid=""B6-life-14-01309"" ref-type=""bibr"">6</xref>]. As mentioned above, CFRD is strongly associated with a decline in pulmonary function, increased frequency of exacerbations and poor",10_6,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"increased frequency of exacerbations and poor nutritional status, resulting in a worse prognosis for the patient [<xref rid=""B7-life-14-01309"" ref-type=""bibr"">7</xref>,<xref rid=""B8-life-14-01309"" ref-type=""bibr"">8</xref>]. CFTR modulators, a group of innovative drugs used in the treatment of CF, have revolutionized the prognosis of these patients; their role is to correct and potentiate defects in the channel function [<xref rid=""B9-life-14-01309"" ref-type=""bibr"">9</xref>]. Various combinations of these",10_7,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"Various combinations of these modulators are available; the most recent formulation available is a triple combination therapy of elexacaftor/tezacaftor/ivacaftor (ETI) approved for patients with at least one copy of the F508del variation [<xref rid=""B10-life-14-01309"" ref-type=""bibr"">10</xref>]. The impact of ETI therapy on pulmonary function and nutritional status has been widely studied and confirmed, while only a few studies have been published regarding the possible outcomes on glycemic control and",10_8,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"the possible outcomes on glycemic control and insulin requirement in patients affected by CFRD. Grancini et al. demonstrated a significant reduction in glycated hemoglobin A1c (HbA1c) values after 6 months of ETI therapy but unchanged insulin requirements [<xref rid=""B9-life-14-01309"" ref-type=""bibr"">9</xref>]. In a large Danish study including 321 patients with CF, a HbA1c decline was reported over 12 months of ETI treatment, which was not associated with a change in insulin usage in the sub-cohort of 26",10_9,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"a change in insulin usage in the sub-cohort of 26 patients with CFRD [<xref rid=""B11-life-14-01309"" ref-type=""bibr"">11</xref>]. Lurquin et al. showed a significant decrease in insulin requirement during follow-up in 17 patients undergoing CFTR modulator therapy with either ETI or tezacaftor/ivacaftor, despite an increase in HbA1c levels [<xref rid=""B12-life-14-01309"" ref-type=""bibr"">12</xref>]. Recently, Cohen et al. demonstrated a decrease of 120 min in the Oral Glucose Tolerance Test (OGTT) value after",10_10,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"Oral Glucose Tolerance Test (OGTT) value after the initiation of CFTR modulator therapy [<xref rid=""B13-life-14-01309"" ref-type=""bibr"">13</xref>]. As stated by Salazar-Barragan et al.’s systematic review, most studies on this topic used small sample sizes, and therefore their power to demonstrate the effectiveness of ETI was limited [<xref rid=""B14-life-14-01309"" ref-type=""bibr"">14</xref>]. Our goal was to evaluate whether ETI is effective for glycemic control and improvement in the total daily dose of",10_11,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"and improvement in the total daily dose of insulin in a larger cohort of patients with CFRD all requiring insulin treatment. The primary aim was to study how HbA1c levels change in adult and pediatric patients affected by cystic fibrosis-related diabetes after one year of elexacaftor/tezacaftor/ivacaftor therapy. The secondary aim was to study the improvement of total daily insulin dose, pulmonary function and metabolism in this population. A retrospective single-center observational study was conducted at",10_12,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"observational study was conducted at the Regional Cystic Fibrosis Centre and the Regional Diabetology Centre of IRCCS Istituto Giannina Gaslini. All patients with insulin-dependent CFRD who started ETI therapy were included. Patients who started insulin therapy after initiating ETI were excluded. The observation period was divided into four different time points: initiation (T0), 3 months (T<sub>3mo</sub>), 6 months (T<sub>6mo</sub>) and 12 months (T<sub>12mo</sub>) of ETI therapy. The number of pulmonary",10_13,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"of ETI therapy. The number of pulmonary exacerbations and hospitalizations, during the year before initiating ETI, was recorded, as well as previous use of CFTR modulators, six-minute walking test (6MWT) and chloride sweat test data during the 12 months prior to ETI initiation (pre-T0). Demographic (age, sex, ethnicity) and clinical data were collected. CFTR genotype, age of CFRD diagnosis, insulin therapy duration, age of ETI initiation and insulin regimen were collected at T0. At T0, T<sub>3mo</sub>,",10_14,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"were collected at T0. At T0, T<sub>3mo</sub>, T<sub>6mo</sub> and T<sub>12mo,</sub> we compared weight, body mass index (BMI), forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), total daily dose of insulin (TDD), basal dose of insulin, bolus dose of insulin, TDD per kilogram and glycated hemoglobin (HbA1c) values. At T0 and T<sub>12mo,</sub> we compared the results of the cystic fibrosis questionnaire (CFQ-R) that measures the health quality of life of patients with CF (the",10_15,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"health quality of life of patients with CF (the higher the score, the better the mental status). At pre-T0 and T<sub>6mo,</sub> we compared 6MWT and chloride sweat test data; and at pre-T0 and T<sub>12mo,</sub> we compared the number of pulmonary exacerbations and hospitalizations. The same data were consequently subanalyzed according to the different CFTR genotypes (Group 1—subjects F508del/F508del vs. Group 2—subjects F508del/any other CF-causing mutation). In total, 28 Caucasian patients (16 males vs.",10_16,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"In total, 28 Caucasian patients (16 males vs. 12 females; 57.1% vs. 42.9%) affected by CF and diagnosed with CFRD undergoing insulin therapy followed at our regional CF centre were included, with a median age of 33 years (SD 13.26, minimum age 12 years, maximum age 56 years) at the start of ETI therapy. Only one patient was excluded due to the initiation of insulin therapy after beginning ETI treatment. Three pediatric patients (10.7% of the cohort) were included in the study (one patient aged 12, two aged",10_17,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"in the study (one patient aged 12, two aged 15). In total, 16 patients presented with genotype F508del with homozygosity and the remaining 12 patients had the genotype F508del with heterozygosity. The type of CFTR modulator therapy used before ETI was lumacaftor/ivacaftor in 12 patients, tezacaftor/ivacaftor in 2 patients; the remaining 14 patients had not taken any modulator therapy prior to ETI. We analyzed the insulin regimen of each patient: 16 patients used only basal insulin, whereas 12 patients",10_18,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"used only basal insulin, whereas 12 patients followed the basal-bolus scheme. The demographic and clinical characteristics are shown in <xref rid=""life-14-01309-t001"" ref-type=""table"">Table 1</xref>. The main results are shown in detail in <xref rid=""life-14-01309-t002"" ref-type=""table"">Table 2</xref>. The TDD (IU) significantly decreased at T<sub>3mo</sub> and T<sub>6mo</sub>, but not at T<sub>12mo</sub>, whereas HbA1c significantly decreased at all time points. The results of the chloride sweat test",10_19,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"points. The results of the chloride sweat test (mmol/L) also decreased significantly, as expected. The number of hospitalizations (n) and pulmonary exacerbations significantly decreased over the study period. All pulmonary function parameters improved significantly at 3, 6 and 12 months, particularly the parameter FEV1%. The patients’ nutritional status significantly improved over the observational period; the BMI (kg/m<sup>2</sup>) increased significantly. The psychological status and quality of life of",10_20,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"The psychological status and quality of life of our patients were assessed via CFQ-R and appeared to improve significantly in the first year of ETI treatment. The results of the subanalysis based on diverse genotypes are illustrated in detail in the <xref rid=""app1-life-14-01309"" ref-type=""app"">Supplementary Material</xref>. The total daily dose of insulin (IU) in homozygous F508del patients only significantly decreased at T0 vs. T<sub>6mo</sub> and HbA1c (%) only significantly decreased at T0 vs.",10_21,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"HbA1c (%) only significantly decreased at T0 vs. T<sub>3mo</sub>. In heterozygous F508del patients, HbA1c decreased significantly at T0 vs. T<sub>6mo</sub> and T0 vs. T<sub>12mo</sub>. The BMI improved significantly in both groups, except for T<sub>12mo</sub> in the homozygous F508del group. As for pulmonary function, all spirometry parameters significantly increased at 3, 6 and 12 months. Patients with heterozygous F508del showed significantly higher FEV1 (mL) at 3 months and 6 months. To the best of our",10_22,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"(mL) at 3 months and 6 months. To the best of our knowledge, this is the first retrospective observational study to demonstrate both an improvement in glycemic control (by means of HbA1c) and reduction in insulin needs after ETI therapy in a cohort of pediatric and adult insulin-dependent patients with CFRD. Our results regarding decreased HbA1c values are concordant with the only other study that demonstrates glycemic control improvement in patients with CFRD under ETI treatment [<xref",10_23,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"in patients with CFRD under ETI treatment [<xref rid=""B9-life-14-01309"" ref-type=""bibr"">9</xref>]. Evidence supporting our findings in patients undergoing CFTR modulator therapy up until now has been contrasting or inconclusive, highlighting only favorable trends in glycemic control in patients with CFRD or impaired glucose intolerance [<xref rid=""B15-life-14-01309"" ref-type=""bibr"">15</xref>,<xref rid=""B16-life-14-01309"" ref-type=""bibr"">16</xref>] or no improvement at all [<xref rid=""B17-life-14-01309""",10_24,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"improvement at all [<xref rid=""B17-life-14-01309"" ref-type=""bibr"">17</xref>]. Volkova et al. suggest that the prevalence of CFRD was lower in patients who received only ivacaftor, therefore underlining the efficacy of the sole use of a single CFTR modulator. This was also noted by Tsabari et al. who examined a cohort that was only administered ivacaftor [<xref rid=""B15-life-14-01309"" ref-type=""bibr"">15</xref>,<xref rid=""B16-life-14-01309"" ref-type=""bibr"">16</xref>]. Our results highlight the innovative",10_25,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"Our results highlight the innovative amelioration in glycemic control while using the triple combined modulator therapy. Many studies have demonstrated ETI’s superiority compared to other modulators for various CF measures such as FEV1, sweat chloride levels, BMI and pulmonary exacerbations [<xref rid=""B18-life-14-01309"" ref-type=""bibr"">18</xref>,<xref rid=""B19-life-14-01309"" ref-type=""bibr"">19</xref>]. Clear glycemic and metabolic outcomes regarding ETI treatment are less studied and yet to be",10_26,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"ETI treatment are less studied and yet to be demonstrated. Scully et al. were among the first to demonstrate the potential improvements in glycemic control following ETI treatment, but chose a study period of 3–11 months for a mixed population (patients with and without CFRD) [<xref rid=""B7-life-14-01309"" ref-type=""bibr"">7</xref>]. These results stand in contrast to those reported by Crow et al. who demonstrated no statistically significant changes in their measures of glycemia and HbA1c, or in basal",10_27,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"their measures of glycemia and HbA1c, or in basal insulin requirements after 6 months of ETI treatment [<xref rid=""B20-life-14-01309"" ref-type=""bibr"">20</xref>]. This stands in contrast to our study in which both HbA1c and insulin requirements were statistically lower after ETI treatment. The physiopathological mechanism behind the amelioration of glycemic control is still unclear and the explanation is likely to be multifactorial, including better intestinal absorption and nutritional status, decreased",10_28,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"absorption and nutritional status, decreased inflammatory state, enhanced beta cell function and improved insulin sensitivity [<xref rid=""B9-life-14-01309"" ref-type=""bibr"">9</xref>]. Compared to the baseline, we observed a reduction in insulin requirement at 3 months and 6 months, but not at 12 months of ETI therapy. Sustained reductions in the total daily insulin doses at 12 months may not have been evident due to the patients’ increased appetite or improved adherence to CFRD treatment, leading to higher",10_29,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"adherence to CFRD treatment, leading to higher insulin doses per kg. No patients discontinued insulin therapy after initiating ETI treatment. More studies are needed to confirm the potentiated effect of ETI treatment in the first few months that could explain the reduction at the beginning of the treatment. HbA1c levels at all three times were significantly lower than at T0. Further studies and longer periods of observation are necessary to better understand this phenomenon. The cohort’s pulmonary function",10_30,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"this phenomenon. The cohort’s pulmonary function improved and all parameters assessing clinical and pulmonary improvements, such as spirometry and number of pulmonary exacerbations and hospitalizations, significantly improved in agreement with previously published studies, as well as nutritional status and BMI [<xref rid=""B21-life-14-01309"" ref-type=""bibr"">21</xref>,<xref rid=""B22-life-14-01309"" ref-type=""bibr"">22</xref>,<xref rid=""B23-life-14-01309"" ref-type=""bibr"">23</xref>,<xref rid=""B24-life-14-01309""",10_31,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"rid=""B24-life-14-01309"" ref-type=""bibr"">24</xref>,<xref rid=""B25-life-14-01309"" ref-type=""bibr"">25</xref>,<xref rid=""B26-life-14-01309"" ref-type=""bibr"">26</xref>]. Because depression and anxiety are frequently diagnosed in patients with CF and associated with a lower quality of life and a lower adherence to airway clearance treatment, we concluded that patients’ mental health status is an important outcome. Indeed, mental health appeared to improve significantly in our patients after beginning ETI",10_32,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"significantly in our patients after beginning ETI treatment according to CFQ-R data, in agreement with other studies [<xref rid=""B27-life-14-01309"" ref-type=""bibr"">27</xref>,<xref rid=""B28-life-14-01309"" ref-type=""bibr"">28</xref>]. We subanalyzed our data based on two different genotypes, F508del with homozygosity and with heterozygosity. Pulmonary function improved constantly and significantly in patients who had F508del with homozygosity, while heterozygous F508del patients showed only a minor",10_33,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"heterozygous F508del patients showed only a minor improvement. These data are likely explained by the fact that patients with heterozygous F508del have a better FEV1 and a smaller margin of improvement in our cohort of patients. The significant increase in BMI our results are in line with other studies in which weight gain appears to be higher in patients with F508del with heterozygosity [<xref rid=""B29-life-14-01309"" ref-type=""bibr"">29</xref>,<xref rid=""B30-life-14-01309"" ref-type=""bibr"">30</xref>]. As",10_34,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">30</xref>]. As for insulin requirements and glycemic control, our results appear contrasting between the two groups, where heterozygous F508del patients did not show any reduction in insulin requirements after one year of treatment, despite a significant reduction in HbA1c values at 6 and 12 months. On the other hand, homozygous F508del patients significantly decreased the amount of insulin required, which was only significant at T<sub>6mo</sub>, accompanied by a smaller decrease in HbA1c",10_35,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"accompanied by a smaller decrease in HbA1c values at T<sub>3mo</sub>. This study has some limitations including its retrospective nature and the lack of visits of some patients at 3–6–12 months post-ETI treatment initiation, as well as the small sample size with only a short follow-up period. In conclusion, our study demonstrated that ETI therapy both significantly improved glycemic control and significantly decreased insulin requirement in a cohort of adult and pediatric patients with CFRD. Further",10_36,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"adult and pediatric patients with CFRD. Further studies with a larger population and a longer follow-up period are needed to better understand the trends in insulin requirements in patients with CFRD on ETI treatment and to appropriately adjust insulin therapy during their follow-up. In future studies, the use of continuous glucose monitoring in our patients affected by CFRD would allow us to consolidate our data.",10_37,One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study,16 10 2024,,Cystic_Fibrosis
"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia <bold>Background:</bold> Cystic fibrosis (CF) is a multisystem disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. We describe the distribution of CFTR mutation profiles in sub-tropical Queensland, Australia, and characterise the phenotypes associated with ‘rare’ CFTR mutation combinations.",11_0,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"with ‘rare’ CFTR mutation combinations. <bold>Methods:</bold> We conducted a retrospective observational study to analyse the CFTR mutation profiles of 322 people with CF (pwCF) under the care of a large adult CF centre in Queensland, Australia. Molecular pathology results were available for all identifiable CFTR mutations. The CFTR2 database was utilised to characterise the less common CFTR mutations to define mutation classes and explore associated phenotypic sequelae. <bold>Results:</bold> In total,",11_1,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"sequelae. <bold>Results:</bold> In total, eighty-seven different genotypes were identified within our CF cohort, with the most abundant mutation being the F508del mutation, 298/322 (92.5%). Thirty-six pwCF with <italic toggle=""yes"">CFTR</italic> mutations are considered to have ‘rare’ CFTR mutations, and eleven with previously undefined phenotypes. For these eleven pwCF, late diagnosis in adulthood was confirmed in 5/11 pwCF (45.5%) with CFTR modulator therapy only initiated in 5/11 (45.5%).",11_2,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"modulator therapy only initiated in 5/11 (45.5%). <bold>Conclusions:</bold> The profile of more common <italic toggle=""yes"">CFTR</italic> genotypes within our cohort of adult pwCF living in Queensland, Australia, generally reflects the global predominance of F508del, G542X, G551D, N1303K, and R117H. The phenotypic heterogeneity of disease seen within the eleven pwCF in our cohort with previously undefined CFTR genotypes highlights that rare mutations can also be associated with severe disease and continue",11_3,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"be associated with severe disease and continue to be at risk of delayed diagnosis. Access to CFTR modulator therapies for this group of pwCF remains limited and should remain a research priority. Cystic fibrosis is a multisystem disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The disease is characterised by suppurative lung disease accompanied by pancreatic insufficiency and a host of other extra-pulmonary clinical manifestations. To date, there are over",11_4,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"clinical manifestations. To date, there are over 2000 different CFTR mutations identified with 719 confirmed to be associated with the development of CF [<xref rid=""B1-jcm-13-06210"" ref-type=""bibr"">1</xref>,<xref rid=""B2-jcm-13-06210"" ref-type=""bibr"">2</xref>]. Comprehensive annotation of 804 of these CFTR mutations (April 2023) is available from the CFTR2 online global database hosted by Johns Hopkins University and supported by the US Cystic Fibrosis Foundation [<xref rid=""B2-jcm-13-06210""",11_5,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"Fibrosis Foundation [<xref rid=""B2-jcm-13-06210"" ref-type=""bibr"">2</xref>]. The introduction of newborn screening for CF has increased the rate of early detection and, coupled with aggressive management strategies for pulmonary infections and optimised nutritional status, has resulted in improved clinical outcomes. Early interventions to reduce the acquisition of complex respiratory pathogens, such as <italic toggle=""yes"">Pseudomonas aeruginosa</italic>, and to slow down or prevent the development of",11_6,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"and to slow down or prevent the development of disease hallmarks, namely bronchiectasis, have become increasingly available. The advent of CFTR modulator therapies dependent on the underlying CFTR mutation profile, together with advances in molecular detection of CFTR gene mutations, has increased the importance of molecular characterisation and the need for a better understanding of the functional outcome of each CFTR mutation. Despite improvements in the ability to identify less common/rare CFTR gene",11_7,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"ability to identify less common/rare CFTR gene mutations, challenges persist around the diagnosis and subsequent management of individuals who present with non-classical CFTR mutation combinations. These individuals may present later in life, sometimes in adulthood because of delayed diagnosis and are often not eligible for current CFTR modulator therapy owing to their rarer mutation combinations [<xref rid=""B3-jcm-13-06210"" ref-type=""bibr"">3</xref>]. The interplay between genotype and phenotype often",11_8,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"interplay between genotype and phenotype often results in a varied clinical presentation, even in people with CF (pwCF) who have ‘classical’ CFTR mutation combinations. However, with certain rarer CFTR mutation combinations, disease manifestations are often atypical and frequently distinct from ‘classical’ disease caused by more common CFTR mutations, such as F508del [<xref rid=""B4-jcm-13-06210"" ref-type=""bibr"">4</xref>]. The contribution of geography and historical migration to the prevalence of less",11_9,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"historical migration to the prevalence of less common/rare CFTR genotypes has not been widely studied. However, historical migration patterns are likely to increase the chances of uncommon combinations of CFTR mutations emerging, particularly with migration from the ‘Old World’ to countries such as Australia. The migration patterns to Australia, therefore, provide the potential for an increase in the prevalence of rarer CFTR genotypes to occur, with the occurrence of clinical phenotypes not previously",11_10,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"occurrence of clinical phenotypes not previously described. In this study, we describe the distribution of CFTR mutation profiles in sub-tropical Queensland, Australia, and characterise the phenotypes associated with ‘rare’ CFTR mutation combinations. Specific focus is given to highlighting the diversity of CFTR mutations and the phenotypic profile of nine unique CFTR mutation combinations not currently described in global databases. We conducted a retrospective observational study to analyse the CFTR",11_11,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"observational study to analyse the CFTR mutation profiles of pwCF managed by the Adult Cystic Fibrosis Centre (ACFC) at The Prince Charles Hospital (TPCH), the largest adult CF centre in Queensland, providing care to 322 pwCF. Diagnoses of CF were made according to the consensus guidelines from the Cystic Fibrosis Foundation [<xref rid=""B5-jcm-13-06210"" ref-type=""bibr"">5</xref>]. Demographic data were collected for all pwCF in the analysis, including CFTR genotype; baseline forced expired volume in one",11_12,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"genotype; baseline forced expired volume in one second (FEV1); sweat chloride (mmol/L); diagnosis of pancreatic insufficiency; diagnosis of CF-related diabetes; diagnosis of CF-related liver disease; HbA1c, bone mineral density (BMD) results; microbiological status; and CFTR modulator prescription. FEV1 was collected as part of spirometry measurements carried out as part of routine clinical care performed on standardised equipment maintained at the ACFC, TCPH. Sweat chloride levels (where available) were",11_13,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
Sweat chloride levels (where available) were checked using the standard method of pilocarpine applied to the skin along with the application of an electrical current to stimulate sweating. Molecular pathology results were available for all identifiable CFTR mutations for the majority of pwCF actively managed by the ACFC. The primary assay utilised was the bi-directional Sanger sequencing of PCR-amplified genomic DNA designed to screen the entire CFTR coding region (exons 1 to 27 plus intron 22 regions,11_14,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"region (exons 1 to 27 plus intron 22 regions 11990–12444). PwCF with alleles not currently identified despite CFTR sequencing were excluded from the analysis. The diagnosis of CF had been made previously in most individuals, usually during Paediatric care or at the time of initial referral to the adult service. A very small number of pwCF was identified in adulthood by clinicians in the ACFC when conducting general respiratory clinics. The CFTR2 database was utilised to further explore the less common CFTR",11_15,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"utilised to further explore the less common CFTR mutations to define mutation classes and the associated phenotypic sequelae. Ethical approval for the study was obtained from the Metro North Health Human Research Ethics Committee (HREC/2022/MNHB/85439).  The profile of more common CFTR genotypes within our cohort of adult pwCF living in Queensland, Australia, generally reflects the global predominance of F508del, G542X, G551D, N1303K, and R117H [<xref rid=""B28-jcm-13-06210"" ref-type=""bibr"">28</xref>].",11_16,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">28</xref>]. These predominant mutations have their geographic origins in Western and Southern Europe and are consistent with the countries of origin of migration patterns to Australia since 1788 when the first European colonisation of Australia occurred. The initial waves of European migrants were predominantly formed of people of Dutch, Irish, Scottish and English heritage. Subsequent migration remained largely limited to countries from Europe owing to the Naturalisation Act of 1903 right",11_17,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"owing to the Naturalisation Act of 1903 right up until its abolition in 1966. In more recent times, Australia has seen increasing numbers of people migrating from wider global origins, such as Eastern Europe, Southeast Asia, and New Zealand, with smaller contributions from North America and Africa. This, combined with an Aboriginal population that inhabited Australia prior to early European settlement, has potentially added to the diversity of the CFTR mutation pool in our current cohort.  In our cohort,",11_18,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"pool in our current cohort.  In our cohort, thirty-six pwCF were identified as having rare mutations (as defined by <50 pwCF recognised globally in the CFTR2 database). Of these pwCF, eleven had CFTR mutation profiles with associated phenotypes not previously described in the literature or defined by the CFTR2 database. There is a significant degree of heterogeneity in the phenotypes exhibited by these mutation combinations, with the role of environmental or other genetic modifiers impact evidenced by the",11_19,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"other genetic modifiers impact evidenced by the significant phenotypic variability noted in two sibling pairs of pwCF with identical genotypes.  In addition to the wide variability in disease phenotype in those pwCF with rare mutations, there was also significant variability in sweat chloride results, although all were below <60 mmol/L, the level above which CF would traditionally be considered. Whilst already well established, this serves as a timely reminder that sweat chloride alone should not be relied",11_20,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"that sweat chloride alone should not be relied upon to diagnose CF, but rather should be used in correlation with genetic screening, clinical assessment and multidisciplinary team assessment, especially in the setting of rare CFTR genotypes. Furthermore, one of the pwCF with a genotype not considered to be disease causing, F508del/I148T, recorded a sweat chloride level of 110 mmol/L highlighting the variability in reliability, and the disconnect that may occur, between sweat chloride results and both CF",11_21,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"occur, between sweat chloride results and both CF genotype and phenotype. Rare CF genotypes are often thought to be reflected by milder phenotypes, a feature felt to occasionally contribute to diagnosis in adulthood. However, the overall phenotypic profile for the eleven pwCF in our cohort with previously undefined CFTR mutation combinations overall exhibited reasonably severe disease with FEV<sub>1</sub> (% predicted) values ranging between 35.4 and 104.4%. Additionally, extra-pulmonary manifestations of",11_22,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"Additionally, extra-pulmonary manifestations of CF were relatively high with pancreatic insufficiency in nearly all individuals (81.8%), CFRD present in approximately a quarter (27.2%) and osteoporosis/osteopenia apparent in just over half (54.5%). Interestingly, liver disease was present in only one pwCF and this was mild with ultrasound changes consistent with hepatic steatosis. Lung microbiology was also consistent with classical CF-related bacterial pathogens, such as <italic toggle=""yes"">P.",11_23,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"pathogens, such as <italic toggle=""yes"">P. aeruginosa</italic> and <italic toggle=""yes"">S. aureus</italic>, present in most individuals, although <italic toggle=""yes"">Aspergillus fumigatus</italic> was only isolated in the two related pwCF with the F508del/V1108L genotype. The other challenge that will be a universal one in CF centres is how to manage pwCF with rarer CFTR genotypes who are currently not eligible for CFTR modulator therapy based on their mutation profile [<xref rid=""B29-jcm-13-06210""",11_24,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"mutation profile [<xref rid=""B29-jcm-13-06210"" ref-type=""bibr"">29</xref>]. Clinical trials did not recruit pwCF with rare mutations unless they were compound heterozygotes for a F508del mutation and, even then, some individuals would not have been eligible because their allelic mutation may not have been characterised as a minimal function, gating or residual function mutation. Anecdotally, we have observed clinical benefits in pwCF commenced on ETI who have an F508del paired with a rare or ‘non-disease",11_25,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"an F508del paired with a rare or ‘non-disease causing’ CFTR mutation but whether pwCF with a combination of rare CFTR mutations would respond is not currently known. Certainly, within our eleven pwCF with rare CFTR mutations, only two had an F508del genotype combination eligible for ETI under the current PBS criteria in Australia, with just over half exhibiting genotypes not suitable for any currently available CFTR modulator therapy (54.5%). Finally, it is worth considering the three pwCF within our",11_26,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"it is worth considering the three pwCF within our cohort with mutation combinations determined to be ‘non-disease causing’ by the CFTR2 database. The combination of F508del/I148T has been determined to potentially exhibit a disease phenotype with mild symptoms in selected organs and/or be associated with the diagnosis of a ‘CFTR-related disorder’. However, it is not expected to result in symptoms and features that fulfil the diagnostic criteria for CF. Similarly, the F508del/M470V genotype is again not",11_27,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"the F508del/M470V genotype is again not considered disease causing. The M470V variant is very common within the general population, with approximately 50% of people possessing this variant. Individuals who are homozygous for the M470V CFTR variant do not appear to have a CF phenotype. The I1027T is a complex allele and would usually be determined not to cause disease, even when combined with a disease-causing mutation. However, all three of these pwCF exhibited clinical phenotypes in keeping with CF,",11_28,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"exhibited clinical phenotypes in keeping with CF, including one abnormal sweat chloride test. These observations reinforce the importance of considering phenotypic characterisation in the diagnosis of CF as well as all the other aspects, such as genotype and sweat chloride results, rather than excluding the diagnosis based on any one specific aspect in isolation. It is also worth noting alternative methods of diagnosis that could be implemented for such pwCF with either inconclusive sweat chloride levels",11_29,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"with either inconclusive sweat chloride levels or CFTR genetic testing results. Diagnostic tests, including nasal potential difference, which are used to measure the voltage across the nasal epithelium as a surrogate for CFTR function, and intestinal current measurements utilising rectal biopsies to carry out ex vivo testing in a Ussing chamber for electrical responses to various secretagogues, may be considered [<xref rid=""B30-jcm-13-06210"" ref-type=""bibr"">30</xref>,<xref rid=""B31-jcm-13-06210""",11_30,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"rid=""B31-jcm-13-06210"" ref-type=""bibr"">31</xref>]. Neither of these testing modalities was carried out for any pwCF in our cohort. The phenotypic heterogeneity of disease seen within the eleven pwCF in our cohort with previously undefined CFTR genotypes highlights that rare mutations can also be associated with severe disease, irrespective of whether they are diagnosed late. These mutation combinations remain a prominent focus of ongoing research, specifically from a CFTR modulator perspective, given the",11_31,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"from a CFTR modulator perspective, given the relative paucity of currently available treatment options. This is true for the eleven pwCF in our cohort with only two pwCF being suitable for the CFTR modulator therapy, ETI. The importance of thorough evaluation of clinical phenotype when making a diagnosis is reflected well in our cohort, especially taking into consideration the lack of diagnostic sweat chloride levels in all but one of the pwCF analysed. Whilst the diagnosis of CF can often be challenging,",11_32,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
"the diagnosis of CF can often be challenging, improvements in diagnostics, including CFTR gene sequencing methodologies [<xref rid=""B32-jcm-13-06210"" ref-type=""bibr"">32</xref>], should aid with earlier detection and thereby earlier implementation of directed therapies, albeit with the caveat that ongoing work around new therapeutic options for this group of pwCF should remain a research priority.",11_33,"Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia",18 10 2024,,Cystic_Fibrosis
Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis The measurement of cytokines in induced sputum and nasal lavage (NL) samples has been performed for years in people with cystic fibrosis (CF). The aim of this study was to directly compare sputum and NL samples and interpret results based on disease severity in patients who were categorized as having mild or severe lung disease. The categorization was based primarily on structural abnormalities detected on,12_0,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"primarily on structural abnormalities detected on lung computed tomography and secondarily on lung function. The serum inflammatory markers neutrophil elastase (NE), IL-1β, 2, 6, 8, 10 and 17a were measured in each sputum and NL sample. Thirty-two sample pairs from 29 patients were included in this study (13 mild, 19 severe). In the patients classified as severe, many systemic inflammatory markers as well as sputum cytokines were significantly higher compared to those in the mild patients. However, all the",12_1,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"to those in the mild patients. However, all the markers measured in the NL were higher in the mild patients (<italic toggle=""yes"">p</italic> =< 0.05 for NE, IL-6 and IL-8). In addition, many cytokines in the NL correlated negatively with those in the sputum samples. Major differences in the cytokine levels were shown although the samples were obtained at the same time in the same patient. Advanced structural lung disease was closely related to systemic and lower airway inflammation, whereas preserved lung",12_2,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"lower airway inflammation, whereas preserved lung function was associated with higher levels in the NL. We hypothesize that the main part of the immune response takes place in the nasal mucosa in patients with minor pulmonary changes. Our results suggest that inflammation must be interpreted individually depending on the compartment in which it is measured. Further research is needed to accurately understand inflammatory markers measured in NL. Cystic fibrosis (CF) is a genetic disease caused by a loss of",12_3,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"(CF) is a genetic disease caused by a loss of function of the CF transmembrane conductance regulator (CFTR) protein that transports chloride and bicarbonate. Hallmarks of the disease include a progressive inflammatory response and repeated infections [<xref rid=""B1-ijms-25-11081"" ref-type=""bibr"">1</xref>]. The frequent monitoring of bronchopulmonary pathogens and correspondingly starting antibiotic therapy early has resulted in good infection control whereas the detection of inflammatory processes has",12_4,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"the detection of inflammatory processes has proven to be more difficult [<xref rid=""B2-ijms-25-11081"" ref-type=""bibr"">2</xref>]. CF airway inflammation starts early in life, often without clinical signs or the concurrent presence of pathogens. Cumulative evidence suggests that mucus plugs can be an important predisposing factor for inflammatory processes and may start the vicious cycle of inflammation, infection and bronchiectasis that characterizes the disease [<xref rid=""B2-ijms-25-11081""",12_5,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"the disease [<xref rid=""B2-ijms-25-11081"" ref-type=""bibr"">2</xref>]. Inflammation is dominated by neutrophils, which gain a pathological phenotype, causing the exocytosis of granules, the loss of phagocytic abilities and delayed apoptosis [<xref rid=""B3-ijms-25-11081"" ref-type=""bibr"">3</xref>]. Neutrophil elastase (NE) is one of the enzymes released excessively by granules and therefore plays an important role in CF airway inflammation [<xref rid=""B3-ijms-25-11081"" ref-type=""bibr"">3</xref>]. NE has been",12_6,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">3</xref>]. NE has been shown to be one of the few markers that correlate with long-term outcomes in paediatric patients [<xref rid=""B4-ijms-25-11081"" ref-type=""bibr"">4</xref>,<xref rid=""B5-ijms-25-11081"" ref-type=""bibr"">5</xref>,<xref rid=""B6-ijms-25-11081"" ref-type=""bibr"">6</xref>]. Due to the pathological function of neutrophils, they undergo necrosis rather than apoptosis, releasing intracellular substances such as interleukins (IL) [<xref rid=""B7-ijms-25-11081""",12_7,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"interleukins (IL) [<xref rid=""B7-ijms-25-11081"" ref-type=""bibr"">7</xref>]. A number of cytokines have been identified in the CF airways, such as IL-1β, IL-2, IL-6, IL-8 and IL-17a as the most investigated [<xref rid=""B8-ijms-25-11081"" ref-type=""bibr"">8</xref>,<xref rid=""B9-ijms-25-11081"" ref-type=""bibr"">9</xref>]. Much research has been carried out to analyze the relationship of inflammatory markers in people with CF and healthy controls. Specifically, IL-8, tumour necrosis factor α (TNFα) and NE were",12_8,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"IL-8, tumour necrosis factor α (TNFα) and NE were among the most frequently investigated, showing significantly higher amounts in CF patients compared to healthy controls [<xref rid=""B10-ijms-25-11081"" ref-type=""bibr"">10</xref>,<xref rid=""B11-ijms-25-11081"" ref-type=""bibr"">11</xref>]. Finding markers that correlate with clinical outcome parameters has been challenging as many studies provide conflicting results [<xref rid=""B8-ijms-25-11081"" ref-type=""bibr"">8</xref>]. Correlations between biomarkers and",12_9,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"Correlations between biomarkers and airway pathogens showed that chronic airway <italic toggle=""yes"">Pseudomonas aeruginosa</italic> (Pa) load was associated with increased NE and IL-17a and <italic toggle=""yes"">Staphylococcus aureus</italic> was associated with increased IL-1β and vascular endothelial growth factor (VEGF) [<xref rid=""B12-ijms-25-11081"" ref-type=""bibr"">12</xref>]. Despite successful research activity in recent years, progress has been limited not only by the complexity of the pathological",12_10,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"not only by the complexity of the pathological CF immune system but also by the problem of finding suitable sample materials. Inflammatory markers can be measured systemically in the serum or locally by means of sputum, bronchoalveolar lavage (BAL) or nasal lavage (NL) samples. Due to highly effective modulator therapies, such as ELX/TEZ/IVA, patients with CF tend to produce less sputum. Alternative sample materials are therefore the subject of active research and NL has been used successfully in several",12_11,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"and NL has been used successfully in several publications [<xref rid=""B13-ijms-25-11081"" ref-type=""bibr"">13</xref>,<xref rid=""B14-ijms-25-11081"" ref-type=""bibr"">14</xref>,<xref rid=""B15-ijms-25-11081"" ref-type=""bibr"">15</xref>,<xref rid=""B16-ijms-25-11081"" ref-type=""bibr"">16</xref>]. However, there are few published studies that focus on the comparison and interpretation of markers measured in various sample materials [<xref rid=""B13-ijms-25-11081"" ref-type=""bibr"">13</xref>,<xref rid=""B17-ijms-25-11081""",12_12,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"rid=""B17-ijms-25-11081"" ref-type=""bibr"">17</xref>,<xref rid=""B18-ijms-25-11081"" ref-type=""bibr"">18</xref>]. Even less studies focus on differences according to the clinical state and disease severity. We therefore aimed to compare systemic and local inflammatory markers measured on the same day in the same patient. The results were interpreted based on the disease severity as the patients were categorized as mild or severe.  This study demonstrated significant results regarding inflammatory markers",12_13,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"results regarding inflammatory markers measured in different body compartments in patients with different disease severity. Systemic inflammatory markers such as IgG including subclasses 1 and 2 were significantly higher in the patients with severe lung disease in our cohort (<xref rid=""ijms-25-11081-f001"" ref-type=""fig"">Figure 1</xref>a–d). IgG is one of the first biomarkers ever studied and high values of it were already connected to severe lung disease several decades ago [<xref rid=""B20-ijms-25-11081""",12_14,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"decades ago [<xref rid=""B20-ijms-25-11081"" ref-type=""bibr"">20</xref>]. More recent investigations in paediatric cohorts have confirmed that despite novel treatment standards, high IgG correlated with worse FEV<sub>1</sub> [<xref rid=""B21-ijms-25-11081"" ref-type=""bibr"">21</xref>]. These results are consistent with our findings showing that a high total IgG and IgG1 correlated with higher (worse) CT bronchiectasis scores. Also, high IgG3 correlated with a decreased ppFVC. A study by Sagel et al. showed that",12_15,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"ppFVC. A study by Sagel et al. showed that circulating inflammatory markers (IL-6, IL-8 and α1-antitrypsin) predicted treatment response in patients with pulmonary exacerbation [<xref rid=""B22-ijms-25-11081"" ref-type=""bibr"">22</xref>]. This study’s findings, together with our results, show that monitoring systemic inflammatory markers should continue to play an important role in the assessment of inflammatory processes. Due to the early diagnosis and thus the rapid start of CF specific therapy involving",12_16,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"the rapid start of CF specific therapy involving novel CFTR modulators, patients with CF tend to produce less sputum. Since the effect of modulators on inflammation is less clear and long-term data are lacking, the search for alternative sample material is still important and NL has been shown to be a promising predictor reflecting airway inflammation. However, the interpretation of cytokines measured in NL is still difficult and there are few studies that compare them to other sample sources. To address",12_17,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"compare them to other sample sources. To address these issues, we compared the cytokines measured in NL and sputum samples with a focus on disease severity. We showed that local inflammatory markers measured in NL (upper airways) and induced sputum (lower airways) showed significant differences in terms of the severity of lung disease. While many cytokines measured in the sputum were significantly higher in the severe group (IL-1β, IL-2, IL-10, IL-17a; <xref rid=""ijms-25-11081-f002"" ref-type=""fig"">Figure",12_18,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"rid=""ijms-25-11081-f002"" ref-type=""fig"">Figure 2</xref>a–d), the cytokines measured simultaneously in the upper respiratory tract were significantly higher in the mild group (NE, IL-6, IL-8; <xref rid=""ijms-25-11081-f002"" ref-type=""fig"">Figure 2</xref>e–g). Initial studies in the 1990s compared cytokines in NL with BAL in paediatric patients and healthy controls and showed no differences between markers in the NL between the groups, whereas in the BAL, the markers were significantly higher in those with CF",12_19,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"were significantly higher in those with CF [<xref rid=""B17-ijms-25-11081"" ref-type=""bibr"">17</xref>]. Another paediatric study addressed the same question in 2005, showing a significant relationship between IL-8 measured in NL with neutrophils and IL-8 measured in sputum, concluding that nasal IL-8 reflects lower airway inflammation [<xref rid=""B18-ijms-25-11081"" ref-type=""bibr"">18</xref>]. The first comparisons between NL and sputum samples were published in 2014 in a mixed paediatric and adult cohort.",12_20,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"in 2014 in a mixed paediatric and adult cohort. All the markers were higher in the sputum, and significantly so for IL-8 and IL-1β. Significant positive correlations were shown between IL-8 measured in both materials. However, their cohort included patients with both mild and severe lung involvement with a mean FEV<sub>1</sub> of 68% [<xref rid=""B13-ijms-25-11081"" ref-type=""bibr"">13</xref>]. In our study, we could hardly detect any significant positive correlations between the NL and sputum samples for the",12_21,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"between the NL and sputum samples for the same cytokines. Rather, there were many negative correlations in both groups, although not all of them were significant. A closer look at cytokines measured in NL samples revealed much higher values in patients with minor structural lung damage compared to a paediatric cohort during the stable phase in a study by Erdmann et al. [<xref rid=""B14-ijms-25-11081"" ref-type=""bibr"">14</xref>]. The patients in this study showed a similar ppFEV<sub>1</sub> but a higher rate",12_22,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"a similar ppFEV<sub>1</sub> but a higher rate of chronic pulmonary colonisation with Pa (23% vs. 0%) and <italic toggle=""yes"">Staph. aureus</italic> (53% vs. 9%). A proportion of 33.3% of the paediatric patients in this study received nebulized antibiotic treatment, while only 18.2% in our cohort received regular treatment, which may explain the significantly lower cytokine levels compared to our data. Major limitations in our study include the small sample size, single-centre study format and the lack of",12_23,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"size, single-centre study format and the lack of healthy controls. We did not consider an unclear dilution effect of the NL as a relevant limitation, in accordance with the literature. The benefits of using the same method and thus having better comparability of the values to other studies outweighed the risk of potentially altered results. Another relevant limitation of our study is the use of DTT in sputum processing, as it is known to alter cytokine values. However, this effect has mainly been shown for",12_24,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"However, this effect has mainly been shown for TNFα [<xref rid=""B23-ijms-25-11081"" ref-type=""bibr"">23</xref>] and, again, we preferred to use the same methodology to have better comparability to other studies. Significantly more patients assigned to the severe group received a CFTR modulator and nebulized antibiotic therapy, which both represented possible biases for the different cytokine values. Nevertheless, the systemic and sputum cytokines were significantly elevated in this group, making it difficult",12_25,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"elevated in this group, making it difficult to interpret this potential influence. In four patients in the severe group, NE could not be measured in the NL samples because the values were below the detection limit. We decided not to include these values in the statistical analysis, but deliberately mentioned these results to emphasize that the nasal NE was generally low or undetectable in this group.  In this study, we demonstrate that patients with supposedly mild CF lung disease have significantly higher",12_26,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"mild CF lung disease have significantly higher cytokine levels in their upper airways compared to patients with progressed structural lung damage. Interpreting these data in view of preserved lung function with a median FEV<sub>1</sub> of 99%, a median LCI of 6.5 and minimal changes in lung CT scans, we hypothesize that the main part of the immune response takes place in the nasal mucosa in patients with minor pulmonary changes. Long-term observational studies will show the extent to which this immune",12_27,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"studies will show the extent to which this immune response affects clinical outcomes. Despite the mild course of the disease in this group, elevated cytokines should not be hastily interpreted as less relevant since high nasal IL-2 and IL-1β levels were correlated with worse lung function. With our results, we would prefer to emphasize that the nose is the gateway to the respiratory tract and an early diagnosis of inflammation in young patients is still crucial. In the patients with severe lung disease,",12_28,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"In the patients with severe lung disease, higher nasal IL-6 and IL-8 levels were correlated with better lung function and high NE was correlated with better CT scores. In this case, the main inflammatory processes happen in the lower airways, posing the question of whether NL is a suitable sample material to monitor inflammation in this patient collective. In conclusion, this study is one of few that compare inflammatory parameters measured in three compartments (systemic and upper and lower respiratory",12_29,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"(systemic and upper and lower respiratory tracts). We claim that inflammation should be interpreted individually and analyzed according to the disease severity, focusing on different compartments. Further research is needed to accurately understand the inflammatory markers measured in NL.",12_30,Cytokines Measured in Nasal Lavage Compared to Induced Sputum in Patients with Mild Cystic Fibrosis,15 10 2024,,Cystic_Fibrosis
"Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis  Cystic fibrosis (CF) is a life-limiting, autosomal recessive disease that affects >88 000 people globally.<xref rid=""R1"" ref-type=""bibr"">1</xref><xref rid=""R5"" ref-type=""bibr"">5</xref> CF is caused by mutations in the CF transmembrane regulator (<italic toggle=""yes"">CFTR</italic>) gene that result in impaired expression, trafficking or function of the CFTR protein.<xref rid=""R1""",13_0,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"or function of the CFTR protein.<xref rid=""R1"" ref-type=""bibr""><sup>1</sup></xref> This leads to multisystem disease that is characterised by progressive lung damage, pancreatic insufficiency and nutritional deficits that result in impaired growth.<xref rid=""R1"" ref-type=""bibr""><sup>1</sup></xref> Lung disease is the leading cause of death among people with CF, and most die prematurely.<xref rid=""R1"" ref-type=""bibr""><sup>1 2</sup></xref> The median predicted age of survival among people with CF in the US",13_1,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"age of survival among people with CF in the US was 36.8 years in 2011, prior to the advent of CFTR modulators (CFTRm).<xref rid=""R6"" ref-type=""bibr""><sup>6 7</sup></xref> Ivacaftor (IVA) was the first CFTRm designed to address the underlying protein defect by increasing the open probability of CFTR channels,<xref rid=""R8"" ref-type=""bibr""><sup>8</sup></xref> thereby potentiating CFTR function. In 2012, the US Food and Drug Administration (FDA) approved IVA for the treatment of CF in people aged ≥6 years",13_2,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"for the treatment of CF in people aged ≥6 years with ≥1 <italic toggle=""yes"">G551D CFTR</italic>-gating mutation based on phase 3 clinical trials showing that IVA improved lung function over up to 48 weeks.<xref rid=""R7"" ref-type=""bibr""><sup>7 9 10</sup></xref> Approval in the US was expanded in 2014 to include 8 additional <italic toggle=""yes"">CFTR-</italic>gating mutations,<xref rid=""R11"" ref-type=""bibr""><sup>11</sup></xref> and later to include people ≥1 month of age with ≥1 of 97 IVA-responsive",13_3,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"≥1 month of age with ≥1 of 97 IVA-responsive mutations,<xref rid=""R11"" ref-type=""bibr""><sup>11</sup></xref> based on data from additional clinical trials and extrapolation of IVA clinical and safety data from older patients.<xref rid=""R12"" ref-type=""bibr""><sup>12</sup></xref> Real-world studies have shown that IVA results in preserved lung function, improved nutritional status and decreases in pulmonary exacerbation (PEx), hospitalisations, death and organ transplant over periods of up to 5 years.<xref",13_4,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"transplant over periods of up to 5 years.<xref rid=""R13"" ref-type=""bibr"">13</xref><xref rid=""R16"" ref-type=""bibr"">16</xref> With a longer follow-up period of up to 7.9 years, this study builds on the existing literature, using robust analytical methods to assess the long-term effectiveness of IVA by comparing clinical outcomes, overall survival (OS), outpatient visits and hospitalisations between people with CF who have <italic toggle=""yes"">CFTR</italic>-gating mutations and received IVA (ie, IVA-treated",13_5,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"mutations and received IVA (ie, IVA-treated cohort) and a comparator cohort of people who are heterozygous for <italic toggle=""yes"">F508del</italic> and a minimal function mutation and did not receive any CFTRm therapies.  Most (90.4%; 1394/1542) people aged ≥6 years with <italic toggle=""yes"">CFTR</italic>-gating mutations (and without <italic toggle=""yes"">R117H</italic> and RF mutations) in the US CFFPR initiated IVA after 31 January 2012 to 31 December 2018. The IVA-treated and comparator cohorts",13_6,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"2018. The IVA-treated and comparator cohorts included 736 and 2944 people with CF, respectively. SMR weighting reweighted the people in the comparator cohort (N=2944) to be similar to those in the IVA-treated cohort (N=736) at baseline resulting in a sample size of 733 people with CF in the comparator cohort. SMR weighting balanced the distribution of baseline characteristics between cohorts (<xref rid=""SP1"" ref-type=""supplementary-material"">online supplemental table S2</xref>). In both cohorts,",13_7,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"supplemental table S2</xref>). In both cohorts, approximately 48% of people were female and >90% were white. The mean (SD) best-available quarterly ppFEV<sub>1</sub> during the first and second years of the baseline period were 80.6 (24.6) and 80.2 (25.3) percentage points, respectively, in the IVA-treated cohort versus 79.7 (12.3) and 79.3 (12.7) percentage points, respectively, in the comparator cohort. Both cohorts had similar, modest declines in lung function between the first and second years of the",13_8,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"between the first and second years of the baseline period, with mean (SD) changes in ppFEV<sub>1</sub> of −0.9 (8.7) and −1.1 (4.5) percentage points per year for the IVA-treated and comparator cohorts, respectively. The mean (SD) number of PEx during the first and second years of the baseline period were 0.6 (1.1) and 0.6 (1.2), respectively, in the IVA-treated cohort and 0.7 (0.6) and 0.6 (0.6), respectively, in the comparator cohort. The mean (SD) BMI in people ≥20 years of age was 22.9 (3.7)",13_9,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"BMI in people ≥20 years of age was 22.9 (3.7) kg/m<sup>2</sup> in the IVA-treated cohort and 22.7 (1.6) kg/m<sup>2</sup> in the comparator cohort. Select SMR-weighted baseline characteristics of the study population are shown in <xref rid=""T1"" ref-type=""table"">table 1</xref>. Over a maximum follow-up period of 7.9 years (mean follow-up: ≈6 years), the IVA-treated cohort had a significantly lower mortality rate (78% lower) than the comparator cohort (HR (95% CI): 0.22 (0.09 to 0.45); <xref rid=""F1""",13_10,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"(HR (95% CI): 0.22 (0.09 to 0.45); <xref rid=""F1"" ref-type=""fig"">figure 1</xref>). When mortality risk in the two cohorts was compared at 12-month increments over a 5-year follow-up period, the SMR-weighted cumulative risk of mortality was lower in the IVA-treated cohort than in the comparator cohort at all time points, with a risk difference (95% CI) of −1.27% (−2.04% to −0.47%) at 12 months and −3.54% (95% CI −5.15% to −1.89%) at 60 months postindex (<xref rid=""SP1""",13_11,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"−1.89%) at 60 months postindex (<xref rid=""SP1"" ref-type=""supplementary-material"">online supplemental figure S3</xref>). The IVA-treated cohort also had a significantly lower rate of lung transplant than the comparator cohort (89% lower; HR (95% CI): 0.11 (0.02 to 0.28); <xref rid=""F2"" ref-type=""fig"">figure 2</xref>). IVA was associated with a marked improvement in lung function (<xref rid=""F3"" ref-type=""fig"">figure 3</xref>). Over a mean (range) SMR-weighted follow-up duration of 5.6 (0.1–7.9) years in",13_12,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"follow-up duration of 5.6 (0.1–7.9) years in the IVA-treated cohort and 6.0 (0.0–7.9) years in the comparator cohort, the mean ppFEV<sub>1</sub> was >8 points higher in the IVA-treated cohort than in the comparator cohort (mean difference in ppFEV<sub>1</sub> (95% CI): 8.46 (7.34 to 9.75); <xref rid=""SP1"" ref-type=""supplementary-material"">online supplemental table S3</xref>). Notably, the mean difference (95% CI) in ppFEV<sub>1</sub> between cohorts increased over time, from 7.98 (6.71 to 9.34) at 12",13_13,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"over time, from 7.98 (6.71 to 9.34) at 12 months to 10.95 (9.22 to 12.72) at 60 months postindex. Across age groups, the largest mean difference (95% CI) in ppFEV<sub>1</sub> spanning all time points was observed in people aged 12 to <18 years, from 10.19 (7.29 to 12.74) at 12 months to 15.26 (11.48 to 18.69) at 60 months. Over a mean (range) SMR-weighted follow-up duration of 5.3 (0.1–7.9) years for the IVA-treated cohort and 5.8 (0.0–7.9) years for the comparator cohort, people aged ≥20 years in the",13_14,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"comparator cohort, people aged ≥20 years in the IVA-treated cohort had a significantly higher mean BMI than those in the comparator cohort (24.30 vs 22.92 kg/m<sup>2</sup>), with a mean difference (95% CI) of 1.20 (0.92 to 1.71) kg/m<sup>2</sup> (<xref rid=""SP1"" ref-type=""supplementary-material"">online supplemental table S3</xref>). Similarly, for people aged 6–19 years, the IVA-treated cohort had a significantly higher mean BMI <italic toggle=""yes"">z</italic>-score than the comparator cohort (mean",13_15,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"than the comparator cohort (mean difference (95% CI): 0.27 (0.25 to 0.40)) over a mean follow-up duration of ≥6.0 years. The rate of PEx was 51% lower in the IVA-treated than in the comparator cohort (rate ratio (95% CI): 0.49 (0.42 to 0.55); <xref rid=""F4"" ref-type=""fig"">figure 4</xref>). People in the IVA-treated cohort had significantly lower rates of all-cause hospitalisations (rate ratio (95% CI): 0.50 (0.43 to 0.56)) and outpatient clinic visits (rate ratio (95% CI): 0.85 (0.81 to 0.88)) than those",13_16,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"ratio (95% CI): 0.85 (0.81 to 0.88)) than those in the comparator cohort. As advances in care continue to extend life expectancy in CF, it is becoming increasingly important to understand the long-term impact of novel therapies, including CFTRm, on clinical outcomes and survival. IVA, the first CFTRm therapy approved to treat the underlying cause of CF in the US,<xref rid=""R7"" ref-type=""bibr""><sup>7</sup></xref> reached its 10-year approval anniversary in 2022. At the time of its approval, expectations",13_17,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"2022. At the time of its approval, expectations were high that IVA could alter the clinical course of CF in eligible patients, leading to increased survival, improved quality of life and reduced treatment burden.<xref rid=""R23"" ref-type=""bibr""><sup>23</sup></xref> With a maximum of 7.9 years of data on treatment outcomes with IVA, this study represents the longest follow-up of people receiving CFTRm to date. These long-term data provide evidence of the durable benefits of IVA, including decreased mortality",13_18,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"benefits of IVA, including decreased mortality and lung transplant, improvements in pulmonary outcomes and nutritional status, and reductions in hospitalisations and outpatient visits. Over a maximum follow-up period of 7.9 years, the mortality rate was 78% lower in the IVA-treated cohort than in the comparator cohort. People receiving IVA also had a significantly lower rate of lung transplant for up to 7 years after IVA initiation. These reductions in the rates of mortality and lung transplant are in line",13_19,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"of mortality and lung transplant are in line with findings from earlier analyses of US CFFPR data,<xref rid=""R13"" ref-type=""bibr""><sup>13 14 16</sup></xref> including a recent cross-sectional analysis in 2019 that reported that IVA reduced the risks of death and organ transplant by ≈60% and ≈70%, respectively.<xref rid=""R16"" ref-type=""bibr""><sup>16</sup></xref> Long-term use of IVA was associated with improved pulmonary outcomes, with sustained improvements in ppFEV<sub>1</sub> and decreased rate of PEx in",13_20,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"in ppFEV<sub>1</sub> and decreased rate of PEx in the IVA-treated versus comparator cohorts. In people with CF receiving IVA, a higher mean ppFEV<sub>1</sub> relative to that in the comparator cohort was observed over the total follow-up period, with increasing mean differences in ppFEV<sub>1</sub> over time. Taken together with data from clinical trials that demonstrated improvements in ppFEV<sub>1</sub> as early as 15 days after IVA initiation<xref rid=""R9"" ref-type=""bibr""><sup>9 10</sup></xref> and",13_21,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"ref-type=""bibr""><sup>9 10</sup></xref> and prior analyses of real-world data showing that improvements in ppFEV<sub>1</sub> were sustained over 3–5 years of IVA treatment,<xref rid=""R13"" ref-type=""bibr""><sup>13 14</sup></xref> these data suggest that IVA leads to better lung function that is sustained with long-term use (up to 7.9 years). Additionally, although higher mean ppFEV<sub>1</sub> values were observed between the IVA-treated versus comparator cohorts across all age groups evaluated in this study,",13_22,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"across all age groups evaluated in this study, the largest improvement in ppFEV<sub>1</sub> was observed in people aged 12 to <18 years at IVA initiation, highlighting the importance of treatment during adolescence, a period characterised by rapid lung function decline.<xref rid=""R24"" ref-type=""bibr""><sup>24 25</sup></xref> In people who received IVA, the rate of PEx was less than half of that in the comparator cohort. While no differences in the number of PEx were observed between the IVA and placebo",13_23,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"of PEx were observed between the IVA and placebo groups in the pivotal clinical trial evaluating people with CF aged 6–11 years (3 vs 4 PEx events, respectively),<xref rid=""R10"" ref-type=""bibr""><sup>10</sup></xref> IVA reduced the risk of PEx by 55% at 48 weeks in a clinical trial evaluating those aged ≥12 years,<xref rid=""R9"" ref-type=""bibr""><sup>9</sup></xref> consistent with the reduction in PEx observed in this study. Similarly, in real-world studies, reductions in the occurrence of PEx have been",13_24,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"reductions in the occurrence of PEx have been demonstrated over 1–5 years of IVA treatment.<xref rid=""R13"" ref-type=""bibr""><sup>13 14</sup></xref> Altogether these findings support that IVA leads to reductions in the rate of PEx that are maintained for up to 7.9 years. Because PEx is associated with increased risk of mortality, lung transplant and lung function decline,<xref rid=""R26"" ref-type=""bibr"">26</xref><xref rid=""R29"" ref-type=""bibr"">29</xref> the sustained reductions in PEx with long-term IVA",13_25,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"sustained reductions in PEx with long-term IVA treatment may contribute to the reductions in mortality and lung transplant and the improvements in lung function observed concurrently in this study. In addition to improving lung function and reducing the rates of mortality and lung transplant, long-term IVA led to improvements in nutritional status, with significantly higher mean BMI and BMI <italic toggle=""yes"">z</italic>-score in the IVA-treated cohort than in the comparator cohort. This is consistent",13_26,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"than in the comparator cohort. This is consistent with the shorter-term improvements in BMI and BMI <italic toggle=""yes"">z</italic>-score demonstrated in clinical trials<xref rid=""R10"" ref-type=""bibr""><sup>10 12</sup></xref> and in previous real-world studies with short-term and long-term follow-up data.<xref rid=""R14"" ref-type=""bibr""><sup>14 15</sup></xref> Because higher BMI has been linked to better lung function in CF,<xref rid=""R30"" ref-type=""bibr""><sup>30</sup></xref> the sustained improvements in",13_27,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"the sustained improvements in BMI observed here provide further evidence for the overall long-term health benefits of IVA. The improvements in lung function and nutritional status with long-term IVA were accompanied by a reduction in healthcare burden in this study. The rate of all-cause hospitalisations was reduced by half, and there were fewer outpatient clinic visits in the IVA-treated cohort than in the comparator cohort. This is consistent with previous real-world analyses, which reported decreases in",13_28,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"real-world analyses, which reported decreases in the rate of hospitalisations as early as 6 months and up to 5 years after IVA initiation<xref rid=""R14"" ref-type=""bibr"">1431</xref><xref rid=""R33"" ref-type=""bibr"">33</xref> and a decrease in outpatient clinic visits in the year after IVA initiation.<xref rid=""R33"" ref-type=""bibr""><sup>33</sup></xref> These findings suggest that IVA reduces disease burden in people with CF, as evidenced by a reduction in hospitalisations and outpatient visits, a benefit that",13_29,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"and outpatient visits, a benefit that was sustained with long-term treatment. As the first drug to treat the underlying cause of CF, IVA represents a major change to the treatment landscape. Consistent with previous evidence<xref rid=""R14"" ref-type=""bibr""><sup>14 15 34</sup></xref> but over a longer follow-up, this study shows that IVA improves survival, preserves lung function, improves nutritional status, and reduces PEx and hospitalisations. More people with CF may be able to gain similar therapeutic",13_30,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"with CF may be able to gain similar therapeutic benefits given the development and approval of elexacaftor/tezacaftor/IVA (ELX/TEZ/IVA)—a CFTRm therapy that combines IVA with the CFTR correctors TEZ and ELX—which expanded the eligibility for CFTRm to include ≈90% of people with CF in the US.<xref rid=""R35"" ref-type=""bibr""><sup>35</sup></xref> Although studies examining the long-term effectiveness of ELX/TEZ/IVA are ongoing, similarities in mechanism of action and shorter-term efficacy observed between IVA",13_31,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"and shorter-term efficacy observed between IVA and ELX/TEZ/IVA in their indicated populations, suggest that similar long-term outcomes may be predicted with ELX/TEZ/IVA. The US CFFPR includes data from an estimated 81% to 84% of people with CF in the US;<xref rid=""R17"" ref-type=""bibr""><sup>17</sup></xref> as such, this study offers a comprehensive view of the clinical profile and health outcomes of people with CF in the US. Importantly, we selected a comparator population that was phenotypically similar to",13_32,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"population that was phenotypically similar to the IVA-treated cohort and used robust methodology to enhance comparability between the cohorts, including SMR weighting based on propensity scores, which allowed for estimating the average treatment effect in the IVA-treated cohort and maximised sample size and power. However, this study had limitations that warrant consideration. First, since this was an observational study, it was only possible to control for measured covariates; this may have resulted in",13_33,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"measured covariates; this may have resulted in residual confounding despite the use of exact matching by age at index date and SMR weighting to minimise differences between groups in measured prognostic factors. A lack of standardised assessments and regular clinic visits for some people in the US CFFPR are also limitations of the data. Second, the results of this study may not be generalisable to all people with a <italic toggle=""yes"">CFTR</italic>-gating mutation in the CFFPR as people with a <italic",13_34,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"mutation in the CFFPR as people with a <italic toggle=""yes"">CFTR</italic>-gating mutation who did not initiate IVA during the study period and were not included in this study may be different from people in the IVA-treated cohort. Third, while we aimed to select a comparator population that was phenotypically similar to the IVA-treated cohort in the CFFPR, mutation classes include phenotypic variation and other differences may exist between people with a <italic toggle=""yes"">CFTR</italic>-gating mutation",13_35,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"toggle=""yes"">CFTR</italic>-gating mutation and people with <italic toggle=""yes"">F508del</italic>/minimal function <italic toggle=""yes"">CFTR</italic> mutations. While these differences may have impacted the results, we minimised this by adjusting for demographic and clinical differences at baseline between cohorts using SMR weighting. Additionally, our analysis may have been subject to some degree of bias from informative censoring, which could have occurred if the patients who discontinued IVA (and were",13_36,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"if the patients who discontinued IVA (and were censored from the study) were different from the patients who continued receiving IVA in terms of disease severity, clinical outcomes or mortality. Finally, because ELX/TEZ/IVA was initially approved by the US FDA for the treatment of CF in October 2019 and a large proportion of people in the IVA-treated and comparator cohorts were expected to initiate ELX/TEZ/IVA thereafter, we limited our analysis to data collected through the end of 2019 to mitigate the",13_37,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"collected through the end of 2019 to mitigate the impact of ELX/TEZ/IVA eligibility on cohort attrition. This real-world study using US CFFPR data over 7.9 years of follow-up shows that people receiving IVA have lower rates of mortality and lung transplant, improvements in lung function and nutritional status, and reductions in PEx, outpatient visits, and hospitalisations compared with phenotypically similar CFTRm-untreated people with CF. These findings add to the body of real-world evidence demonstrating",13_38,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"to the body of real-world evidence demonstrating that IVA results in sustained and durable benefits in people with CF, including slowing disease progression and decreasing the associated healthcare burden.",13_39,Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis,6 2024,,Cystic_Fibrosis
"Are school settings restricting access to daily physical activity for children with cystic fibrosis? Parents’ perspectives and recommendations for practice Cystic Fibrosis (CF) is an inherited, life-limiting disease caused by a fault in the Cystic Fibrosis Transmembrane Conductor (CFTR) gene that affects the movement of salt and water in and out of the body’s cells (Roda et al., <xref rid=""cit0031"" ref-type=""bibr"">2022</xref>). This dysfunction results in a build-up of thick sticky mucus which disrupts",14_0,Are school settings restricting access to daily physical activity for children with cystic fibrosis? Parents’ perspectives and recommendations for practice,22 10 2024,,Cystic_Fibrosis
"a build-up of thick sticky mucus which disrupts airway clearance leading to bacterial colonization and lung damage (Roda et al., <xref rid=""cit0031"" ref-type=""bibr"">2022</xref>). CF can also affect other organs in the body including, but not limited to, the pancreas and liver. There are currently over 90,000 people worldwide (Roda et al., <xref rid=""cit0031"" ref-type=""bibr"">2022</xref>) and 10,908 people in the UK living with CF (Cystic Fibrosis Trust, <xref rid=""cit0010"" ref-type=""bibr"">2023</xref>), and",14_1,Are school settings restricting access to daily physical activity for children with cystic fibrosis? Parents’ perspectives and recommendations for practice,22 10 2024,,Cystic_Fibrosis
"rid=""cit0010"" ref-type=""bibr"">2023</xref>), and despite there being advances in treatment such as modulator therapies, the disease continues to limit survival, impacts upon quality of life and results in a huge burden of daily care for people with CF and their families (Bell et al., <xref rid=""cit0003"" ref-type=""bibr"">2020</xref>). The median predicted survival age for people born today with CF in the UK is 53.3 years. This means that half of this population is predicted to die before they reach this age.",14_2,Are school settings restricting access to daily physical activity for children with cystic fibrosis? Parents’ perspectives and recommendations for practice,22 10 2024,,Cystic_Fibrosis
"is predicted to die before they reach this age. The majority (61.7%) of CF deaths in the UK in 2021 were respiratory related (Cystic Fibrosis Trust, <xref rid=""cit0010"" ref-type=""bibr"">2023</xref>). Therefore, one of the main aims of CF care is to preserve lung function and to utilize multidisciplinary teams to assist with this including consultants, nurses, physiotherapists, dietitians and psychologists (Cystic Fibrosis Trust, <xref rid=""cit0010"" ref-type=""bibr"">2023</xref>). Daily physiotherapy for",14_3,Are school settings restricting access to daily physical activity for children with cystic fibrosis? Parents’ perspectives and recommendations for practice,22 10 2024,,Cystic_Fibrosis
"Daily physiotherapy for children with CF helps to clear the thick mucus from their lungs. A range of techniques are often used including active breathing cycles, pep devices and physical activity (PA) (Cystic Fibrosis Trust, <xref rid=""cit0010"" ref-type=""bibr"">2023</xref>). A systematic review (Puppo et al., <xref rid=""cit0030"" ref-type=""bibr"">2020</xref>) of PA in children with CF highlights PA as an important part of care, as engaging in high levels of PA is associated with improved airway clearance, an",14_4,Are school settings restricting access to daily physical activity for children with cystic fibrosis? Parents’ perspectives and recommendations for practice,22 10 2024,,Cystic_Fibrosis
"is associated with improved airway clearance, an increase in lung function and improvements in bone density, along with high engagement levels of PA being positively associated with better health-related quality of life. PA is defined as “any bodily movement produced by skeletal muscles” (Caspersen et al., <xref rid=""cit0006"" ref-type=""bibr"">1985</xref>), and the World Health Organization (Bull et al., <xref rid=""cit0005"" ref-type=""bibr"">2020</xref>) recommends that school-aged children should participate",14_5,Are school settings restricting access to daily physical activity for children with cystic fibrosis? Parents’ perspectives and recommendations for practice,22 10 2024,,Cystic_Fibrosis
"that school-aged children should participate in at least 60 min of moderate-to-vigorous PA (MVPA) daily. For children with CF, these PA guidelines are applicable and important (Southern et al., <xref rid=""cit0035"" ref-type=""bibr"">2024</xref>). The recently updated European Cystic Fibrosis Society (ECFS) standards for care of people with CF (Southern et al., <xref rid=""cit0035"" ref-type=""bibr"">2024</xref>), reinforce the importance of physical activity to facilitate mucociliary clearance. It also highlights",14_6,Are school settings restricting access to daily physical activity for children with cystic fibrosis? Parents’ perspectives and recommendations for practice,22 10 2024,,Cystic_Fibrosis
"mucociliary clearance. It also highlights that a personal approach should be taken, however people with CF should aim to maximize their PA. Further, the UK government’s statutory guidance on supporting pupils at school with medical conditions states that children with medical conditions should be properly supported at school (Department for Education, <xref rid=""cit0015"" ref-type=""bibr"">2014b</xref>). However, there is currently limited guidance for schools on the promotion of PA for children with CF, and",14_7,Are school settings restricting access to daily physical activity for children with cystic fibrosis? Parents’ perspectives and recommendations for practice,22 10 2024,,Cystic_Fibrosis
"on the promotion of PA for children with CF, and they can often fall into the “protected child syndrome” in which they are more likely to be encouraged to be sedentary than engage in PA (Thornton, <xref rid=""cit0036"" ref-type=""bibr"">1997</xref>); which could be further detrimental to the health of children with CF. Considering the time children spend at school in England (32.5 h a week) (Length of the school week: non statutory guidance [Internet], Department for Education (DfE) <xref rid=""cit0016""",14_8,Are school settings restricting access to daily physical activity for children with cystic fibrosis? Parents’ perspectives and recommendations for practice,22 10 2024,,Cystic_Fibrosis
"for Education (DfE) <xref rid=""cit0016"" ref-type=""bibr"">2023</xref>) and the daily treatment needed in the care of children with CF, the school environment provides a key opportunity for children to engage in PA as part of their daily CF care. Additionally, one of the key messages from the Lancet’s Respiratory Medicine Commission on the future of CF care outlines that we need to consider management approaches that help to maintain health whilst also minimizing the burden of care for patients and their",14_9,Are school settings restricting access to daily physical activity for children with cystic fibrosis? Parents’ perspectives and recommendations for practice,22 10 2024,,Cystic_Fibrosis
"the burden of care for patients and their families (Bell et al., <xref rid=""cit0003"" ref-type=""bibr"">2020</xref>). Therefore, the school environment could create an opportunity to contribute to the daily healthcare needs of children with CF whilst also reducing some of the burden from families, especially since the UK government recommends that all children should accumulate at least 30 min of daily PA in the school setting (HM Government, <xref rid=""cit0021"" ref-type=""bibr"">2017</xref>). Although there is",14_10,Are school settings restricting access to daily physical activity for children with cystic fibrosis? Parents’ perspectives and recommendations for practice,22 10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">2017</xref>). Although there is limited research into the school-based PA of children with CF, one recent study advises that teachers could incorporate PA into the daily routines of children with CF to improve their health outcomes (Valencia-Peris et al., <xref rid=""cit0037"" ref-type=""bibr"">2021</xref>). Furthermore, research still suggests levels of PA during school hours for all children are not enough and schools should develop strategies to help children engage in more PA in the school",14_11,Are school settings restricting access to daily physical activity for children with cystic fibrosis? Parents’ perspectives and recommendations for practice,22 10 2024,,Cystic_Fibrosis
"to help children engage in more PA in the school setting (Grao-Cruces et al., <xref rid=""cit0019"" ref-type=""bibr"">2020</xref>). This suggests that schools could offer PA opportunities for children with CF in an inclusive way by targeting all children. It is therefore important to gain parental perspectives on this, as they are the ones who manage the daily care routine for their children with CF and considering their experiences will be essential in what they consider safe, ethical and effective use of PA",14_12,Are school settings restricting access to daily physical activity for children with cystic fibrosis? Parents’ perspectives and recommendations for practice,22 10 2024,,Cystic_Fibrosis
"consider safe, ethical and effective use of PA in the daily maintenance of their child’s CF. To the authors’ knowledge, this is the first study to investigate parental views of PA levels during the school day for children with CF. Therefore, the overall aim of this study is to explore parents’ perceptions of school-based PA for their children with CF.  All the themes outlined below in <xref rid=""t0001"" ref-type=""table"">Table I</xref> are a representation of the Group Experiential Themes<table-wrap",14_13,Are school settings restricting access to daily physical activity for children with cystic fibrosis? Parents’ perspectives and recommendations for practice,22 10 2024,,Cystic_Fibrosis
"of the Group Experiential Themes<table-wrap position=""float"" id=""t0001""><label>Table I.</label><caption><p>Representation of group experiential themes.</p></caption><table frame=""hsides"" rules=""groups""><colgroup><col width=""1*"" align=""left""></col><col width=""1*"" align=""left""></col><col width=""1*"" align=""left""></col><col width=""1*"" align=""left""></col><col width=""1*"" align=""left""></col></colgroup><thead><tr><th align=""left"">First order themes</th><th align=""center"">Importance of PA at school for children",14_14,Are school settings restricting access to daily physical activity for children with cystic fibrosis? Parents’ perspectives and recommendations for practice,22 10 2024,,Cystic_Fibrosis
"of PA at school for children with CF</th><th align=""center"">Barriers to school-based PA for children with CF</th><th align=""center"">Facilitators of school-based PA for children with CF</th><th align=""center"">Educate the educators on school-based PA for children with CF</th></tr></thead><tbody><tr><td align=""left"">Sub themes</td><td align=""left"">− Time at school<break></break>− PA part of daily routine<break></break>− Parental pressures/treatment burden</td><td align=""left"">− Teachers’",14_15,Are school settings restricting access to daily physical activity for children with cystic fibrosis? Parents’ perspectives and recommendations for practice,22 10 2024,,Cystic_Fibrosis
"burden</td><td align=""left"">− Teachers’ misconceptions<break></break>− Emotional and -physical barriers<break></break>− PA is not a priority</td><td align=""left"">− Windows of opportunity<break></break>− Seeing is believing<break></break>− School promotes PA for all</td><td align=""left"">− PA should be inclusive and personalized<break></break>− More guidance needed<break></break>− Health Care Plans</td></tr></tbody></table></table-wrap> The purpose of this study was to explore parents’ perceptions of PA",14_16,Are school settings restricting access to daily physical activity for children with cystic fibrosis? Parents’ perspectives and recommendations for practice,22 10 2024,,Cystic_Fibrosis
"study was to explore parents’ perceptions of PA behaviours of their children with CF during the primary school day. The results of this study will be discussed according to the four group experiential themes, identified from the data analysis and in the context of previous studies, theory, and government documents. Finally, a set of recommended guidelines will be provided. The strengths of this study lie in the rich data set of parents of children with CF from across the UK (including, England, Wales and",14_17,Are school settings restricting access to daily physical activity for children with cystic fibrosis? Parents’ perspectives and recommendations for practice,22 10 2024,,Cystic_Fibrosis
"from across the UK (including, England, Wales and Northern Ireland), and the ages of their children ranged from 5 to 10 years. Furthermore, these findings support transferability of the results across the UK. However, a limitation of this study is that, only mothers volunteered to take part, therefore fathers’ experiences have not been considered. Future directions for research would be to collect the experiences and perceptions of CF healthcare providers, teachers and children with CF related to",14_18,Are school settings restricting access to daily physical activity for children with cystic fibrosis? Parents’ perspectives and recommendations for practice,22 10 2024,,Cystic_Fibrosis
"teachers and children with CF related to school-based PA opportunities in maintaining health and reducing the burden of care on families. Overall, the findings of this study evidence that although parents recognized the benefits of school-based PA for their children with CF, systemic barriers in school settings often inhibit its implementation. This aligns with recent health policies aimed at increasing activity levels among children but highlights a gap for specific provisions for children with CF. The",14_19,Are school settings restricting access to daily physical activity for children with cystic fibrosis? Parents’ perspectives and recommendations for practice,22 10 2024,,Cystic_Fibrosis
"for specific provisions for children with CF. The integration of PA into the school setting should be seen as a component of CF care that extends beyond the medical setting and the home environment. This would promote a broader understanding of inclusivity in the school environment, showing that a well-rounded education includes physical health maintenance, particularly for children with CF. Therefore, guidelines have been developed, to inform parents, primary schools and CF healthcare professionals to",14_20,Are school settings restricting access to daily physical activity for children with cystic fibrosis? Parents’ perspectives and recommendations for practice,22 10 2024,,Cystic_Fibrosis
"schools and CF healthcare professionals to help children with CF engage in inclusive daily PA, with the hope of maintaining health-outcomes for children with CF and reducing the burden of care on families.",14_21,Are school settings restricting access to daily physical activity for children with cystic fibrosis? Parents’ perspectives and recommendations for practice,22 10 2024,,Cystic_Fibrosis
"The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa Cystic Fibrosis (CF) airway disease is characterized by impaired mucociliary clearance, chronic, polymicrobial infections and robust, neutrophil-dominated inflammation. Pulmonary disease is the leading cause of morbidity and mortality in people with CF and is due to progressive airflow obstruction and ultimately respiratory failure. One of the earliest abnormalities in CF airway disease is",15_0,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"earliest abnormalities in CF airway disease is the recruitment of neutrophils to the lungs. Neutrophil activation leads to the release of their intracellular content, including neutrophil elastase (NE), that damages lung tissues in CF. Our goal is to characterize a known bacterial NE inhibitor, ecotin, in the CF airway environment. Our results indicate that ecotins cloned from four Gram-negative bacterial species (<italic toggle=""yes"">Campylobacter rectus</italic>, <italic toggle=""yes"">Campylobacter",15_1,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"<italic toggle=""yes"">Campylobacter showae</italic>, <italic toggle=""yes"">Escherichia coli</italic> and <italic toggle=""yes"">Pseudomonas aeruginosa)</italic> inhibit NE activity in CF sputum samples in a dose-dependent manner. Although we observed differences in the NE-inhibitory activity of the tested ecotins with the <italic toggle=""yes"">Campylobacter</italic> homologs being the most effective in NE inhibition in CF sputa, none of the ecotins impaired the ability of human neutrophils to kill major CF",15_2,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"the ability of human neutrophils to kill major CF respiratory pathogens, <italic toggle=""yes"">P. aeruginosa</italic> or <italic toggle=""yes"">S. aureus</italic>, <italic toggle=""yes"">in vitro</italic>. Overall, we demonstrate that bacterial ecotins inhibit NE activity in CF sputa without compromising bacterial killing by neutrophils. Cystic Fibrosis (CF) is a recessive genetic disease affecting about 80,000 people worldwide [<xref rid=""bib1"" ref-type=""bibr"">1</xref>]. Severe lung disease causes the majority",15_3,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"Severe lung disease causes the majority of the morbidity and mortality in people with CF (PwCF). Progression of CF lung disease has been primarily associated with chronic inflammation, partially mediated by neutrophils, and with the persistence of polymicrobial infections [<xref rid=""bib2"" ref-type=""bibr"">2</xref>]. Persistent inflammatory signals in the CF airways cause activation of recruited neutrophils which contributes to lung tissue damage overtime [<xref rid=""bib3"" ref-type=""bibr"">3</xref>].",15_4,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"[<xref rid=""bib3"" ref-type=""bibr"">3</xref>]. Neutrophils contain many antimicrobial proteins and enzymes capable of limiting infections. In general, neutrophils kill and trap microbes in two major ways, via the intracellular mechanism of phagocytosis and the extracellular mechanism of neutrophil extracellular trap (NET) formation [<xref rid=""bib4"" ref-type=""bibr"">[4]</xref>, <xref rid=""bib5"" ref-type=""bibr"">[5]</xref>, <xref rid=""bib6"" ref-type=""bibr"">[6]</xref>]. In CF, neutrophils accumulate in large",15_5,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"In CF, neutrophils accumulate in large numbers in the airways and release their intracellular cargo which has been associated with tissue damage and lung disease progression. Several studies underscore the importance of neutrophils and neutrophil-derived products driving CF airway disease progression. For example, the number of neutrophils and the levels of DNA, myeloperoxidase (MPO), NE, and neutrophil chemoattractants (IL-8, TNF-α, IL-1β) in the sputum all correlate with CF lung disease severity [<xref",15_6,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"correlate with CF lung disease severity [<xref rid=""bib7"" ref-type=""bibr"">[7]</xref>, <xref rid=""bib8"" ref-type=""bibr"">[8]</xref>, <xref rid=""bib9"" ref-type=""bibr"">[9]</xref>, <xref rid=""bib10"" ref-type=""bibr"">[10]</xref>, <xref rid=""bib11"" ref-type=""bibr"">[11]</xref>, <xref rid=""bib12"" ref-type=""bibr"">[12]</xref>, <xref rid=""bib13"" ref-type=""bibr"">[13]</xref>, <xref rid=""bib14"" ref-type=""bibr"">[14]</xref>, <xref rid=""bib15"" ref-type=""bibr"">[15]</xref>, <xref rid=""bib16"" ref-type=""bibr"">[16]</xref>, <xref",15_7,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"rid=""bib16"" ref-type=""bibr"">[16]</xref>, <xref rid=""bib17"" ref-type=""bibr"">[17]</xref>, <xref rid=""bib18"" ref-type=""bibr"">[18]</xref>]. Neutrophil elastase (NE) is a serine protease that is a requisite for the normal antimicrobial function of neutrophils [<xref rid=""bib19"" ref-type=""bibr"">19</xref>]. Extracellular NE degrades interstitial collagen fibers enabling neutrophil cell migration, while intracellular NE kills bacteria within the phagosome [<xref rid=""bib19"" ref-type=""bibr"">19</xref>]. In CF,",15_8,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"rid=""bib19"" ref-type=""bibr"">19</xref>]. In CF, however, NE is released from neutrophils in the airways in large quantities, causes harm by targeting host proteins within the lung tissue, irreversibly damages the airways over time, and is one of the several host components that are thought to drive chronic inflammation and lung disease progression [<xref rid=""bib20"" ref-type=""bibr"">[20]</xref>, <xref rid=""bib21"" ref-type=""bibr"">[21]</xref>, <xref rid=""bib22"" ref-type=""bibr"">[22]</xref>, <xref rid=""bib23""",15_9,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">[22]</xref>, <xref rid=""bib23"" ref-type=""bibr"">[23]</xref>, <xref rid=""bib24"" ref-type=""bibr"">[24]</xref>]. NE is one of the amplest host enzymes found in the CF lung that degrades elastin, fibronectin, and collagen [<xref rid=""bib25"" ref-type=""bibr"">25</xref>]. NE has also been shown to impair other host defenses by injuring bronchial epithelial cells and destroying the lung extracellular matrix [<xref rid=""bib23"" ref-type=""bibr"">23</xref>,<xref rid=""bib26"" ref-type=""bibr"">26</xref>]. The",15_10,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"rid=""bib26"" ref-type=""bibr"">26</xref>]. The chronic release of NE by neutrophils causes airway remodeling contributing to worsened lung damage and function in PwCF [<xref rid=""bib23"" ref-type=""bibr"">23</xref>,<xref rid=""bib27"" ref-type=""bibr"">27</xref>]. NE is elevated in the bronchoalveolar fluid of CF infants and toddlers, and is the best predictor of future bronchieactasis [<xref rid=""bib28"" ref-type=""bibr"">28</xref>,<xref rid=""bib29"" ref-type=""bibr"">29</xref>]. There are only a few clinical studies",15_11,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"There are only a few clinical studies testing NE inhibitors in CF and the results are variable. For example, AZD9668, a reversible and selective NE inhibitor, significantly reduced sputum inflammatory biomarkers in PwCF, but failed to decrease sputum neutrophil counts and NE activity, and did not improve lung function [<xref rid=""bib30"" ref-type=""bibr"">30</xref>]. Another phase II clinical trial using inhaled alpha-1-antitrypsin in CF showed no impact on lung function, but did diminish free NE activity,",15_12,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"lung function, but did diminish free NE activity, neutrophil counts, <italic toggle=""yes"">P. aeruginosa</italic> loads and IL-8 levels [<xref rid=""bib31"" ref-type=""bibr"">31</xref>]. Thus, the potential efficacy of NE inhibitors in CF still needs to be explored, since it remains insufficiently clear whether the recently developed highly effective modulator therapies (HEMT) are effective in controlling the inflammatory response and whether HEMTs would require adjunct, anti-inflammatory therapies in the",15_13,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"adjunct, anti-inflammatory therapies in the future [<xref rid=""bib32"" ref-type=""bibr"">32</xref>]. Bacteria have also evolved mechanisms to resist the antimicrobial properties of neutrophils. Specifically, Gram-negative bacteria have developed strategies to evade harm by immune cell-derived serine proteases, such as NE, through the production of a protein called ecotin [<xref rid=""bib33"" ref-type=""bibr"">33</xref>,<xref rid=""bib34"" ref-type=""bibr"">34</xref>]. Ecotin was first described in <italic",15_14,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"Ecotin was first described in <italic toggle=""yes"">E. coli</italic> as a protease inhibitor [<xref rid=""bib34"" ref-type=""bibr"">34</xref>,<xref rid=""bib35"" ref-type=""bibr"">35</xref>]. Ecotin is a small, homodimeric protein of approximately 38 kDa that is resistant to boiling and stable at pH 1.0, demonstrating exceptional stability [<xref rid=""bib36"" ref-type=""bibr"">36</xref>]. In bacteria expressing ecotin, the protein translocates to the periplasmic space and protects the bacterium from host proteases.",15_15,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"and protects the bacterium from host proteases. Since its first discovery in <italic toggle=""yes"">E. coli</italic>, ecotin homologs have been observed in over 300 organisms including <italic toggle=""yes"">P. aeruginosa</italic>, which is a dominant pathogen in CF airways [<xref rid=""bib34"" ref-type=""bibr"">34</xref>,<xref rid=""bib37"" ref-type=""bibr"">[37]</xref>, <xref rid=""bib38"" ref-type=""bibr"">[38]</xref>, <xref rid=""bib39"" ref-type=""bibr"">[39]</xref>]. We recently identified and characterized ecotin",15_16,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"We recently identified and characterized ecotin homologs in <italic toggle=""yes"">Campylobacter rectus</italic> and <italic toggle=""yes"">Campylobacter showae</italic> and showed that they inhibit free or NET-bound NE in a dose-dependent manner [<xref rid=""bib37"" ref-type=""bibr"">37</xref>]. Our previous research showed that recombinantly expressed ecotins cloned from two <italic toggle=""yes"">Campylobacter</italic> species, <italic toggle=""yes"">C. rectus</italic> and <italic toggle=""yes"">C. showae,</italic>",15_17,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"and <italic toggle=""yes"">C. showae,</italic> and cloned from <italic toggle=""yes"">E. coli</italic> were able to inhibit human NE [<xref rid=""bib37"" ref-type=""bibr"">37</xref>]. In this study we also recombinantly expressed the <italic toggle=""yes"">P. aeruginosa</italic> ecotin. The objective of this study was to determine whether ecotins from four different, Gram-negative bacteria are capable of inhibiting NE enzymatic activity in CF airway samples.   This study describes the ability of various ecotins to",15_18,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"study describes the ability of various ecotins to inhibit NE enzymatic activity in human CF sputum samples without compromising neutrophil-mediated bacterial killing of two dominant CF lung pathogens, <italic toggle=""yes"">P. aeruginosa</italic> or <italic toggle=""yes"">S. aureus.</italic> The ecotin homologs from <italic toggle=""yes"">C. rectus</italic>, <italic toggle=""yes"">C. showae</italic>, <italic toggle=""yes"">E. coli</italic>, and <italic toggle=""yes"">P. aeruginosa</italic> showed variability in their",15_19,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"aeruginosa</italic> showed variability in their capacity to inhibit NE activity in the CF sputa while none compromised neutrophil-mediated bacterial killing and/or bacterial growth. <italic toggle=""yes"">C. rectus</italic> and <italic toggle=""yes"">C. showae</italic> ecotins displayed a strong inhibition of NE activity in CF sputa, with complete inhibition at the higher doses tested. In contrast, <italic toggle=""yes"">E. coli</italic> and <italic toggle=""yes"">P. aeruginosa</italic> ecotins were both weak",15_20,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"aeruginosa</italic> ecotins were both weak inhibitors of NE activity in CF sputa and in some instances, failed to show any inhibitory action. The NE-inhibitory patterns of the tested ecotins in the CF sputa are different from our studies using purified human NE where no differences were observed: IC<sub>50</sub> values (nM) for <italic toggle=""yes"">E. coli</italic> (4.64 ± 0.23), <italic toggle=""yes"">C. rectus</italic> (4.49 ± 0.25) and <italic toggle=""yes"">C. showae</italic> (4.78 ± 0.31) ecotins (34).",15_21,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"showae</italic> (4.78 ± 0.31) ecotins (34). The reason for this could possibly be explained by differences between purified human NE and the more complex CF sputum samples. Based on protein sequence alignments, the <italic toggle=""yes"">P. aeruginosa</italic> ecotin is more similar to the <italic toggle=""yes"">E. coli</italic> ecotin with approximately 60 % identity. There is low amino acid similarity between ecotin homologs from the <italic toggle=""yes"">Campylobacter</italic> species compared to <italic",15_22,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"species compared to <italic toggle=""yes"">E. coli</italic> and <italic toggle=""yes"">P. aeruginosa</italic> [<xref rid=""bib34"" ref-type=""bibr"">34</xref>,<xref rid=""bib37"" ref-type=""bibr"">37</xref>]. For example, the <italic toggle=""yes"">C. rectus</italic> and <italic toggle=""yes"">C. showae</italic> ecotins have 27 % and 33 % amino acid identity to the <italic toggle=""yes"">E. coli</italic> and 25 % and 27 % identity to the <italic toggle=""yes"">P. aeruginosa</italic> ecotin [<xref rid=""bib34""",15_23,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"aeruginosa</italic> ecotin [<xref rid=""bib34"" ref-type=""bibr"">34</xref>]. The two cysteines (Cys50 and Cys87) which form an intra-subunit disulfide bond in the <italic toggle=""yes"">E. coli</italic> ecotin are conserved [<xref rid=""bib37"" ref-type=""bibr"">37</xref>]. However, the substrate binding pocket residues are different compared to <italic toggle=""yes"">E. coli</italic> [<xref rid=""bib37"" ref-type=""bibr"">37</xref>] and these might influence the oligomerization capacity of the heterotrimeric <italic",15_24,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"capacity of the heterotrimeric <italic toggle=""yes"">E. coli</italic> ecotin-NE complex [<xref rid=""bib42"" ref-type=""bibr"">42</xref>]. Altogether, these differences may play a role in the ability to bind and inhibit NE active sites in more complex media such as CF sputa. This idea is supported by our previous data showing that the <italic toggle=""yes"">C. rectus</italic> ecotin was capable of protecting a <italic toggle=""yes"">C. jejuni</italic> protein glycosylation mutant from proteolytic attack within",15_25,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
mutant from proteolytic attack within chicken cecal samples by approximately 5 × 10<sup>6</sup>,15_26,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"<funding-source id=""gs1""><institution-wrap><institution-id institution-id-type=""doi"">10.13039/100026585</institution-id><institution>CFU</institution></institution-wrap></funding-source> more compared to the <italic toggle=""yes"">C. showae</italic> ecotin [<xref rid=""bib37"" ref-type=""bibr"">37</xref>]. NE concentrations in CF sputum samples varies across a wide range in our study that is consistent with prior observations made by other groups [<xref rid=""bib53"" ref-type=""bibr"">[53]</xref>, <xref rid=""bib54""",15_27,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">[53]</xref>, <xref rid=""bib54"" ref-type=""bibr"">[54]</xref>, <xref rid=""bib55"" ref-type=""bibr"">[55]</xref>]. Unfortunately, the same CF supernatants could not be tested in each figure as only limited amounts of these supernatants were available and some were only used in experiments for one or two readouts. The CF sputum contains NE in multiple compartments such as free NE released from neutrophils as well as NE bound to NETs or exosomes [<xref rid=""bib13"" ref-type=""bibr"">13</xref>,<xref",15_28,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"rid=""bib13"" ref-type=""bibr"">13</xref>,<xref rid=""bib25"" ref-type=""bibr"">25</xref>,<xref rid=""bib56"" ref-type=""bibr"">56</xref>]. The differences between the ecotin species and their ability to inhibit NE in the complete sputa versus NETs could be due to the efficacy of ecotin to inhibit NE in the different compartments and to the differences in NE compartmentalization among different CF sputa. Dissecting the components of the CF sputa and the affinity for each ecotin to inhibit NE found in different",15_29,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"for each ecotin to inhibit NE found in different compartments could help explain this result. Additionally, PwCF infected with <italic toggle=""yes"">P. aeruginosa</italic> may contain <italic toggle=""yes"">P. aeruginosa</italic> ecotin in their lung environment, which has been shown to bind to the biofilm exopolysaccharide matrix and likely protects neighboring <italic toggle=""yes"">P. aeruginosa</italic> cells from NE-mediated damage [<xref rid=""bib57"" ref-type=""bibr"">57</xref>]. Despite <italic",15_30,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">57</xref>]. Despite <italic toggle=""yes"">P. aeruginosa</italic> ecotins being present in the CF lung, NE is active and causes severe damage of lung tissues. Therefore, <italic toggle=""yes"">P. aeruginosa</italic> ecotins may only be efficient in protecting the microbe from NE within biofilms, but the quantities of ecotin that are released are likely unable to inhibit lung tissue damage caused by NE. Our data suggests that addition of exogenous ecotin inhibits NE activity in the CF sputum",15_31,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"ecotin inhibits NE activity in the CF sputum while does not interfere with neutrophil-mediated killing of CF clinical isolates <italic toggle=""yes"">in vitro</italic>. These results raise the question whether ecotin could be of interest for studies on its potential to be a new NE-targeting therapeutic. There are currently no approved NE inhibitors for human use. Sivelestat was used a positive control in this study as it has been shown to reduce NE activity, however, clinical trials deemed this drug",15_32,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"however, clinical trials deemed this drug ineffective in PwCF [<xref rid=""bib45"" ref-type=""bibr"">45</xref>]. A meta-analysis analyzing the clinical trials performed with sivelestat in patients with acute respiratory distress syndrome showed that the compound did not improve mortality and did not alter the duration of mechanical ventilation [<xref rid=""bib58"" ref-type=""bibr"">58</xref>]. It has been shown that NE inhibition by sivelestat did not enhance the occurrence of infections, suggesting that NE",15_33,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"the occurrence of infections, suggesting that NE inhibitors could improve lung function without worsening infections [<xref rid=""bib45"" ref-type=""bibr"">45</xref>,<xref rid=""bib59"" ref-type=""bibr"">59</xref>,<xref rid=""bib60"" ref-type=""bibr"">60</xref>]. Therefore, new inhibitors against NE with a known mechanism of action are needed. Ecotin from <italic toggle=""yes"">C. rectus</italic> and <italic toggle=""yes"">C. showae</italic> showed the same inhibitory effects as sivelestat, with complete NE inhibition in",15_34,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"as sivelestat, with complete NE inhibition in the CF sputa. Altogether, our study characterizes the effect of four ecotin homologs on their inhibitory activity of NE in CF sputa and neutrophil-mediated bactericidal responses. This is the first study to characterize the <italic toggle=""yes"">P. aeruginosa</italic> ecotin and its limited ability to inhibit NE in the CF sputum. This is also the first study to test ecotin as an NE inhibitor in CF airway disease. Our <italic toggle=""yes"">in vitro</italic> data",15_35,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"Our <italic toggle=""yes"">in vitro</italic> data suggest that the ecotins from <italic toggle=""yes"">C. rectus</italic> and <italic toggle=""yes"">C. showae</italic> have the potential to significantly reduce NE activity in the CF airways, however more studies are needed to determine the effect on the reduction of lung injury. Future studies will also test ecotin in the βENaC-Tg CF mouse model demonstrating a neutrophilic and NE-mediated, CF-like lung disease. Our team has characterized this mouse model and",15_36,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"Our team has characterized this mouse model and has observed significant lung inflammation mediated by neutrophils (64). The addition of ecotin <italic toggle=""yes"">in vivo</italic> to measure its effect on NE activity and lung injury would further confirm that ecotin has potential for therapeutic use in CF lung disease. Since ecotin is a bacterial protein, administering it to mammalian organisms carries the risk of inducing an inflammatory or antibody response. Therefore, the safety of administering",15_37,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"response. Therefore, the safety of administering ecotin, or its future derivatives, need to be carefully investigated. Ecotin was reported to exhibit a broad range of inhibitory activity against exogenous serine proteases such as trypsin, chymotrypsin, factor Xa, kallikrein, urokinase, factor XII, and NE [<xref rid=""bib34"" ref-type=""bibr"">[34]</xref>, <xref rid=""bib35"" ref-type=""bibr"">[35]</xref>, <xref rid=""bib36"" ref-type=""bibr"">[36]</xref>, <xref rid=""bib37"" ref-type=""bibr"">[37]</xref>,<xref rid=""bib61""",15_38,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">[37]</xref>,<xref rid=""bib61"" ref-type=""bibr"">[61]</xref>, <xref rid=""bib62"" ref-type=""bibr"">[62]</xref>, <xref rid=""bib63"" ref-type=""bibr"">[63]</xref>]. Delivering ecotin directly to airways, therefore, likely represents a better approach to inhibit airway proteases without interfering with proteases in the blood or the gut lumen. A limitation of the current study is the small number of CF subjects recruited and their sputum samples used. Also, only two strains of each CF pathogen were",15_39,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"Also, only two strains of each CF pathogen were tested in the neutrophil killing assays. In the future, the effect of ecotins on NE will be expanded to sputum samples of a larger CF study cohort using more bacterial clinical isolates. Lung function decline is the main cause of morbidity and mortality in PwCF, with NE correlating with decreased lung function. NE has been a target in PwCF for years with no successful, approved therapeutics thus far. Our future work will aim to better characterize the effect",15_40,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"work will aim to better characterize the effect of ecotin, and its derivatives, on inhibiting NE activity and its consequences in CF. All human subject studies were performed according to the guidelines of the World Medical Association's Declaration of Helsinki. Healthy human subjects were recruited at the University of Georgia (UGA) and provided informed consent for blood donation for neutrophil isolation according to the protocol UGA# 2012-10769-06 approved by the Institutional Review Board of the",15_41,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"approved by the Institutional Review Board of the University of Georgia. This work was funded by the <funding-source id=""gs3""><institution-wrap><institution-id institution-id-type=""doi"">10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source> awards (<award-id award-type=""grant"" rid=""gs3"">R01HL136707-01A1</award-id> to B. Rada) and the <funding-source id=""gs7""><institution-wrap><institution-id",15_42,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"id=""gs7""><institution-wrap><institution-id institution-id-type=""doi"">10.13039/100000897</institution-id><institution>Cystic Fibrosis Foundation</institution></institution-wrap></funding-source> (<award-id award-type=""grant"" rid=""gs7"">003303I221</award-id> to B. Rada). This work was also supported by the <funding-source id=""gs4""><institution-wrap><institution-id institution-id-type=""doi"">10.13039/100016220</institution-id><institution>Georgia CTSA</institution></institution-wrap></funding-source> Training",15_43,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"Training Grant, <award-id award-type=""grant"" rid=""gs4"">TL1 TR002382</award-id> and <award-id award-type=""grant"" rid=""gs4"">UL1TR002378</award-id>. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Cystic Fibrosis Foundation. Data will be made available on request. <bold>Kayla M. Fantone:</bold> Writing – review & editing, Writing – original draft, Validation, Methodology, Investigation, Formal analysis,",15_44,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"Methodology, Investigation, Formal analysis, Data curation, Conceptualization. <bold>Harald Nothaft:</bold> Writing – review & editing, Validation, Supervision, Methodology, Formal analysis, Conceptualization. <bold>Yeongseo Son:</bold> Formal analysis, Data curation. <bold>Arlene A. Stecenko:</bold> Writing – review & editing, Methodology. <bold>Christine M. Szymanski:</bold> Writing – review & editing, Resources, Project administration, Investigation, Conceptualization. <bold>Balázs Rada:</bold> Writing",15_45,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"<bold>Balázs Rada:</bold> Writing – review & editing, Supervision, Methodology, Funding acquisition, Formal analysis, Conceptualization. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.",15_46,The bacterial serine protease inhibitor ecotin inhibits neutrophil elastase enzymatic activity in cystic fibrosis sputa,05 10 2024,,Cystic_Fibrosis
"Current landscape of cystic fibrosis gene therapy Cystic fibrosis is a life-threatening disease that is caused by mutations in <italic toggle=""yes"">CFTR</italic>, a gene which encodes an ion channel that supports proper function of several epithelial tissues, most critically the lung. Without CFTR, airway barrier mechanisms are impaired, allowing for chronic, recurrent infections that result in airway remodeling and deterioration of lung structure and function. Small molecule modulators can rescue existing,",16_0,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"Small molecule modulators can rescue existing, defective CFTR protein; however, they still leave a subset of people with CF with no current disease modifying treatments, aside from lung transplantation. Gene therapy directed to the lung is a promising strategy to modify CF disease in the organ most associated with morbidity and mortality. It is accomplished through delivery of a CFTR transgene with an airway permissive vector. Despite more than three decades of research in this area, a lung directed gene",16_1,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"of research in this area, a lung directed gene therapy has yet to be realized. There is hope that with improved delivery vectors, sufficient transduction of airway cells can achieve therapeutic levels of functional CFTR. In order to do this, preclinical programs need to meet a certain level of CFTR protein expression <italic toggle=""yes"">in vitro</italic> and <italic toggle=""yes"">in vivo</italic> through improved transduction, particularly in relevant airway cell types. Furthermore, clinical programs must",16_2,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"cell types. Furthermore, clinical programs must be designed with sensitive methods to detect CFTR expression and function as well as methods to measure meaningful endpoints for lung structure, function and disease. Here, we discuss the current understanding of how much and where <italic toggle=""yes"">CFTR</italic> needs to be expressed, the most advanced vectors for <italic toggle=""yes"">CFTR</italic> delivery and clinical considerations for detecting CFTR protein and function in different patient subsets.",16_3,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"and function in different patient subsets. Cystic fibrosis (CF) is the most common autosomal recessive disease and affects approximately 40,000 people in the United States and 80,000 people worldwide (<xref rid=""B16"" ref-type=""bibr"">Cromwell et al., 2023</xref>). It is caused by variants in the <italic toggle=""yes"">Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)</italic> which encodes a chloride channel that is found on the membrane of many cell types in the body (<xref rid=""B80""",16_4,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"of many cell types in the body (<xref rid=""B80"" ref-type=""bibr"">Riordan, 1989</xref>; <xref rid=""B87"" ref-type=""bibr"">Saint-Criq and Gray, 2017</xref>). Lack of CFTR function at the apical surface of secretory epithelial tissues such as the lung and pancreas is the cause of morbidity, although many organs are affected including the reproductive system, intestine, liver, bone, and kidney. In the classic CF disease progression, pulmonary complications as a result of thick inspissated mucus, chronic bacterial",16_5,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"of thick inspissated mucus, chronic bacterial colonization and ongoing lung destruction are the principal cause of death. The average life span of people with CF (PwCF) has drastically improved over the years to mid to late 40s (mid-50s if born after 2018) but has historically struggled to get beyond childhood without therapeutic intervention (<xref rid=""B13"" ref-type=""bibr"">Castellani and Assael, 2017</xref>; <xref rid=""B53"" ref-type=""bibr"">McBennett et al., 2022</xref>). A person with CF experiences an",16_6,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"2022</xref>). A person with CF experiences an annual decline in lung function of 1%–2%, and without a lung transplantation or disease-modifying therapy, 80% will succumb to respiratory failure (<xref rid=""B49"" ref-type=""bibr"">Lyczak et al., 2002</xref>; <xref rid=""B45"" ref-type=""bibr"">Leung et al., 2020</xref>). Significant understanding of the genetic basis for CF and the resulting pathophysiology has led to the development of CFTR modulators, small molecules that correct and/or potentiate dysfunctional",16_7,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"that correct and/or potentiate dysfunctional CFTR protein to clinically meaningful output with daily medication (<xref rid=""B61"" ref-type=""bibr"">Middleton et al., 2019</xref>). However, there is still great unmet need for PwCF that are unable to benefit from modulators due to their specific <italic toggle=""yes"">CFTR</italic> variant, intolerable side effects or lack of access (10%–20% of patients) (<xref rid=""B37"" ref-type=""bibr"">Hubert et al., 2017</xref>; <xref rid=""B11"" ref-type=""bibr"">Burgener and",16_8,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"<xref rid=""B11"" ref-type=""bibr"">Burgener and Moss, 2018</xref>). Therefore, a gene therapy for CF which introduces a functional <italic toggle=""yes"">CFTR</italic> gene into patients’ cells could treat >4,000 patients in the US unable to use modulators. Despite identification of the genetic cause more than three decades ago, <italic toggle=""yes"">CFTR</italic> gene therapy has yet to progress beyond clinical trials due to a lack of sustained efficacy and prolonged lung function improvements in patients. New",16_9,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"lung function improvements in patients. New insights into the expression and function of CFTR in relevant cell types, novel delivery methods for introducing <italic toggle=""yes"">CFTR</italic> into target airway cells and more sensitive measurements for lung function in the clinic, particularly in young children or those patients with milder disease most likely to benefit from early CFTR intervention, are promising steps toward a clinically approved CF gene therapy. CF disease is characterized by a spectrum",16_10,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"CF disease is characterized by a spectrum of severity due to the more than 2000 variants in the <italic toggle=""yes"">CFTR</italic> gene that result in defects of mRNA production, protein production, trafficking, folding, regulation, conductance, or turnover rate. These variants have been organized into seven classes, summarized in <xref rid=""T1"" ref-type=""table"">Table 1</xref>, based upon the functional consequence of the variant (<xref rid=""F1"" ref-type=""fig"">Figure 1A</xref>). PwCF can either have two",16_11,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"1A</xref>). PwCF can either have two copies of the same variant (homozygous) or two different disease-causing variants (heterozygous). People with Class I variants lack CFTR protein production resulting from disruption of the <italic toggle=""yes"">CFTR</italic> coding sequence (e.g., – frameshift mutations). The Class I variant transcripts are either unstable due to premature termination (Class IA) or code for a truncated, dysfunctional protein product (Class IB). Class II variants, including the most",16_12,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"(Class IB). Class II variants, including the most common ΔF508, affect the correct trafficking of the protein and result in the loss of CFTR expression at the cell surface. Class III variants include those in which the regulation of the CFTR channel is defective. CFTR variant Classes IV-VI may have a milder CF phenotype with Class IV variants having reduced conduction properties, Class V having decreased stability of mRNA or protein, and Class VI resulting in enhanced CFTR turnover rates (<xref rid=""B50""",16_13,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"in enhanced CFTR turnover rates (<xref rid=""B50"" ref-type=""bibr"">MacDonald et al., 2007</xref>). Class VII variants have large deletions that prevent mRNA production, although sometimes these are included as a subtype of Class 1 (<xref rid=""B21"" ref-type=""bibr"">DeBoeck and Amaral, 2016</xref>). CFTR modulator therapy can improve trafficking and gating of minimal function Class II-VI proteins. However, it is ineffective in Class I/VII patients with no functional protein. These patients represent the most",16_14,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"protein. These patients represent the most underserved CF population with the most severe form of the disease. Importantly, gene sequencing in new patient cohorts are revealing novel variants and variability in phenotypes with known variants (<xref rid=""B30"" ref-type=""bibr"">Gaikwad et al., 2020</xref>). This underlies the need for a variant agnostic gene therapy that can deliver a wildtype <italic toggle=""yes"">CFTR</italic> transgene to lung cells in order to significantly benefit all PwCF. CF was",16_15,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"order to significantly benefit all PwCF. CF was initially identified and named for the pancreatic phenotype which caused mortality and precluded visible defects in lung function and development of lung disease. Following the emergence of enzyme therapies that resolved the pancreatic insufficiency and nutritional programs for gastrointestinal malabsorption, palliative lung treatments including airway clearance techniques and antibiotic therapy could only extend life expectancy in PwCF to their early 30s",16_16,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"extend life expectancy in PwCF to their early 30s (<xref rid=""B47"" ref-type=""bibr"">Lopes-Pacheco, 2016</xref>). At this time, 90% of patient mortality was still driven by lung disease. Aside from lung transplantation, CFTR modulators represent the current best therapeutic option for patients with relevant CFTR variants, which can benefit from improved transporter function or correction of misfolded transporter proteins. CFTR modulators are not curative but can offer profound disease modifying effects,",16_17,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"but can offer profound disease modifying effects, particularly with the development of the triple combination elexacaftor-tezacaftor-ivafactor (ELX/TEZ/IVA) (<xref rid=""B35"" ref-type=""bibr"">Heijerman et al., 2019</xref>; <xref rid=""B61"" ref-type=""bibr"">Middleton et al., 2019</xref>). An interim analysis of ELX/TEZ/IVA demonstrated that the post-treatment annualized rate of death and lung transplantation was 72% and 85% lower than the historical population (<xref rid=""B8"" ref-type=""bibr"">Bower et al.,",16_18,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"(<xref rid=""B8"" ref-type=""bibr"">Bower et al., 2023</xref>) Nevertheless, emerging real-world data also suggest higher rates of adverse events and discontinuation of CFTR modulators compared to clinical trial data. Adverse events described include respiratory (dyspena and chest tightness), gastrointestinal (nausea, abdominal pain and diarrhea) and neuropsychiatric (depression and anxiety), among others (<xref rid=""B96"" ref-type=""bibr"">Talwalkar et al., 2017</xref>; <xref rid=""B18"" ref-type=""bibr"">Dagenais",16_19,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"<xref rid=""B18"" ref-type=""bibr"">Dagenais et al., 2020</xref>; <xref rid=""B90"" ref-type=""bibr"">Shteinberg and Taylor-Cousar, 2020</xref>). Although CFTR modulator therapy has presented vast improvements to quality and duration of life for many PwCF, 6%–10% of patients with CF will not benefit from this therapy because they lack eligible CFTR variants (<ext-link http://www.w3.org/1999/xlink href=""http://CFF.org"" ext-link-type=""uri"">CFF.org</ext-link>). Combined with patients who cannot tolerate CFTR",16_20,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"Combined with patients who cannot tolerate CFTR modulators due to adverse events (possibly as high as 20% (<xref rid=""B37"" ref-type=""bibr"">Hubert et al., 2017</xref>; <xref rid=""B10"" ref-type=""bibr"">Burgel et al., 2019</xref>) more than 20%–25% of PwCF remain underserved with lung transplantation and/or quality of end-of-life care as their only options (<xref rid=""B59"" ref-type=""bibr"">Mercier et al., 2021</xref>; <xref rid=""B36"" ref-type=""bibr"">Hisert et al., 2023</xref>). Patients who are ineligible or",16_21,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"al., 2023</xref>). Patients who are ineligible or unable to tolerate CFTR modulatory therapy present a high unmet need. Given the monogenic molecular cause of CF, and evidence that lung disease is the primary cause of morbidity with current therapeutics, there is great potential for a lung directed gene therapy to improve quality of life and extend lifespan in these patients. Gene therapies are composed of vectors that can bind and enter, or transduce, specific target cells and deliver wildtype genes to",16_22,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"target cells and deliver wildtype genes to generate functional protein. To understand the level of airway transduction necessary for a <italic toggle=""yes"">CFTR</italic> gene therapy to rescue lung function, several groups have measured the amount of <italic toggle=""yes"">CFTR</italic> expressing cells required to restore function in a CF airway model <italic toggle=""yes"">in vitro</italic>. <italic toggle=""yes"">In vitro</italic> models, often described as the Air-Liquid Interface (ALI) culture method, use",16_23,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"Air-Liquid Interface (ALI) culture method, use primary human bronchial epithelial cells (HBECs) derived from bronchial brushing or transplanted CF lungs, and are considered the gold standard to measure CFTR function from CFTR variants and to validate the efficacy of CFTR therapeutics preclinically (<xref rid=""B7"" ref-type=""bibr"">Awatade et al., 2018</xref>). HBEC cultures form tight junctions, which allows the use of electrophysiological measurement techniques (e.g., Ussing chambers) to assess airway",16_24,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"(e.g., Ussing chambers) to assess airway conductance and ion transport. Rescue of CFTR-mediated ion transport in CF HBECs has translated to clinically relevant lung function improvements (<xref rid=""B41"" ref-type=""bibr"">Keating et al., 2018</xref>). For example, the CFTR modulator lumacaftor/ivacaftor restores CFTR function to approximately 14% of normal levels <italic toggle=""yes"">in vitro</italic> (<xref rid=""B97"" ref-type=""bibr"">VanGoor et al., 2011</xref>). This resulted in sustained 2%–4% improvement",16_25,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"This resulted in sustained 2%–4% improvement in FEV1 and 30% reduction in exacerbations (<xref rid=""B101"" ref-type=""bibr"">Wainwright et al., 2015</xref>). Cell mixing experiments using genetically engineered cell lines as well as patient-derived primary human bronchial epithelial cells have demonstrated that epithelial sheets containing 6%–10% WT CFTR-expressing cells generated functional activity similar to epithelial sheets containing 100% WT CFTR-expressing cells (<xref rid=""B39"" ref-type=""bibr"">Johnson",16_26,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"cells (<xref rid=""B39"" ref-type=""bibr"">Johnson et al., 1992</xref>; <xref rid=""B19"" ref-type=""bibr"">Dannhoffer et al., 2009</xref>). Gene transfer studies using an adenoviral delivery vector that transduced only 20% of CF HBECs fully rescued ion transport with a WT <italic toggle=""yes"">CFTR</italic> transgene (<xref rid=""B25"" ref-type=""bibr"">Excoffon et al., 2009</xref>), and a similar study using a human parainfluenza viral vector demonstrated normal CFTR activity with 25% of the epithelium transduced",16_27,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"activity with 25% of the epithelium transduced (<xref rid=""B112"" ref-type=""bibr"">Zhang L et al., 2009</xref>). Further methods of deriving a relationship between CFTR expression, function and disease severity include utilization of <italic toggle=""yes"">in vitro</italic> airway models and clinical sequencing of patient samples and lung function data. Recently, a group edited human bronchial epithelial cells (HBECs) to express patient specific <italic toggle=""yes"">CFTR</italic> variants and measured the",16_28,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"variants and measured the resulting CFTR protein activity using electrophysiology assays. In this study, patient variants associated with full expressivity of CF disease (meaning they developed pancreatic, lung and sweat chloride phenotypes) were demonstrated to have less than 10% WT CFTR protein activity <italic toggle=""yes"">in vitro</italic> (<xref rid=""B54"" ref-type=""bibr"">McCague et al., 2019</xref>). Additionally, PwCF having a common splicing variant (3272-26A>G/F508del) were found to express",16_29,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"(3272-26A>G/F508del) were found to express approximately 5% of the normal levels of wildtype (WT)-<italic toggle=""yes"">CFTR</italic> mRNA and have milder CF disease (<xref rid=""B78"" ref-type=""bibr"">Ramalho et al., 2012</xref>). This suggests that having only 5% WT-CFTR is sufficient to ameliorate severe disease phenotypes. Studies such as these have established the bar of 5%–10% normal CFTR activity to achieve significant health benefit in PwCF. Similarly, a study found a non-linear, logarithmic",16_30,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"a study found a non-linear, logarithmic relationship between CFTR activity (predicted by variant status) and lung function, suggesting that even small increases in functional CFTR would provide vast improvement in people with severe lung disease. These data again suggest that low levels of airway epithelial cell transduction can improve lung function in a CF airway, with a target of 5%–10% transduction ameliorating severe disease and a target of 10%–25% transduction restoring lung function in PwCF (<xref",16_31,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"restoring lung function in PwCF (<xref rid=""F2"" ref-type=""fig"">Figure 2</xref>). In order to target the right cells with a CFTR gene therapy, we need to understand where and how CFTR normally functions. The upper airway is primarily comprised of basal cells, which cover the basolateral membrane and act as progenitor cells for all airway cell types, along with secretory cells that produce mucus to trap pathogens, and ciliated cells, which have hairlike projections that sweep mucus and its attached pathogens",16_32,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"that sweep mucus and its attached pathogens from the airway (mucociliary clearance). In the lung, defective CFTR function results in decreased anion secretion (chloride and bicarbonate) ((<xref rid=""B79"" ref-type=""bibr"">Rich et al., 1990</xref>)). The change in osmolarity leads to the removal of water from the airway secretions, which become relatively dehydrated and viscous making them difficult to remove by either mucociliary clearance or by cough. Subsequently, the retained secretions invite",16_33,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"Subsequently, the retained secretions invite opportunistic bacterial and fungal infections. Work from CF transgenic animal models has elucidated CF lung pathogenesis (<xref rid=""B95"" ref-type=""bibr"">Sun et al., 2010</xref>). For example, newborn <italic toggle=""yes"">CFTR−/−</italic> pigs display early congenital airway abnormalities, including lowering of pH which hinders the bacteria killing function of airway surface liquid, defects in mucus detachment from submucosal glands, and early infection that",16_34,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"from submucosal glands, and early infection that precedes inflammation and remodeling (<xref rid=""B94"" ref-type=""bibr"">Stoltz et al., 2015</xref>). The complex tasks of mucus production and hydration, bacteria killing and mucociliary clearance are distributed among specialized airway cell types (<xref rid=""F3"" ref-type=""fig"">Figure 3</xref>). Understanding which cells can utilize CFTR to restore these functions is critical to understanding which cell should be targeted with a gene therapy. In addition to",16_35,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"be targeted with a gene therapy. In addition to high expression in the submucosal glands, it is now appreciated that airway secretory and basal cells express the majority of <italic toggle=""yes"">CFTR</italic> in the surface airway epithelium but at low levels (∼1-2 mRNA transcripts) per cell (<xref rid=""B69"" ref-type=""bibr"">Okuda et al., 2021</xref>). The recently discovered pulmonary ionocyte, despite being only 1%–2% of the airway epithelium, expresses the remaining <italic toggle=""yes"">CFTR</italic>",16_36,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"the remaining <italic toggle=""yes"">CFTR</italic> (>30 mRNA transcripts per cell) (<xref rid=""B64"" ref-type=""bibr"">Montoro et al., 2018</xref>; <xref rid=""B74"" ref-type=""bibr"">Plasschaert et al., 2018</xref>). In order to elucidate the function of CFTR in these distinct cell types, transgenic ferrets were used to ablate ionocytes thus demonstrating their role in airway surface liquid (ASL) absorption and secretion and mucus viscosity (<xref rid=""B110"" ref-type=""bibr"">Yuan et al., 2023</xref>). It was",16_37,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">Yuan et al., 2023</xref>). It was further revealed through manipulation of ionocyte abundance and expression of cell type specific ion channels in HBECs <italic toggle=""yes"">in vitro</italic> that CFTR plays distinct roles in ASL absorption and secretion, in ionocytes and secretory cells, respectively (<xref rid=""B44"" ref-type=""bibr"">Lei et al., 2023</xref>). Finally, using single cell electrophysiology experiments, it was shown that ionocytes regulate ASL pH through an anion exchanger that",16_38,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"regulate ASL pH through an anion exchanger that secretes bicarbonate into the lumen, thus increasing the pH (<xref rid=""B48"" ref-type=""bibr"">Luan et al., 2024</xref>). These data demonstrate that distinct, specialized cell types utilize CFTR to maintain ion homeostasis in order to modulate ASL hydration, mucus viscosity, and pH. Ideally, a lung-directed gene therapy would target all airway cells that endogenously express <italic toggle=""yes"">CFTR</italic> in both the surface airway epithelium and",16_39,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"in both the surface airway epithelium and submucosal glands. It is unclear whether an inhaled gene therapy would reach distal <italic toggle=""yes"">CFTR</italic>-high serous cells in submucosal glands; however, proximally located progenitor cells may be more accessible (<xref rid=""B38"" ref-type=""bibr"">Jiang and Engelhardt, 1998</xref>; <xref rid=""B6"" ref-type=""bibr"">Anderson et al., 2017</xref>). There may be benefit in transducing some surface airway epithelial cells in order to disrupt the mucus barrier",16_40,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"cells in order to disrupt the mucus barrier for repeat dosing, although it is still unclear whether all airway cells can use CFTR effectively (<xref rid=""B72"" ref-type=""bibr"">Ostrowski et al., 2007</xref>). The best preclinical model for CFTR restoration and function is the HBEC culture model which is composed of the surface airway epithelial cells but lacks submucosal gland cells. It's critical to remember that CFTR modulators work on existing endogenous protein; therefore, HBEC models can predict how a",16_41,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"protein; therefore, HBEC models can predict how a modulator will work on all CFTR expressing cells in the body. However, in gene therapy studies, <italic toggle=""yes"">in vitro</italic> models should be combined with animal biodistribution studies to determine which airway cell types are reached <italic toggle=""yes"">in vivo</italic>. While efficacy studies <italic toggle=""yes"">in vivo</italic> are also highly desirable, there are few CF animal models and gene therapy vectors can be species specific",16_42,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"and gene therapy vectors can be species specific preventing their translatability (<xref rid=""B25"" ref-type=""bibr"">Excoffon et al., 2009</xref>; <xref rid=""B92"" ref-type=""bibr"">Steines et al., 2016</xref>). Nebulization of CF pigs with a pig tropic vector expressing <italic toggle=""yes"">CFTR</italic> demonstrated that delivery to the surface epithelial cells of the trachea demonstrated improvements in ASL pH and partial rescue of bacteria killing (<xref rid=""B92"" ref-type=""bibr"">Steines et al.,",16_43,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"(<xref rid=""B92"" ref-type=""bibr"">Steines et al., 2016</xref>). These data, along with the partial transduction of epithelial sheets <italic toggle=""yes"">in vitro,</italic> hint that not all cells need to be transduced throughout the lung to achieve therapeutic benefit. (<xref rid=""B113"" ref-type=""bibr"">Zhang et al., 1998</xref>; <xref rid=""B71"" ref-type=""bibr"">Ostedgaard et al., 2002</xref>) The durability of the gene therapy will be determined by the percentage and turnover of the cell types transduced.",16_44,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"and turnover of the cell types transduced. Studies in mice suggest secretory cells turnover every 11 days (<xref rid=""B105"" ref-type=""bibr"">Watson et al., 2015</xref>). Extrapolating this to humans, a gene therapy that targets only differentiated cells, including secretory cells and ionocytes, may need redosing on a yearly basis but one that reaches basal cells as well may not need redosing for 5–10 years. The CF lung environment may also influence turnover (<xref rid=""B12"" ref-type=""bibr"">Carraro et al.,",16_45,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"(<xref rid=""B12"" ref-type=""bibr"">Carraro et al., 2021</xref>). Ultimately, a durable gene therapy would contain either 1) a highly lung tropic vector that is non-immunogenic so that it can be readministered without eliciting an immune response or 2) an editing or integrating cargo targeted to basal cells which can repopulate the airway epithelium during turnover, thus expanding and retaining functional <italic toggle=""yes"">CFTR</italic> long term. Finally, the genetic cargo will influence the expression",16_46,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"the genetic cargo will influence the expression and function of a gene therapy. This review focuses on a gene transfer strategy rather than an editing strategy. To design a cargo for gene transfer, the sequence of the <italic toggle=""yes"">CFTR</italic> transgene is strongly considered. An obvious choice would be to express the wildtype <italic toggle=""yes"">CFTR</italic> transgene, but not all gene delivery platforms can deliver a transgene of this size (∼4.5 kb). To overcome this limitation for AAV-based",16_47,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"To overcome this limitation for AAV-based viral delivery where transgenes must be limited to <4.4 kb, a functional <italic toggle=""yes"">CFTR</italic> minigene has been generated from deletions in the regulatory (R) domain (<xref rid=""B113"" ref-type=""bibr"">Zhang et al., 1998</xref>; <xref rid=""B71"" ref-type=""bibr"">Ostedgaard et al., 2002</xref>). Elements such as reduced CpG content in the transgene are also a potential consideration, as it may decrease the risk for an immune response (<xref rid=""B84""",16_48,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"the risk for an immune response (<xref rid=""B84"" ref-type=""bibr"">Ronzitti et al., 2020</xref>). Furthermore, gain of function <italic toggle=""yes"">CFTR</italic> variants have been shown to further enhance efficacy (<xref rid=""B106"" ref-type=""bibr"">Woodall et al., 2023</xref>). The promoter included to express the <italic toggle=""yes"">CFTR</italic> transgene can be cell-type specific but given the plethora of cell types expressing CFTR in the lung, this may limit its functional rescue. Alternatively, a",16_49,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"may limit its functional rescue. Alternatively, a strong, ubiquitous promoter can boost expression, thus improving efficacy, but may push expression beyond physiologically-relevant levels which can result in diminished pharmacology and safety considerations through the mis-localization of CFTR (<xref rid=""B26"" ref-type=""bibr"">Farmen et al., 2005</xref>). The promoter is also included in the cargo packaging capacity, notably limiting certain vectors such as AAV. Although there are clear benefits to",16_50,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"such as AAV. Although there are clear benefits to expressing the wild type <italic toggle=""yes"">CFTR</italic> transgene to minimize the risk of novel epitope formation and deliver clear therapeutic benefit, further safety and efficacy benefits may emerge following optimization studies, and the field has yet to fully align on the best therapeutic approach (further reviewed in <xref rid=""s5-1"" ref-type=""sec"">Section 5.1</xref>). Gene therapies offer disease modulation of a misfolded protein with multiple",16_51,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"modulation of a misfolded protein with multiple agents acting as both correctors and potentiators of CFTR. CF has historically been considered a strong candidate for gene therapy approaches since the genetic cause was identified in 1989 (<xref rid=""B81"" ref-type=""bibr"">Riordan et al., 1989</xref>; <xref rid=""B98"" ref-type=""bibr"">Wagner et al., 1999</xref>). Furthermore, the lung is a seemingly accessible organ for an inhaled or bronchoscopically-delivered gene therapy which would have the potential to",16_52,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"gene therapy which would have the potential to address the most severe manifestation of disease and prolong lifespan in PwCF. However, over 20 clinical trials have attempted airway delivery of genetic material through modified or synthetic vectors to lung epithelial cells (<xref rid=""B5"" ref-type=""bibr"">Alton et al., 2016</xref>) and failed to achieve therapeutically relevant levels of expression. These failures are largely attributed to a number of factors, including insufficient potency, a lack of",16_53,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"including insufficient potency, a lack of relevant cell specificity, and CF mucosal and immune barriers. Here, we briefly summarize the field of <italic toggle=""yes"">CFTR</italic> gene therapy with particular focus on the advantages and limitations of advanced gene delivery vectors (<xref rid=""T2"" ref-type=""table"">Table 2</xref>). Due to improvements in standard of care, including CFTR modulators, there are now more adults with CF than children, and it is predicted that the new era of modulators will",16_54,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"is predicted that the new era of modulators will increase lifespan in PwCF beyond the fifth decade of life (<xref rid=""B2"" ref-type=""bibr"">Allen et al., 2023</xref>). In PROMISE, a real world, post approval observational study, 6-month data demonstrated improvements in FEV1, body mass index, quality of life, and sweat chloride concentration (<xref rid=""B67"" ref-type=""bibr"">Nichols et al., 2021b</xref>). Therefore, the development of modulators has resulted in a CF community where a large population exhibit",16_55,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"a CF community where a large population exhibit mild, possibly stable, lung disease and a smaller population have no disease-modifying therapy or cannot tolerate the available therapies. Future therapeutics will be challenged with demonstrating efficacy in people currently on modulators with marginal windows for clinical improvements. CF gene therapies have shown promising stabilization or temporary improvement of lung function clinical endpoints (<xref rid=""B5"" ref-type=""bibr"">Alton et al., 2016</xref>;",16_56,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">Alton et al., 2016</xref>; <xref rid=""B86"" ref-type=""bibr"">Rowe et al., 2023</xref>) but have not demonstrated a sustained improvement in lung function; and going forward, a growing number of gene therapy programs are competing for a small pool of PwCF for their clinical trials. This necessitates greater prioritization of preclinical programs using various gene therapy vectors (<xref rid=""T2"" ref-type=""table"">Table 2</xref>) and novel, sensitive endpoints for lung function.",16_57,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"<italic toggle=""yes"">CFTR</italic> gene therapy has been on the horizon since the discovery of the <italic toggle=""yes"">CFTR</italic> gene in 1989. Although many viral and non-viral delivery vectors have been tested, none have yet achieved the transduction, expression, and durability necessary to improve lung function in PwCF. A goal of 10%–25% rescue of CFTR expression by a gene therapy has been derived based on experiments in highly relevant airway <italic toggle=""yes"">in vitro</italic> models and CF",16_58,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"toggle=""yes"">in vitro</italic> models and CF clinical phenotypes of <italic toggle=""yes"">CFTR</italic> variants that have been sequenced and analyzed for expression and function. High transduction and durable functional restoration are most likely to be achieved by a highly lung tropic vector that can express wild type <italic toggle=""yes"">CFTR</italic>, and has the potential to either transduce basal stem cell progenitors or to be readministered. Furthermore, a large repertoire of exploratory endpoints",16_59,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"a large repertoire of exploratory endpoints testing more sensitive lung function measurements should be included in clinical trials given the complex tasks of CFTR function and how they lead to lung function decline and lung disease. Finally, earlier intervention has the potential to stave off lung inflammation and remodeling that initiate CF lung disease but may also have a positive improvement in durability of the gene therapy without the increase in cellular turnover that drives remodeling. Despite the",16_60,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"turnover that drives remodeling. Despite the challenges of developing a <italic toggle=""yes"">CFTR</italic> gene therapy, advances in delivery vectors, expression enhancers and clinical endpoints provide hope that success is on the horizon.",16_61,Current landscape of cystic fibrosis gene therapy,08 10 2024,,Cystic_Fibrosis
"Gallbladder sludge and microlithiasis disappearance in a cystic fibrosis patient 1 year after triple combination therapy initiation Gallstones, microlithiasis, gallbladder sludge, and micro‐gallbladder are frequently reported in cystic fibrosis patients, and modulators could modify gallbladder disease, probably reducing biliary secretions viscosity.",17_0,Gallbladder sludge and microlithiasis disappearance in a cystic fibrosis patient 1 year after triple combination therapy initiation,17 10 2024,,Cystic_Fibrosis
"<boxed-text position=""anchor"" content-type=""graphic"" id=""ccr39468-blkfxd-0001""><graphic http://www.w3.org/1999/xlink href=""CCR3-12-e9481-g002.jpg"" position=""anchor"" id=""jats-graphic-1""></graphic></boxed-text>",17_1,Gallbladder sludge and microlithiasis disappearance in a cystic fibrosis patient 1 year after triple combination therapy initiation,17 10 2024,,Cystic_Fibrosis
<bold>Corrado Tagliati:</bold> Conceptualization; data curation; methodology; writing – original draft. <bold>Daniele Veri:</bold> Conceptualization; data curation; methodology; writing – original draft. <bold>Andrea Pietra:</bold> Conceptualization; data curation; methodology; writing – original draft. <bold>Giuseppe Lanni:</bold> Conceptualization; data curation; methodology; writing – original draft. <bold>Davide Battista:</bold> Conceptualization; data curation; methodology; writing – original draft.,17_2,Gallbladder sludge and microlithiasis disappearance in a cystic fibrosis patient 1 year after triple combination therapy initiation,17 10 2024,,Cystic_Fibrosis
curation; methodology; writing – original draft. <bold>Marco Fogante:</bold> Conceptualization; data curation; methodology; writing – original draft. <bold>Giulio Argalia:</bold> Supervision; validation; visualization. <bold>Cecilia Lanza:</bold> Supervision; validation; visualization. <bold>Stefano Pantano:</bold> Conceptualization; data curation; methodology; writing – original draft. <bold>Francesca Collini:</bold> Conceptualization; data curation; methodology; writing – original draft. <bold>Maria Di,17_3,Gallbladder sludge and microlithiasis disappearance in a cystic fibrosis patient 1 year after triple combination therapy initiation,17 10 2024,,Cystic_Fibrosis
writing – original draft. <bold>Maria Di Sabatino:</bold> Conceptualization; data curation; methodology; writing – original draft. <bold>Pietro Ripani:</bold> Supervision; validation; visualization. None. The authors declare no conflicts of interest. Written informed consent was obtained from the patient to publish this report in accordance with the journal's patient consent policy.,17_4,Gallbladder sludge and microlithiasis disappearance in a cystic fibrosis patient 1 year after triple combination therapy initiation,17 10 2024,,Cystic_Fibrosis
"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis Investigation of chronic cystic fibrosis (CF) lung infections has been limited by a lack of murine models that reproduce obstructive lung pathology, chronicity of bacterial infections, and complex inflammation in human CF lung pathology. Three different approaches have been used separately to address these limitations, including using transgenic <italic",18_0,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"limitations, including using transgenic <italic toggle=""yes"">Scnn1b-Tg</italic> mice overexpressing a lung epithelial sodium channel to mimic the mucus-rich and hyperinflammatory CF lung environment, using synthetic CF sputum medium (SCFM) in an acute infection to induce bacterial phenotypes consistent with human CF, or using agar beads to promote chronic infections. Here, we combine these three models to establish a chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> lung infection model using",18_1,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"aeruginosa</italic> lung infection model using SCFM agar beads and <italic toggle=""yes"">Scnn1b</italic>-Tg mice (SCFM-Tg-mice) to recapitulate nutrients, mucus, and inflammation characteristic of the human CF lung environment. Like people with CF, SCFM-Tg-mice failed to clear bacterial infections. Lung function measurements showed that infected SCFM-Tg-mice had decreased inspiratory capacity and compliance, elevated airway resistance, and significantly reduced FVC and FEV0.1. Using spectral flow cytometry",18_2,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"FVC and FEV0.1. Using spectral flow cytometry and multiplex cytokine arrays we show that, like people with CF, SCFM-Tg-mice developed inflammation characterized by eosinophil infiltration and Th2 lymphocytic cytokine responses. Chronically infected SCFM-Tg-mice developed an exacerbated mix of innate and Th1, Th2, and Th17-mediated inflammation, causing higher lung cellular damage, and elevated numbers of unusual Siglec F<sup>+</sup> neutrophils. Thus, SCFM-Tg-mice represents a powerful tool to investigate",18_3,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"represents a powerful tool to investigate bacterial pathogenesis and potential treatments for chronic CF lung infections and reveal a potential role for Siglec F<sup>+</sup> neutrophils in CF inflammation. <italic toggle=""yes"">Pseudomonas aeruginosa</italic> is a Gram-negative opportunistic bacterium responsible for persistent lung infections in people with muco-obstructive and chronic inflammation like cystic fibrosis (CF). Although primary <italic toggle=""yes"">P. aeruginosa</italic> infection does not",18_4,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"aeruginosa</italic> infection does not seem to cause declined lung function in CF patients (<xref rid=""R1"" ref-type=""bibr"">1</xref>), adaptation and changes in <italic toggle=""yes"">P. aeruginosa</italic> virulence and antibiotic resistance during chronic infections are thought to be the most common cause of pulmonary exacerbations (<xref rid=""R2"" ref-type=""bibr"">2</xref>). Pulmonary exacerbations caused by bacterial infections are characterized by increased mucus production and an amplified inflammatory",18_5,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"mucus production and an amplified inflammatory response leading to irreversible airway damage and a decrease in respiratory spirometry (<xref rid=""R2"" ref-type=""bibr"">2</xref>, <xref rid=""R3"" ref-type=""bibr"">3</xref>). Studying bacterial interactions with the host environment has been challenging since <italic toggle=""yes"">P. aeruginosa</italic> modulates its gene expression in response to environmental nutrients and stress conditions, making <italic toggle=""yes"">in vitro</italic> characterization poorly",18_6,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"vitro</italic> characterization poorly relevant to <italic toggle=""yes"">in vivo</italic> infections (<xref rid=""R4"" ref-type=""bibr"">4</xref>, <xref rid=""R5"" ref-type=""bibr"">5</xref>). To overcome this issue, a synthetic CF sputum-mimicking medium (SCFM2) was developed, and <italic toggle=""yes"">P. aeruginosa</italic> grown in SCFM2 have genetic fitness determinants and gene expression profiles that mirror bacteria grown in sputum collected from people with CF (<xref rid=""R6"" ref-type=""bibr"">6</xref>–<xref",18_7,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"CF (<xref rid=""R6"" ref-type=""bibr"">6</xref>–<xref rid=""R8"" ref-type=""bibr"">8</xref>). However, even with SCFM2, <italic toggle=""yes"">in vitro</italic> studies lack crucial host factors mediating host-pathogen interactions, including the highly inflammatory and oxidative environment produced by immune cells. Multiple <italic toggle=""yes"">in vivo</italic> murine models of chronic <italic toggle=""yes"">P. aeruginosa</italic> infections have been developed over a period of time spanning more than 3 decades",18_8,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"a period of time spanning more than 3 decades (<xref rid=""R9"" ref-type=""bibr"">9</xref>). To establish chronic <italic toggle=""yes"">P. aeruginosa</italic> infections in mice, different strategies have been developed such as growing the strains in aggregates or adding alginate to promote biofilm-like phenotypes (<xref rid=""R10"" ref-type=""bibr"">10</xref>–<xref rid=""R12"" ref-type=""bibr"">12</xref>), using fibrinogen plug models (<xref rid=""R13"" ref-type=""bibr"">13</xref>, <xref rid=""R14""",18_9,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">13</xref>, <xref rid=""R14"" ref-type=""bibr"">14</xref>), or by embedding bacteria in agar beads (<xref rid=""R15"" ref-type=""bibr"">15</xref>–<xref rid=""R18"" ref-type=""bibr"">18</xref>). Using these strategies, most studies were successful in establishing chronic infections in mice. However, these models do not recapitulate CF infections as they utilized healthy mice lacking key pathological lung characteristics seen in human CF disease, including mucus plug and immune cell infiltration (<xref",18_10,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"mucus plug and immune cell infiltration (<xref rid=""R11"" ref-type=""bibr"">11</xref>, <xref rid=""R13"" ref-type=""bibr"">13</xref>, <xref rid=""R16"" ref-type=""bibr"">16</xref>, <xref rid=""R18"" ref-type=""bibr"">18</xref>, <xref rid=""R19"" ref-type=""bibr"">19</xref>). Cystic fibrosis transmembrane conductance regulator (CFTR) mutant mice showed higher sensitivity to <italic toggle=""yes"">P. aeruginosa</italic> infections and developed higher inflammation compared to WT counterparts during chronic infections (<xref",18_11,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"WT counterparts during chronic infections (<xref rid=""R15"" ref-type=""bibr"">15</xref>, <xref rid=""R17"" ref-type=""bibr"">17</xref>). However, like healthy mice, they did not spontaneously develop mucus plugs and complex inflammation underlying CF disease, and thus CFTR mutant mice are not ideal models for studying <italic toggle=""yes"">P. aeruginosa</italic> behavior during chronic CF infections. Notably, the inflammatory response of these models was mainly neutrophilic, while human CF lung inflammation is",18_12,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"neutrophilic, while human CF lung inflammation is also characterized by eosinophilia and lymphocytosis (<xref rid=""R20"" ref-type=""bibr"">20</xref>–<xref rid=""R22"" ref-type=""bibr"">22</xref>). In an attempt to improve the CF mouse model, CF mice with S489X <italic toggle=""yes"">CFTR</italic> mutations were infected with a mucoid clinical isolate of <italic toggle=""yes"">P. aeruginosa</italic> embedded in tryptic soy broth agarose beads. In this agar bead-CF mouse model, CF mice suffered higher mortality than",18_13,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"model, CF mice suffered higher mortality than normal mice, had higher inflammation, and experienced greater weight loss, but the CF mice did not have higher bacterial burdens and also lacked the mucus plugging and pulmonary disease in people with CF (<xref rid=""R23"" ref-type=""bibr"">23</xref>). <italic toggle=""yes"">Scnn1b</italic> transgenic (<italic toggle=""yes"">Scnn1b</italic>-Tg) mice overexpress the βENaC epithelium sodium channel in their lungs, causing CF-like lung pathology including mucus",18_14,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"causing CF-like lung pathology including mucus accumulation and neutrophil infiltration (<xref rid=""R24"" ref-type=""bibr"">24</xref>, <xref rid=""R25"" ref-type=""bibr"">25</xref>). These mice were described to spontaneously develop a juvenile asthmatic inflammation that partially resolved in early adulthood (<xref rid=""R26"" ref-type=""bibr"">26</xref>). Furthermore, these mice were shown to be more sensitive to infection and develop higher inflammatory responses in early days after <italic toggle=""yes"">P.",18_15,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"in early days after <italic toggle=""yes"">P. aeruginosa</italic> infection (<xref rid=""R12"" ref-type=""bibr"">12</xref>, <xref rid=""R13"" ref-type=""bibr"">13</xref>), making them a compelling model to study chronic bacterial infections. Most recently, SCFM2 was used to pre-culture <italic toggle=""yes"">P. aeruginosa</italic> prior to acute lung infection of WT C57BL/6J mice and transcriptomic analyses of bacteria in infected mice revealed that this pre-culture condition promoted improved CF gene expression",18_16,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"condition promoted improved CF gene expression phenotypes in the infecting <italic toggle=""yes"">P. aeruginosa</italic> compared to bacteria pre-grown on Pseudomonas Isolation Agar (<xref rid=""R27"" ref-type=""bibr"">27</xref>). Yet, the authors acknowledged several limitations and suggested that the <italic toggle=""yes"">Scnn1b</italic>-Tg mouse model could further recapitulate CF disease physiology, which we test here. The different mouse models were only partially characterized in terms of lung mechanics and",18_17,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"characterized in terms of lung mechanics and immune response during lung infection, leaving a blind spot in our knowledge of the host-pathogen interaction during chronic infections with <italic toggle=""yes"">P. aeruginosa</italic>. Here, we sought to overcome limitations of previous murine <italic toggle=""yes"">P. aeruginosa</italic> chronic lung infection models. First, we used <italic toggle=""yes"">Scnn1b</italic>-Tg mice to recapitulate the underlying inflammation and obstructive lung pathology seen in",18_18,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"and obstructive lung pathology seen in human CF disease. Next, we used agar beads to promote biofilm aggregate formation and promote chronic infection. Third, we used SCFM2 agar to recapitulate the human CF nutrient environment and promote CF-like gene expression in <italic toggle=""yes"">P. aeruginosa</italic>. Using this multifaceted model named SCFM-Tg-mice, we showed that SCFM-Tg-mice failed to efficiently clear bacterial infection. We used highly translational lung function measurements to demonstrate",18_19,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"lung function measurements to demonstrate the underlying obstructive disease in these mice, and the efficiency of these parameters to track lung decline during chronic infections. We also deciphered the complex immune and inflammatory responses of this model compared to their WT littermates using spectral flow cytometry and a multiplex cytokine array. Like people with CF, chronically infected <italic toggle=""yes"">Scnn1b</italic>-Tg mice developed an exacerbated and complex mix of innate and Th1, Th2, and",18_20,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"and complex mix of innate and Th1, Th2, and Th17-mediated inflammation, causing higher lung cellular damage. Finally, we unveiled new potential players in this complex inflammatory response.  Establishing a murine model of <italic toggle=""yes"">P. aeruginosa</italic> chronic infection that mimics the complex CF lung environment has been challenging investigators for decades (<xref rid=""R9"" ref-type=""bibr"">9</xref>). Researchers have used different engineered murine models, but most of them failed to develop",18_21,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"murine models, but most of them failed to develop spontaneous chronic infections or were limited in recapitulating key aspects of CF lung pathology (<xref rid=""R9"" ref-type=""bibr"">9</xref>). In this study, we used the <italic toggle=""yes"">Scnn1b</italic>-Tg mouse (<xref rid=""R24"" ref-type=""bibr"">24</xref>, <xref rid=""R25"" ref-type=""bibr"">25</xref>), a model already described to develop mucus plugs, inflammation, and obstructive disease, to mimic the CF lung environment. We also used sputum-mimicking media",18_22,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"environment. We also used sputum-mimicking media to embed <italic toggle=""yes"">P. aeruginosa</italic> to further simulate the nutritional and biofilm-promoting environment found in CF airways (<xref rid=""R7"" ref-type=""bibr"">7</xref>). We assessed pulmonary function using SCIREQ flexiVent and used highly translational parameters to characterize our model (<xref rid=""F1"" ref-type=""fig"">Figs. 1</xref> and <xref rid=""F2"" ref-type=""fig"">2</xref>, and fig. S1). We showed that chronic <italic toggle=""yes"">P.",18_23,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"We showed that chronic <italic toggle=""yes"">P. aeruginosa</italic> infection decreased inspiratory capacity and compliance, elevated airway resistance, and significantly reduced FVC and FEV0.1, an equivalent of the gold standard FEV1 measure in clinical spirometry (<xref rid=""R50"" ref-type=""bibr"">50</xref>). We also demonstrated a greater susceptibility to lung function decline for <italic toggle=""yes"">Scnn1b</italic>-Tg mice compared to WT C57BL/6 littermates (Table S1). Similar to human CF disease, our",18_24,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"(Table S1). Similar to human CF disease, our model mainly develops obstructive lung disease that is mixed with restrictive disorder during chronic infection with <italic toggle=""yes"">P. aeruginosa</italic>. CF inflammation is a complex mix of innate and lymphoid inflammation(<xref rid=""R22"" ref-type=""bibr"">22</xref>). It is characterized by high secretion of pro-inflammatory cytokines like IL-6, IL-1β, and TNFα, but also type 2 (IL-4, IL-5, IL-33) and type 3 (IL-17) inflammatory cytokines (<xref rid=""R22""",18_25,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"3 (IL-17) inflammatory cytokines (<xref rid=""R22"" ref-type=""bibr"">22</xref>, <xref rid=""R44"" ref-type=""bibr"">44</xref>, <xref rid=""R51"" ref-type=""bibr"">51</xref>). Our characterization of the lung immune response also showed a complex inflammatory environment resembling the one described in people with CF and is summarized in <xref rid=""F8"" ref-type=""fig"">Fig. 8</xref>. We first confirmed the presence of chronic inflammation at baseline <italic toggle=""yes"">Scnn1b</italic>-Tg mice characterized by higher",18_26,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"mice characterized by higher counts of myeloid- and lymphoid-derived cell counts in the alveolar space (figs. S2 and S3). During chronic infection, although the innate cell counts were similar between <italic toggle=""yes"">Scnn1b</italic>-Tg mice and their WT littermates (<xref rid=""F3"" ref-type=""fig"">Fig. 3</xref>), we showed an exacerbated inflammation by the highly secreted pro-inflammatory cytokines IL-6, IL-1β, and TNFα, and chemokines MIP-1α, CXCL10, MIP-2, and KC/GRO (<xref rid=""F5""",18_27,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"MIP-1α, CXCL10, MIP-2, and KC/GRO (<xref rid=""F5"" ref-type=""fig"">Fig. 5</xref>). This suggests that monocytes, macrophages, and neutrophils may be hyperactivated in the <italic toggle=""yes"">Scnn1b</italic>-Tg lungs. We also describe for the first time the presence of an atypical neutrophil subset positive for the surface lectin Siglec F (<xref rid=""F4"" ref-type=""fig"">Fig. 4</xref>, H and I, and fig. S2). Little is known about these Siglec F<sup>+</sup> neutrophils but they were recently described as long",18_28,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"but they were recently described as long life-span and high ROS activity neutrophils, and were shown to be deleterious in tissue fibrosis and tumor tolerance (<xref rid=""R52"" ref-type=""bibr"">52</xref>–<xref rid=""R55"" ref-type=""bibr"">55</xref>). In a mouse nasal mucosae infection model, high IL-17 secreting Siglec F<sup>+</sup> neutrophils were associated with a better clearance <italic toggle=""yes"">Bordetella pertussis</italic> (<xref rid=""R56"" ref-type=""bibr"">56</xref>). In our study, it is not clear",18_29,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"In our study, it is not clear whether the high recruitment of Siglec F<sup>+</sup> neutrophils is deleterious or a response to the infection to tentatively clear <italic toggle=""yes"">P. aeruginosa.</italic> Shin et al. also described the induction of these unique neutrophils in air pollutant-induced lung damage (<xref rid=""R57"" ref-type=""bibr"">57</xref>). Siglec F<sup>+</sup> neutrophils were associated with exacerbated asthma and triggered emphysema by producing high levels of cysteinyl leukotrienes and",18_30,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"high levels of cysteinyl leukotrienes and neutrophil extracellular traps. <italic toggle=""yes"">In vivo</italic>, Siglec F<sup>+</sup> neutrophils enhanced IL-5 and IL-13 production by Th2 cells and IL-17 secretion by CD4<sup>+</sup> T cells (<xref rid=""R57"" ref-type=""bibr"">57</xref>). Here, since Siglec F<sup>+</sup> neutrophils were already present in the BAL of uninfected <italic toggle=""yes"">Scnn1b</italic>-Tg mice and recruited during chronic infection, we hypothesize that this unique population could",18_31,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"we hypothesize that this unique population could be involved in higher type 2 and 3 inflammatory cytokines seen in the <italic toggle=""yes"">Scnn1b</italic>-Tg mice during chronic infections. Presently, Siglec F<sup>+</sup> neutrophils have not been described in people with CF. However, a unique neutrophil subset called low-density neutrophils was also found in the blood of CF patients and other inflammatory diseases (<xref rid=""R58"" ref-type=""bibr"">58</xref>, <xref rid=""R59"" ref-type=""bibr"">59</xref>).",18_32,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"<xref rid=""R59"" ref-type=""bibr"">59</xref>). Like Siglec F<sup>+</sup> neutrophils, low-density neutrophils showed increased IL-17 production, enhanced degranulation, and decreased phagocytosis (<xref rid=""R58"" ref-type=""bibr"">58</xref>, <xref rid=""R60"" ref-type=""bibr"">60</xref>, <xref rid=""R61"" ref-type=""bibr"">61</xref>). Furthermore, this particular neutrophil subset was associated with pulmonary exacerbations, declined lung function, and disease progression in CF patients (<xref rid=""R59""",18_33,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"progression in CF patients (<xref rid=""R59"" ref-type=""bibr"">59</xref>, <xref rid=""R62"" ref-type=""bibr"">62</xref>). Although we cannot directly compare low-density neutrophils with our Siglec F<sup>+</sup> neutrophils, we speculate that these two neutrophil subsets may have similar effects on chronic inflammation. Since Siglec F<sup>+</sup> neutrophils, but not total neutrophil counts, were increased in <italic toggle=""yes"">Scnn1b</italic>-Tg mice and by the infection (<xref rid=""F4"" ref-type=""fig"">Fig.",18_34,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"the infection (<xref rid=""F4"" ref-type=""fig"">Fig. 4</xref> and fig. S2), we speculate that this specific neutrophil subset may modulate inflammation during chronic infection with <italic toggle=""yes"">P. aeruginosa</italic>. To our knowledge, this is the first time these Siglec F<sup>+</sup> neutrophils have been observed in a CF-like model. Another feature of our model is the evident infiltration of effector CD4<sup>+</sup> T cells at baseline (<xref rid=""F5"" ref-type=""fig"">Fig. 5</xref> and fig. S3) and",18_35,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"ref-type=""fig"">Fig. 5</xref> and fig. S3) and their proliferation during chronic infection in the <italic toggle=""yes"">Scnn1b</italic>-Tg mice (<xref rid=""F5"" ref-type=""fig"">Fig. 5</xref>). Lymphocytosis was also described in CF patients (<xref rid=""R22"" ref-type=""bibr"">22</xref>, <xref rid=""R63"" ref-type=""bibr"">63</xref>) and a skewed response toward Th2 and Th17 inflammation in these patients was associated with <italic toggle=""yes"">P. aeruginosa</italic> infection, declined lung function, and higher",18_36,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"infection, declined lung function, and higher mortality (<xref rid=""R37"" ref-type=""bibr"">37</xref>, <xref rid=""R44"" ref-type=""bibr"">44</xref>). Mueller <italic toggle=""yes"">et al</italic>. demonstrated how this skewed T cell response could result from the CFTR deficiency in lymphocytes (<xref rid=""R64"" ref-type=""bibr"">64</xref>). Interestingly, <italic toggle=""yes"">Scnn1b</italic>-Tg mice, which do not lack the CFTR channel, also show Th2 and Th17 responses during chronic infection (<xref rid=""F7""",18_37,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"during chronic infection (<xref rid=""F7"" ref-type=""fig"">Figure 7</xref>). <italic toggle=""yes"">P. aeruginosa</italic> toxins can also increase type 2 inflammation resulting in higher eosinophil infiltration, cytokine (IL-4, IL-13) and IgE secretion, and mucus production (<xref rid=""R65"" ref-type=""bibr"">65</xref>). It is unclear whether <italic toggle=""yes"">P. aeruginosa</italic> had a role in the maintenance of the Th2 response in our <italic toggle=""yes"">Scnn1b</italic>-Tg mice since no Th2 response was",18_38,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"mice since no Th2 response was induced in WT mice (<xref rid=""F7"" ref-type=""fig"">Fig. 7</xref>). This difference could mean that either the <italic toggle=""yes"">P. aeruginosa</italic> secretome is modulated by the CF-like environment, or that other independent factors are responsible for the Th2 maintenance in the <italic toggle=""yes"">Scnn1b</italic>-Tg mice. Fritzsching <italic toggle=""yes"">et al.</italic> described spontaneous type 2 inflammation in juvenile <italic toggle=""yes"">Scnn1b</italic>-Tg mice",18_39,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"<italic toggle=""yes"">Scnn1b</italic>-Tg mice caused by impaired mucous clearance (<xref rid=""R26"" ref-type=""bibr"">26</xref>). These mice developed an exacerbated eosinophilic response to allergen challenge. In our study, our <italic toggle=""yes"">Scnn1b</italic>-Tg mice also had higher baseline levels of IL-4 and IL-5 and eosinophil counts (<xref rid=""F7"" ref-type=""fig"">Fig. 7</xref> and fig. S2). We believe this underlying asthmatic inflammation could have played a role in the exacerbated inflammatory",18_40,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"played a role in the exacerbated inflammatory response seen in <italic toggle=""yes"">Scnn1b</italic>-Tg mice during chronic infection. Finally, IL-17 is a key player in Th17-mediated (type 3) inflammation and T cell-mediated neutrophil mobilization and activation (<xref rid=""R33"" ref-type=""bibr"">33</xref>, <xref rid=""R42"" ref-type=""bibr"">42</xref>, <xref rid=""R43"" ref-type=""bibr"">43</xref>). IL-17-mediated inflammation was also described in CF patients and was correlated with pulmonary exacerbations and",18_41,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"was correlated with pulmonary exacerbations and infection with <italic toggle=""yes"">P. aeruginosa</italic> (<xref rid=""R44"" ref-type=""bibr"">44</xref>, <xref rid=""R45"" ref-type=""bibr"">45</xref>). The fact that KC/GRO and IL-17 were both upregulated during chronic infection in <italic toggle=""yes"">Scnn1b</italic>-Tg mice (<xref rid=""F6"" ref-type=""fig"">Figs. 6</xref> and <xref rid=""F7"" ref-type=""fig"">7</xref>, and Table S1) underscores the importance of the Th17/neutrophil interplay in the immune response of",18_42,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"interplay in the immune response of this model. To counterbalance and resolve inflammation, regulatory T cells bear an important role by secreting the anti-inflammatory cytokine IL-10. Regulatory T cells were shown to be decreased in CF patients, and positively correlated with FEV1 (<xref rid=""R66"" ref-type=""bibr"">66</xref>). Compared to WT mice, regulatory T cells were increased in <italic toggle=""yes"">Scnn1b</italic>-Tg mice during infection (<xref rid=""F5"" ref-type=""fig"">Fig. 5</xref>), which is",18_43,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"rid=""F5"" ref-type=""fig"">Fig. 5</xref>), which is opposite to what has been reported for CF patients. Nevertheless, their low proportion (1/10<sup>4</sup> to 1/10<sup>3</sup> T cells) (<xref rid=""F5"" ref-type=""fig"">Fig. 5</xref>) and the almost undetectable levels of IL-10 (<xref rid=""F6"" ref-type=""fig"">Fig. 6</xref>) suggest a limited role for the T cell subset in our model. Another T cell subset present in our panel is the CD8<sup>+</sup> T cell. Activated and central memory CD8<sup>+</sup> T cells are",18_44,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"and central memory CD8<sup>+</sup> T cells are important players of type 1 inflammation in response to intracellular pathogens and were upregulated in both WT and <italic toggle=""yes"">Scnn1b</italic>-Tg mice during chronic infection (<xref rid=""F5"" ref-type=""fig"">Fig. 5</xref>). The marked upregulation in central memory CD8<sup>+</sup> T cells (<xref rid=""F5"" ref-type=""fig"">Fig. 5</xref>) and IL-15 secretion (<xref rid=""F6"" ref-type=""fig"">Fig. 6</xref>) in WT mice following infection suggest a role for",18_45,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"in WT mice following infection suggest a role for these cells in <italic toggle=""yes"">P. aeruginosa</italic> clearance. In <italic toggle=""yes"">Scnn1b</italic>-Tg mice, naïve CD8<sup>+</sup> T cells were significantly increased, as for the CD8-derived double negative (DN) T cells (<xref rid=""F5"" ref-type=""fig"">Fig. 5</xref>). Little is known about the role of these DN T cells during infection. Induction of DN T cells in murine models was described in response to intracellular pathogens such as <italic",18_46,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"to intracellular pathogens such as <italic toggle=""yes"">Leishmania major</italic> and <italic toggle=""yes"">Francisella tularensis</italic> (<xref rid=""R67"" ref-type=""bibr"">67</xref>–<xref rid=""R69"" ref-type=""bibr"">69</xref>). In these studies, DN T cells were highly activated and produced IFNγ, TNFα, IL-17, and granzyme B. Although these DN T cells were protective against intracellular pathogens, it is unclear whether they had a role in <italic toggle=""yes"">P. aeruginosa</italic> clearance in our study. To",18_47,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"aeruginosa</italic> clearance in our study. To our knowledge, elevated CD8<sup>+</sup> and DN T cells are not described in CF patients thus, their presence during chronic infection in our mice may represent a limitation of using this model to study the inflammatory response to <italic toggle=""yes"">P. aeruginosa</italic> infection. With its lung obstructive disease, underlying complex inflammation, tissue damage and inability to clear bacterial infection, we believe our SCFM-Tg-mouse model is a suitable",18_48,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"we believe our SCFM-Tg-mouse model is a suitable model to study the host-pathogen interaction during chronic lung infections with <italic toggle=""yes"">P. aeruginosa</italic> and possibly with other pathogens. One primary limitation to our model is that it does not involve a CFTR deficiency, and thus cannot be used for modeling CFTR modulator therapies (<xref rid=""R24"" ref-type=""bibr"">24</xref>, <xref rid=""R70"" ref-type=""bibr"">70</xref>). Because bacterial infections tend to persist in people with CF, even",18_49,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"tend to persist in people with CF, even after CFTR modulator treatment (<xref rid=""R71"" ref-type=""bibr"">71</xref>, <xref rid=""R72"" ref-type=""bibr"">72</xref>), it is important to consider alternative models for modulator-related studies, but also consider their limitations. Other rodent and non-rodent models have been used to reproduce the CF lung pathology (<xref rid=""R9"" ref-type=""bibr"">9</xref>, <xref rid=""R73"" ref-type=""bibr"">73</xref>). CFTR-defective pigs and ferrets have similar lung pathologies to",18_50,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"pigs and ferrets have similar lung pathologies to CF patients and are the only pre-clinical models to develop spontaneous lung infections (<xref rid=""R74"" ref-type=""bibr"">74</xref>–<xref rid=""R79"" ref-type=""bibr"">79</xref>). However, their severe intestinal disease, substantial cost and the strict legislations behind their usage in research can make these models challenging to use in research (<xref rid=""R80"" ref-type=""bibr"">80</xref>). Rat models including the CFTR knockout, the F508del CFTR and the",18_51,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"the CFTR knockout, the F508del CFTR and the humanized G551D models also develop defective in ion transport, airway mucus plugs, and multiorgan defects (<xref rid=""R81"" ref-type=""bibr"">81</xref>–<xref rid=""R84"" ref-type=""bibr"">84</xref>), making them appealing to study CFTR dysfunction using modulators. However, as for mice, rats do not develop spontaneous lung infection, and agar bead strategies were also used in this model to establish chronic infection (<xref rid=""R85"" ref-type=""bibr"">85</xref>).",18_52,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"(<xref rid=""R85"" ref-type=""bibr"">85</xref>). Furthermore, although these rats showed a higher neutrophilic response to infection (<xref rid=""R84"" ref-type=""bibr"">84</xref>, <xref rid=""R85"" ref-type=""bibr"">85</xref>), it is not known whether they develop the complex asthmatic inflammation and lymphocytosis seen in CF patients and in our mouse model. Since our model utilizes SCFM2, and SCFM2 was shown to induce <italic toggle=""yes"">P. aeruginosa</italic> transcriptional profiles similar to those in human CF",18_53,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
"profiles similar to those in human CF sputum in normal mice (<xref rid=""R27"" ref-type=""bibr"">27</xref>), we are confident that this SCFM-Tg-mouse model will be a valuable tool for investigating potential antimicrobials and the evolution of microbes during chronic infection.",18_54,"A chronic <italic toggle=""yes"">Pseudomonas aeruginosa</italic> mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis",07 10 2024,,Cystic_Fibrosis
Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,19_0,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"<fig position=""anchor"" id=""d101e285""><graphic http://www.w3.org/1999/xlink href=""ajplung.00010.2024r01"" position=""float""></graphic></fig> Cystic fibrosis (CF) is a genetic disorder characterized by recurrent airway infections, inflammation, impaired mucociliary clearance, and progressive decline in lung function. The disease may start in the small airways; however, this is difficult to prove due to the limited accessibility of the small airways with the current single-photon mucociliary clearance assay.",19_1,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"single-photon mucociliary clearance assay. Here, we developed a dynamic positron emission tomography assay with high spatial and temporal resolution. We tested that mucociliary clearance is abnormal in the small airways of newborn cystic fibrosis pigs. Clearance of [<sup>68</sup>Ga]-tagged macroaggregated albumin from small airways started immediately after delivery and continued for the duration of the study. Initial clearance was fast but slowed down a few minutes after delivery. Cystic fibrosis pigs’",19_2,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"few minutes after delivery. Cystic fibrosis pigs’ small airways cleared significantly less than non-CF pigs’ small airways (non-CF 25.1 ± 3.1% vs. CF 14.6 ± 0.1%). Stimulation of the cystic fibrosis airways with the purinergic secretagogue uridine-5′-triphosphate (UTP) further impaired clearance (non-CF with UTP 20.9 ± 0.3% vs. CF with UTP 13.0 ± 1.8%). None of the cystic fibrosis pigs treated with UTP (<italic toggle=""yes"">n</italic> = 6) cleared more than 20% of the delivered dose. These data indicate",19_3,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
20% of the delivered dose. These data indicate that mucociliary clearance in the small airways is fast and can easily be missed if the assay is not sensitive enough. The data also indicate that mucociliary clearance is impaired in the small airways of cystic fibrosis pigs. This defect is exacerbated by stimulation of mucus secretions with purinergic agonists. <bold>NEW & NOTEWORTHY</bold> We developed a novel positron emission tomography scan assay with unprecedented temporal and spatial resolution to,19_4,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"unprecedented temporal and spatial resolution to measure mucociliary clearance in the small airways. We proved a long-standing but unproven assertion that mucociliary clearance is inherently abnormal in the small airways of newborn cystic fibrosis piglets that are otherwise free of infection or inflammation. This technique can be easily extended to other airway diseases such as asthma, idiopathic pulmonary fibrosis, or chronic obstructive pulmonary disease. Cystic fibrosis (CF) is a genetic disease caused",19_5,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"Cystic fibrosis (CF) is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (<italic toggle=""yes"">CFTR</italic>) gene with high morbidity and mortality arising from airway involvement (<xref rid=""B1"" ref-type=""bibr"">1</xref>–<xref rid=""B3"" ref-type=""bibr"">3</xref>). Although previous observations in autopsy studies (<xref rid=""B4"" ref-type=""bibr"">4</xref>), spirometry studies (<xref rid=""B5"" ref-type=""bibr"">5</xref>), multiple breath washout studies (<xref",19_6,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"multiple breath washout studies (<xref rid=""B6"" ref-type=""bibr"">6</xref>), and computed tomography (CT) and hyperpolarized <sup>3</sup>He MRI studies (<xref rid=""B7"" ref-type=""bibr"">7</xref>) have hinted at the role of small airways (<xref rid=""B8"" ref-type=""bibr"">8</xref>, <xref rid=""B9"" ref-type=""bibr"">9</xref>) in CF pathogenesis, this hypothesis remained untested due to the lack of a suitable animal model and technical difficulties accessing the small airways (<xref rid=""B2"" ref-type=""bibr"">2</xref>).",19_7,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"(<xref rid=""B2"" ref-type=""bibr"">2</xref>). The mammalian airways branch in a dichotomous pattern for ∼22 generations (<xref rid=""B10"" ref-type=""bibr"">10</xref>, <xref rid=""B11"" ref-type=""bibr"">11</xref>). With each generation of branching, a parent airway splits into ∼2 smaller and shorter daughter airways (<xref rid=""B12"" ref-type=""bibr"">12</xref>, <xref rid=""B13"" ref-type=""bibr"">13</xref>). The small airways are distinctively different from the rest of the conducting airways. They contribute the least to",19_8,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"conducting airways. They contribute the least to total airway resistance (<xref rid=""B14"" ref-type=""bibr"">14</xref>). They have a distinct cuboidal appearance, lack submucosal glands, lack complete cartilage rings, and their secretory cells express surfactant protein D (SPD) (<xref rid=""B15"" ref-type=""bibr"">15</xref>). SPD has a role in reducing airway surface liquid (ASL) surface tension and may help prevent airway closure on expiration (<xref rid=""B16"" ref-type=""bibr"">16</xref>). In young piglets, the",19_9,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">16</xref>). In young piglets, the airways with a diameter less the 200 µm have these characteristics (<xref rid=""B17"" ref-type=""bibr"">17</xref>). We developed a porcine animal model of CF with targeted disruption of the <italic toggle=""yes"">CFTR</italic> gene (<xref rid=""B18"" ref-type=""bibr"">18</xref>). At birth, these pigs show no signs of infection or inflammation; yet their airways are unable to transport particles or kill bacteria (<xref rid=""B19"" ref-type=""bibr"">19</xref>–<xref",19_10,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"(<xref rid=""B19"" ref-type=""bibr"">19</xref>–<xref rid=""B21"" ref-type=""bibr"">21</xref>). As they grow older, they develop the hallmarks of human CF airway disease, including spontaneous bacterial infection, neutrophilic inflammation, and mucus plugging (<xref rid=""B18"" ref-type=""bibr"">18</xref>). We wanted to test the hypothesis that mucociliary clearance is impaired in the small airways of newborn CF piglets that are free of infection or inflammation. However, the current single-photon mucociliary clearance",19_11,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"the current single-photon mucociliary clearance assays are lacking in temporal and spatial resolution. To circumvent these limitations, we developed a novel dynamic positron emission tomography (PET) technique to measure mucus transport in the small airways (<xref rid=""B22"" ref-type=""bibr"">22</xref>).  To investigate small airway clearance, we used two complementary approaches. We first extended the main airway by extrapolating the airway centerline to the pleura. With this approach, we minimized the",19_12,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"the pleura. With this approach, we minimized the signal from the parenchyma, but we limited our analysis to a small number of distal airways. Second, we analyzed the clearance of the peripheral 1.5-mm three-dimensional (3-D) shell where most of the airways are smaller than 200 µm. The submucosal gland duct opening is the site where mucus strands with abnormal biophysical properties get stuck and impede mucociliary transport in the CF large airways (<xref rid=""B20"" ref-type=""bibr"">20</xref>, <xref rid=""B21""",19_13,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"ref-type=""bibr"">20</xref>, <xref rid=""B21"" ref-type=""bibr"">21</xref>). The small airways lack submucosal glands (<xref rid=""B17"" ref-type=""bibr"">17</xref>), so it is conceivable that mucociliary clearance is normal in the CF small airways. Our data show the opposite and indicate that mucociliary clearance is also impaired in the pristine small airways of newborn CF pigs before the onset of infection or inflammation. This defect is accentuated by the stimulation of mucus secretion with purinergic agonists.",19_14,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"of mucus secretion with purinergic agonists. In autopsy studies in CF, mucus plugging or mucoviscidosis in the small airways is a common pathologic finding (<xref rid=""B43"" ref-type=""bibr"">43</xref>). However, the origin of mucus in these mucus plugs is debated. One possibility is that the mucus is secreted in the small airways but because it is not properly cleared, it piles up into mucus plugs (<xref rid=""B8"" ref-type=""bibr"">8</xref>, <xref rid=""B44"" ref-type=""bibr"">44</xref>). Another possibility is",19_15,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"Another possibility is that the mucus originates in the large airways and is deposited in the small airways by mere gravity (<xref rid=""B45"" ref-type=""bibr"">45</xref>). In prior work in newborn CF pigs, we described an unusual abrupt backward movement of mucus strands secreted by submucosal glands in the large airways (<xref rid=""B21"" ref-type=""bibr"">21</xref>). This behavior may offer an explanation. The mucus strands snap, ricochet, and lodge in the small airways. Our current data, however, support the",19_16,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"airways. Our current data, however, support the former explanation and provide insight into the origin of mucus plugs in the small airways. Secretory cells in small airways express mostly mucin 5B (MUC5B), and goblet cells in large airways express mostly mucin 5AC (MUC5AC) (<xref rid=""B46"" ref-type=""bibr"">46</xref>). Submucosal glands in the large airways secrete mostly MUC5B. Because the mucus plugs in the small airways of humans with CF are positive for both MUC5B and MUC5AC (<xref rid=""B45""",19_17,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"for both MUC5B and MUC5AC (<xref rid=""B45"" ref-type=""bibr"">45</xref>), it is reasonable to believe that they may originate in part from submucosal glands in the large airways or a combination of secretory cells and goblet cells (<xref rid=""B46"" ref-type=""bibr"">46</xref>, <xref rid=""B47"" ref-type=""bibr"">47</xref>). CF as a chronic airway inflammatory disease is characterized by goblet cell metaplasia and increased mucus secretion (<xref rid=""B48"" ref-type=""bibr"">48</xref>). In healthy small airways, the",19_18,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"In healthy small airways, the mucin genes are constitutively expressed in secretory cells and mucins are continuously secreted in low amounts (<xref rid=""B46"" ref-type=""bibr"">46</xref>). In goblet cells, mucins are stored in granules and are released in a large amount in response to certain stimuli. Purinergic agonists are potent mucin secretagogues and result in a marked increase (>100 fold) in mucin secretion (<xref rid=""B49"" ref-type=""bibr"">49</xref>). Purinergic agonists exert other effects that are",19_19,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"Purinergic agonists exert other effects that are predicted to increase mucociliary clearance such as activation of non-CFTR chloride channels and increases in ciliary beat frequency (<xref rid=""B42"" ref-type=""bibr"">42</xref>). Our data indicate that excessive mucin secretion in CF small airways impairs mucociliary clearance. This finding is consistent with the ovalbumin-induced allergic goblet cell metaplasia mouse model where purinergic stimulation with adenosine triphosphate (ATP) resulted in excessive",19_20,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"triphosphate (ATP) resulted in excessive mucus occluding the airways (<xref rid=""B50"" ref-type=""bibr"">50</xref>). We previously reported that a combination of acidic ASL pH and decreased liquid secretion in the lumen of submucosal glands contributes to the abnormal viscoelastic properties of mucus strands (<xref rid=""B20"" ref-type=""bibr"">20</xref>, <xref rid=""B21"" ref-type=""bibr"">21</xref>, <xref rid=""B47"" ref-type=""bibr"">47</xref>). Small airway epithelial cultures obtained from pig CF airways have",19_21,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"cultures obtained from pig CF airways have decreased Cl secretion, acidic ASL pH, and increased ASL viscosity (<xref rid=""B17"" ref-type=""bibr"">17</xref>). In vivo measurements are not available due to difficulties accessing the small airways. However, in flattened excised small airways, we found that CF airways cleared fluorescent microspheres slower than non-CF. Moreover, after purinergic stimulation, most of the microspheres in CF pigs got stuck (<xref rid=""B51"" ref-type=""bibr"">51</xref>). Inhalation",19_22,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"rid=""B51"" ref-type=""bibr"">51</xref>). Inhalation deposition patterns of particles in the airways depend, in addition to the physical and chemical characteristics of the particles, on the anatomy and physiology of the respiratory tract (<xref rid=""B52"" ref-type=""bibr"">52</xref>). The small airways of large mammals, including humans and pigs, are similar in size to the large airways of small animals such as mice. This distinction raises the question of whether, in small animals such as mice, the deposition",19_23,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"in small animals such as mice, the deposition of small particles is like that in large mammals such as pigs and humans and whether they are equipped with the same mucus clearance mechanisms. Interestingly, mice airways lack submucosal glands (<xref rid=""B53"" ref-type=""bibr"">53</xref>). In the large airways of humans and pigs with CF, CFTR-mediated <inline-formula><math xmlns=""http://www.w3.org/1998/Math/MathML""><mrow xmlns=""http://www.w3.org/1998/Math/MathML""><mrow",19_24,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"xmlns=""http://www.w3.org/1998/Math/MathML""><mrow xmlns=""http://www.w3.org/1998/Math/MathML""><msubsup xmlns=""http://www.w3.org/1998/Math/MathML""><mrow xmlns=""http://www.w3.org/1998/Math/MathML""><mtext xmlns=""http://www.w3.org/1998/Math/MathML"">HCO</mtext></mrow><mn xmlns=""http://www.w3.org/1998/Math/MathML"">3</mn><mo xmlns=""http://www.w3.org/1998/Math/MathML"">−</mo></msubsup></mrow></mrow></math></inline-formula> secretion is lacking (<xref rid=""B54"" ref-type=""bibr"">54</xref>). As a result, H<sup>+</sup>",19_25,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"As a result, H<sup>+</sup> secretion by ATPase H<sup>+</sup>/K<sup>+</sup> transporting non-gastric alpha2 subunit (ATP12A) is unopposed and the ASL is abnormally acidic (<xref rid=""B19"" ref-type=""bibr"">19</xref>). In mice with CF, the absence of CFTR has little effect on ASL pH because ATP12A is not expressed in mouse airways (<xref rid=""B55"" ref-type=""bibr"">55</xref>). This may be a reason why CF mice do not get CF airway disease. The small airways of humans and pigs do not express ATP12A either (<xref",19_26,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"and pigs do not express ATP12A either (<xref rid=""B55"" ref-type=""bibr"">55</xref>). They are more like mouse airways. Thus, the lack of CFTR-mediated <inline-formula><math xmlns=""http://www.w3.org/1998/Math/MathML""><mrow xmlns=""http://www.w3.org/1998/Math/MathML""><mrow xmlns=""http://www.w3.org/1998/Math/MathML""><msubsup xmlns=""http://www.w3.org/1998/Math/MathML""><mrow xmlns=""http://www.w3.org/1998/Math/MathML""><mtext xmlns=""http://www.w3.org/1998/Math/MathML"">HCO</mtext></mrow><mn",19_27,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"xmlns=""http://www.w3.org/1998/Math/MathML"">3</mn><mo xmlns=""http://www.w3.org/1998/Math/MathML"">−</mo></msubsup></mrow></mrow></math></inline-formula> secretion may have little effect on ASL pH and MCC. However, we found that pigs’ small airways express a V-type proton pump ATPase (ATP6V0D) that is also expressed in the clear cells of the vas deferens (<xref rid=""B51"" ref-type=""bibr"">51</xref>). The localization of this pump on the cell luminal surface is pH-dependent (<xref rid=""B51""",19_28,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"luminal surface is pH-dependent (<xref rid=""B51"" ref-type=""bibr"">51</xref>). Under alkaline pH, it is translocated to the apical membrane where it results in net H<sup>+</sup> secretion (<xref rid=""B51"" ref-type=""bibr"">51</xref>). The ASL pH in cultures of small airways from CF and non-CF pigs is alkaline enough (>7) to allow translocation of the V-ATPase to the apical membrane and, as a result, the CF small airway epithelial cultures were more acidic than their non-CF counterpart (<xref rid=""B19""",19_29,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"than their non-CF counterpart (<xref rid=""B19"" ref-type=""bibr"">19</xref>). Our data are consistent with an abnormal small airway MCT that may be related to abnormally acidic small airway ASL pH (<xref rid=""B51"" ref-type=""bibr"">51</xref>). However, these findings need to be confirmed with direct measurements in vivo and with interventions predicted to alkalinize the ASL. Purinergic stimulation is predicted to induce Cl<sup>−</sup> secretion from non-CFTR channels such as TMEM16A (<xref rid=""B56""",19_30,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"channels such as TMEM16A (<xref rid=""B56"" ref-type=""bibr"">56</xref>). Because of this, a P2Y receptor agonist was tested in people with CF. A phase III trial on 466 people with CF showed no clinical benefit of denufosol compared with placebo (<xref rid=""B57"" ref-type=""bibr"">57</xref>). Even though we have not measured ASL height in CF small airways, our data suggest that increased mucus secretion and the abnormal viscoelastic property of CF mucus outweigh the effects of increased ASL height on small airway",19_31,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"effects of increased ASL height on small airway mucociliary clearance (<xref rid=""B58"" ref-type=""bibr"">58</xref>). This study has many advantages. First, this novel technique measures mucociliary clearance in vivo with high temporal and spatial resolution (<xref rid=""B59"" ref-type=""bibr"">59</xref>, <xref rid=""B60"" ref-type=""bibr"">60</xref>). This technique allows for three-dimensional data analysis in contrast to planar data acquisition with single-photon techniques (<xref rid=""B61""",19_32,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"with single-photon techniques (<xref rid=""B61"" ref-type=""bibr"">61</xref>). In addition, the accompanying high-resolution CT scan allows for regional data analysis. Because each event is recorded and timestamped, reconstruction of the data into images with a range of time frames on the order of seconds is possible and allows capturing of fast clearance (<xref rid=""B59"" ref-type=""bibr"">59</xref>, <xref rid=""B62"" ref-type=""bibr"">62</xref>). Second, we study newborn CF pigs with pristine lungs that lack",19_33,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"newborn CF pigs with pristine lungs that lack infection, inflammation, or airway remodeling. Studying these animals in the newborn age allows us to solely evaluate the innate host defense defects at an early timepoint (<xref rid=""B19"" ref-type=""bibr"">19</xref>, <xref rid=""B23"" ref-type=""bibr"">23</xref>). The animals are also spontaneously breathing during the procedure and are only instrumented for delivery, which allow them to maintain their own airway humidification. Studying pigs is advantageous because",19_34,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"Studying pigs is advantageous because their respiratory physiology resembles humans. They have gland-containing proximal large airways, much like humans, and the CF porcine model reproduces all the hallmarks of CF airway disease, as seen in people with CF (<xref rid=""B2"" ref-type=""bibr"">2</xref>). Third, we delivered radiotracer particles of relevant size directly into the distal airways. Single-photon assays aerosolize radiotracers via a nebulizer that results in a large amount of the tracer depositing in",19_35,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"in a large amount of the tracer depositing in the central large airways even when the target is the peripheral small airways. A distal delivery via a bronchoscope ensures deposition into the most distal airways. This work also has limitations. First, this study is done on a human scanner, designed for imaging lungs in adult humans, with transfer function of the camera that is much larger than the size of newborn piglets. Because of this size discrepancy, the high-resolution CT scan also could not resolve",19_36,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"high-resolution CT scan also could not resolve the small airways (<200 µm airways) in the small-size newborn pigs (<xref rid=""B17"" ref-type=""bibr"">17</xref>). In addition, the particles were instilled into the distal airways and not aerosolized. This becomes less important as we transition this technique for use in humans. To circumvent these limitations, we used two complementary analysis schemes. A traditional concentric 3-D shell scheme with a set depth to encompass most of the small airways and a",19_37,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"to encompass most of the small airways and a region of interest scheme extending from the main airway to the pleura. Second, these schemes are still limited. The concentric 3-D shell will also contain alveoli. The tracer trapped and retained in the alveolar space will underestimate the mucociliary clearance. The smallest airway diameter the CT scan can resolve is 2 mm. Therefore, the extended region of interest to the pleura starts from an airway with a diameter of 2 mm and will contain some airways that",19_38,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"of 2 mm and will contain some airways that are considered large and are rich in submucosal glands. This will overestimate mucociliary clearance. Third, lung disease is known to be heterogeneous, and here, only a subset of the small airways is analyzed. This work, along with previous studies, further characterizes mucus transport in small and large airways in healthy and CF pigs (<xref rid=""B20"" ref-type=""bibr"">20</xref>, <xref rid=""B21"" ref-type=""bibr"">21</xref>, <xref rid=""B47"" ref-type=""bibr"">47</xref>,",19_39,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"<xref rid=""B47"" ref-type=""bibr"">47</xref>, <xref rid=""B63"" ref-type=""bibr"">63</xref>, <xref rid=""B64"" ref-type=""bibr"">64</xref>). The fast temporal aspect of PET allowed us to assess mucociliary clearance in small airways at relevant time points. Therapeutic interventions aimed at treating small airway disease in CF will benefit from this technique. Moreover, since small airways have been implicated in the pathogenesis of diseases that lack large animal models such as asthma, chronic obstructive pulmonary",19_40,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"such as asthma, chronic obstructive pulmonary disease (COPD), and MUC5B promoter variant rs35705950-related idiopathic pulmonary fibrosis (IPF), it would be important to translate this methodology to study humans with these diseases (<xref rid=""B65"" ref-type=""bibr"">65</xref>, <xref rid=""B66"" ref-type=""bibr"">66</xref>). All study data are included in the article and/or supporting information. Code for PET analysis is available from the corresponding author upon request. This work was funded in part by NIH,",19_41,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"request. This work was funded in part by NIH, K08: HL135433 (to M.H.A.A.); NIH, R01: HL167025 (to M.H.A.A.), HL136813 (to D.A.S. and J.Z.); NIH, PPG: HL091842, HL051670 (to D.A.S. and J.Z.); and Cystic Fibrosis Foundation: ABOU20A0-KB (to M.H.A.A.), STOLTZ16XX0 (to D.A.S. and M.H.A.A.), and STOLTZ19R0 (to D.A.S. and M.H.A.A.). The authors declare the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The University of Iowa Research",19_42,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"of this article. The University of Iowa Research Foundation has licensed intellectual property related to gene-modified pigs to Exemplar Genetics. Royalties from that license are shared with D.A.S. D.A.S. has no other financial ties to Exemplar Genetics. None of the other authors has any conflicts of interest, financial or otherwise, to disclose. C.G.S., D.W.D., D.A.S., J.Z., and M.H.A.A. conceived and designed research; C.G.S., B.M.H., N.D.G., R.J.A., D.W.D., and M.H.A.A. performed experiments; C.G.S.,",19_43,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"and M.H.A.A. performed experiments; C.G.S., D.W.D., J.J.S., D.A.S., J.Z., and M.H.A.A. analyzed data; C.G.S., D.W.D., J.J.S., D.A.S., J.Z., and M.H.A.A. interpreted results of experiments; C.G.S., D.A.S., J.Z., and M.H.A.A. prepared figures; C.G.S., D.A.S., J.Z., and M.H.A.A. drafted manuscript; C.G.S., B.M.H., N.D.G., R.J.A., D.W.D., J.J.S., D.A.S., J.Z., and M.H.A.A. edited and revised manuscript; C.G.S., B.M.H., N.D.G., R.J.A., D.W.D., J.J.S., D.A.S., J.Z., and M.H.A.A. approved final version of",19_44,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"J.Z., and M.H.A.A. approved final version of manuscript.",19_45,Mucociliary clearance is impaired in small airways of cystic fibrosis pigs,1 10 2024,,Cystic_Fibrosis
"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study <bold>Background:</bold> The combination of elexacaftor–tezacaftor–ivacaftor modulators (ETI) has improved clinical outcomes for people with cystic fibrosis (pwCF). <bold>Objectives:</bold> This study aimed to evaluate changes in nutritional and morphofunctional assessments, as well as anxiety, depression symptoms, and",20_0,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"as well as anxiety, depression symptoms, and quality of life, in pwCF after starting ETI therapy. <bold>Methods:</bold> This was a prospective observational study. We measured body composition (fat mass [FM] and fat-free mass [FFM]) using bioelectrical impedance analysis (BIA) and skinfold thickness measurements (SMs). We also assessed hand grip strength, dietary intake via surveys, blood and stool biomarkers, symptoms of anxiety and depression using the Hospital Anxiety and Depression Scale [HADS], and",20_1,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"Hospital Anxiety and Depression Scale [HADS], and quality of life through the Cystic Fibrosis Questionnaire—Revised (CFQR). <bold>Results:</bold> A total of 31 pwCF were evaluated. Significant improvements were observed in respiratory function and quality of life, alongside an average weight increase of approximately 5 kg (60% FM and 40% FFM). The prevalence of malnutrition, based on BMI and the FFM index, decreased significantly, while the rate of overweight/obesity increased. Biomarker analysis indicated",20_2,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"increased. Biomarker analysis indicated better nutrient absorption and reduced intestinal inflammation, as evidenced by significant changes in faecal calprotectin, nitrogen, and fat levels, as well as blood lipid and vitamin profiles. <bold>Conclusions:</bold> Despite a reduction in caloric intake, an increase in weight was observed one year after initiating ETI. This increase was attributed to gains in both FM and FFM, suggesting improved metabolic efficiency and nutrient absorption. Both SM and BIA were",20_3,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"and nutrient absorption. Both SM and BIA were found to be useful assessment tools. These findings indicate the need to modify the nutritional approach, focusing on the quality rather than the quantity of intake, and aiming for an appropriate body composition (FFM) rather than solely focusing on BMI. Cystic fibrosis (CF) is a disease caused by the alteration of a single gene, the CFTR gene (cystic fibrosis transmembrane conductance regulator). The protein encoded by the CFTR gene functions as a chloride",20_4,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"encoded by the CFTR gene functions as a chloride channel, and mutations result in a defect in chloride transport in the epithelial cells of the respiratory, hepatobiliary, gastrointestinal, reproductive, pancreatic, and sweat gland systems. Due to the multitude of organs and systems it affects, CF is a complex and multisystemic disease that requires a multidisciplinary approach [<xref rid=""B1-nutrients-16-03293"" ref-type=""bibr"">1</xref>]. Currently, the triple combination of CFTR modulators,",20_5,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"the triple combination of CFTR modulators, elexacaftor–tezacaftor–ivacaftor (ETI), has become the new standard of care for people with CF (pwCF) carrying at least one F508del CFTR variant [<xref rid=""B2-nutrients-16-03293"" ref-type=""bibr"">2</xref>,<xref rid=""B3-nutrients-16-03293"" ref-type=""bibr"">3</xref>]. Data from randomised clinical trials revealed improvements in respiratory outcomes (respiratory symptoms, lung function, exacerbations) and body mass index [<xref rid=""B2-nutrients-16-03293""",20_6,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"mass index [<xref rid=""B2-nutrients-16-03293"" ref-type=""bibr"">2</xref>,<xref rid=""B4-nutrients-16-03293"" ref-type=""bibr"">4</xref>,<xref rid=""B5-nutrients-16-03293"" ref-type=""bibr"">5</xref>], which were largely confirmed in real-world studies [<xref rid=""B6-nutrients-16-03293"" ref-type=""bibr"">6</xref>,<xref rid=""B7-nutrients-16-03293"" ref-type=""bibr"">7</xref>,<xref rid=""B8-nutrients-16-03293"" ref-type=""bibr"">8</xref>]. CF-associated poor nutritional status is a multifactorial syndrome caused by nutrient",20_7,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"is a multifactorial syndrome caused by nutrient malabsorption, inadequate nutrient intake, decreased appetite, and higher energy needs [<xref rid=""B9-nutrients-16-03293"" ref-type=""bibr"">9</xref>]. Poor nutritional status is linked to worse pulmonary function and increased mortality in pwCF. Improved nutritional CF care significantly reduced the rate of malnutrition before the generalisation of ETI modulator treatment; however, figures close to 25% continued to be reported in both children and adults [<xref",20_8,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"to be reported in both children and adults [<xref rid=""B10-nutrients-16-03293"" ref-type=""bibr"">10</xref>,<xref rid=""B11-nutrients-16-03293"" ref-type=""bibr"">11</xref>]. The guidelines emphasise the need to conduct a longitudinal assessment of body composition to obtain estimates of fat mass (FM) and fat-free mass (FFM) [<xref rid=""B3-nutrients-16-03293"" ref-type=""bibr"">3</xref>,<xref rid=""B12-nutrients-16-03293"" ref-type=""bibr"">12</xref>] because their association with respiratory outcomes is stronger than",20_9,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"with respiratory outcomes is stronger than for BMI alone, and because a normal or high BMI can mask low FFM [<xref rid=""B13-nutrients-16-03293"" ref-type=""bibr"">13</xref>,<xref rid=""B14-nutrients-16-03293"" ref-type=""bibr"">14</xref>,<xref rid=""B15-nutrients-16-03293"" ref-type=""bibr"">15</xref>]. This could be important in the context of CFTR modulator therapy [<xref rid=""B3-nutrients-16-03293"" ref-type=""bibr"">3</xref>,<xref rid=""B15-nutrients-16-03293"" ref-type=""bibr"">15</xref>]. The choice of body",20_10,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"ref-type=""bibr"">15</xref>]. The choice of body composition (BC) method should be guided based on availability, resources, technical factors, and clinical factors [<xref rid=""B12-nutrients-16-03293"" ref-type=""bibr"">12</xref>]. Weight improvements have been published in the vast majority of real-life studies after ETI treatment [<xref rid=""B6-nutrients-16-03293"" ref-type=""bibr"">6</xref>,<xref rid=""B7-nutrients-16-03293"" ref-type=""bibr"">7</xref>,<xref rid=""B8-nutrients-16-03293"" ref-type=""bibr"">8</xref>].",20_11,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"ref-type=""bibr"">8</xref>]. However, few have evaluated the change in BC [<xref rid=""B11-nutrients-16-03293"" ref-type=""bibr"">11</xref>,<xref rid=""B16-nutrients-16-03293"" ref-type=""bibr"">16</xref>,<xref rid=""B17-nutrients-16-03293"" ref-type=""bibr"">17</xref>,<xref rid=""B18-nutrients-16-03293"" ref-type=""bibr"">18</xref>,<xref rid=""B19-nutrients-16-03293"" ref-type=""bibr"">19</xref>], and the findings regarding which components—fat mass and/or fat-free mass—increase remain inconsistent. Additionally, no study has",20_12,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"remain inconsistent. Additionally, no study has examined the use of anthropometric methods, such as skinfold thickness measurements (SMs), in patient follow-up. These could be particularly useful in settings where more advanced techniques like bioelectrical impedance analysis (BIA), dual-energy X-ray absorptiometry (DXA), ultrasonography, or computed tomography (CT) are unavailable. The mechanisms behind weight gain after ETI remain unclear and are likely multifactorial. Improvements in intestinal",20_13,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"likely multifactorial. Improvements in intestinal absorption [<xref rid=""B20-nutrients-16-03293"" ref-type=""bibr"">20</xref>] and changes in biomarkers such as lipids and vitamins have been observed [<xref rid=""B8-nutrients-16-03293"" ref-type=""bibr"">8</xref>,<xref rid=""B20-nutrients-16-03293"" ref-type=""bibr"">20</xref>]. Moreover, only one study has prospectively evaluated dietary intake [<xref rid=""B21-nutrients-16-03293"" ref-type=""bibr"">21</xref>]. It is important to note that dietary intake may be",20_14,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"is important to note that dietary intake may be influenced by anxiety and depression symptoms, which are common in pwCF and may, in turn, affect their quality of life in all its dimensions [<xref rid=""B22-nutrients-16-03293"" ref-type=""bibr"">22</xref>]. To date, no study has holistically evaluated all these aspects. With this background, the objective of this study was to prospectively and comprehensively assess mid-term changes in morphofunctional evaluation, including body composition (via BIA and SM),",20_15,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"including body composition (via BIA and SM), hand dynamometry, prospective dietary surveys, blood and stool biomarkers, as well as symptoms of anxiety and depression, and quality of life in adults with cystic fibrosis (pwCF) following the initiation of ETI therapy. Design: Prospective observational study of routine clinical practice. Adult pwCF from the Cystic Fibrosis Adult Unit who began taking elexacaftor–tezacaftor–ivacaftor were eligible for inclusion and were studied at baseline and one year after",20_16,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"and were studied at baseline and one year after starting ETI treatment. A total of 34 adults with CF who initiated ETI were recruited, among which three were excluded during follow-up (one for lack of compliance and two for voluntarily undertaking a low-calorie diet to lose weight during the follow-up period). The patients began treatment with ETI at a mean age of 30.7 ± 9 years, and the average follow-up time was 1 year and 1 month. F508del homozygotes made up 29% of the study cohort, F508del",20_17,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"made up 29% of the study cohort, F508del heterozygotes 58%, and four patients (13%) received treatment as compassionate use (without the F508del mutation). Twenty-seven (87%) had pancreatic insufficiency, eight (26%) had carbohydrate intolerance, and seven had CF-related diabetes (22.5%), among which six received insulin treatment (19%). All patients treated with insulin continued the treatment after one year, and one person with carbohydrate intolerance achieved a normal curve without changes in the rest.",20_18,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"a normal curve without changes in the rest. Seven subjects were receiving oral nutritional supplements (ONSs) before treatment, and one person was on enteral nutrition via gastrostomy. After one year, only two continued ONSs, and gastrostomy was removed 6 months after starting ETI. Seven patients had HADSa (Hospital Anxiety and Depression Scale anxiety subscale) scores above 8, and after one year, only five remained the same; two had HADSd (depression subscale) scores above 8, and these remained unchanged",20_19,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"scores above 8, and these remained unchanged after one year. <xref rid=""nutrients-16-03293-t001"" ref-type=""table"">Table 1</xref>, <xref rid=""nutrients-16-03293-t002"" ref-type=""table"">Table 2</xref>, <xref rid=""nutrients-16-03293-t003"" ref-type=""table"">Table 3</xref>, <xref rid=""nutrients-16-03293-t004"" ref-type=""table"">Table 4</xref> and <xref rid=""nutrients-16-03293-t005"" ref-type=""table"">Table 5</xref> summarise the changes before and after treatment with ETI. We observed significant differences in",20_20,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"with ETI. We observed significant differences in respiratory spirometric parameters, exacerbations, and chronic colonisation by Staphylococcus aureus (<xref rid=""nutrients-16-03293-t001"" ref-type=""table"">Table 1</xref>); weight and body composition (BMI, FM, FFM, FFM index, and the percentage of people with malnutrition, overweight/obesity, and FFM malnutrition), both measured by SM and BIA (<xref rid=""nutrients-16-03293-t002"" ref-type=""table"">Table 2</xref>); calories from dietary intake and grams of",20_21,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"calories from dietary intake and grams of macronutrients (total and monounsaturated fats and carbohydrates) (<xref rid=""nutrients-16-03293-t003"" ref-type=""table"">Table 3</xref>); LDL cholesterol, HbA1C, immunoglobulin G, vitamin A, nitrogen, fat, and faecal calprotectin (<xref rid=""nutrients-16-03293-t004"" ref-type=""table"">Table 4</xref>); and quality of life dimensions: vitality, body, eating, treatment, health, weight, and respiratory (<xref rid=""nutrients-16-03293-t005"" ref-type=""table"">Table 5</xref>).",20_22,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"ref-type=""table"">Table 5</xref>). The weight gain was significantly greater (<italic toggle=""yes"">p</italic> < 0.05) in patients with CF with a BMI less than 18.5 kg/m² at the beginning (<italic toggle=""yes"">n</italic> = 7: 7.2 ± 5 kg) and also in those with overweight or obesity (OW/O) (<italic toggle=""yes"">n</italic> = 5: 9.7 ± 5.4 kg) compared to those with normal weight (<italic toggle=""yes"">n</italic> = 19: 2.7 ± 2.7 kg). We observed significant negative correlations between the increase in weight",20_23,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"correlations between the increase in weight (<italic toggle=""yes"">p</italic> = 0.043), FM (<italic toggle=""yes"">p</italic> = 0.023), and FFM (<italic toggle=""yes"">p</italic> = 0.033) measured by skinfolds and the baseline FEV1/FVC ratio, as well as positive correlations between the number of severe exacerbations in the year prior to starting ETI and the increase in FFM (BIA) (<italic toggle=""yes"">p</italic> = 0.022) and almost significant FFM by skinfolds (<italic toggle=""yes"">p</italic> = 0.08). In our",20_24,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"(<italic toggle=""yes"">p</italic> = 0.08). In our study, we observed an average weight increase of approximately 5 kg during the first year of follow-up, consisting of 60% fat mass and 40% fat-free mass. Both skinfold measurements and bioelectrical impedance analysis were useful, yielding very similar results. These changes were accompanied by improvements in pulmonary function, quality of life, a decrease in caloric intake, and enhancements in biomarkers related to absorption and intestinal inflammation.",20_25,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"to absorption and intestinal inflammation. Adults with CF one year after initiating ETI treatment increased weight at the expense of FM and FFM. Both SM and BIA were useful for the longitudinal monitoring of body composition. These changes were parallel to improvements in pulmonary function, quality of life, biomarkers related to absorption and intestinal inflammation, and a decrease in caloric intake and the need for oral nutritional supplements. These results emphasise the importance of monitoring",20_26,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"results emphasise the importance of monitoring patients with CF with a focus on the quality rather than quantity of intake, and on body composition and exercise rather than BMI. Future studies with larger cohorts are essential to validate these results and further elucidate the mechanisms underlying these changes.",20_27,"Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study",28 9 2024,,Cystic_Fibrosis
"TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis Cystic fibrosis (CF) is a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (<italic toggle=""yes"">CFTR</italic>) gene, resulting in defective chloride ion channels. This leads to thick, dehydrated mucus that severely disrupts mucociliary clearance in the respiratory system and triggers infection that eventually is the cause of death of CF patients. Current therapeutic strategies primarily",21_0,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"Current therapeutic strategies primarily focus on restoring CFTR function, blocking epithelial sodium channels to prevent mucus dehydration, or directly targeting mucus to reduce its viscosity. Among the ion channels expressed in ciliated bronchial epithelial cells, the transient receptor potential vanilloid 4 (TRPV4) channel emerges as a significant channel in CF pathogenesis. Activation of TRPV4 channels affects the regulation of airway surface liquid by modulating sodium absorption and intracellular",21_1,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"by modulating sodium absorption and intracellular calcium levels, which indirectly influences CFTR activity. TRPV4 is also involved in the regulatory volume decrease (RVD) process and enhances inflammatory responses in CF patients. Here, we combine current findings on TRPV4 channel modulation as a promising therapeutic approach for CF. Although limited studies have directly explored TRPV4 in CF, emerging evidence indicates that TRPV4 activation can significantly impact key pathological processes in the",21_2,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"impact key pathological processes in the disease. Further investigation into TRPV4 modulators could lead to innovative treatments that alleviate severe respiratory complications and improve outcomes for CF patients. The human airway is protected by an advanced defense system that maintains lung sterility. Inhaled particles are consistently cleared from the airways via mucociliary clearance (MCC), which is crucial for respiratory health [<xref rid=""B1-ijms-25-10551"" ref-type=""bibr"">1</xref>]. The MCC system",21_3,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"ref-type=""bibr"">1</xref>]. The MCC system comprises two primary components: mucus secreted by goblet cells and submucosal glands, which trap microbes and debris, and tiny hair-like motile cilia that line the airways and beat in a continuous rhythmic motion. The apical airway surface is lined by a complex airway surface liquid (ASL), consisting of two distinct layers. The upper gel-like mucus layer traps inhaled pathogens, while the underlying less viscous periciliary liquid (PCL) lubricates the airway",21_4,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"periciliary liquid (PCL) lubricates the airway surface, enabling the cilia to beat efficiently (<xref rid=""ijms-25-10551-f001"" ref-type=""fig"">Figure 1</xref>A) [<xref rid=""B2-ijms-25-10551"" ref-type=""bibr"">2</xref>,<xref rid=""B3-ijms-25-10551"" ref-type=""bibr"">3</xref>]. Adenosine triphosphate (ATP) is a vital energy source for ciliary motion. Motile cilia are primarily found on the ciliated epithelium lining the respiratory tract, brain ventricles, fallopian tubes, and spinal cord [<xref",21_5,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"fallopian tubes, and spinal cord [<xref rid=""B3-ijms-25-10551"" ref-type=""bibr"">3</xref>,<xref rid=""B4-ijms-25-10551"" ref-type=""bibr"">4</xref>]. Respiratory cilia are highly specialized hair-like structures primarily composed of microtubule-based organelles originating from basal bodies on the apical membranes of airway epithelial cells [<xref rid=""B3-ijms-25-10551"" ref-type=""bibr"">3</xref>,<xref rid=""B5-ijms-25-10551"" ref-type=""bibr"">5</xref>]. Each ciliated airway epithelial cell contains approximately",21_6,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"airway epithelial cell contains approximately 200–300 cilia. The structure of a motile cilium includes a microtubule-based axoneme with two single microtubules at the center, surrounded by nine peripheral doublet microtubules, forming a “9 + 2” arrangement. Each outer microtubule pair is equipped with inner and outer dynein arms, which produce the required energy for motility through ATP hydrolysis [<xref rid=""B3-ijms-25-10551"" ref-type=""bibr"">3</xref>,<xref rid=""B4-ijms-25-10551""",21_7,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"rid=""B4-ijms-25-10551"" ref-type=""bibr"">4</xref>,<xref rid=""B6-ijms-25-10551"" ref-type=""bibr"">6</xref>] (<xref rid=""ijms-25-10551-f001"" ref-type=""fig"">Figure 1</xref>B). Motile cilia beat in a coordinated metachronous pattern, facilitating the movement of inhaled debris trapped in the mucus layer out of the airways [<xref rid=""B7-ijms-25-10551"" ref-type=""bibr"">7</xref>]. The cilium moves forward quickly and forcefully in a power stroke to propel the mucus gel layer. This is followed by a slower recovery",21_8,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"gel layer. This is followed by a slower recovery phase, during which the cilium bends backward at a 90° angle, moving along the same plane to return to its initial position [<xref rid=""B2-ijms-25-10551"" ref-type=""bibr"">2</xref>,<xref rid=""B3-ijms-25-10551"" ref-type=""bibr"">3</xref>]. Defects in ciliary function can severely hinder MCC, leading to various airway diseases such as cystic fibrosis, a classic example of a respiratory disorder resulting from defective MCC [<xref rid=""B7-ijms-25-10551""",21_9,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"from defective MCC [<xref rid=""B7-ijms-25-10551"" ref-type=""bibr"">7</xref>]. The TRPV4 cation channel, a member of the transient receptor potential (TRP) vanilloid subfamily, plays a crucial role in cell volume homeostasis, medium viscosity, and the regulation of ciliary beat frequency (CBF) in epithelial cells [<xref rid=""B8-ijms-25-10551"" ref-type=""bibr"">8</xref>,<xref rid=""B9-ijms-25-10551"" ref-type=""bibr"">9</xref>]. Activated by various stimuli such as heat, mechanical forces, hypo-osmolarity, and",21_10,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"as heat, mechanical forces, hypo-osmolarity, and arachidonic acid metabolites, TRPV4 integrates multiple environmental signals through its diverse regulatory sites [<xref rid=""B10-ijms-25-10551"" ref-type=""bibr"">10</xref>]. TRPV4 has demonstrated high druggability, with various chemotypes yielding potent ligands that exhibit oral bioavailability and favorable drug-like characteristics [<xref rid=""B11-ijms-25-10551"" ref-type=""bibr"">11</xref>]. This channel is essential for the physiology of ciliated",21_11,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"is essential for the physiology of ciliated epithelia and has been implicated in modulating respiratory function. Understanding the signaling mechanisms that govern TRPV4 function is vital, as it holds potential as a therapeutic target for respiratory diseases, including cystic fibrosis, the most prevalent muco-obstructive disease [<xref rid=""B12-ijms-25-10551"" ref-type=""bibr"">12</xref>,<xref rid=""B13-ijms-25-10551"" ref-type=""bibr"">13</xref>]. Cystic fibrosis (CF) is an inherited condition caused by",21_12,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"fibrosis (CF) is an inherited condition caused by mutations in the cystic fibrosis transmembrane conductance regulator (<italic toggle=""yes"">CFTR</italic>) gene. Over 2000 CFTR mutations have been identified, leading to dysregulated ion transport characterized by increased sodium absorption and reduced chloride and bicarbonate secretion into the ASL [<xref rid=""B14-ijms-25-10551"" ref-type=""bibr"">14</xref>]. This imbalance decreases the water content in both the mucus and periciliary layers, producing",21_13,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"both the mucus and periciliary layers, producing thick, sticky mucus that impairs ciliary function [<xref rid=""B15-ijms-25-10551"" ref-type=""bibr"">15</xref>]. Although infants with CF are born with seemingly normal lungs, they progressively develop chronic lung disease due to impaired mucociliary clearance, resulting in recurrent infections and bronchiectasis [<xref rid=""B16-ijms-25-10551"" ref-type=""bibr"">16</xref>,<xref rid=""B17-ijms-25-10551"" ref-type=""bibr"">17</xref>]. Respiratory failure remains the",21_14,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"Respiratory failure remains the leading cause of mortality in individuals with cystic fibrosis [<xref rid=""B18-ijms-25-10551"" ref-type=""bibr"">18</xref>]. Cystic fibrosis was considered a fatal childhood disease, with limited treatment options and an inappropriate prognosis [<xref rid=""B19-ijms-25-10551"" ref-type=""bibr"">19</xref>]. The transient receptor potential (TRP) multigene superfamily channels were originally discovered in Drosophila as phototransduction proteins. This action led to the",21_15,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"proteins. This action led to the identification of a large family of proteins (<xref rid=""ijms-25-10551-f003"" ref-type=""fig"">Figure 3</xref>) [<xref rid=""B33-ijms-25-10551"" ref-type=""bibr"">33</xref>,<xref rid=""B34-ijms-25-10551"" ref-type=""bibr"">34</xref>]. There are 28 mammalian TRP channels, which are divided into seven subfamilies: TRPA (ankyrin), TRPM (melastatin), TRPC (canonical), TRPV (vanilloid), TRPP (polycystin), TRPML (mucolipin), and TRPN (NOMPC-like). The latter is found only in invertebrates",21_16,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"The latter is found only in invertebrates and fish [<xref rid=""B17-ijms-25-10551"" ref-type=""bibr"">17</xref>,<xref rid=""B35-ijms-25-10551"" ref-type=""bibr"">35</xref>,<xref rid=""B36-ijms-25-10551"" ref-type=""bibr"">36</xref>]. TRP channels are involved in a variety of sensory responses, such as heat, cold, pain, stress, vision, and taste, and can be triggered by numerous stimuli. Their primary presence on the cell surface, interaction with various physiological signaling pathways, and distinctive structure make",21_17,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"pathways, and distinctive structure make TRP channels probable for drug targets. This involvement suggests their potential to treat a broad spectrum of diseases [<xref rid=""B37-ijms-25-10551"" ref-type=""bibr"">37</xref>]. TRP ion channels are broadly expressed in various tissues and cell types and are involved in diverse physiological processes, such as the sensation of different stimuli or ion homeostasis [<xref rid=""B38-ijms-25-10551"" ref-type=""bibr"">38</xref>]. TRP channels are nonselective cation",21_18,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"TRP channels are nonselective cation channels, only a few are highly Ca<sup>2+</sup>-selective, and some are permeable for Mg<sup>2+</sup> ions. The TRP channel family can be activated by different mechanisms, from ligand binding, voltage, and changes in temperature to covalent modifications of nucleophilic residues [<xref rid=""B34-ijms-25-10551"" ref-type=""bibr"">34</xref>]. When TRP channels are activated, they cause the cellular membrane to depolarize, subsequently triggering voltage-dependent ion",21_19,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"subsequently triggering voltage-dependent ion channels and alterations in intracellular Ca<sup>2+</sup> levels. Consequently, TRP channels are essential for functioning in intracellular organelles such as endosomes and lysosomes [<xref rid=""B39-ijms-25-10551"" ref-type=""bibr"">39</xref>]. TRP gene mutation has been linked to various pathological states, including pain, skeletal dysplasia, lung diseases, and neurodegenerative disorders [<xref rid=""B40-ijms-25-10551"" ref-type=""bibr"">40</xref>,<xref",21_20,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"ref-type=""bibr"">40</xref>,<xref rid=""B41-ijms-25-10551"" ref-type=""bibr"">41</xref>]. Targeting the TRP channels may offer new therapeutic approaches for related diseases [<xref rid=""B28-ijms-25-10551"" ref-type=""bibr"">28</xref>]. In lung diseases, TRPA1, TRPC4, TRPC6, TRPM2, TRPM8, TRPV1, and TRPV4 are the TRP channels most abundantly expressed in lung tissues (<xref rid=""ijms-25-10551-f003"" ref-type=""fig"">Figure 3</xref>) [<xref rid=""B36-ijms-25-10551"" ref-type=""bibr"">36</xref>]. TRP channels play a crucial",21_21,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"TRP channels play a crucial role in maintaining cellular ion homeostasis, particularly for Ca<sup>2+</sup> and Na<sup>+</sup> that are vital for various functions in respiratory tract cells. Additionally, TRP channels may help detect and defend against harmful substances in inhaled air [<xref rid=""B42-ijms-25-10551"" ref-type=""bibr"">42</xref>]. Many TRP channels are present in immune cells, where they regulate functions such as cytokine expression, migration, and phagocytic activity [<xref",21_22,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"migration, and phagocytic activity [<xref rid=""B12-ijms-25-10551"" ref-type=""bibr"">12</xref>]. In the epithelial layer, the expression of TRP channels is significant in the pathogenesis of inflammatory disorders, primarily through the control of chemokine and cytokine expression and release. TRPA1 channels, for example, were found to modulate the inflammatory response in CF bronchial epithelia exposed to planktonic bacteria or mucopurulent material, mimicking <italic toggle=""yes"">P. aeruginosa</italic>",21_23,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"<italic toggle=""yes"">P. aeruginosa</italic> infection [<xref rid=""B12-ijms-25-10551"" ref-type=""bibr"">12</xref>,<xref rid=""B43-ijms-25-10551"" ref-type=""bibr"">43</xref>]. TRPC6 channels in respiratory diseases are also involved in various cell types, such as macrophages, neutrophils, and smooth muscle cells. In CF human airway epithelial cells, TRPC6-mediated Ca<sup>2+</sup> influx was significantly increased compared to non-CF cells when exposed to a diacylglycerol analog that activates TRPC6, highlighting",21_24,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"analog that activates TRPC6, highlighting the significance of these channels in CF [<xref rid=""B44-ijms-25-10551"" ref-type=""bibr"">44</xref>]. The TRPV4 cation channel, a member of the transient receptor potential (TRP) vanilloid subfamily, plays a crucial role in cell volume homeostasis [<xref rid=""B45-ijms-25-10551"" ref-type=""bibr"">45</xref>], medium viscosity regulation [<xref rid=""B46-ijms-25-10551"" ref-type=""bibr"">46</xref>], and the modulation of ciliary beat frequency [<xref rid=""B47-ijms-25-10551""",21_25,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"beat frequency [<xref rid=""B47-ijms-25-10551"" ref-type=""bibr"">47</xref>]. The TRPV family, involving TRPV1 through TRPV6, consists of polymodal channels that can sense thermal, acidic, mechanical stress, and osmotic stimuli (<xref rid=""ijms-25-10551-t001"" ref-type=""table"">Table 1</xref>) [<xref rid=""B48-ijms-25-10551"" ref-type=""bibr"">48</xref>]. TRPV4 channels respond to various stimuli and are activated by heat, mechanical stimuli, hypo-osmolarity, and arachidonic acid metabolites [<xref",21_26,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"and arachidonic acid metabolites [<xref rid=""B49-ijms-25-10551"" ref-type=""bibr"">49</xref>]. Activation of TRPV4 increases intracellular calcium levels, which enhances ciliary beat frequency [<xref rid=""B50-ijms-25-10551"" ref-type=""bibr"">50</xref>]. This mechanism can help alleviate obstructive pulmonary diseases, highlighting the potential of TRPV4 as a therapeutic target in cystic fibrosis [<xref rid=""B10-ijms-25-10551"" ref-type=""bibr"">10</xref>]. Cystic fibrosis, the most common inherited disease",21_27,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"fibrosis, the most common inherited disease affecting respiratory cilia, is caused by mutations in the CFTR gene, leading to impaired electrolyte balance and severe respiratory complications, including mucociliary dysfunction and eventually respiratory failure [<xref rid=""B15-ijms-25-10551"" ref-type=""bibr"">15</xref>,<xref rid=""B89-ijms-25-10551"" ref-type=""bibr"">89</xref>,<xref rid=""B90-ijms-25-10551"" ref-type=""bibr"">90</xref>]. Despite the critical role of cilia in CF pathology, molecular studies of",21_28,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"of cilia in CF pathology, molecular studies of ciliated cells in human airways remain limited [<xref rid=""B17-ijms-25-10551"" ref-type=""bibr"">17</xref>]. CF is characterized by impaired mucociliary clearance due to thick, dehydrated mucus that cilia cannot effectively clear from the airways, leading to recurrent infections and, eventually, respiratory failure [<xref rid=""B15-ijms-25-10551"" ref-type=""bibr"">15</xref>,<xref rid=""B91-ijms-25-10551"" ref-type=""bibr"">91</xref>]. This pathology results from the",21_29,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"This pathology results from the dysfunction of the CFTR chloride channel, which disrupts ion balance by reducing Cl<sup>-</sup> secretion and increasing Na<sup>+</sup> absorption through the epithelial sodium channel (ENaC), resulting in the dehydration of the ASL and production of viscous mucus [<xref rid=""B17-ijms-25-10551"" ref-type=""bibr"">17</xref>,<xref rid=""B90-ijms-25-10551"" ref-type=""bibr"">90</xref>,<xref rid=""B92-ijms-25-10551"" ref-type=""bibr"">92</xref>]. Multiple studies have explored potential",21_30,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"Multiple studies have explored potential therapeutic strategies for CF, including restoring CFTR function [<xref rid=""B93-ijms-25-10551"" ref-type=""bibr"">93</xref>], blocking ENaC [<xref rid=""B94-ijms-25-10551"" ref-type=""bibr"">94</xref>,<xref rid=""B95-ijms-25-10551"" ref-type=""bibr"">95</xref>,<xref rid=""B96-ijms-25-10551"" ref-type=""bibr"">96</xref>], and reducing mucus viscosity [<xref rid=""B97-ijms-25-10551"" ref-type=""bibr"">97</xref>]. Here, we present the various effects of TRPV4 modulation in CF. Over the",21_31,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"effects of TRPV4 modulation in CF. Over the past decade, TRPV4 has emerged as a promising pharmacological target, with significant progress in developing potent and selective modulators. Understanding the druggability of TRPV4 channels and their ligands is essential for developing therapies in various medical fields such as oncology, cardiovascular diseases, and respiratory diseases. Although TRPV4 shows promising therapeutic potential, its druggability depends on the development of specific and effective",21_32,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"on the development of specific and effective ligands [<xref rid=""B41-ijms-25-10551"" ref-type=""bibr"">41</xref>]. While biophysical and biochemical studies have advanced our understanding of TRPV4’s gating mechanisms and modulators [<xref rid=""B11-ijms-25-10551"" ref-type=""bibr"">11</xref>,<xref rid=""B106-ijms-25-10551"" ref-type=""bibr"">106</xref>,<xref rid=""B107-ijms-25-10551"" ref-type=""bibr"">107</xref>], more structural studies are needed to clarify modulator binding sites, mutations, and functional changes",21_33,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"binding sites, mutations, and functional changes [<xref rid=""B108-ijms-25-10551"" ref-type=""bibr"">108</xref>]. Recently, a human TRPV4 structure has shown that certain compounds bind in a common region, the vanilloid pocket, located within a cytosol-facing cavity between the S1–S4 helices and the TRP box (<xref rid=""ijms-25-10551-f005"" ref-type=""fig"">Figure 5</xref>) [<xref rid=""B109-ijms-25-10551"" ref-type=""bibr"">109</xref>,<xref rid=""B110-ijms-25-10551"" ref-type=""bibr"">110</xref>]. The hTRPV4 cavity is",21_34,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"ref-type=""bibr"">110</xref>]. The hTRPV4 cavity is primarily composed of aromatic and polar residues, with polar side chains concentrated near the top of the transmembrane helix and aromatic rings centrally positioned [<xref rid=""B64-ijms-25-10551"" ref-type=""bibr"">64</xref>]. This arrangement allows various ligands, both agonists and antagonists, to enter and stably bind within the cavity [<xref rid=""B69-ijms-25-10551"" ref-type=""bibr"">69</xref>]. The identification of selective and potent TRPV4 antagonists",21_35,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"of selective and potent TRPV4 antagonists has enhanced our understanding of the functions of TRPV4 and was crucial for advancing therapies targeting this channel [<xref rid=""B111-ijms-25-10551"" ref-type=""bibr"">111</xref>]. The first synthetic TRPV4-selective agonist identified was 4α-PDD, which has shown efficacy in activating TRPV4 without triggering protein kinase C (PKC) activity, a common side effect in related compounds (<xref rid=""ijms-25-10551-t003"" ref-type=""table"">Table 3</xref>) [<xref",21_36,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"ref-type=""table"">Table 3</xref>) [<xref rid=""B112-ijms-25-10551"" ref-type=""bibr"">112</xref>]. Site-directed mutagenesis experiments suggested that 4α-PDD binds within a pocket between the S3 and S4 helices, with key residues Y556, L584, W586, Y591, and R594 playing crucial roles in TRPV4 gating dependent on 4α-PDD [<xref rid=""B113-ijms-25-10551"" ref-type=""bibr"">113</xref>]. Advances in TRPV4 structural studies reveal that the agonist shares the same binding site as 4α-PDD [<xref rid=""B114-ijms-25-10551""",21_37,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"site as 4α-PDD [<xref rid=""B114-ijms-25-10551"" ref-type=""bibr"">114</xref>]. GSK1016790A, a highly potent and selective activator, effectively induces TRPV4-mediated calcium influx and enhances ciliary activity in airway epithelial cells [<xref rid=""B115-ijms-25-10551"" ref-type=""bibr"">115</xref>]. GSK1016790A is also extensively used in pharmacological research to explore TRPV4 activation [<xref rid=""B116-ijms-25-10551"" ref-type=""bibr"">116</xref>]. Endogenous activators, including oxidative metabolites of",21_38,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"activators, including oxidative metabolites of arachidonic acid like 5,6-epoxyeicosatrienoic acid, further demonstrate TRPV4’s therapeutic potential [<xref rid=""B117-ijms-25-10551"" ref-type=""bibr"">117</xref>]. RN-1734 was found to be selective for TRPV4 and could thus be a valuable pharmacological tool for TRPV4 studies [<xref rid=""B106-ijms-25-10551"" ref-type=""bibr"">106</xref>]. Recent cryo-EM structures suggest that these agonists share the same ligand-binding site as synthetic antagonists [<xref",21_39,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"site as synthetic antagonists [<xref rid=""B69-ijms-25-10551"" ref-type=""bibr"">69</xref>]. In recent years, several TRPV4 inhibitors have been developed, including HC-067047, RN-1734, RN-9893, GSK2193874, PF-05214030, GSK2798745, and GSK3491943 (<xref rid=""ijms-25-10551-t003"" ref-type=""table"">Table 3</xref>) [<xref rid=""B118-ijms-25-10551"" ref-type=""bibr"">118</xref>]. The structure shows that the HC-067047 molecule is positioned within the vanilloid pocket, surrounded by residues shared with the agonists",21_40,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"surrounded by residues shared with the agonists 4α-PDD and GSK1016790A [<xref rid=""B69-ijms-25-10551"" ref-type=""bibr"">69</xref>]. Functional assays further confirmed the importance of these residues for HC-067047 binding, as alanine substitutions at these sites significantly reduced the compound’s inhibitory effect [<xref rid=""B69-ijms-25-10551"" ref-type=""bibr"">69</xref>]. GSK2798745 is the first TRPV4 inhibitor to undergo clinical trial evaluation aimed at treating pulmonary edema associated with",21_41,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"aimed at treating pulmonary edema associated with congestive heart failure [<xref rid=""B119-ijms-25-10551"" ref-type=""bibr"">119</xref>]. Early-phase trials have shown that GSK2798745 is safe and well-tolerated in humans [<xref rid=""B119-ijms-25-10551"" ref-type=""bibr"">119</xref>,<xref rid=""B120-ijms-25-10551"" ref-type=""bibr"">120</xref>]. The variability in efficacy among different TRPV4 modulators, such as the lower potency of 4α-PDD compared to GSK1016790A, highlights the importance of continual research on",21_42,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"the importance of continual research on new compounds, and research into the pharmacokinetics, safety, and efficacy of these modulators will be crucial in translating these findings into clinical practice. As this review highlights the complex role of TRPV4 activation in CF, some studies highlight the potential benefits of TRPV4 activation [<xref rid=""B80-ijms-25-10551"" ref-type=""bibr"">80</xref>,<xref rid=""B81-ijms-25-10551"" ref-type=""bibr"">81</xref>,<xref rid=""B82-ijms-25-10551""",21_43,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"rid=""B82-ijms-25-10551"" ref-type=""bibr"">82</xref>,<xref rid=""B83-ijms-25-10551"" ref-type=""bibr"">83</xref>], while others suggest that inhibiting TRPV4 could significantly reduce lung inflammation [<xref rid=""B100-ijms-25-10551"" ref-type=""bibr"">100</xref>]. Their evidence indicates that TRPV4 exacerbates the inflammatory response in CF, contributing to tissue damage via dysregulated signaling pathways. One study mentions that TRPV4’s dual role in mechanosensation and immune regulation, termed",21_44,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"in mechanosensation and immune regulation, termed “mechanoimmunology”, implicates it in both barrier function and immune responses [<xref rid=""B121-ijms-25-10551"" ref-type=""bibr"">121</xref>]. This intersection of mechanical and immune functions could provide new therapeutic insights for managing CF, though the full extent of TRPV4’s involvement is yet to be understood.",21_45,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"<table-wrap position=""anchor"" id=""ijms-25-10551-t003""><object-id pub-id-type=""pii"">ijms-25-10551-t003_Table 3</object-id><label>Table 3</label><caption><p>Small molecules of TRPV4.</p></caption><table frame=""hsides"" rules=""groups""><tbody><tr><td align=""left"" valign=""middle"" style=""border-top:solid thin;border-bottom:solid thin"" rowspan=""1"" colspan=""1""><bold>Activators</bold></td><td align=""left"" valign=""middle"" style=""border-top:solid thin;border-bottom:solid thin"" rowspan=""1"" colspan=""1""><bold>Chemical",21_46,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"thin"" rowspan=""1"" colspan=""1""><bold>Chemical Structure</bold></td><td align=""left"" valign=""middle"" style=""border-top:solid thin;border-bottom:solid thin"" rowspan=""1"" colspan=""1""><bold>Species</bold></td><td align=""left"" valign=""middle"" style=""border-top:solid thin;border-bottom:solid thin"" rowspan=""1"" colspan=""1""><bold>pEC<sub>50</sub> (µM)</bold></td><td align=""left"" valign=""middle"" style=""border-top:solid thin;border-bottom:solid thin"" rowspan=""1"" colspan=""1""><bold>Remarks</bold></td><td align=""left""",21_47,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"align=""left"" valign=""middle"" style=""border-top:solid thin;border-bottom:solid thin"" rowspan=""1"" colspan=""1""><bold>References</bold></td></tr><tr><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">GSK1016790A</td><td align=""center"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1""><inline-graphic http://www.w3.org/1999/xlink href=""ijms-25-10551-i001.jpg""></inline-graphic></td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin""",21_48,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">Human<break></break>Mouse</td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">8.7<break></break>7.7</td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">A potent and selective TRPV4 activator induces Ca<sup>2+</sup> influx</td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">[<xref rid=""B113-ijms-25-10551""",21_49,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"colspan=""1"">[<xref rid=""B113-ijms-25-10551"" ref-type=""bibr"">113</xref>,<xref rid=""B122-ijms-25-10551"" ref-type=""bibr"">122</xref>,<xref rid=""B123-ijms-25-10551"" ref-type=""bibr"">123</xref>]</td></tr><tr><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">4α-PDD</td><td align=""center"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1""><inline-graphic http://www.w3.org/1999/xlink href=""ijms-25-10551-i002.jpg""></inline-graphic></td><td align=""left""",21_50,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">Human</td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">6.5</td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">Known to activate TRPV4; it increases the ciliary beat frequency</td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">[<xref rid=""B72-ijms-25-10551"" ref-type=""bibr"">72</xref>,<xref",21_51,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"ref-type=""bibr"">72</xref>,<xref rid=""B123-ijms-25-10551"" ref-type=""bibr"">123</xref>,<xref rid=""B124-ijms-25-10551"" ref-type=""bibr"">124</xref>]</td></tr><tr><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">RN-1747</td><td align=""center"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1""><inline-graphic http://www.w3.org/1999/xlink href=""ijms-25-10551-i003.jpg""></inline-graphic></td><td align=""left"" valign=""middle"" style=""border-bottom:solid",21_52,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">Human<break></break>Mouse<break></break>Rat</td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">6.1<break></break>5.4<break></break>5.4 </td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">Selective TRPV4 agonist</td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">[<xref rid=""B106-ijms-25-10551""",21_53,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"colspan=""1"">[<xref rid=""B106-ijms-25-10551"" ref-type=""bibr"">106</xref>,<xref rid=""B123-ijms-25-10551"" ref-type=""bibr"">123</xref>] </td></tr><tr><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1""><bold>Inhibitors</bold></td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1""><bold>Chemical Structure</bold></td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1""><bold>Species</bold></td><td",21_54,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"colspan=""1""><bold>Species</bold></td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1""><bold>IC<sub>50</sub> (nM)</bold></td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1""><bold>Remarks</bold></td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1""><bold>References</bold></td></tr><tr><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1""",21_55,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">GSK2798745</td><td align=""center"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1""><inline-graphic http://www.w3.org/1999/xlink href=""ijms-25-10551-i004.jpg""></inline-graphic></td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">Human<break></break>Rat</td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">1.8 <break></break>1.6 </td><td",21_56,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"colspan=""1"">1.8 <break></break>1.6 </td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">A potent inhibitor and selective and orally active TRPV4 ion channel </td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">[<xref rid=""B119-ijms-25-10551"" ref-type=""bibr"">119</xref>,<xref rid=""B120-ijms-25-10551"" ref-type=""bibr"">120</xref>,<xref rid=""B125-ijms-25-10551"" ref-type=""bibr"">125</xref>]</td></tr><tr><td align=""left""",21_57,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">HC-067047</td><td align=""center"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1""><inline-graphic http://www.w3.org/1999/xlink href=""ijms-25-10551-i005.jpg""></inline-graphic></td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">Human<break></break>Rat<break></break>Mouse</td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1""",21_58,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">48<break></break>133<break></break>17</td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">A potent and selective TRPV4 inhibitor </td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">[<xref rid=""B126-ijms-25-10551"" ref-type=""bibr"">126</xref>]</td></tr><tr><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">GSK2193874</td><td",21_59,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"thin"" rowspan=""1"" colspan=""1"">GSK2193874</td><td align=""center"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1""><inline-graphic http://www.w3.org/1999/xlink href=""ijms-25-10551-i006.jpg""></inline-graphic></td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">Human<break></break>Rat</td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">40<break></break>2</td><td align=""left"" valign=""middle""",21_60,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">A potent, orally active, and selective TRPV4 blocker </td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">[<xref rid=""B127-ijms-25-10551"" ref-type=""bibr"">127</xref>]</td></tr><tr><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">PF-05214030</td><td align=""center"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1""",21_61,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1""><inline-graphic http://www.w3.org/1999/xlink href=""ijms-25-10551-i007.jpg""></inline-graphic></td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">Human<break></break>Rat</td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">4<break></break>27</td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">A TRPV4 inhibitor </td><td",21_62,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"colspan=""1"">A TRPV4 inhibitor </td><td align=""left"" valign=""middle"" style=""border-bottom:solid thin"" rowspan=""1"" colspan=""1"">[<xref rid=""B118-ijms-25-10551"" ref-type=""bibr"">118</xref>,<xref rid=""B128-ijms-25-10551"" ref-type=""bibr"">128</xref>]</td></tr></tbody></table></table-wrap> TRPV4 channels play a crucial physiological role in the airway epithelium, particularly in CBF regulation and mucus clearance, which are essential processes for maintaining healthy lung function. However, current research on the",21_63,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"lung function. However, current research on the specific modulation of TRPV4 in airway epithelial cells remains limited. In this review, we combined current research on TRPV4 channel modulation and its impact on the regulation of CBF in the airway epithelium. This offers valuable insights into mucus clearance mechanisms in CF and highlights the potential of TRPV4 as a therapeutic target for enhancing airway clearance in CF patients. Given the potential effects, further studies are necessary to fully",21_64,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
"effects, further studies are necessary to fully elucidate the role of TRPV4 in airway physiology and its therapeutic potential. This could guide new treatments aimed at enhancing airway clearance and improving the quality of life for patients with cystic fibrosis.",21_65,TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis,30 9 2024,,Cystic_Fibrosis
Treatment of Psychological Symptoms in Patients with Cystic Fibrosis The aim of this article is to identify and illustrate the most used psychological techniques in the field of cystic fibrosis (CF) and to help clinicians choose the most appropriate strategy among various possibilities. The disease and its medical treatments can be difficult to tolerate and can cause anxiety about health status or feelings of hopelessness and stress. The prevalence of depression and anxiety is 2.3 times higher in adults,22_0,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"and anxiety is 2.3 times higher in adults with CF than in community samples. A strong correlation has been identified between elevated psychological distress and unfavorable health outcomes, including, among others, impaired lung function, reduced BMI, an increased incidence of pulmonary exacerbations, and an elevated risk of transplantation. The use of psychological interventions is useful in addressing these common distresses in CF patients. Aware of the necessity of identifying efficacious interventions",22_1,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"of identifying efficacious interventions for all levels of depression and anxiety in CF patients, this study presents an overview of the research on psychological interventions for patients with CF, in order to complement the treatments suggested by the international guidelines on mental health in CF cases. In fact, the aim of this study is to conduct a review and quantitative synthesis of the psychological intervention techniques that are currently available for individuals with CF. Cystic fibrosis (CF)",22_2,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"for individuals with CF. Cystic fibrosis (CF) is a progressive, multisystem genetic disease, frequently characterized by respiratory distress due to recurrent pulmonary infections and associated damage [<xref rid=""B1-jcm-13-05806"" ref-type=""bibr"">1</xref>]. Previously, the treatments available for CF were only capable of controlling symptoms and limiting complications. Conventional therapeutic approaches were directed towards the treatment or prevention of damage to specific organ systems, employing a",22_3,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"of damage to specific organ systems, employing a range of techniques, including the administration of nebulized medications for respiratory disorders, insulin for diabetes, and pancreatic enzyme supplementation. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators target specific genetic mutations, and have markedly transformed the lives of individuals with CF [<xref rid=""B2-jcm-13-05806"" ref-type=""bibr"">2</xref>,<xref rid=""B3-jcm-13-05806"" ref-type=""bibr"">3</xref>,<xref",22_4,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"ref-type=""bibr"">3</xref>,<xref rid=""B4-jcm-13-05806"" ref-type=""bibr"">4</xref>]. Over time, studies in CF management have led to a rapidly growing adult CF population, necessitating the development of new perspectives for patients (renewed parenting plans, adaptation to change) [<xref rid=""B5-jcm-13-05806"" ref-type=""bibr"">5</xref>]. Nevertheless, the long-term consequences of these novel therapeutic modalities on the diverse manifestations of CF remain under investigation. Although CF remains a",22_5,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"remain under investigation. Although CF remains a life-shortening disease, survival rates have improved due to several factors. These include early diagnosis through routine neonatal screening, the combination of the CFTR modulators ivacaftor, tezacaftor, and elexacaftor [<xref rid=""B6-jcm-13-05806"" ref-type=""bibr"">6</xref>], the promulgation of evidence-based guidelines to optimize nutritional and pulmonary health, and the development of interdisciplinary treatments specific to CF [<xref",22_6,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"treatments specific to CF [<xref rid=""B7-jcm-13-05806"" ref-type=""bibr"">7</xref>]. Notwithstanding the advancements, the quality of life for those living with CF remains significantly impaired by a considerable burden of painful symptoms and the necessity for daily treatments [<xref rid=""B8-jcm-13-05806"" ref-type=""bibr"">8</xref>]. An epidemiological study of over 6000 individuals with CF revealed high rates of depression and anxiety, occurring at a frequency two to three times higher in those with CF than",22_7,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"two to three times higher in those with CF than in the general population [<xref rid=""B9-jcm-13-05806"" ref-type=""bibr"">9</xref>]. Moreover, the presence of untreated depression and anxiety in individuals with CF has been linked to adverse effects on health-related quality of life (HRQoL), adherence to treatment regimens, medical outcomes, and healthcare costs [<xref rid=""B9-jcm-13-05806"" ref-type=""bibr"">9</xref>,<xref rid=""B10-jcm-13-05806"" ref-type=""bibr"">10</xref>,<xref rid=""B11-jcm-13-05806""",22_8,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"rid=""B11-jcm-13-05806"" ref-type=""bibr"">11</xref>]. Therefore, international mental health guidelines, developed by the CF Foundation (CFF) and the European CF Society (ECFS), recommend routine screening, treatment, and preventive efforts for depression and anxiety as a component of standard CF care [<xref rid=""B12-jcm-13-05806"" ref-type=""bibr"">12</xref>,<xref rid=""B13-jcm-13-05806"" ref-type=""bibr"">13</xref>]. Psychological interventions have been demonstrated to be an efficacious approach for patients with",22_9,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"to be an efficacious approach for patients with CF, facilitating a reduction in emotional burden and the management of numerous mental health concerns. Moreover, a number of studies have evaluated the subjective and objective impacts of various psychological interventions on health outcomes in individuals with CF and their close family members. These studies have assessed a range of health-related outcomes, including quality of life and lung function. Nevertheless, no review has been conducted to",22_10,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"Nevertheless, no review has been conducted to synthesize the various techniques employed in the treatment of these patients. The objective of this study is to conduct a review and quantitative synthesis of the psychological intervention techniques that are currently available for individuals with CF, including cognitive–behavioral therapy (CBT), telemedicine, narrative medicine, supportive counseling, and family psychoeducation, with the aim of improving psychological and psychosocial variables (e.g.,",22_11,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"psychological and psychosocial variables (e.g., quality of life, levels of stress or distress, psychopathology, etc.). Access to evidence-based mental health care that meets the specific needs of individuals with CF is limited. Several factors contribute to this challenge, including difficulties related to insurance or financial support, a lack of understanding of CF by community workers, limited availability of mental health workers with the appropriate training, and long waiting lists [<xref",22_12,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"training, and long waiting lists [<xref rid=""B14-jcm-13-05806"" ref-type=""bibr"">14</xref>]. A survey of 1454 CF caregivers concluded that additional training and educational resources are required for CF centers to implement mental health guidelines. It is noteworthy that 47% of the healthcare professionals surveyed expressed a desire to receive training in cognitive behavioral therapy [<xref rid=""B15-jcm-13-05806"" ref-type=""bibr"">15</xref>]. In the case of individuals with CF who present with mild symptoms",22_13,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"with CF who present with mild symptoms of depression or anxiety, the guidelines suggest that monitoring, repeat screening, and the implementation of supportive interventions and psychoeducation should be considered. For those with moderate to severe symptoms, the guidelines recommend the introduction of evidence-based interventions, such as cognitive–behavioral therapy (CBT), as a subsequent step [<xref rid=""B16-jcm-13-05806"" ref-type=""bibr"">16</xref>]. CBT is an evidence-based intervention that helps CF",22_14,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"is an evidence-based intervention that helps CF patients develop adaptive coping skills. It has been demonstrated to improve health-related quality of life (HRQoL) [<xref rid=""B17-jcm-13-05806"" ref-type=""bibr"">17</xref>], promote emotional well-being, and treat depression and anxiety in populations with general and chronic illnesses [<xref rid=""B18-jcm-13-05806"" ref-type=""bibr"">18</xref>,<xref rid=""B19-jcm-13-05806"" ref-type=""bibr"">19</xref>]. The CFF/ECFS guidelines are recommended for individuals who",22_15,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"guidelines are recommended for individuals who have been screened for elevated symptoms of depression or anxiety [<xref rid=""B13-jcm-13-05806"" ref-type=""bibr"">13</xref>]. Nevertheless, efficacious CBT and particular protocols are available for numerous medical conditions, including diabetes, COPD, HIV/AIDS, epilepsy, and cancer [<xref rid=""B20-jcm-13-05806"" ref-type=""bibr"">20</xref>,<xref rid=""B21-jcm-13-05806"" ref-type=""bibr"">21</xref>,<xref rid=""B22-jcm-13-05806"" ref-type=""bibr"">22</xref>,<xref",22_16,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"ref-type=""bibr"">22</xref>,<xref rid=""B23-jcm-13-05806"" ref-type=""bibr"">23</xref>,<xref rid=""B24-jcm-13-05806"" ref-type=""bibr"">24</xref>,<xref rid=""B25-jcm-13-05806"" ref-type=""bibr"">25</xref>,<xref rid=""B26-jcm-13-05806"" ref-type=""bibr"">26</xref>]. Recently, there have been notable advancements in the field of psychological interventions for individuals with CF. These developments have been driven by the growing recognition of the urgent need for evidence-based CBT approaches in addressing the psychological",22_17,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"CBT approaches in addressing the psychological challenges faced by this population. A significant study was conducted with the objective of developing an innovative eight-session CBT-based intervention for the prevention and treatment of depression and anxiety, with the specific aim of tailoring the intervention to the needs of those with CF [<xref rid=""B27-jcm-13-05806"" ref-type=""bibr"">27</xref>]. The results of these analyses indicate that a CF-specific CBT-based mental health intervention, designed to",22_18,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"CBT-based mental health intervention, designed to be integrated into routine CF care, is an acceptable approach. A further study indicates that behavioral sleep interventions are efficacious in the treatment of common sleep difficulties in young people with CF. The results indicate that SLEEP-CF is an acceptable and feasible behavioral sleep intervention, even in a population with normal sleeping habits [<xref rid=""B28-jcm-13-05806"" ref-type=""bibr"">28</xref>]. Based on the principles of CBT, a web-based",22_19,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"Based on the principles of CBT, a web-based psychological support program was developed for parents of children with CF who are severely distressed [<xref rid=""B29-jcm-13-05806"" ref-type=""bibr"">29</xref>]. The web-based writing therapy comprises nine sessions, which have been adapted to meet the specific needs of caregivers. It was observed that, on average, the anxiety symptoms experienced by the caregivers, including fear of disease progression and symptoms of depression, decreased in a statistically",22_20,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"of depression, decreased in a statistically significant and clinically relevant manner to a normal level between the pre-treatment and post-treatment periods. This resulted in a notable improvement in the quality of life of the caregivers, and the beneficial effects were sustained at the three-month follow-up assessment. The web-care method has demonstrated promise as an effective approach for enhancing the mental health and quality of life of parents. Another cognitive–behavioral counseling program has",22_21,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"cognitive–behavioral counseling program has also been conducted for the benefit of caregivers of children, in which the semistructured interviews were subjected to thematic analysis [<xref rid=""B30-jcm-13-05806"" ref-type=""bibr"">30</xref>]. In conclusion, there is some evidence that behavioral interventions targeting specific disease-related symptoms and behaviors are effective. Telemedicine, also known as ‘telehealth’ (or e-health), involves the use of electronic devices to exchange information for a",22_22,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"electronic devices to exchange information for a variety of activities: ‘to keep patients and their healthcare providers in contact, especially those who live in remote geographical areas’ [<xref rid=""B31-jcm-13-05806"" ref-type=""bibr"">31</xref>], ‘for the diagnosis and treatment of illness and injury, for research and evaluation, and for the continuing education of healthcare professionals’ [<xref rid=""B32-jcm-13-05806"" ref-type=""bibr"">32</xref>]. The main goal of telemedicine is to improve the clinical",22_23,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"goal of telemedicine is to improve the clinical health status of patients, for example, by helping to monitor respiratory parameters and improve access to care [<xref rid=""B33-jcm-13-05806"" ref-type=""bibr"">33</xref>]. The World Health Organization (WHO) defines telemedicine as ‘the provision of health care services when patients and caregivers are separated by distance’. Studies have shown that activating a telemedicine system in CF allows the patient to monitor certain biometric parameters such as oxygen",22_24,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"certain biometric parameters such as oxygen saturation, weight, and respiratory function at home and send them directly to the referral center [<xref rid=""B31-jcm-13-05806"" ref-type=""bibr"">31</xref>]. In the context of the global coronavirus (2019-nCoV) pandemic, which has resulted in significant limitations on access to medical environments, the role of telemedicine has been pivotal in maintaining contact with patients with CF who are experiencing psychological distress [<xref rid=""B34-jcm-13-05806""",22_25,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"distress [<xref rid=""B34-jcm-13-05806"" ref-type=""bibr"">34</xref>], and in a post-pandemic world, the necessity of this tool for psychological well-being should be taken into account. A growing body of evidence suggests that e-health can effectively assist healthcare professionals in the management of individuals with CF. Consequently, telemedicine can facilitate clinical visits, adherence to daily treatment, including respiratory physiotherapy and exercise, the early identification of pulmonary",22_26,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"exercise, the early identification of pulmonary exacerbations, and the management of psychological problems. In response to the global coronavirus (2019-nCoV) pandemic, the CF team at the Bambino Gesù Children’s Hospital (Rome, Italy) devised a telehealth psychological support intervention for teenagers and young awCFs, as well as their caregivers. This intervention, which was made available during the period of social distancing, provided participants with cognitive–behavioral strategies to mitigate",22_27,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"with cognitive–behavioral strategies to mitigate stress and emotional challenges associated with the pandemic [<xref rid=""B35-jcm-13-05806"" ref-type=""bibr"">35</xref>]. The participants, comprising patients aged 12–36 years and caregivers of patients younger than 18 years, completed four individual telemedicine sessions with a psychologist. The sessions focused on self-care, coping skills, mood-enhancing exercises, and individual emotional challenges, as well as the use of screening instruments, including",22_28,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"as the use of screening instruments, including the Patient Health Questionnaire-8 item (PHQ-8) and the Generalized Anxiety Disorder-7 item (GAD-7). The intervention demonstrated a reduction in stress levels from the pre-test to the post-test period in both patients and parents. A high prevalence of depression and anxiety was reported at baseline in both groups (71%). A significant reduction in depressive symptoms was observed following the intervention (38%), whereas anxiety levels remained unchanged.",22_29,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"(38%), whereas anxiety levels remained unchanged. Another study examined the efficacy of administering Acceptance and Commitment Therapy (ACT) [<xref rid=""B36-jcm-13-05806"" ref-type=""bibr"">36</xref>] in an electronic format in meeting patient needs and improving clinical symptoms [<xref rid=""B37-jcm-13-05806"" ref-type=""bibr"">37</xref>]. ACT places an emphasis on the acceptance of circumstances, which serves to reduce the avoidance of anxiety and depressive symptoms commonly associated with CF. The",22_30,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"symptoms commonly associated with CF. The participants were 28 awCFs with elevated clinical symptoms who completed six sessions of ACT for CF. The participants completed measures of depression, anxiety, and cognitive function at the outset of the study, following the intervention, and at the three-month follow-up. Lung function was assessed at three-month intervals prior to and following the administration of the treatment. The results of the study are as follows: the majority of participants (79%) opted",22_31,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"follows: the majority of participants (79%) opted for telehealth as their preferred mode of treatment. Ninety-six percent of participants completed all six sessions, and ninety-three percent expressed a strong desire to continue treatment with ACT. The results demonstrated a statistically significant reduction in a composite psychological distress score from before to after treatment in the ACT with FC group. Furthermore, the efficacy of ACT with FC delivered electronically was comparable to that of ACT",22_32,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"electronically was comparable to that of ACT delivered in person. Given the effect size associated with the reduction in psychosocial distress, it can be concluded that ACT with CF delivered via telemedicine or in person is a feasible and potentially effective treatment for improving anxiety and depressive symptoms In another study, the Coping and Learning to Manage Stress with CF (CALM) intervention was developed for CF patients exhibiting high levels of depression or anxiety symptoms [<xref",22_33,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"levels of depression or anxiety symptoms [<xref rid=""B38-jcm-13-05806"" ref-type=""bibr"">38</xref>]. The CALM intervention is a telehealth cognitive–behavioral stress management (CBSM) intervention that has been specifically adapted for individuals with CF. CBSM is an established method for reducing symptoms of depression [<xref rid=""B39-jcm-13-05806"" ref-type=""bibr"">39</xref>] and anxiety [<xref rid=""B40-jcm-13-05806"" ref-type=""bibr"">40</xref>], improving quality of life [<xref rid=""B41-jcm-13-05806""",22_34,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"quality of life [<xref rid=""B41-jcm-13-05806"" ref-type=""bibr"">41</xref>], and increasing the use of coping skills and social support [<xref rid=""B42-jcm-13-05806"" ref-type=""bibr"">42</xref>]. This pilot study is a randomized controlled trial (RCT) that compares awCFs who receive six telehealth-based CALM sessions. The participants completed the assessments at three time points: at baseline (week 0), following the intervention (week 8), and at the three-month follow-up (week 20). Eligible participants were",22_35,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"follow-up (week 20). Eligible participants were required to be at least 18 years of age and to exhibit symptoms of depression or anxiety (i.e., scores ≥ 5 on the PHQ-9 or GAD-7). Following the administration of the six telehealth sessions, the CALM intervention was found to be an efficacious approach for the reduction of depressive and anxiety symptoms, as well as an improvement in coping strategies and health-related quality of life. Specifically, an e-health CBT intervention was developed, representing",22_36,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"CBT intervention was developed, representing another digital mental health intervention for depression and anxiety in awCFs. The eight-session program was led by a therapist and delivered via the Internet [<xref rid=""B43-jcm-13-05806"" ref-type=""bibr"">43</xref>]. The e-health CF-CBT program provides psychoeducation and an introduction to fundamental CBT skills for the prevention and treatment of depression and anxiety, including relaxation techniques, behavioral activation, cognitive restructuring/adaptive",22_37,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"activation, cognitive restructuring/adaptive thinking, and step-by-step exposure to cope with anxiety. The program is designed to address the emotional challenges associated with living with CF, including CF-specific stressors (e.g., medical procedures, uncertainty about illness, hospitalizations, survivor guilt) and effective coping strategies [<xref rid=""B44-jcm-13-05806"" ref-type=""bibr"">44</xref>]. The preliminary efficacy of the intervention is promising, as evidenced by statistically significant",22_38,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"as evidenced by statistically significant improvements in depression and anxiety, as well as in health-related quality of life, perceived stress, and adjustment. The utilization of digital tools, such as mobile health (mHealth), has the potential to positively impact the physical and psychological well-being of adolescents with CF [<xref rid=""B45-jcm-13-05806"" ref-type=""bibr"">45</xref>]. As defined by the WHO in 2011, mHealth is ‘the practice of medicine and public health supported by mobile devices,",22_39,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"and public health supported by mobile devices, including but not limited to phones, patient monitoring devices, digital assistants, and other wireless devices’ [<xref rid=""B46-jcm-13-05806"" ref-type=""bibr"">46</xref>]. The results of the study indicate that these new technologies have a beneficial impact on pediatric patients in two key areas: (a) enhanced enjoyment, socialization, and emotional expression; (b) diminished pain, anxiety, distress, and stress. The implementation of telehealth and mHealth",22_40,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"The implementation of telehealth and mHealth interventions for individuals with CF presents a valuable opportunity to overcome obstacles to mental health care access and reduce the overall healthcare burden. Narrative medicine can improve understanding of the discomfort and difficulties associated with the disease, thereby increasing patient motivation and participation in interdisciplinary care [<xref rid=""B47-jcm-13-05806"" ref-type=""bibr"">47</xref>]. A fundamental aspect of this approach is the",22_41,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"A fundamental aspect of this approach is the engagement in dialog with individuals who are afflicted with illness and pain. Storytelling has become an effective way for patients to share their experiences of illness. It is regarded as an effective approach for gaining insight into how individuals make sense of their past experiences, situate themselves within the social context of their lives, and interpret and give meaning to the present. This process can also be applied to understanding and processing",22_42,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"also be applied to understanding and processing illness. Narrative medicine interventions have the potential to be effective tools for facilitating behavior change and patient education [<xref rid=""B47-jcm-13-05806"" ref-type=""bibr"">47</xref>]. By enabling patients to share their experiences with one another, these interventions can promote health and provide a sense of understanding. The narrative medicine method has been applied by numerous researchers to patients with a variety of diseases. In the case",22_43,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"patients with a variety of diseases. In the case of Chagas disease, the use of this method provided sufficient and useful material for work on the disease context in biopsychosocial dimensions. This approach offers affected individuals the opportunity to raise their voices and enhance their life stories, thereby transforming themselves into the protagonists of their own narratives and knowledge [<xref rid=""B48-jcm-13-05806"" ref-type=""bibr"">48</xref>]. Storytelling is a well-established and increasingly",22_44,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"is a well-established and increasingly utilized research method in the fields of health and social sciences [<xref rid=""B49-jcm-13-05806"" ref-type=""bibr"">49</xref>]. While used effectively in Chagas disease, narrative medicine is also being explored for patients with other pathologies and CF. A study was conducted to identify the barriers and facilitators of physical activity in patients with a chronic disease using a storytelling methodology [<xref rid=""B50-jcm-13-05806"" ref-type=""bibr"">50</xref>]. All",22_45,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"ref-type=""bibr"">50</xref>]. All patients who participated in this study had previously engaged in at least one physical activity promotion program, thereby establishing a foundation for the potential benefits of storytelling. The narrative therapy group intervention was employed with parents of children with physical health problems with the objective of facilitating a connection between parents and their abilities and resources. This technique provided parents with a secure environment in which to discuss",22_46,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"with a secure environment in which to discuss difficulties, gain a new perspective on their situation, connect with other parents’ experiences, develop strategies for fostering independence in their children, and participate in challenging situations [<xref rid=""B51-jcm-13-05806"" ref-type=""bibr"">51</xref>]. A qualitative narrative study was also conducted on patients on the waiting list for a kidney transplant who were hospitalized in a serious condition [<xref rid=""B52-jcm-13-05806""",22_47,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"a serious condition [<xref rid=""B52-jcm-13-05806"" ref-type=""bibr"">52</xref>]. The life stories of patients with chronic kidney disease and its treatments reveal the discomfort associated with the condition and its treatment. Moreover, another study has demonstrated that the narrative approach enhances the quality of care provided to children with chronic illnesses, including Crohn’s disease and HIV infection [<xref rid=""B53-jcm-13-05806"" ref-type=""bibr"">53</xref>]. The use of narrative exploration has been",22_48,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"The use of narrative exploration has been demonstrated to be an effective method for understanding and addressing the needs of children with complex illnesses, and the use of this kind of approach enables the identification of the primary needs of patients with varying health conditions. Another 2020 study also investigated the lived experiences of individuals with chronic illnesses in four patient groups: children with asthma, teenagers with diabetes, young adults with depression, and adult patients with",22_49,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"adults with depression, and adult patients with chronic obstructive pulmonary disease (COPD) [<xref rid=""B54-jcm-13-05806"" ref-type=""bibr"">54</xref>]. A narrative analysis was conducted to elucidate the manner in which the experiences of vulnerability were conveyed within the four patient groups, with the presentation of four discrete narratives, one from each patient group. The results demonstrate that the narratives elucidate the diverse competencies and capabilities that are requisite for navigating the",22_50,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"that are requisite for navigating the experience of living with a chronic illness, contingent on the specific condition in question. Concurrently, the narratives illustrate how distinctive competencies and difficulties associated with chronic illness can be mitigated or perceived as assets. By drawing upon the resources of significant others, the surrounding environment, and the individual self, the storyteller can identify potential avenues for interpreting the experience of living with a chronic illness",22_51,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"the experience of living with a chronic illness in a manner that may foster a sense of hope for the future. In a separate study, disease narratives were employed to examine the experiences of individuals with chronic inflammatory bowel disease in the Netherlands. The findings indicate that these narratives facilitate the comprehension of the disease and the management of its consequences. They offer patients information and exemplars of effective coping strategies for their condition. Moreover, patients",22_52,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"for their condition. Moreover, patients who read a positive illness narrative are more likely to internalize the emotional tone of the narrative and experience positive emotions such as joy, inspiration, and comfort [<xref rid=""B55-jcm-13-05806"" ref-type=""bibr"">55</xref>]. Additionally, a narrative approach was employed, utilizing patients’ personal accounts to facilitate self-management of heart disease [<xref rid=""B56-jcm-13-05806"" ref-type=""bibr"">56</xref>]. Other studies have likewise demonstrated the",22_53,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"Other studies have likewise demonstrated the efficacy of narrative medicine in promoting disease self-management among individuals with type 2 diabetes [<xref rid=""B57-jcm-13-05806"" ref-type=""bibr"">57</xref>,<xref rid=""B58-jcm-13-05806"" ref-type=""bibr"">58</xref>]. The participants disseminated information and practical strategies for diabetes self-management, including the locations where healthier food alternatives could be purchased and the methods for cooking certain foods. Furthermore, they shared",22_54,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"cooking certain foods. Furthermore, they shared their experiences regarding various health services and professionals, as well as reliable resources for self-management. These processes may, in turn, contribute to the formation of a sense of community, which could facilitate peer support, empowerment, and active engagement in disease self-management. Similarly, studies have been conducted in the CF field that explore these concepts, yet this area remains underexplored. A 2023 study employed a narrative and",22_55,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"A 2023 study employed a narrative and play-based methodology to investigate the subjective experiences of young children (aged 3–6 years) with type 1 diabetes or CF [<xref rid=""B59-jcm-13-05806"" ref-type=""bibr"">59</xref>]. The method combines visual tools, medical play, and narratives, thereby providing multiple avenues for children to express their perceptions and opinions and enabling the researcher to observe children’s internal experiences [<xref rid=""B60-jcm-13-05806"" ref-type=""bibr"">60</xref>]. In",22_56,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"ref-type=""bibr"">60</xref>]. In this manner, the children grasped the essence of their condition through concrete experiences and the impact of the disease and treatment on their daily lives. Another study assessed the efficacy of a novel therapeutic approach for CF, namely the metacognitive narrative imagination intervention. This approach integrates narrative and metacognitive mental imagery therapies [<xref rid=""B61-jcm-13-05806"" ref-type=""bibr"">61</xref>]. The metacognitive theory posits that negative",22_57,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"The metacognitive theory posits that negative metacognitive beliefs are associated with mental disorders [<xref rid=""B62-jcm-13-05806"" ref-type=""bibr"">62</xref>]. It is postulated that an anomalous cognitive model impairs the capacity to process ordinary emotional distress, thereby perpetuating it [<xref rid=""B63-jcm-13-05806"" ref-type=""bibr"">63</xref>]. In metacognitive therapy, maladaptive metacognitive processes and beliefs are modified through positive mental imagery, thereby establishing more flexible",22_58,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"imagery, thereby establishing more flexible thinking and reducing psychological distress [<xref rid=""B61-jcm-13-05806"" ref-type=""bibr"">61</xref>]. A total of 13 patients, aged 10 to 17 years, received three one-hour sessions and were assessed for emotional functioning, anxiety, and depression at the outset of the study and at four and eight weeks thereafter. The participants reported significant improvements in anxiety and alterations in emotional functioning. Participants and their parents evaluated the",22_59,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"Participants and their parents evaluated the metacognitive intervention with narrative imagery in terms of usability and preference. Nevertheless, while the methodology and narrative medicine techniques employed in these studies are promising and effective, they still require further expansion. Mental health professionals face distinctive challenges when counseling patients with chronic diseases, such as CF. It is therefore crucial for mental health professionals to possess the requisite skills, such as",22_60,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"to possess the requisite skills, such as exemplary communication and active listening skills, to effectively engage with this specific age group. Healthcare teams encounter distinctive challenges pertaining to the turbulence of adolescence and treatment compliance [<xref rid=""B64-jcm-13-05806"" ref-type=""bibr"">64</xref>]. This necessitates a comprehensive understanding of the typical changes that occur during the course of child development. In recent years, scholars have conducted research on the",22_61,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"years, scholars have conducted research on the experiences of adolescents with CF as they transition to adulthood. Their findings have highlighted differences in perspectives between male and female participants [<xref rid=""B65-jcm-13-05806"" ref-type=""bibr"">65</xref>]. It is therefore recommended that professional counselors devote particular attention to this period of significant upheaval. Female participants reported experiencing depression, negative body image, and fear of diabetes as a potential",22_62,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"body image, and fear of diabetes as a potential complication of CF. In contrast, male participants demonstrated greater independence and only disclosed their fear of developing diabetes as the disease advanced. It is recommended that professional counselors working with young people with CF consider these findings. Counselors should pay particular attention to issues related to treatment adherence, the potential for further physical complications of CF, and the importance of maintaining a positive outlook.",22_63,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"the importance of maintaining a positive outlook. It is therefore imperative that professional counselors working with young patients with CF tailor their interventions to specific developmental stages, exploring the level of acceptance of the disease and developing modalities that are appropriate for the age group in question. It is of great importance that professional counselors prepare counseling interventions for young people with CF, taking into account the additional psychosocial and developmental",22_64,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"the additional psychosocial and developmental challenges associated with the development. Many young patients share specific psychological and developmental needs as they grow up [<xref rid=""B66-jcm-13-05806"" ref-type=""bibr"">66</xref>]. Nevertheless, young people with chronic illnesses face challenges in emotional development while managing physical symptoms [<xref rid=""B67-jcm-13-05806"" ref-type=""bibr"">67</xref>]. Counseling professionals who demonstrate greater sensitivity to the progression and impact",22_65,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"greater sensitivity to the progression and impact of this disease are better positioned to guide their intervention efforts. Professional counselors must have a comprehensive understanding of the disease and the various clinical complications that affect their patients in order to be sensitive to the trauma experienced by children and families coping with the disease [66ex64]. Furthermore, children with chronic illnesses may have an even higher incidence of mental health and psychosocial problems [<xref",22_66,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"of mental health and psychosocial problems [<xref rid=""B68-jcm-13-05806"" ref-type=""bibr"">68</xref>,<xref rid=""B69-jcm-13-05806"" ref-type=""bibr"">69</xref>]. Consequently, professional counselors must enhance their understanding, competencies, and awareness of not only the physical challenges affecting children with CF, but also the emotional obstacles they confront. For example, young people with CF may experience severe psychological difficulties (depression, hopelessness, suicidal ideation) and physical",22_67,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"hopelessness, suicidal ideation) and physical complications (impaired lung function, malnutrition) as their chronic condition progresses. The combination of these comorbidities contributes to the complexity of sustaining an intensive treatment modality [<xref rid=""B68-jcm-13-05806"" ref-type=""bibr"">68</xref>,<xref rid=""B69-jcm-13-05806"" ref-type=""bibr"">69</xref>,<xref rid=""B70-jcm-13-05806"" ref-type=""bibr"">70</xref>] that also promotes psychosocial development and family system functioning [<xref",22_68,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"development and family system functioning [<xref rid=""B71-jcm-13-05806"" ref-type=""bibr"">71</xref>]. It is the responsibility of professional counselors to delineate the circumstances under which parents will be informed of instances of self-harm or suicidal and homicidal ideation. Given the high prevalence of depression and suicidal ideation among children with chronic illnesses [<xref rid=""B70-jcm-13-05806"" ref-type=""bibr"">70</xref>,<xref rid=""B71-jcm-13-05806"" ref-type=""bibr"">71</xref>,<xref",22_69,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"ref-type=""bibr"">71</xref>,<xref rid=""B72-jcm-13-05806"" ref-type=""bibr"">72</xref>], it is evident that coping with the challenges and effects of CF is a constant concern for these children. In order to provide evidence-based practices to clients with CF, as well as their loved ones, it is essential that professional counselors maintain an up-to-date knowledge base on mental health research related to this particular target population. Although research indicates that individuals with chronic illnesses are",22_70,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"that individuals with chronic illnesses are at an elevated risk for developing depression [<xref rid=""B72-jcm-13-05806"" ref-type=""bibr"">72</xref>], it is advised that depressive symptoms be regularly assessed and monitored, and that the level of illness acceptance in CF patients be examined. It is essential that professional counselors working with children with CF further tailor their interventions to align with the specific symptom patterns exhibited by each patient. It is imperative that professional",22_71,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"each patient. It is imperative that professional counselors establish a relationship with the child as an individual, rather than as a child with a disability [<xref rid=""B66-jcm-13-05806"" ref-type=""bibr"">66</xref>]. In their 2004 study, Chesson et al. put forth recommendations for addressing the needs of children with chronic illnesses through counseling [<xref rid=""B73-jcm-13-05806"" ref-type=""bibr"">73</xref>]. Firstly, it is essential that counselors ascertain the child’s understanding of the nature of",22_72,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"the child’s understanding of the nature of counseling, including its purpose, potential benefits, the roles of the parties involved, and communication. While parental support and involvement are crucial aspects of counseling children [<xref rid=""B74-jcm-13-05806"" ref-type=""bibr"">74</xref>,<xref rid=""B75-jcm-13-05806"" ref-type=""bibr"">75</xref>], it is essential to avoid relying solely on parental reports as a substitute for exploring the child’s perspective on counseling. The impact of chronic illnesses",22_73,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"on counseling. The impact of chronic illnesses such as CF on the family system is well documented [<xref rid=""B76-jcm-13-05806"" ref-type=""bibr"">76</xref>]. However, within the therapeutic counseling relationship, children with CF must be empowered to perceive themselves as the experts in their own lives and mental health, regardless of their age. Secondly, counselors working with children should limit the amount of talking they do in sessions. Instead, they should facilitate children’s involvement through",22_74,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"should facilitate children’s involvement through natural modes of expression, such as play and drawing. It is recommended that counseling sessions be structured to include discussions alongside an activity, rather than relying solely on face-to-face conversation, in order to enhance the development of a therapeutic relationship. The formation of interdependent and healthy relationships with counselors may facilitate the development of independence and trust in children undergoing counseling, despite the",22_75,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"in children undergoing counseling, despite the challenges posed by disease progression [<xref rid=""B77-jcm-13-05806"" ref-type=""bibr"">77</xref>]. The negative impact of chronic illness on social functioning [<xref rid=""B78-jcm-13-05806"" ref-type=""bibr"">78</xref>] can result in social withdrawal, which can be exacerbated when counseling approaches are focused on the child utilizing adult techniques. It is therefore recommended that professional counselors implement age- and developmentally appropriate",22_76,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"implement age- and developmentally appropriate modifications to the counseling session. Similarly, the implementation of group counseling modalities should be considered as a means of counteracting the social isolation of these children. Thirdly, professional counselors who develop a therapeutic relationship with a child with CF must include interactions that address the traumatic impact of living with the disease. Children with CF are subjected to physically stressful and painful experiences during",22_77,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"stressful and painful experiences during medical treatment. The authors Geldard and Geldard proposed that professional counselors clarify the nature of counseling and differentiate it from medical treatment [<xref rid=""B74-jcm-13-05806"" ref-type=""bibr"">74</xref>]. Furthermore, they propose the creation of an environment that is conducive to acceptance and the free expression of thoughts and feelings. It is suggested that professional counselors clarify the distinction between counseling and medical",22_78,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"the distinction between counseling and medical procedures (for example, that counseling does not involve the use of needles or painful medical procedures). Similarly, Chesson et al. advise that counselors should endeavor to establish a therapeutic relationship with the child over the course of several shorter sessions, with the objective of fostering a sense of trust [<xref rid=""B73-jcm-13-05806"" ref-type=""bibr"">73</xref>]. This approach avoids the potential pitfalls of rushing the process of building the",22_79,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"pitfalls of rushing the process of building the counseling relationship and encourages active listening in order to gain a deeper understanding of the child’s world. In the context of chronic illnesses such as CF, acute emotional reactions are an inevitable consequence, which may increase the child’s propensity to engage in self-injurious behavior [<xref rid=""B79-jcm-13-05806"" ref-type=""bibr"">79</xref>]. It is essential that the counseling process be characterized by consistency and transparency with",22_80,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"by consistency and transparency with regard to the manner in which the child’s treatment progress is shared between adults. It is of the highest importance that family members are involved in all aspects of the treatment of children with CF from the moment of diagnosis onwards. In fact, the diagnosis of a chronic illness has a significant impact on parents and families [<xref rid=""B70-jcm-13-05806"" ref-type=""bibr"">70</xref>,<xref rid=""B71-jcm-13-05806"" ref-type=""bibr"">71</xref>]. Nevertheless, family",22_81,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"ref-type=""bibr"">71</xref>]. Nevertheless, family members (in particular, parents) frequently bear the responsibility of fostering an environment that enables children to cultivate resilience and autonomy. It is therefore recommended that professional consultants work with the family system to ensure that parents of children with CF have access to the necessary emotional support, family functioning and balance, including participation in one’s own counseling if necessary [<xref rid=""B80-jcm-13-05806""",22_82,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"if necessary [<xref rid=""B80-jcm-13-05806"" ref-type=""bibr"">80</xref>]. Similarly, professional counselors may be required to educate parents on the CF disease process, with a view to assisting them in identifying strategies to enhance resilience in their children [<xref rid=""B77-jcm-13-05806"" ref-type=""bibr"">77</xref>]. Additionally, the counseling technique may be employed by members of the CF care team to facilitate the provision of education and support to patients regarding the initiation of CFTR",22_83,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"to patients regarding the initiation of CFTR modulator therapies (elexacaftor/tezacaftor/ivacaftor) [<xref rid=""B81-jcm-13-05806"" ref-type=""bibr"">81</xref>]. Family-centered care is considered optimal in pediatric healthcare because families play a crucial role in a child’s treatment [<xref rid=""B82-jcm-13-05806"" ref-type=""bibr"">82</xref>,<xref rid=""B83-jcm-13-05806"" ref-type=""bibr"">83</xref>]. This model is a healthcare paradigm that fosters collaboration between all parties involved [<xref",22_84,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"collaboration between all parties involved [<xref rid=""B84-jcm-13-05806"" ref-type=""bibr"">84</xref>,<xref rid=""B85-jcm-13-05806"" ref-type=""bibr"">85</xref>], incorporates family members into the provision of care for children [<xref rid=""B84-jcm-13-05806"" ref-type=""bibr"">84</xref>], and engages parents as co-decision-makers in their children’s healthcare when feasible [<xref rid=""B86-jcm-13-05806"" ref-type=""bibr"">86</xref>]. The approach is biopsychosocial in nature, acknowledging the intricate",22_85,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"in nature, acknowledging the intricate interconnectivity between biological, psychological, and social elements that collectively shape an individual’s health and well-being [<xref rid=""B87-jcm-13-05806"" ref-type=""bibr"">87</xref>]. The concept of family-centered care also extends to the child [<xref rid=""B88-jcm-13-05806"" ref-type=""bibr"">88</xref>] and is associated with a number of positive outcomes. These include improved health and well-being of the child, increased parental satisfaction with the care",22_86,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"increased parental satisfaction with the care provided, greater resources for improving health efficiency, increased access to care, and improved communication between families and transition providers [<xref rid=""B89-jcm-13-05806"" ref-type=""bibr"">89</xref>]. Qualitative studies indicate that family-centered care offers a flexible framework for support that can be integrated into various sectors, including health, education, and social systems [<xref rid=""B90-jcm-13-05806"" ref-type=""bibr"">90</xref>]. A",22_87,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"ref-type=""bibr"">90</xref>]. A number of studies have devised psychoeducational interventions for the families of children with illnesses. The objective of one of the studies was to ascertain the impact of systemic family psychotherapeutic interventions on the quality of parent–child relationships and the optimization of the child’s glycemic control [<xref rid=""B91-jcm-13-05806"" ref-type=""bibr"">91</xref>]. A significant reduction in glycated hemoglobin (HbA1c) values was observed following the",22_88,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"(HbA1c) values was observed following the implementation of a family psychotherapy plan. Therefore, it can be concluded that systemic family psychotherapy is an effective method for managing the disease and strengthening parent–child relationships. Another study was published a few years ago that examined parent education programs for families with children with special healthcare needs [<xref rid=""B92-jcm-13-05806"" ref-type=""bibr"">92</xref>]. The presence of chronic health conditions in children and",22_89,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"of chronic health conditions in children and teenagers can result in a significant increase in the care burden experienced by parents [<xref rid=""B93-jcm-13-05806"" ref-type=""bibr"">93</xref>]. Caregivers face increased burdens due to the need for home treatment and hospital visits [<xref rid=""B94-jcm-13-05806"" ref-type=""bibr"">94</xref>]. The stress theory posits that the primary stressors experienced by caregivers include the level of care required, the severity of the illness, the patient’s health status,",22_90,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"of the illness, the patient’s health status, and behavioral issues. This can result in a subjective sense of burden, leading caregivers to feel overwhelmed and under pressure. Consequently, there is a potential for caregivers to develop anxiety or depression, which may result in adverse mental and physical health outcomes [<xref rid=""B95-jcm-13-05806"" ref-type=""bibr"">95</xref>]. Furthermore, it has been demonstrated that depressive symptoms in caregivers may have a detrimental impact on the patient’s",22_91,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"may have a detrimental impact on the patient’s ability to adhere to treatment regimens, which in turn may accelerate disease progression [<xref rid=""B96-jcm-13-05806"" ref-type=""bibr"">96</xref>]. The advent of a chronic illness in one family member can have a profound impact on the entire family, affecting all family members [<xref rid=""B97-jcm-13-05806"" ref-type=""bibr"">97</xref>]. Research indicates that a child’s illness can result in significant alterations to the family’s lifestyle. Parents of children",22_92,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"to the family’s lifestyle. Parents of children with chronic illnesses frequently experience feelings of responsibility for their child’s condition, which can give rise to a range of emotional responses, including anxiety, guilt, helplessness, and feelings of incapacity [<xref rid=""B98-jcm-13-05806"" ref-type=""bibr"">98</xref>]. Consequently, family members are compelled to redefine their roles, interaction patterns, and relationships within and outside the family in order to adapt to the new situation [<xref",22_93,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"in order to adapt to the new situation [<xref rid=""B99-jcm-13-05806"" ref-type=""bibr"">99</xref>]. The coping strategies employed by parents of children with a disease such as CF may result in a redefinition of expectations and a re-evaluation of the importance of specific aspects of the child’s life. Such parents may experience a sense of loss, grieving the altered circumstances and the loss of what they previously considered to be their “normal” experience [<xref rid=""B97-jcm-13-05806""",22_94,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"“normal” experience [<xref rid=""B97-jcm-13-05806"" ref-type=""bibr"">97</xref>,<xref rid=""B98-jcm-13-05806"" ref-type=""bibr"">98</xref>,<xref rid=""B99-jcm-13-05806"" ref-type=""bibr"">99</xref>]. In addition to the emotional distress associated with grief and mourning, parents and children frequently confront uncertainty about the future. As regards existential distress, the most common existential needs of adults with CF are fears about the worsening of the disease, feelings about death and dying, fears about the",22_95,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"feelings about death and dying, fears about the worsening of cystic fibrosis, uncertainty about the future, and concerns for others [<xref rid=""B100-jcm-13-05806"" ref-type=""bibr"">100</xref>]. This sense of uncertainty may be attributed to a lack of knowledge about the disease, its intricacies, treatment, potential side effects and management, the establishment of trusting relationships with healthcare providers, the quality of life, and the child’s capacity to cope. This uncertainty is associated with",22_96,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"to cope. This uncertainty is associated with elevated levels of emotional distress, diminished quality of life, and impaired psychosocial adjustment, as parents and children anticipate the worst and prepare for it [<xref rid=""B101-jcm-13-05806"" ref-type=""bibr"">101</xref>]. This can impede parents’ capacity to perform fundamental tasks such as monitoring the child’s health, consistently enforcing behavioral expectations, promoting independence and self-management, and caring for and supervising other",22_97,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"and caring for and supervising other siblings [<xref rid=""B102-jcm-13-05806"" ref-type=""bibr"">102</xref>]. It is evident that families frequently require assistance in a multitude of domains. One of the primary responsibilities of medical personnel is to provide support to patients. In a study conducted in 2001, the development, implementation, and evaluation of a psychoeducational program for families with a child diagnosed with CF are described in detail [<xref rid=""B103-jcm-13-05806""",22_98,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"in detail [<xref rid=""B103-jcm-13-05806"" ref-type=""bibr"">103</xref>]. To our knowledge, this is the only study so far that examined this type of program. The impact of a family-oriented rehabilitation program in a recovery regimen on psychological symptoms reported by parents of chronically ill children is now well documented [<xref rid=""B104-jcm-13-05806"" ref-type=""bibr"">104</xref>,<xref rid=""B105-jcm-13-05806"" ref-type=""bibr"">105</xref>]. Indeed, one study examined the change in psychological symptoms",22_99,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"examined the change in psychological symptoms and quality of life in children and adolescents with congenital heart disease, cancer, or CF after a family-oriented inpatient rehabilitation program [<xref rid=""B106-jcm-13-05806"" ref-type=""bibr"">106</xref>]. Following rehabilitation, patients exhibited notable improvement in their symptoms, which was sustained for a period of six months in those who could be monitored. Another study aimed to assess the efficacy of insight-oriented psychological therapy (IOT)",22_100,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"of insight-oriented psychological therapy (IOT) as a treatment for unresolved grief (UG) in parents of children with CF compared to illness education [<xref rid=""B107-jcm-13-05806"" ref-type=""bibr"">107</xref>]. IOT is designed to assist patients in developing new insights into their suffering, thereby facilitating a positive transformation in their internal world and state of mind. In the context of potential UG in parents of children diagnosed with CF, IOT at the parental level may prove to be a valuable",22_101,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"at the parental level may prove to be a valuable intervention for affected families. The objective of the brief IOT was to assist parents in developing a more profound comprehension of the ramifications of UG pertaining to their child’s diagnosis on their daily coping mechanisms, interpersonal relationships, and apprehensions regarding their child’s future. This was pursued with the intention of inciting a psychological transformation that would culminate in a sense of resolution in relation to their",22_102,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"in a sense of resolution in relation to their child’s CF diagnosis. In conclusion, insight-oriented therapy appeared to facilitate the resolution of grief and bereavement in parents. Subsequently, another study is being planned to develop and validate a support program for family caregivers of children with CF in Iran (2024–2025) [<xref rid=""B108-jcm-13-05806"" ref-type=""bibr"">108</xref>]. Furthermore, the above studies demonstrated that reinforcing CF education about the disease, treatment, potential side",22_103,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"about the disease, treatment, potential side effects, and quality of life enabled parents to identify solutions for psychological and disease management issues. Providing parents with CF education immediately following diagnosis (during a period characterized by elevated stress, shock, and disbelief) may facilitate the acquisition and processing of information in a more accurate and comprehensive manner. The results indicate the necessity of addressing parents’ psychological distress and identifying a",22_104,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"parents’ psychological distress and identifying a targeted intervention for parents, which may include psychoeducation and/or psychotherapy. In light of the documented impact of social support in other chronic diseases (e.g., diabetes, cancer, and heart disease) on mental health [<xref rid=""B109-jcm-13-05806"" ref-type=""bibr"">109</xref>], physical health [<xref rid=""B110-jcm-13-05806"" ref-type=""bibr"">110</xref>], and treatment adherence [<xref rid=""B111-jcm-13-05806"" ref-type=""bibr"">111</xref>,<xref",22_105,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"ref-type=""bibr"">111</xref>,<xref rid=""B112-jcm-13-05806"" ref-type=""bibr"">112</xref>], one study investigated the influence of social support on awCFs [<xref rid=""B113-jcm-13-05806"" ref-type=""bibr"">113</xref>]. The present study sought to elucidate the interrelationships between social support, mental and physical health, treatment activities, and disease-specific quality of life in a sample of awCFs. The results indicated that social support was associated with better emotional, social, and role",22_106,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"with better emotional, social, and role functioning. It is possible that social support improves mental and physical health symptoms, leading to a greater ability to function in various areas of life. Social support also predicted better vitality, better body image, and better perception of overall health. Now that the link between social support and health-related quality of life in awCFs has been empirically explored, a multidisciplinary team can adopt this theory. Firstly, healthcare professionals can",22_107,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"theory. Firstly, healthcare professionals can facilitate social engagement between patients and members of their communities. Secondly, they can design and implement modifications to clinical interventions that acknowledge the significance of social support on well-being. Furthermore, another study demonstrated that social support was associated with a reduction in the prevalence of mental and physical health symptoms among awCFs [<xref rid=""B113-jcm-13-05806"" ref-type=""bibr"">113</xref>]. Indeed, a virtual",22_108,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"ref-type=""bibr"">113</xref>]. Indeed, a virtual one-to-one peer support program was established the following year for awCFs and their family members to assess the relationship between social support and health outcomes [<xref rid=""B114-jcm-13-05806"" ref-type=""bibr"">114</xref>]. Social networks and peer support have been demonstrated to exert a beneficial influence on physical, mental, and social health outcomes through the enhancement of coping mechanisms, including problem-solving abilities, access to",22_109,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"including problem-solving abilities, access to information, and perceived control. Such coping resources can serve as a buffer in periods of stress [<xref rid=""B115-jcm-13-05806"" ref-type=""bibr"">115</xref>]. Peer support is a form of social support that involves the sharing of experiences and information among individuals with similar circumstances in a nonhierarchical relationship. It allows patients and family members to discuss complex health challenges that others in their social network may not",22_110,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"that others in their social network may not understand. In one study [<xref rid=""B116-jcm-13-05806"" ref-type=""bibr"">116</xref>], the objective was to develop a national CF-specific virtual peer support program to help people feel less alone and more supported. The objective was to address the needs of CF patients who sought to connect with their peers to exchange information regarding the management of daily life with a chronic disease. The most frequently reported benefits were social and emotional in",22_111,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"reported benefits were social and emotional in nature, including feelings of increased support, decreased isolation, and the formation of new friendships. The data demonstrate that one-on-one virtual peer support is an acceptable and beneficial approach for both individuals with CF and their family members. It may therefore be replicable in clinical settings. Another technique that has been demonstrated to be effective in addressing adherence issues in individuals with CF is motivational interviewing. In",22_112,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"with CF is motivational interviewing. In particular, the evidence substantiating the efficacy of motivational interviewing (MI) in enhancing adaptation and adherence in physical health and CF is examined. The review also provides an overview of the fundamental principles of MI, its application in medical settings, and recommendations for integrating MI techniques into the routine care of individuals with CF [<xref rid=""B117-jcm-13-05806"" ref-type=""bibr"">117</xref>]. A pilot study implemented a journaling",22_113,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"A pilot study implemented a journaling program with the objective of improving the mental and physical health outcomes of individuals with CF [<xref rid=""B118-jcm-13-05806"" ref-type=""bibr"">118</xref>]. Eight adolescents between the ages of 12 and 17, all of whom had been diagnosed with CF and were under the care of a single CF clinical center, were sent weekly journal prompts via email. These prompts explored a range of topics, including treatment adherence, feelings of difference associated with CF,",22_114,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"feelings of difference associated with CF, anxiety, depression, and interpersonal relationships. The participants expressed positive feedback regarding the study and that they experienced an improvement in their feelings of anxiety and depression. All participants indicated that they would recommend the study to others with CF. In conclusion, the journaling intervention for individuals with CF was found to be both feasible and well received. Furthermore, there is a necessity to develop self-care programs",22_115,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"is a necessity to develop self-care programs as a psychological technique for well-being. A review of the literature was conducted to assess the efficacy of self-care support interventions for children and youth with asthma, CF, and diabetes [<xref rid=""B76-jcm-13-05806"" ref-type=""bibr"">76</xref>]. The findings were synthesized narratively to examine the effectiveness of self-care support interventions on health status, psychosocial well-being, knowledge about the condition, use of health services, and",22_116,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"about the condition, use of health services, and participant satisfaction. There is compelling evidence that interventions targeting children and youth, utilizing telemedicine or group health methodologies, and delivered in community settings are highly effective. To exemplify, a study was conducted to ascertain the efficacy of an educational program on self-management, designated “Airways”, for children with CF between the ages of six and two and their caregivers with regard to adherence to aerosolized",22_117,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"with regard to adherence to aerosolized medications and airway clearance techniques (ACTs) [<xref rid=""B119-jcm-13-05806"" ref-type=""bibr"">119</xref>]. Assessments were conducted at two time points: immediately prior to and following the intervention period, and at 6 and 12 months post-intervention. The pen-and-paper educational program was completed by the child and caregiver together at home on diary sheets over a 10-week period. The “Air Pathways” program provided information and behavioral exercises,",22_118,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"provided information and behavioral exercises, developed practice assessment, treatment, and decision-making skills, and provided strategies to overcome barriers to treatment. The implementation of the program yielded positive outcomes with regard to adherence, self-management, children’s knowledge of ACT, and their attitudes towards the regular administration of both aerosol and ACT treatments. The favorable outcomes indicate that self-management is an efficacious educational instrument for school-aged",22_119,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"educational instrument for school-aged children with CF and their caregivers. Other methods may be employed as adjunctive therapy to improve quality of life. These include singing [<xref rid=""B120-jcm-13-05806"" ref-type=""bibr"">120</xref>], which is considered a means of emotional expression, and yoga practice [<xref rid=""B121-jcm-13-05806"" ref-type=""bibr"">121</xref>], which has been demonstrated to alleviate symptoms of pain, sleep disturbances, anxiety, and depression in CF patients. It is recommended",22_120,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"and depression in CF patients. It is recommended that professional counselors employ multidimensional strategies when working with patients with special needs, as these individuals are at greater risk of psychological difficulties, including those with chronic illnesses and their parents. Psychological interventions appear to offer a promising strategy for treating patients with chronic illnesses in general. In light of the multiple demands placed upon patients, it is recommended that personalized",22_121,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"patients, it is recommended that personalized interventions be employed to enhance adaptation to the disease and adherence to therapy. Such interventions should increase CF knowledge and target coping skills. The primary objective was to identify and map the current evidence on the effectiveness of psychological interventions for CF. This general overview of available techniques enables the selection of the most appropriate one for the patient, taking into account their needs, personality characteristics,",22_122,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"account their needs, personality characteristics, specific problems, and the organizational context in which the work is carried out and the resources available. It is imperative that measures are taken to ensure that CF centers have highly qualified professionals who are able to select the most appropriate strategies and personalized techniques to support the emotional burden of the disease. There is still much to be discovered about the long-term effects of this condition. It is therefore a priority to",22_123,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"of this condition. It is therefore a priority to study a wider range of treatment modalities and digital interventions if clinical practice is to be improved. Further studies may investigate additional techniques that have not yet been validated for use in CF but have demonstrated efficacy in other contexts. As an illustration, a promising technique for alleviating anxiety and depressive symptoms in CF patients is Rational–Emotional Behavior Intervention (REBT). This approach has demonstrated remarkable",22_124,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"(REBT). This approach has demonstrated remarkable efficacy in the treatment of other diseases. REBT is one of the cognitive–behavioral therapies created by Ellis [<xref rid=""B122-jcm-13-05806"" ref-type=""bibr"">122</xref>], which posits that all individuals are born with self-destructive tendencies. In the event of an action or situation that is contrary to their goals, values, or desires (typically a failure or rejection, for example), individuals have the option of experiencing positive emotions such as",22_125,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"option of experiencing positive emotions such as regret, disappointment, or frustration, which encourage them to revisit the situation and implement changes to address the adversity. Conversely, human beings have the capacity to choose whether to be overwhelmed by feelings of terror, panic, depression, self-pity, or self-doubt, which can impede their ability to adapt to adversity. Instead of their intrinsic goals and values, these emotions can influence their decision-making processes. REBT is an",22_126,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"their decision-making processes. REBT is an evidence-based therapeutic approach that aims to modify negative beliefs held by individuals about themselves, their future, and the world. As posited by REBT practitioners, irrational beliefs, including those characterized by fear, catastrophizing, demand, low frustration tolerance, and self/other/destructive cognitions, are identified as the primary causal factor in the development of emotional disorders in both healthy and ill individuals [<xref",22_127,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"in both healthy and ill individuals [<xref rid=""B123-jcm-13-05806"" ref-type=""bibr"">123</xref>]. REBT employs a set of cognitive, emotional, and behavioral techniques to alter fundamental perspectives, which the therapist demonstrates and guides the patient in utilizing to significantly reduce distress [<xref rid=""B122-jcm-13-05806"" ref-type=""bibr"">122</xref>]. This technique has been employed to alleviate the psychological distress of numerous patients afflicted with serious illnesses, including cancer",22_128,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"with serious illnesses, including cancer [<xref rid=""B123-jcm-13-05806"" ref-type=""bibr"">123</xref>], colorectal cancer [<xref rid=""B124-jcm-13-05806"" ref-type=""bibr"">124</xref>], leukemia [<xref rid=""B125-jcm-13-05806"" ref-type=""bibr"">125</xref>], congenital heart disease [<xref rid=""B126-jcm-13-05806"" ref-type=""bibr"">126</xref>], visual impairment [<xref rid=""B127-jcm-13-05806"" ref-type=""bibr"">127</xref>,<xref rid=""B128-jcm-13-05806"" ref-type=""bibr"">128</xref>], type II diabetes [<xref",22_129,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"type II diabetes [<xref rid=""B129-jcm-13-05806"" ref-type=""bibr"">129</xref>], hypertension [<xref rid=""B130-jcm-13-05806"" ref-type=""bibr"">130</xref>], Down syndrome and intellectual disability [<xref rid=""B131-jcm-13-05806"" ref-type=""bibr"">131</xref>], post-traumatic stress disorder [<xref rid=""B132-jcm-13-05806"" ref-type=""bibr"">132</xref>], autism [<xref rid=""B133-jcm-13-05806"" ref-type=""bibr"">133</xref>], eating disorders [<xref rid=""B134-jcm-13-05806"" ref-type=""bibr"">134</xref>], depression [<xref",22_130,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"ref-type=""bibr"">134</xref>], depression [<xref rid=""B135-jcm-13-05806"" ref-type=""bibr"">135</xref>], and mental disorders in the elderly [<xref rid=""B136-jcm-13-05806"" ref-type=""bibr"">136</xref>]. Other highly efficacious techniques for the treatment of anxiety and depression include mindfulness [<xref rid=""B137-jcm-13-05806"" ref-type=""bibr"">137</xref>], which has yet to be explored in the context of CF, and psychodynamic therapy, which has the potential to enhance clinical remission [<xref",22_131,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"potential to enhance clinical remission [<xref rid=""B138-jcm-13-05806"" ref-type=""bibr"">138</xref>], address somatoform pain disorders [<xref rid=""B139-jcm-13-05806"" ref-type=""bibr"">139</xref>,<xref rid=""B140-jcm-13-05806"" ref-type=""bibr"">140</xref>], and improve interpersonal functioning [<xref rid=""B141-jcm-13-05806"" ref-type=""bibr"">141</xref>]. Further research is needed to expand the repertoire of techniques that can enhance the well-being of CF patients. Future areas of research could include the",22_132,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"Future areas of research could include the psychological treatment effectiveness evaluation of CF patients and their caregivers, as well as further assessment of routine screening of multidisciplinary teams caring for CF patients. A better understanding of the factors and mechanisms of mental distress could contribute to the development of advanced treatment programs that produce more optimal treatment outcomes. The patient-centered recommendations could also be relevant for future interventions targeting",22_133,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"be relevant for future interventions targeting psychosocial aspects. Psychological interventions are reported to be efficacious in chronic diseases such as CF. Currently, early diagnosis and improved survival in CF emphasize the need for these interventions to help patients with coping mechanisms, adhere to prescribed therapies, and improve their quality of life. In our opinion, a psychologist should always be included in the CF care team as their role is essential to reach these goals.",22_134,Treatment of Psychological Symptoms in Patients with Cystic Fibrosis,28 9 2024,,Cystic_Fibrosis
"Elexacaftor/tezacaftor/ivacaftor’s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment Full text not available in PMC",23_0,"Elexacaftor/tezacaftor/ivacaftor’s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment",5 9 2024,,Cystic_Fibrosis
"Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis In the study, 46 patients with cystic fibrosis at the age of 10 and above, who underwent OGTT between 2012 and 2020 in the Department of Pediatric Endocrinology in Dicle University Faculty of Medicine, were included. Among the patients who were diagnosed with CF, those who had acute pulmonary exacerbation, those who were receiving systemic steroid treatment due to allergic bronchopulmonary aspergillosis and those with known",24_0,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"aspergillosis and those with known diabetes, were excluded from the study. Data such as gender, age at diagnosis, age at the time of participation in the study, anthropometric measurements (body weight, height, body mass index), pubertal assessment results, lung function (FEV1 %), fasting blood glucose levels, insulin levels and the OGTT results were obtained from the medical records of the patients. The Harpenden Stadiometer (Holtain Ltd., Crymych, UK) was used to measure height, and an electronic scale",24_1,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"used to measure height, and an electronic scale with an accuracy of 0.1 kg was used to measure body weight. Body mass index (BMI) was calculated using the formula weight (kg)/[height (m)]<sup>2</sup>. The height, weight and BMI standard deviation scores (SDS) were calculated using the web-based Child Metrics software<sup>[<xref rid=""ref11"" ref-type=""bibr"">11</xref>]</sup> according to national data.<sup>[<xref rid=""ref12"" ref-type=""bibr"">12</xref>]</sup> Systemic examinations were performed in all",24_2,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"Systemic examinations were performed in all patients; puberty findings were evaluated according to the Tanner Scale.<sup>[<xref rid=""ref13"" ref-type=""bibr"">13</xref>]</sup> In the follow-up of 46 patients who were diagnosed with cystic fibrosis, the OGTT was performed. For the OGTT, 1.75 g/kg (maximum 75 grams) of glucose solution was given to the patients after eight hours of fasting, and the plasma glucose and insulin levels were measured at 0 and 120 minutes. The plasma glucose level was evaluated using",24_3,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"The plasma glucose level was evaluated using an automated analyzer, and the insulin level was determined using the immunochemical method. The patients were classified according to the OGTT results, in compliance with the current guidelines.<sup>[<xref rid=""ref1"" ref-type=""bibr"">1</xref>,<xref rid=""ref10"" ref-type=""bibr"">10</xref>]</sup>",24_4,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"<list list-type=""order""><list-item><p>Normal glucose tolerance (NGT): Fasting plasma glucose <100 mg/dl and plasma glucose level measured at hour 2 of OGTT <140 mg/dl,</p></list-item><list-item><p>Impaired glucose tolerance (IGT): Fasting plasma glucose <126 mg/dl and plasma glucose measured at hour 2 of OGTT between 140-199 mg/dl,</p></list-item><list-item><p>Cystic fibrosis-related diabetes (CFRD): Fasting plasma glucose ≥126 mg/dl and plasma glucose measured at hour 2 of OGTT ≥200",24_5,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"plasma glucose measured at hour 2 of OGTT ≥200 mg/dl.</p></list-item></list> Patients with IGT and CFRD were classified as patients with abnormal glucose tolerance (AGT). Patient groups of normal and abnormal glucose tolerance were compared in the analysis. <bold>Ethics Approval:</bold> The study was performed in accordance with the rules of Declaration of Helsinki and this study was initiated after the approval of the Dicle University Faculty of Medicine Ethics Committee (Number: 2021/111, Date:",24_6,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"Ethics Committee (Number: 2021/111, Date: 04.02.2021). Among the 46 patients with CF included in the study, 19 were female (41%) and 27 were male (59%). The median age at diagnosis of CF of the patients was 5.92 (1.4-9) years, while the median age at the time of participation in the study was 13.97 (11-16.4) years. 33 of the patients included in the study were in the pubertal period and 13 were in the prepubertal period. Anthropometric measurements, laboratory data and FEV1 levels of the patients are",24_7,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"data and FEV1 levels of the patients are summarized in <xref rid=""T1"" ref-type=""table"">Table 1</xref>. In the evaluation of the OGTT results of the patients, NGT was detected in 37 (80.4%), IGT was detected in 4 (8.6%) and CFRD was detected in 5 (10.8%) patients. When the patients were classified as NGT and AGT according to the OGTT results, it was observed that 37 (80.4%) had NGT and 9 (19.5%) had AGT. Anthropometric measurements, laboratory data and FEV1 values of the patient group with normal glucose",24_8,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"values of the patient group with normal glucose tolerance and the patient group with AGT are summarized in <xref rid=""T2"" ref-type=""table"">Table 2</xref>. Cystic fibrosis is a common multisystem disease. In 85% of the cases, exocrine pancreatic insufficiency develops. Damage to the exocrine pancreatic tissue over the years leads to the loss of islet cells, which results in the development of CFRD.<sup>[<xref rid=""ref14"" ref-type=""bibr"">14</xref>,<xref rid=""ref15"" ref-type=""bibr"">15</xref>]</sup> Although",24_9,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"ref-type=""bibr"">15</xref>]</sup> Although the frequency of CFRD has been found to be 12-34% in general, these values vary depending on the age and ethnicity. It is estimated that CFRD develops in 5-6% of the patients with CF in the USA and Europe.[<xref rid=""ref6"" ref-type=""bibr"">6</xref>,<xref rid=""ref16"" ref-type=""bibr"">16</xref>] In our country, the frequency of CFRD has been reported as 3.4%.<sup>[<xref rid=""ref17"" ref-type=""bibr"">17</xref>]</sup> In some centers, the OGTT is still not routinely",24_10,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"In some centers, the OGTT is still not routinely performed in patients with CF and the diagnosis of CFRD is made according to fasting blood glucose levels. Therefore, the frequency of CFRD is estimated to be higher than it has been reported in the literature.<sup>[<xref rid=""ref6"" ref-type=""bibr"">6</xref>,<xref rid=""ref16"" ref-type=""bibr"">16</xref>,<xref rid=""ref17"" ref-type=""bibr"">17</xref>]</sup> In the single-center prospective study conducted by Laang et al.<sup>[<xref rid=""ref18""",24_11,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"conducted by Laang et al.<sup>[<xref rid=""ref18"" ref-type=""bibr"">18</xref>]</sup>, it was shown that the frequency of CFRD increased from 11% to 24% with routinely performed annual oral glucose tolerance tests. In another study with a high rate of annual OGTT screening, in which 527 patients with CF were evaluated, it was reported that the frequency of CFRD in the adolescent age group was 19%.<sup>[<xref rid=""ref19"" ref-type=""bibr"">19</xref>]</sup> In a recent study conducted in Canada, 256 patients",24_12,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"a recent study conducted in Canada, 256 patients between the ages of 10 and 18 years were screened and the frequency of CFRD was found as 8.6%.<sup>[<xref rid=""ref20"" ref-type=""bibr"">20</xref>]</sup> In the study of Haliloglu et al.<sup>[<xref rid=""ref21"" ref-type=""bibr"">21</xref>]</sup>, which was conducted in our country, 45 patients with CF between the ages of 5 and 18 years were evaluated with the OGTT and the frequency of CFRD was found as 11.1%. In our study, 46 patients with CF between the ages of",24_13,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"study, 46 patients with CF between the ages of 10 and 18 were evaluated with the OGTT and the frequency of CFRD was found as 10.8% (5 patients). The frequency of CFRD found in our study was consistent with the literature.<sup>[<xref rid=""ref20"" ref-type=""bibr"">20</xref>,<xref rid=""ref21"" ref-type=""bibr"">21</xref>]</sup> In addition, IGT was present in 4 (8.6%) patients in our study. In 4 (44.4%) of the 9 patients with abnormal glucose tolerance, fasting blood glucose level was within the normal range. If",24_14,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"glucose level was within the normal range. If the OGTT had not been routinely performed in the patients in our study, the diagnosis of one patient, who had normal fasting blood glucose but impaired glucose tolerance, and three patients, who had CFRD, would have been missed. Similar to our study, it was stated in previous studies that fasting blood glucose level alone did not have adequate sensitivity in detecting abnormal glucose tolerance in patients with cystic fibrosis.<sup>[<xref rid=""ref22""",24_15,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"with cystic fibrosis.<sup>[<xref rid=""ref22"" ref-type=""bibr"">22</xref>]</sup> In addition, it was reported that even in children under the age of 10, CFRD was detected with routine OGTT screening.<sup>[<xref rid=""ref23"" ref-type=""bibr"">23</xref>]</sup> As in the above-mentioned studies, we recommend annual OGTT screening in order to detect abnormal glucose tolerance in patients with CF.Otherwise, only evaluating the fasting blood glucose levels will cause the diagnosis to be missed in almost half of the",24_16,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"the diagnosis to be missed in almost half of the patients with abnormal glucose tolerance. The symptoms of cystic fibrosis-related diabetes are usually indistinct and the disease progresses insidiously. It has been reported that increase in body weight and decrease in growth rate despite adequate nutritional support should be an indicator of CFRD development.<sup>[<xref rid=""ref7"" ref-type=""bibr"">7</xref>]</sup> In a study, in which 25 patients with CF between the ages of 2 and 18 were included, patients",24_17,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"the ages of 2 and 18 were included, patients with normal and abnormal glucose tolerance were compared; it was reported that the height, body weight and BMI SDS values were found to be significantly lower in the patients with AGT compared to the patients with NGT.<sup>[<xref rid=""ref24"" ref-type=""bibr"">24</xref>]</sup> In a recent study conducted by Nguyen et al.<sup>[<xref rid=""ref25"" ref-type=""bibr"">25</xref>]</sup>, in which 281 patients with CF were evaluated with the OGTT, it was shown that the height",24_18,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"with the OGTT, it was shown that the height and body weight SDS values were lower in patients diagnosed with CFRD than in patients with NGT. In the same study, it was stated that the weight SDS was less affected than the height SDS in patients with CFRD, and the height SDS value had begun to decrease in the first ten years of life, long before the first OGTT screening was performed. The authors of the study reported that growth retardation in patients with CF mayreflect early-stage glucose metabolism",24_19,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"with CF mayreflect early-stage glucose metabolism disorders.<sup>[<xref rid=""ref25"" ref-type=""bibr"">25</xref>]</sup> In another study conducted by Jain et al.<sup>[<xref rid=""ref22"" ref-type=""bibr"">22</xref>]</sup>, it was reported that there was no significant difference between the patients with NGT and AGT in terms of anthropometric parameters. In our study, the anthropometric parameters of patients with NGT and AGT were compared. It was found that the body weight and height SDS values were lower in",24_20,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"body weight and height SDS values were lower in patients with NGT than the patients with AGT. However, the difference was not statistically significant. These findings were similar to the findings of the study of Jain et al.<sup>[<xref rid=""ref22"" ref-type=""bibr"">22</xref>]</sup> In patients with cystic fibrosis, the primary cause of death is pulmonary insufficiency. The known potential risk factors for pulmonary insufficiency are malnutrition, chronic Pseudomonas aeruginosa infection, pancreatic",24_21,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"Pseudomonas aeruginosa infection, pancreatic insufficiency and CFRD. In many previous studies, it has been reported that patients with AGT have worse pulmonary functions than patients with NGT.<sup>[<xref rid=""ref26"" ref-type=""bibr"">26</xref>-<xref rid=""ref29"" ref-type=""bibr"">29</xref>]</sup> In these studies, it has been shown that in patients with CF, increased glucose in airway epithelial cells helps the growth of pathogenic bacteria in the respiratory tract, blunts the immune response and makes the",24_22,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"tract, blunts the immune response and makes the patients more susceptible to pulmonary infection.<sup>[<xref rid=""ref30"" ref-type=""bibr"">30</xref>]</sup> In addition, studies have shown that the increase in blood glucose levels in patients with CF starts in the early stages of life.<sup>[<xref rid=""ref31"" ref-type=""bibr"">31</xref>,<xref rid=""ref32"" ref-type=""bibr"">32</xref>]</sup> In a study, high glucose levels were detected in patients with CF under the age of 10, which was found to be associated with a",24_23,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"of 10, which was found to be associated with a decrease in pulmonary functions.<sup>[<xref rid=""ref32"" ref-type=""bibr"">32</xref>,<xref rid=""ref33"" ref-type=""bibr"">33</xref>]</sup> In the study of Lanng et al.<sup>[<xref rid=""ref31"" ref-type=""bibr"">31</xref>]</sup>, in which 38 children and adults who developed CFRD were evaluated, a gradual decrease in pulmonary functions of the patients, starting about 4 years before the diagnosis of CFRD, was shown. In contrast to the above-mentioned studies, Jain et",24_24,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"contrast to the above-mentioned studies, Jain et al.<sup>[<xref rid=""ref22"" ref-type=""bibr"">22</xref>]</sup> reported in their study that there was no significant difference between the NGT and AGT groups in terms of pulmonary functions. In our study, pulmonary functions of patients with NGT and AGT were compared. It was shown that the FEV1 percentage was lower in patients with AGT than in patients with NGT. The difference between the groups was not significant. Our findings were consistent with the study",24_25,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"Our findings were consistent with the study of Jain et al.<sup>[<xref rid=""ref22"" ref-type=""bibr"">22</xref>]</sup> Studies have shown that gender is a risk factor in the development of cystic fibrosis-related diabetes. Some studies have shown that the frequency of CFRD is higher in female patients<sup>[<xref rid=""ref21"" ref-type=""bibr"">21</xref>,<xref rid=""ref34"" ref-type=""bibr"">34</xref>,<xref rid=""ref35"" ref-type=""bibr"">35</xref>]</sup>, and some studies have suggested that life expectancy is shorter in",24_26,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"have suggested that life expectancy is shorter in female patients compared to male patients.<sup>[<xref rid=""ref36"" ref-type=""bibr"">36</xref>,<xref rid=""ref37"" ref-type=""bibr"">37</xref>]</sup> In patients with cystic fibrosis, the main cause of diabetes development is insulin deficiency due to the loss of pancreatic islet cells.<sup>[<xref rid=""ref14"" ref-type=""bibr"">14</xref>,<xref rid=""ref15"" ref-type=""bibr"">15</xref>]</sup> However, these studies reported that female patients with CF had higher insulin",24_27,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"that female patients with CF had higher insulin levels than male patients.<sup>[<xref rid=""ref21"" ref-type=""bibr"">21</xref>,<xref rid=""ref34"" ref-type=""bibr"">34</xref>,<xref rid=""ref35"" ref-type=""bibr"">35</xref>]</sup> Although the reason for this is not exactly known, studies show that bacterial infections occur earlier and more frequently in women, and this may cause systemic inflammatory response, resulting in insulin resistance.<sup>[<xref rid=""ref35"" ref-type=""bibr"">35</xref>]</sup> In addition,",24_28,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"ref-type=""bibr"">35</xref>]</sup> In addition, Battezzati et al.<sup>[<xref rid=""ref38"" ref-type=""bibr"">38</xref>]</sup> have reported that increased insulin clearance contributes to the deterioration of glucose tolerance in adult female patients with CF. In our study, contrary to the literature, it has been shown that both the frequency of CFRD and the insulin levels are higher in male patients with CF than in female patients. This may be due to the small number of patients included in our study. The",24_29,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"number of patients included in our study. The limitation of this study is that it was designed retrospectively. OGTT results of all cases tested in the study covering the years 2012-2020 could not be obtained. The small number of patients and the lack of a power analysis when planning the study can be considered another limitation. In conclusion, we detected abnormal glucose tolerance approximately in 1 out of 5 patients with cystic fibrosis who were at the age of 10 and above. Almost half (44.4%) of the",24_30,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"age of 10 and above. Almost half (44.4%) of the patients with abnormal glucose tolerance were found to have normal fasting blood glucose level. Therefore, CFRD screening should be performed with OGTT instead of fasting blood glucose in patients with cystic fibrosis. Although the differences were not statistically significant, anthropometric measurements and pulmonary functions were found to be lower in patients with AGT than in patients with NGT. Therefore, detecting CFRD on time may provide better",24_31,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
detecting CFRD on time may provide better anthropometric measurements and pulmonary functions.,24_32,Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis,2024,,Cystic_Fibrosis
"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum <italic toggle=""yes"">Staphylococcus aureus</italic> is one of the most common pathogens isolated from the lungs of people with cystic fibrosis (CF), but little is known about its ability to colonize this niche. We performed a Tn-seq screen to identify genes necessary for <italic toggle=""yes"">S. aureus</italic> growth in media prepared from <italic",25_0,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"growth in media prepared from <italic toggle=""yes"">ex vivo</italic> CF sputum. We identified 19 genes that were required for growth in all sputum media tested and dozens more that were required for growth in at least one sputum medium. Depleted mutants of interest included insertions in many genes important for surviving metal starvation as well as the primary regulator of cysteine metabolism <italic toggle=""yes"">cymR</italic>. To investigate the mechanisms by which these genes contribute to <italic",25_1,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"by which these genes contribute to <italic toggle=""yes"">S. aureus</italic> growth in sputum, we quantified low-molecular-weight thiols, nutrient transition metals, and the host metal-sequestration protein calprotectin in sputum from 11 individuals with CF. In all samples, the abundance of calprotectin exceeded nutrient metal concentration, explaining the <italic toggle=""yes"">S. aureus</italic> requirement for metal-starvation genes. Further, all samples contain potentially toxic quantities of cysteine and",25_2,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"potentially toxic quantities of cysteine and sufficient glutathione to satisfy the organic sulfur requirements of <italic toggle=""yes"">S. aureus</italic>. Deletion of the cysteine importer genes <italic toggle=""yes"">tcyA</italic> and <italic toggle=""yes"">tcyP</italic> in the ∆<italic toggle=""yes"">cymR</italic> background restored growth to wild-type levels in CF sputum, suggesting that the mechanism by which <italic toggle=""yes"">cymR</italic> is required for growth in sputum is to prevent uncontrolled",25_3,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"for growth in sputum is to prevent uncontrolled import of cysteine or cystine from this environment. Overall, this work demonstrates that calprotectin and cysteine limit <italic toggle=""yes"">S. aureus</italic> growth in CF sputum. Cystic fibrosis (CF) is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, which normally transports chloride ions into the extracellular space (<xref rid=""R1"" ref-type=""bibr"">1</xref>–<xref rid=""R3""",25_4,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"rid=""R1"" ref-type=""bibr"">1</xref>–<xref rid=""R3"" ref-type=""bibr"">3</xref>). CFTR dysfunction affects multiple organ systems, the most clinically important of which is the respiratory tract. Impaired chloride transport by airway epithelial cells leads to reduced mucus hydration, which severely impairs mucociliary clearance, a key defense against respiratory pathogens (<xref rid=""R4"" ref-type=""bibr"">4</xref>, <xref rid=""R5"" ref-type=""bibr"">5</xref>). People with CF (pwCF) are especially vulnerable to chronic",25_5,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"CF (pwCF) are especially vulnerable to chronic lung infection by a range of pathogens, the most common and best-studied of which are <italic toggle=""yes"">Pseudomonas aeruginosa</italic> and <italic toggle=""yes"">Staphylococcus aureus</italic> (<xref rid=""R6"" ref-type=""bibr"">6</xref>). <italic toggle=""yes"">S. aureus</italic> is typically the earliest microbe detected in airway secretions of children with CF (<xref rid=""R7"" ref-type=""bibr"">7</xref>). For the past 20 years it has overtaken <italic",25_6,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"For the past 20 years it has overtaken <italic toggle=""yes"">P. aeruginosa</italic> as the most prevalent bacterial species in the lungs of pwCF, with over 60% of individuals culture-positive for <italic toggle=""yes"">S. aureus</italic> (<xref rid=""R7"" ref-type=""bibr"">7</xref>). The subset of <italic toggle=""yes"">S. aureus</italic> infections caused by methicillin-resistant <italic toggle=""yes"">S. aureus</italic> (MRSA) has also been steadily increasing (<xref rid=""R7"" ref-type=""bibr"">7</xref>). <italic",25_7,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"rid=""R7"" ref-type=""bibr"">7</xref>). <italic toggle=""yes"">S. aureus</italic> lung infections lead to heightened inflammation, frequent hospitalizations, reduced lung function which can become permanent, and lower overall survival; each of these outcomes is further worsened if the infection is caused by MRSA (<xref rid=""R8"" ref-type=""bibr"">8</xref>–<xref rid=""R10"" ref-type=""bibr"">10</xref>). These infections are typically chronic and difficult to treat with traditional antibiotics (<xref rid=""R11""",25_8,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"with traditional antibiotics (<xref rid=""R11"" ref-type=""bibr"">11</xref>). Additionally, while highly-effective modulator treatments restore CFTR function, there are significant barriers to access for these treatments, including the high cost and lack of availability in many countries (<xref rid=""R12"" ref-type=""bibr"">12</xref>). Moreover, modulators do not eradicate bacterial infection in most pwCF (<xref rid=""R13"" ref-type=""bibr"">13</xref>). Despite the prevalence and importance of <italic toggle=""yes"">S.",25_9,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"and importance of <italic toggle=""yes"">S. aureus</italic> infections in pwCF, surprisingly little is known about how <italic toggle=""yes"">S. aureus</italic> grows in this niche. Modeling CF lung infection in research settings has many challenges. Animal models of CF are available in a wide range of species, including zebrafish, mice, rats, ferrets, pigs, and sheep (<xref rid=""R14"" ref-type=""bibr"">14</xref>). Each of these models is useful and appropriate for certain applications, but all are imperfect. For",25_10,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"certain applications, but all are imperfect. For example, mice with <italic toggle=""yes"">Cftr</italic> mutations do not spontaneously develop lung disease, nor are they particularly susceptible to bacterial infection, making them ill-suited to model <italic toggle=""yes"">S. aureus</italic> lung infections (<xref rid=""R15"" ref-type=""bibr"">15</xref>). Only the porcine and ferret models recapitulate the lung pathology and impaired bacterial clearance observed in humans with CF, although these are both",25_11,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"in humans with CF, although these are both impractical for most research applications (<xref rid=""R16"" ref-type=""bibr"">16</xref>, <xref rid=""R17"" ref-type=""bibr"">17</xref>). Airway epithelial tissue culture models have been successful in drug development applications, but are less appropriate for microbiological studies due to the absence of key aspects of infection such as mucus and immune cells (<xref rid=""R18"" ref-type=""bibr"">18</xref>). An alternative to animal or tissue culture models is an <italic",25_12,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"to animal or tissue culture models is an <italic toggle=""yes"">ex vivo</italic> culture model using mucus expectorated from the lower airways, known as sputum. In the CF lung environment, <italic toggle=""yes"">S. aureus</italic> typically localizes within the mucus rather than on epithelial surfaces (<xref rid=""R19"" ref-type=""bibr"">19</xref>). This characteristic makes <italic toggle=""yes"">S. aureus</italic> a particularly good candidate for the <italic toggle=""yes"">ex vivo</italic> sputum culture model.",25_13,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"vivo</italic> sputum culture model. <italic toggle=""yes"">Ex vivo</italic> models of infection also have the advantage of eliminating the use of animals. With recent advancements in highly-effective CFTR modulator therapies, fewer pwCF are able to expectorate sputum. To overcome the increasing scarcity of <italic toggle=""yes"">ex vivo</italic> CF sputum, there has been increased interest in developing a fully synthetic <italic toggle=""yes"">in vitro</italic> model of growth in CF sputum. One such <italic",25_14,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"model of growth in CF sputum. One such <italic toggle=""yes"">in vitro</italic> model is synthetic cystic fibrosis sputum medium (SCFM), the composition of which is based on thorough chemical analyses of CF sputum samples (<xref rid=""R20"" ref-type=""bibr"">20</xref>). SCFM has been thoroughly validated for modeling <italic toggle=""yes"">P. aeruginosa</italic> growth in CF sputum, but less data are available regarding its suitability for modeling the growth of <italic toggle=""yes"">S. aureus</italic> or other",25_15,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"<italic toggle=""yes"">S. aureus</italic> or other microbes (<xref rid=""R20"" ref-type=""bibr"">20</xref>–<xref rid=""R22"" ref-type=""bibr"">22</xref>). In this study, we used a forward genetic screening approach to identify genes required for <italic toggle=""yes"">S. aureus</italic> growth in <italic toggle=""yes"">ex vivo</italic> CF sputum and SCFM. We also explored the heterogeneity of <italic toggle=""yes"">S. aureus</italic> growth in independent sputum samples and the <italic toggle=""yes"">S. aureus</italic>",25_16,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"and the <italic toggle=""yes"">S. aureus</italic> genes required for growth in each. The results of our genetic analysis were contextualized by quantifying key components that influence bacterial growth, including calprotectin, nutrient metals, and low-molecular-weight thiols, in multiple sputum samples. Overall, this work presents a comprehensive analysis of <italic toggle=""yes"">S. aureus</italic> growth in CF sputum and the constituents of sputum that impact this growth.  In this study we investigated the",25_17,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"this growth.  In this study we investigated the environment experienced by <italic toggle=""yes"">S. aureus</italic> in the CF lung, beginning with a Tn-seq screen to determine the <italic toggle=""yes"">S. aureus</italic> genes required in <italic toggle=""yes"">ex vivo</italic> CF sputum. By comparing four unique sputum samples as well as a pooled sputum medium, we identified 19 genes that were required for <italic toggle=""yes"">S. aureus</italic> growth in all sputum media and many more genes that were",25_18,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"in all sputum media and many more genes that were required for growth in at least one sputum medium. Mutants significantly depleted from all sputum samples include insertions in metabolic genes, those necessary for metal homeostasis, and the regulator of cysteine metabolism <italic toggle=""yes"">cymR</italic>. To decipher the roles of these genes in the unique environment of CF sputum, we quantified transition metals, the host protein calprotectin, and LMW thiols in sputum from 11 individuals. These",25_19,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"LMW thiols in sputum from 11 individuals. These analyses revealed that calprotectin was in stoichiometric excess relative to the total metals present, suggesting that bioavailable iron, copper, and zinc are substantially lower than the total measured concentrations (<xref rid=""R46"" ref-type=""bibr"">46</xref>–<xref rid=""R48"" ref-type=""bibr"">48</xref>). We also measured much more cysteine and GSH in sputum than previously appreciated. Together, results from this study provide a holistic understanding of the",25_20,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"study provide a holistic understanding of the environment encountered by <italic toggle=""yes"">S. aureus</italic> during chronic infection of the CF lung and the genes it requires to survive and replicate in this milieu. We performed Tn-seq in four unique media, each prepared from an independent CF sputum sample. This approach allowed us not only to identify genes that are generally required for growth in CF sputum, but to assess the extent to which the genetic requirements for growth are similar or",25_21,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"genetic requirements for growth are similar or different in distinct individuals. Previous studies, primarily in <italic toggle=""yes"">P. aeruginosa</italic>, used pooled CF sputa from multiple donors to minimize the effects of heterogeneity between samples. However, comparing Tn-seq results from individual sputum revealed phenotypes that were masked in the pooled medium, highlighting the power of exploring heterogeneity as a complement to studying generalizable phenotypes. For example, mutants of <italic",25_22,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"phenotypes. For example, mutants of <italic toggle=""yes"">graRS</italic> and <italic toggle=""yes"">vraGF</italic> were enriched in two sputum media and depleted in two sputum media, while there was no major enrichment or depletion in the pooled medium. This phenotypic pattern suggests that there are important roles for <italic toggle=""yes"">graRS</italic> and <italic toggle=""yes"">vraGF</italic> during growth in CF sputum that likely differ from person-to-person. Sputum heterogeneity may explain why some of",25_23,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"Sputum heterogeneity may explain why some of the genes we selected for validation studies did not exhibit growth defects in monoculture, such as <italic toggle=""yes"">nanE</italic>, involved in the metabolism of sialic acid (<xref rid=""R29"" ref-type=""bibr"">29</xref>). Mucins are heavily decorated with sialic acid moieties and thus, sialic acid is abundant in CF sputum (<xref rid=""R53"" ref-type=""bibr"">53</xref>). Although <italic toggle=""yes"">S. aureus</italic> is unable to liberate sialic acid from mucin,",25_24,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"is unable to liberate sialic acid from mucin, other bacterial species commonly found in the CF lung, including <italic toggle=""yes"">Schaalia odontolytica</italic>, <italic toggle=""yes"">Prevotella melaninongenica</italic>, and <italic toggle=""yes"">Streptococcus</italic> spp., are capable of doing so (<xref rid=""R54"" ref-type=""bibr"">54</xref>–<xref rid=""R58"" ref-type=""bibr"">58</xref>). The requirement for <italic toggle=""yes"">nanE</italic> in some sputum media but not others could indicate sialic acid",25_25,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"media but not others could indicate sialic acid cross-feeding by other bacterial species present in those sputum samples. One of the most prominent gene signatures we observed in the Tn-seq results was that of metal homeostasis. Mutants in genes involved in iron uptake and heme biosynthesis, including the <italic toggle=""yes"">sir</italic> and <italic toggle=""yes"">fhu</italic> operons as well as <italic toggle=""yes"">hemL,</italic> were significantly depleted in all four individual sputum media.",25_26,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"depleted in all four individual sputum media. Additionally, we identified the zinc-independent ribosomal protein encoded by <italic toggle=""yes"">rpsN2</italic> and the staphylopine exporter <italic toggle=""yes"">cntE</italic> as required for growth in sputum. Together, these hits suggest that <italic toggle=""yes"">S. aureus</italic> experiences metal starvation in CF sputum. Somewhat paradoxically, we also identified genes important for detoxifying metal stress, including the manganese and copper exporters",25_27,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"including the manganese and copper exporters encoded by <italic toggle=""yes"">mntE</italic> and <italic toggle=""yes"">copA</italic>, respectively. Identifying multiple metal homeostasis genes prompted us to quantify the transition metals present in sputum. Host sequestration of essential nutrient transition metals has long been appreciated to serve as a key defense against bacterial pathogens, a phenomenon known as nutritional immunity (<xref rid=""R38"" ref-type=""bibr"">38</xref>–<xref rid=""R40""",25_28,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"ref-type=""bibr"">38</xref>–<xref rid=""R40"" ref-type=""bibr"">40</xref>). Calprotectin is an abundant host protein that mediates nutritional immunity by binding and sequestering transition metals; thus, measuring calprotectin is critical for contextualizing metal availability (<xref rid=""R40"" ref-type=""bibr"">40</xref>, <xref rid=""R46"" ref-type=""bibr"">46</xref>). Our analysis of calprotectin and nutrient metal concentrations in CF sputum revealed that calprotectin was far more abundant than copper, iron, or",25_29,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"was far more abundant than copper, iron, or zinc in every sample tested. To our knowledge, sputum samples have not previously been analyzed for concentrations of both calprotectin and nutrient metals. ICP-MS quantifies all metals in a sample, whether or not they are protein-bound. Our data measuring the relative quantity of calprotectin suggests that the metals may not be accessible to bacteria. The excess of calprotectin relative to nutrient metals in CF sputum suggests that ∆<italic",25_30,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"metals in CF sputum suggests that ∆<italic toggle=""yes"">cntE</italic> and ∆<italic toggle=""yes"">rpsN2</italic> mutants exhibited significant growth defects in CF sputum medium due to metal starvation imposed by calprotectin. Loss of <italic toggle=""yes"">cntE</italic> prevents export of the metallophore staphylopine, which is primarily used for zinc acquisition (<xref rid=""R41"" ref-type=""bibr"">41</xref>). Sensitivity of ∆<italic toggle=""yes"">cntE</italic> to zinc starvation is at least partially due to",25_31,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"to zinc starvation is at least partially due to toxic accumulation of staphylopine in the cytosol rather than the inability to acquire zinc (<xref rid=""R34"" ref-type=""bibr"">34</xref>, <xref rid=""R35"" ref-type=""bibr"">35</xref>). To test whether the growth defect of the ∆<italic toggle=""yes"">cntE</italic> mutant is due to zinc starvation or staphylopine toxicity, we investigated the growth of a <italic toggle=""yes"">cntA::Tn</italic> mutant, which is impaired for staphylopine import (<xref rid=""R41""",25_32,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"impaired for staphylopine import (<xref rid=""R41"" ref-type=""bibr"">41</xref>). The mutant lacking <italic toggle=""yes"">cntA</italic> (<italic toggle=""yes"">cntA</italic>::Tn) exhibited an approximately 10-fold growth defect in CF sputum medium (<italic toggle=""yes"">p</italic> = 0.15). A possible explanation for this observation is that metal starvation plays a role in the growth defect of the ∆<italic toggle=""yes"">cntE</italic> mutant but that staphylopine toxicity may also contribute. Recent studies have",25_33,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"toxicity may also contribute. Recent studies have similarly underscored the selective pressure that calprotectin imposes on bacteria. For example, Tn-seq performed on <italic toggle=""yes"">S. aureus</italic> growing in TSB containing calprotectin identified genes that overlap strikingly with our CF sputum Tn-seq results, including the <italic toggle=""yes"">cnt</italic> operon and <italic toggle=""yes"">rpsN2</italic> (<xref rid=""R59"" ref-type=""bibr"">59</xref>). That is, simply adding calprotectin to rich",25_34,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"That is, simply adding calprotectin to rich medium is sufficient to recapitulate many phenotypes observed in CF sputum medium. Additionally, it was noted that adding calprotectin to SCFM improves the accuracy of SCFM in recapitulating the transcriptional landscape of <italic toggle=""yes"">P. aeruginosa</italic> during growth in CF sputum (<xref rid=""R60"" ref-type=""bibr"">60</xref>). The strong effect of calprotectin on <italic toggle=""yes"">S. aureus</italic> also likely explains why there was little overlap",25_35,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"also likely explains why there was little overlap in our Tn-seq screen in SCFM3, which does not contain calprotectin, and our results in CF sputum. Our Tn-seq data are also interesting in the context of the <italic toggle=""yes"">S. aureus</italic> transcriptional response during growth in CF sputum. Many of the genes we identified as essential for growth in CF sputum media are also upregulated in <italic toggle=""yes"">S. aureus</italic> isolated from CF sputum samples, including the <italic",25_36,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"from CF sputum samples, including the <italic toggle=""yes"">cnt</italic> operon, <italic toggle=""yes"">nanE</italic>, and <italic toggle=""yes"">copA</italic> (<xref rid=""R22"" ref-type=""bibr"">22</xref>). Ibberson and Whiteley mapped clinical isolate reads to a reduced core genome of 1,960 genes, so neither <italic toggle=""yes"">rpsN2</italic> nor <italic toggle=""yes"">cymR</italic> were analyzed; however, <italic toggle=""yes"">tcyA</italic> and <italic toggle=""yes"">tcyP</italic> were downregulated, consistent",25_37,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"were downregulated, consistent with our <italic toggle=""yes"">cymR</italic> analysis (<xref rid=""R22"" ref-type=""bibr"">22</xref>). A ∆<italic toggle=""yes"">cymR</italic> deletion mutant exhibited a significant growth defect in CF sputum, which cannot be explained by calprotectin-mediated metal starvation and instead suggests a role for cysteine toxicity during growth in CF sputum. To explore whether cysteine could be present at toxic levels in CF sputum, we quantified the total amount of cysteine and GSH in",25_38,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"the total amount of cysteine and GSH in the same samples in which we quantified calprotectin and metals. We found that cysteine concentrations ranged from 65 – 3,350 μM and GSH concentrations ranged from 11 – 296 μM, much higher quantities of both thiols than previously reported (<xref rid=""R20"" ref-type=""bibr"">20</xref>, <xref rid=""R50"" ref-type=""bibr"">50</xref>). Excess cysteine has long been known to cause toxicity in bacteria, by either metabolic or oxidative stress (<xref rid=""R61""",25_39,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"metabolic or oxidative stress (<xref rid=""R61"" ref-type=""bibr"">61</xref>–<xref rid=""R63"" ref-type=""bibr"">63</xref>). Our genetic data and thiol profiling results together suggest that in the absence of <italic toggle=""yes"">cymR</italic>, <italic toggle=""yes"">S. aureus</italic> likely imports a toxic amount of cysteine, causing attenuated growth in CF sputum. The exact mechanism by which cysteine is toxic to <italic toggle=""yes"">S. aureus</italic> in CF sputum is yet to be determined. The simplest",25_40,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"CF sputum is yet to be determined. The simplest explanation is that excess intracellular cysteine or oxidized cystine interacts with intracellular iron to inflict oxidative damage and attenuate growth, similar to what was shown in <italic toggle=""yes"">E. coli</italic> (<xref rid=""R63"" ref-type=""bibr"">63</xref>). However, we do not favor this hypothesis due to the fact that cysteine remained toxic to the ∆<italic toggle=""yes"">cymR</italic> mutant even in the presence of equimolar GSH, a potent antioxidant.",25_41,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"presence of equimolar GSH, a potent antioxidant. Further, our thiol profiling data showed that GSH is present in CF sputum in high enough concentrations to fulfill the organic sulfur requirements of <italic toggle=""yes"">S. aureus</italic> without the need to import any free cysteine at all (<xref rid=""R51"" ref-type=""bibr"">51</xref>). An alternative hypothesis is that dysregulated cysteine import perturbs metabolic flux, leading to reduced growth. The dispensability of cysteine importers TcyABC and TcyP",25_42,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"of cysteine importers TcyABC and TcyP could suggest that <italic toggle=""yes"">S. aureus</italic> does not primarily use cysteine as a source of nutrient sulfur during growth in CF sputum as it does in other niches, including systemic infection (<xref rid=""R52"" ref-type=""bibr"">52</xref>). Avoiding free cysteine import altogether when other organosulfur sources are available could be a protective strategy against cysteine intoxication. Although the manganese efflux pump <italic toggle=""yes"">mntE</italic> was",25_43,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"pump <italic toggle=""yes"">mntE</italic> was identified by Tn-seq as important in all sputum media, the <italic toggle=""yes"">mntE</italic>::Tn mutant did not exhibit a growth defect in monoculture. This discrepancy is likely due to technical differences in the preparation of sputum medium. For Tn-seq experiments, sputum was homogenized in SMM, which contains manganese, while the sputum media used for validation studies were prepared in buffered base without manganese (<xref rid=""R20""",25_44,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"buffered base without manganese (<xref rid=""R20"" ref-type=""bibr"">20</xref>, <xref rid=""R25"" ref-type=""bibr"">25</xref>). This hypothesis is supported by the fact that <italic toggle=""yes"">mntE</italic> was also identified as required for growth in SMM containing glucose in a pilot Tn-seq screen (data not shown). Additionally, the concentration of Mn (21 – 361 nM) we detected in sputum is not likely to cause toxicity (<xref rid=""R64"" ref-type=""bibr"">64</xref>, <xref rid=""R65"" ref-type=""bibr"">65</xref>, <xref",25_45,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"<xref rid=""R65"" ref-type=""bibr"">65</xref>, <xref rid=""R32"" ref-type=""bibr"">32</xref>). Mutants in the remaining two genes, <italic toggle=""yes"">ylaN</italic> and <italic toggle=""yes"">pruA</italic>, grew poorly compared to WT in monoculture but these growth defects were not statistically significant. This may be a result of the technical limitations of this growth model. WT <italic toggle=""yes"">S. aureus</italic> only replicates approximately 100-fold in sputum medium, so minor or variable growth defects",25_46,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"medium, so minor or variable growth defects are difficult to detect statistically, though they may be biologically relevant. While we focused on genes required for growth in CF sputum, our Tn-seq screen also identified several mutants that were enriched in all four sputum media, indicating that these genes are actually detrimental to <italic toggle=""yes"">S. aureus</italic> growth in sputum. Most notably, transposon mutants in the <italic toggle=""yes"">rsbUVW</italic>-<italic toggle=""yes"">sigB</italic>",25_47,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"toggle=""yes"">sigB</italic> operon were enriched across all of the sputum media. SigB is the general stress response sigma factor in <italic toggle=""yes"">S. aureus</italic>, and RsbU, RsbV, and RsbW are posttranslational regulators of SigB (<xref rid=""R66"" ref-type=""bibr"">66</xref>, <xref rid=""R67"" ref-type=""bibr"">67</xref>). This finding is particularly interesting because this operon is known to accumulate inactivating mutations during long-term colonization of the CF lung (<xref rid=""R68""",25_48,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"colonization of the CF lung (<xref rid=""R68"" ref-type=""bibr"">68</xref>). It has been hypothesized that isolates deficient in the general stress response emerge during long-term colonization due to their reduced virulence and, consequently, reduced immunogenicity (<xref rid=""R68"" ref-type=""bibr"">68</xref>). However, these genes were identified as hits in all four sputum media in the absence of an active immune response, suggesting that inactivation of the general stress response in <italic toggle=""yes"">S.",25_49,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"stress response in <italic toggle=""yes"">S. aureus</italic> instead confers a general growth advantage in CF sputum. In summary, we found that despite heterogeneity between samples, there exists a core set of genes required for growth in CF sputum. Many of these genes are involved in surviving metal starvation, which we propose is imposed by the high concentration of calprotectin present in CF sputum relative to available nutrient metals. We also establish that cysteine toxicity is a",25_50,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"We also establish that cysteine toxicity is a calprotectin-independent source of stress on <italic toggle=""yes"">S. aureus</italic> growing in CF sputum. These new insights into <italic toggle=""yes"">S. aureus</italic> growth in CF sputum fill an important gap in our understanding of how this key pathogen is able to establish and maintain infections in the CF lung environment.",25_51,"Analysis of genetic requirements and nutrient availability for <italic toggle=""yes"">Staphylococcus aureus</italic> growth in cystic fibrosis sputum",25 9 2024,,Cystic_Fibrosis
"Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease Exosomes, membrane-bound extracellular vesicles, ranging from approximately 30–200 nm in diameter, are released by almost all cell types and play critical roles in intercellular communication. In response to the prevailing stress, the exosome-bound protein signatures vary in abundance and composition. To identify the bronchoalveolar lavage fluid (BALF)",26_0,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"identify the bronchoalveolar lavage fluid (BALF) exosome-bound proteins associated with mucoinflammatory lung disease and to gain insights into their functional implications, we compared BALF exosomes-derived proteins from adult <italic toggle=""yes"">Scnn1b</italic> transgenic (<italic toggle=""yes"">Scnn1b</italic>-Tg+) and wild type (WT) mice. A total of 3,144 and 3,119 proteins were identified in BALF exosomes from <italic toggle=""yes"">Scnn1b</italic>-Tg+ and WT mice, respectively. Using cutoff criteria",26_1,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"and WT mice, respectively. Using cutoff criteria (Log<sub>2</sub> fold-change > 1 and adjusted <italic toggle=""yes"">p</italic>-value < 0.05), the comparison of identified proteins revealed 127 and 30 proteins that were significantly upregulated and downregulated, respectively, in <italic toggle=""yes"">Scnn1b</italic>-Tg+ versus WT mice. In addition, 52 and 27 proteins were exclusively enriched in <italic toggle=""yes"">Scnn1b</italic>-Tg+ and WT mice, respectively. The identified exosome-bound proteins from",26_2,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"The identified exosome-bound proteins from the homeostatic airspaces of WT mice were mostly relevant to the normal physiological processes. The protein signatures enriched in the BALF exosomes of <italic toggle=""yes"">Scnn1b</italic>-Tg+ mice were relevant to macrophage activation and mucoinflammatory processes. Ingenuity pathway analyses revealed that the enriched proteins in <italic toggle=""yes"">Scnn1b</italic>-Tg+ mice contributed to the inflammatory responses and antimicrobial defense pathways.",26_3,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"responses and antimicrobial defense pathways. Selective proteins including, RETNLA/FIZZ1, LGALS3/Galectin-3, S100A8/MRP8, and CHIL3/YM1 were immunolocalized to specific cell types. The comparative analysis between enriched BALF exosome proteins and previously identified differentially upregulated genes in <italic toggle=""yes"">Scnn1b</italic>-Tg+ versus WT mice suggested that the compartment-/cell-specific upregulation in gene expression dictates the enrichment of their respective proteins in the lung",26_4,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"of their respective proteins in the lung airspaces. Taken together, this study demonstrates that the BALF exosome-bound protein signatures reflect disease-relevant disturbances. Our findings suggest that the exosomes carry disease-relevant protein signatures that can be used as a diagnostic as well as predictive biomarkers for mucoinflammatory lung disease. Mucoinflammatory lung diseases including, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), primary ciliary dyskinesia (PCD), and",26_5,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"(COPD), primary ciliary dyskinesia (PCD), and non-cystic fibrosis bronchiectasis, are characterized by mucus plugging, impaired mucociliary clearance (MCC), airway inflammation, and recurrent infections (<xref rid=""B44"" ref-type=""bibr"">Mall et al., 2018</xref>; <xref rid=""B5"" ref-type=""bibr"">Boucher, 2019</xref>; <xref rid=""B6"" ref-type=""bibr"">Burgel et al., 2009</xref>). Most of these pathological features of mucoinflammatory lung diseases are displayed by <italic toggle=""yes"">Scnn1b</italic> transgenic",26_6,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"<italic toggle=""yes"">Scnn1b</italic> transgenic (<italic toggle=""yes"">Scnn1b</italic>-Tg+) mice (<xref rid=""B43"" ref-type=""bibr"">Mall et al., 2004</xref>; <xref rid=""B45"" ref-type=""bibr"">Mall et al., 2008</xref>). The <italic toggle=""yes"">Scnn1b</italic>-Tg+ mouse overexpresses <italic toggle=""yes"">sodium channel non-voltage-gated 1, beta subunit</italic> (<italic toggle=""yes"">Scnn1b</italic>) transgene in club cell secretory protein (CCSP) expressing airway epithelial cells. This overexpression of <italic",26_7,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"epithelial cells. This overexpression of <italic toggle=""yes"">Scnn1b</italic> transgene causes hyperabsorption of sodium ions and, as a consequence, establishes an osmotic gradient that draws water into the airway epithelial cells leading to airway surface liquid dehydration, mucin hyperconcentration, and impaired MCC (<xref rid=""B43"" ref-type=""bibr"">Mall et al., 2004</xref>; <xref rid=""B45"" ref-type=""bibr"">Mall et al., 2008</xref>). In our previous report, transcriptomic analyses on whole lung and",26_8,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"report, transcriptomic analyses on whole lung and alveolar macrophages revealed differential gene signatures in the <italic toggle=""yes"">Scnn1b</italic>-Tg+ versus wild-type (WT) mice (<xref rid=""B60"" ref-type=""bibr"">Saini et al., 2014</xref>). However, apart from selective cytokine analyses (<xref rid=""B43"" ref-type=""bibr"">Mall et al., 2004</xref>; <xref rid=""B45"" ref-type=""bibr"">Mall et al., 2008</xref>; <xref rid=""B37"" ref-type=""bibr"">Lewis et al., 2020a</xref>; <xref rid=""B13"" ref-type=""bibr"">Choudhary",26_9,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"<xref rid=""B13"" ref-type=""bibr"">Choudhary et al., 2021a</xref>; <xref rid=""B62"" ref-type=""bibr"">Saini et al., 2016</xref>; <xref rid=""B46"" ref-type=""bibr"">Mao et al., 2023</xref>; <xref rid=""B61"" ref-type=""bibr"">Saini et al., 2018</xref>; <xref rid=""B35"" ref-type=""bibr"">Lewis et al., 2020b</xref>; <xref rid=""B36"" ref-type=""bibr"">Lewis et al., 2017</xref>), comprehensive analyses of airspace protein contents between <italic toggle=""yes"">Scnn1b</italic>-Tg+ versus WT mice have not yet been conducted.",26_10,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"versus WT mice have not yet been conducted. Exosomes are nano-sized extracellular vesicles (30–200 nm) released by almost all cell types and play critical roles in intercellular communications (<xref rid=""B23"" ref-type=""bibr"">Gurung et al., 2021</xref>; <xref rid=""B47"" ref-type=""bibr"">McVey et al., 2019</xref>; <xref rid=""B70"" ref-type=""bibr"">Théry et al., 2002</xref>). Exosomes are known to regulate homeostatic as well as pathological processes in various organ systems (<xref rid=""B70""",26_11,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"in various organ systems (<xref rid=""B70"" ref-type=""bibr"">Théry et al., 2002</xref>; <xref rid=""B28"" ref-type=""bibr"">Kalluri and LeBleu, 2020</xref>; <xref rid=""B51"" ref-type=""bibr"">Pathan et al., 2018</xref>; <xref rid=""B25"" ref-type=""bibr"">Holtzman and Lee, 2020</xref>). Multi-omics approaches including transcriptomics, metabolomics, and proteomics, have significantly enhanced our understanding of the exosome contents and their biological relevance during pathophysiological processes (<xref rid=""B64""",26_12,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"pathophysiological processes (<xref rid=""B64"" ref-type=""bibr"">Shaba et al., 2022</xref>; <xref rid=""B10"" ref-type=""bibr"">Chitoiu et al., 2020</xref>). Increasing evidence suggests that bronchoalveolar lavage fluid (BALF) exosomes contribute to inflammatory outcomes in various lung diseases, including asthma, COPD, CF, and PCD (<xref rid=""B72"" ref-type=""bibr"">Torregrosa Paredes et al., 2012</xref>; <xref rid=""B58"" ref-type=""bibr"">Rollet-Cohen et al., 2018</xref>; <xref rid=""B29"" ref-type=""bibr"">Kaur et al.,",26_13,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"<xref rid=""B29"" ref-type=""bibr"">Kaur et al., 2021</xref>). Additionally, BALF-derived exosomal miRNAs from COPD patients showed unique miRNA signatures as compared to the healthy subjects, indicating their potential use as biomarkers to track the disease progression (<xref rid=""B29"" ref-type=""bibr"">Kaur et al., 2021</xref>). Recent studies indicate that exosomal proteomic analyses can be used to gain insights into lung diseases (<xref rid=""B58"" ref-type=""bibr"">Rollet-Cohen et al., 2018</xref>; <xref",26_14,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"et al., 2018</xref>; <xref rid=""B12"" ref-type=""bibr"">Choudhary et al., 2021b</xref>; <xref rid=""B74"" ref-type=""bibr"">Velázquez-Enríquez et al., 2021</xref>). Our recent study revealed that exosome-bound protein signatures from ozone-stressed airspaces reflect the molecular processes involved in mucoinflammatory lung disease (<xref rid=""B12"" ref-type=""bibr"">Choudhary et al., 2021b</xref>). In this study, to gain insights into the proteomic differences and their association with the pathological endpoints,",26_15,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"association with the pathological endpoints, we compared exosome-bound protein signatures between <italic toggle=""yes"">Scnn1b</italic>-Tg+ and WT adult mice. We hypothesized that alterations in the composition of exosome-bound protein signatures in <italic toggle=""yes"">Scnn1b</italic>-Tg+ mice are suggestive of mucoinflammatory lung disease. To test this hypothesis, exosomes harvested from the BALF of adult WT and <italic toggle=""yes"">Scnn1b</italic>-Tg+ mice were subjected to liquid chromatography-mass",26_16,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
mice were subjected to liquid chromatography-mass spectrometry (LC-MS/MS) followed by bioinformatic analyses. The results from this study provide critical insights into the relevance of exosome-bound protein signatures in the pathological manifestation of mucoinflammatory lung disease in this transgenic mouse model and suggest their potential application as diagnostic and predictive biomarkers for mucoinflammatory diseases.   Exosome-mediated intercellular communications play important roles in normal and,26_17,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"communications play important roles in normal and pathological conditions through the transfer of various bioactive compounds including proteins, lipids, DNA, and RNA molecules (<xref rid=""B28"" ref-type=""bibr"">Kalluri and LeBleu, 2020</xref>; <xref rid=""B16"" ref-type=""bibr"">De Toro et al., 2015</xref>; <xref rid=""B66"" ref-type=""bibr"">Stoorvogel et al., 2002</xref>). Our recent proteomic-oriented report revealed interesting findings from airspaces-derived exosomes from ozone-stressed airspaces in mice",26_18,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"exosomes from ozone-stressed airspaces in mice (<xref rid=""B12"" ref-type=""bibr"">Choudhary et al., 2021b</xref>). In this study, to gain insights into the proteomic differences and their association with the pathological endpoints, we hypothesized that alterations in the composition of exosome-bound protein signatures in <italic toggle=""yes"">Scnn1b</italic>-Tg+ mice are suggestive of mucoinflammatory lung disease. To investigate this, we addressed a series of questions: (1) Do <italic",26_19,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"addressed a series of questions: (1) Do <italic toggle=""yes"">Scnn1b</italic>-Tg+ mice exhibit differential composition of proteins in the airspace exosomes as compared to WT mice? (2) What proteins are enriched in exosomes derived from <italic toggle=""yes"">Scnn1b</italic>-Tg+ airspaces? (3) Do the exosomal proteins reflect macrophage activation patterns and mucoinflammatory disturbances in the <italic toggle=""yes"">Scnn1b</italic>-Tg+ airspace? (4) Which biological pathways are influenced by exosome-bound",26_20,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"pathways are influenced by exosome-bound proteins in <italic toggle=""yes"">Scnn1b</italic>-Tg+ versus WT mice? Protein signatures found enriched in the BALF exosomes from WT mice were suggestive of normal tissue functions. For example, homeodomain-only protein homeobox (HOPX), which is required for developing mouse neocortex (<xref rid=""B73"" ref-type=""bibr"">Vaid et al., 2018</xref>), was enriched in WT mice. Glutathione peroxidase 8 (GPX8), which protects cytosol from H<sub>2</sub>O<sub>2</sub> leakage in",26_21,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"from H<sub>2</sub>O<sub>2</sub> leakage in the endoplasmic reticulum (<xref rid=""B56"" ref-type=""bibr"">Ramming et al., 2014</xref>), and the growth factor midkine (MDK) which regulates the renin-angiotensin system and mediates the interaction between the kidneys and lungs in mice (<xref rid=""B24"" ref-type=""bibr"">Hobo et al., 2009</xref>), were enriched in WT mice BALF exosomes. Interestingly, several exosomal proteins that were exclusively expressed in WT mice BALF exosomes were also involved in normal",26_22,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"mice BALF exosomes were also involved in normal biosynthesis, i.e., keratin, type I cuticular Ha2 (KRT32), a type I hair keratin, involved in exoskeleton formation (<xref rid=""B1"" ref-type=""bibr"">Adav et al., 2023</xref>), pleckstrin homology domain-containing, family G member 5 (PLEKHG5), a guanine-nucleotide exchange factors to activate ras homolog family member A (RhoA) (<xref rid=""B15"" ref-type=""bibr"">De Toledo et al., 2001</xref>; <xref rid=""B53"" ref-type=""bibr"">Qian et al., 2019</xref>), and antigen",26_23,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"et al., 2019</xref>), and antigen peptide transporter 1 (TAP1), the subunit of transporter associated with antigen processing (<xref rid=""B18"" ref-type=""bibr"">Gaudet and Wiley, 2001a</xref>; <xref rid=""B19"" ref-type=""bibr"">Gaudet and Wiley, 2001b</xref>). These data indicate that under homeostatic conditions, exosome-bound proteins in bronchoalveolar airspaces are relevant to normal physiological processes. A large number of protein signatures relevant to inflammation, macrophage activation, and mucous",26_24,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"inflammation, macrophage activation, and mucous cell metaplasia were found enriched in the BALF exosomes from <italic toggle=""yes"">Scnn1b</italic>-Tg+ mice. CD177, a specific marker of neutrophil activation (<xref rid=""B34"" ref-type=""bibr"">Lévy et al., 2021</xref>; <xref rid=""B4"" ref-type=""bibr"">Bayat et al., 2010</xref>), was the most abundant protein present within the exosomes from <italic toggle=""yes"">Scnn1b</italic>-Tg+ mice. Extracellular vesicle-derived ITGAM, which is involved in acute lung injury",26_25,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"ITGAM, which is involved in acute lung injury (<xref rid=""B26"" ref-type=""bibr"">Hu et al., 2023</xref>), was highly expressed in the exosome of <italic toggle=""yes"">Scnn1b</italic>-Tg+ versus WT mice. Neutrophil elastase (NE), a key inflammatory protease (<xref rid=""B75"" ref-type=""bibr"">Voynow and Shinbashi, 2021</xref>; <xref rid=""B52"" ref-type=""bibr"">Pham, 2006</xref>), and a known promoter of mucous cell metaplasia in the <italic toggle=""yes"">Scnn1b</italic>-Tg+ mice (<xref rid=""B20""",26_26,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"mice (<xref rid=""B20"" ref-type=""bibr"">Gehrig et al., 2014</xref>), Lymphocyte antigen 6 family member G (Ly6G) and MPO, two distinct neutrophil markers (<xref rid=""B33"" ref-type=""bibr"">Lee et al., 2013</xref>; <xref rid=""B3"" ref-type=""bibr"">Aratani, 2018</xref>), and CTSG, a serine protease, acting as a chemoattractant for mononuclear cells and neutrophils (<xref rid=""B8"" ref-type=""bibr"">Chertov et al., 1997</xref>), were exclusively expressed in BALF exosomes of <italic toggle=""yes"">Scnn1b</italic>-Tg+",26_27,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"of <italic toggle=""yes"">Scnn1b</italic>-Tg+ mice. Moreover, MMP-9 and MMP-12, the proteolytic enzymes, were also exclusively expressed in the BALF exosome of <italic toggle=""yes"">Scnn1b</italic>-Tg+ mice. Of note, the roles of MMP-9 and MMP-12 are well-established in the pathogenesis of COPD (<xref rid=""B48"" ref-type=""bibr"">Molet et al., 2005</xref>; <xref rid=""B50"" ref-type=""bibr"">Papakonstantinou et al., 2015</xref>; <xref rid=""B40"" ref-type=""bibr"">Liu et al., 2020</xref>). Our previous report indicated",26_28,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"al., 2020</xref>). Our previous report indicated that an admixture of activated macrophages was present in the BALF of <italic toggle=""yes"">Scnn1b</italic>-Tg+ mice, with predominantly classically-activated (M1) macrophages in neonates and alternatively-activated (M2) macrophages in adulthood (<xref rid=""B60"" ref-type=""bibr"">Saini et al., 2014</xref>). Consistent with this report, M2 activation-relevant protein signatures showed a significant enrichment within the BALF exosomes of <italic",26_29,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"enrichment within the BALF exosomes of <italic toggle=""yes"">Scnn1b</italic>-Tg+ mice. CHIL3/YM1, an M2 alternative activation marker in mice (<xref rid=""B55"" ref-type=""bibr"">Raes et al., 2005</xref>; <xref rid=""B54"" ref-type=""bibr"">Raes et al., 2002</xref>), forms eosinophilic crystals in the cytoplasm of alveolar macrophages and multinucleate giant cells, and within the alveolar spaces (<xref rid=""B22"" ref-type=""bibr"">Guo et al., 2000</xref>). YM1/2 contributes to Th2 cytokine production and allergic",26_30,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"to Th2 cytokine production and allergic airway inflammation (<xref rid=""B7"" ref-type=""bibr"">Cai et al., 2009</xref>). <italic toggle=""yes"">Chil3</italic>, an mRNA for CHIL3/YM1, showed significantly upregulated expression in the alveolar macrophage of <italic toggle=""yes"">Scnn1b</italic>-Tg+ mice (<xref rid=""B60"" ref-type=""bibr"">Saini et al., 2014</xref>). Consistent with this report, CHIL3/YM1 was enriched in the BALF exosomes from <italic toggle=""yes"">Scnn1b</italic>-Tg+ mice and the macrophage-specific",26_31,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"mice and the macrophage-specific immunolocalization of this protein suggests its origination from macrophages. Galectin-3 (LGALS3), a β-galactoside-binding lectin, is also expressed by alternatively activated macrophages (<xref rid=""B42"" ref-type=""bibr"">MacKinnon et al., 2008</xref>; <xref rid=""B49"" ref-type=""bibr"">Nishi et al., 2007</xref>). Galectin-3 was enriched in BALF exosomes from ozone-exposed mice (<xref rid=""B12"" ref-type=""bibr"">Choudhary et al., 2021b</xref>). Galectin-3 was exclusively enriched",26_32,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"Galectin-3 was exclusively enriched in airspace-derived exosomes from <italic toggle=""yes"">Scnn1b</italic>-Tg+ mice and had macrophage-specific immunolocalization in <italic toggle=""yes"">Scnn1b</italic>-Tg+ lungs. FIZZ1 (Found in Inflammatory Zone 1/RETNLA), another well-known alternative macrophage activation marker in mice (<xref rid=""B54"" ref-type=""bibr"">Raes et al., 2002</xref>), was found significantly upregulated in the alveolar macrophages of <italic toggle=""yes"">Scnn1b</italic>-Tg+ lungs (<xref",26_33,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"toggle=""yes"">Scnn1b</italic>-Tg+ lungs (<xref rid=""B60"" ref-type=""bibr"">Saini et al., 2014</xref>). The airway epithelial-specific immunolocalization of FIZZ1 has been reported in hypoxia-exposed (<xref rid=""B69"" ref-type=""bibr"">Teng et al., 2003</xref>) and ozone-exposed mice (<xref rid=""B12"" ref-type=""bibr"">Choudhary et al., 2021b</xref>). Consistent with these reports, FIZZ1 immunostaining was localized to the airway epithelium of <italic toggle=""yes"">Scnn1b</italic>-Tg+ mice. These reports suggest that",26_34,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"mice. These reports suggest that exosome-bound FIZZ1 originates from airway epithelial cells in <italic toggle=""yes"">Scnn1b</italic>-Tg+ airspace. While we were able to identify the cellular sources of exosomes-bound protein signatures, it remains unclear whether the exosomes continue to exchange their cargo after their extracellular release. Mucoinflammatory lung diseases are characterized by intrapulmonary accumulations of hyper-concentrated mucus, which contributes to the vulnerability to recurrent",26_35,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"contributes to the vulnerability to recurrent infections (<xref rid=""B5"" ref-type=""bibr"">Boucher, 2019</xref>; <xref rid=""B41"" ref-type=""bibr"">Livraghi-Butrico et al., 2017</xref>). To investigate the BALF exosome-bound protein signatures potentially relevant to the development of lung mucoinflammation, we compared the presence of protein signatures associated with mucoinflammatory lung diseases in the BALF exosomes of <italic toggle=""yes"">Scnn1b</italic>-Tg+ mice versus WT mice. Numerous proteins",26_36,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"mice versus WT mice. Numerous proteins previously shown to be involved in mucoinflammatory lung diseases were enriched in the exosomes from <italic toggle=""yes"">Scnn1b</italic>-Tg+ mice, including S100A9, CAMP, S100A8, PGLYRP1, LTF, BPIFB1, LIPA, APOB, APOC3, CD5L, CD14, CTSD, and LGALS3. <italic toggle=""yes"">Scnn1b</italic>-Tg+ mice present with neutrophilic inflammation in airspace (<xref rid=""B43"" ref-type=""bibr"">Mall et al., 2004</xref>) and enriched S100A8 was found in airspaces-derived exosomes of",26_37,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"S100A8 was found in airspaces-derived exosomes of ozone-challenged mice (<xref rid=""B12"" ref-type=""bibr"">Choudhary et al., 2021b</xref>). These findings were consistent with the increased S100A8 expression in BALF exosome and neutrophils of <italic toggle=""yes"">Scnn1b</italic>-Tg+ mice (<xref rid=""F3"" ref-type=""fig"">Figure 3C</xref>; <xref rid=""F4"" ref-type=""fig"">Figures 4A, B</xref>). Similarly, the upregulation of protein signatures relevant to MCM, i.e., SCGB1A1 and CLCA1, was consistent with the",26_38,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"i.e., SCGB1A1 and CLCA1, was consistent with the previous study that <italic toggle=""yes"">Scnn1b</italic>-Tg+ mice have increased numbers of mucous cells in airways versus their WT littermates (<xref rid=""B45"" ref-type=""bibr"">Mall et al., 2008</xref>). BALF exosome-bound proteins from stressed airways might contribute to the functional and disease-associated pathways (<xref rid=""B12"" ref-type=""bibr"">Choudhary et al., 2021b</xref>). Ingenuity pathways analysis (IPA) on the differentially expressed proteins",26_39,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"(IPA) on the differentially expressed proteins within the exosomes gathered in this study revealed activation of several canonical pathways including neutrophil degranulation, antimicrobial peptides, regulation of TLR by endogenous ligand, neutrophil extracellular trap signaling pathway, and Fc-gamma receptor-dependent phagocytosis. Additionally, enriched protein-protein interaction (PPI) networks from airspace-derived exosomes from BALF of <italic toggle=""yes"">Scnn1b</italic>-Tg+ mice revealed the major",26_40,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"mice revealed the major subsets including neutrophil degranulation, immune system, innate immune system, and antimicrobial peptides. However, the PPI analyses from protein signatures upregulated and exclusively expressed in WT mice presented endoplasmic reticulum-associated networks including the endomembrane system, endoplasmic reticulum, and endoplasmic reticulum membrane, which might potentially help maintain the homeostatic conditions of biosynthesis. Increasing research on exosomes have showed its",26_41,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"Increasing research on exosomes have showed its potential in translational medicine and have provided novel insights for the clinical diagnostics and therapeutic strategies as biomarkers, vaccines, and drug carriers (<xref rid=""B31"" ref-type=""bibr"">Khan et al., 2015</xref>; <xref rid=""B2"" ref-type=""bibr"">Alvarez-Erviti et al., 2011</xref>; <xref rid=""B68"" ref-type=""bibr"">Tan et al., 2014</xref>; <xref rid=""B39"" ref-type=""bibr"">Li et al., 2013</xref>). This is the first study to provide a detailed",26_42,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"This is the first study to provide a detailed proteomics analysis of exosomes from <italic toggle=""yes"">Scnn1b</italic>-Tg+ airspaces and our findings revealed that BALF exosomes-bound protein signatures reflect the muco-obstructive lung disease-relevant disturbances. These protein signatures could be used for diagnostic or prognostic monitoring of patients with muco-obstructive lung disease, as well as to design novel exosome-based therapies. There are also limitations to this study. First, this study",26_43,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"also limitations to this study. First, this study characterized proteomic signatures in male mice only. Although the size and concentration of the BALF exosome in <italic toggle=""yes"">Scnn1b</italic>-Tg+ male and <italic toggle=""yes"">Scnn1b</italic>-Tg+ female animals were comparable, the sex-specific differential enrichment of exosomal proteins cannot be ruled out. Second, we were unable to perform functional studies to determine the biological influence of exosome-derived proteins in cell-based or animal",26_44,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"exosome-derived proteins in cell-based or animal models. Collectively, our data provides a detailed proteomics analysis of the exosomes from <italic toggle=""yes"">Scnn1b</italic>-Tg+ and WT mice airspaces. With the immunolocalization approach, we were able to identify cellular sources of some of the disease-relevant proteins. The comparative analysis between enriched BALF exosome proteins and upregulated gene transcriptomes in <italic toggle=""yes"">Scnn1b</italic>-Tg+ versus WT mice revealed the relevance of",26_45,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
versus WT mice revealed the relevance of the mRNA level changes and their impact on the protein signatures in the airspaces. We believe this study will create a foundation for future mechanistic studies aiming at understanding the pathogenesis of mucoinflammatory lung diseases and facilitating the identification of novel molecular and cellular processes for the eventual therapeutic targeting during the progression of pulmonary diseases. This study also suggests that the exosomes from BALF carry,26_46,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
also suggests that the exosomes from BALF carry disease-relevant protein signatures that can be used as diagnostic predictive biomarkers for mucoinflammatory diseases.,26_47,Airspaces-derived exosomes contain disease-relevant protein signatures in a mouse model of cystic fibrosis (CF)-like mucoinflammatory lung disease,25 9 2024,,Cystic_Fibrosis
"7522 Effects of Trikafta On Bone Mineral Density And Body Composition In Patients With Cystic Fibrosis 
<bold>Disclosure: N. Mon:</bold> None. <bold>S.S. Krishnasamy:</bold> None. <bold>G. Bakeerathan:</bold> None. <bold>L. Healy:</bold> None. <bold>E. Favier:</bold> None. <bold>S. Foushee:</bold> None.",27_0,7522 Effects of Trikafta On Bone Mineral Density And Body Composition In Patients With Cystic Fibrosis,05 10 2024,,Cystic_Fibrosis
"<bold>Background:</bold> Cystic fibrosis related bone disease (CFBD) is a common complication of adult Cystic fibrosis (CF) patients due to calcium, vitamin D and K malabsorption from exocrine pancreatic insufficiency, increased inflammatory cytokines, glucocorticoid therapy, delayed puberty, physical inactivity, and hypogonadism. Newer CF transmembrane conductance regulator (CFTR) modulator therapy elexacaftor/tezacaftor/ivacaftor (Trikafta) has proven benefit in pulmonary and nutritional outcomes. There",27_1,7522 Effects of Trikafta On Bone Mineral Density And Body Composition In Patients With Cystic Fibrosis,05 10 2024,,Cystic_Fibrosis
"in pulmonary and nutritional outcomes. There is limited data on effects of Trikafta on bone health and body composition. The aim is to examine the effects of Trikafta on bone mineral density (BMD) at the lumbar spine (LS) and femoral neck (FN), and body composition in terms of fat free mass index (FFMI) and fat mass index (FMI) in our CF patients. Method: We conducted a cross sectional and retrospective review of 38 adults with CF (Ages 20-59, 28 males and 10 females) in our CF clinic. Body Mass Index",27_2,7522 Effects of Trikafta On Bone Mineral Density And Body Composition In Patients With Cystic Fibrosis,05 10 2024,,Cystic_Fibrosis
"and 10 females) in our CF clinic. Body Mass Index (BMI), Body composition measured by bioelectric impedance analysis, BMD of LS and FN by Dual-energy X-ray absorptiometry, Vitamin D level, and forced expiratory volume in one second (FEV1 % predicted) in patients taking Trikafta were analyzed and compared with control CF group who were not on Trikafta. <bold>Results:</bold> 38 subjects on Trikafta, aged 33.29 ± 10.36 years with FEV1 % predicted 65.11± 28.14% were studied. Serum 25-hydroxyvitamin D level was",27_3,7522 Effects of Trikafta On Bone Mineral Density And Body Composition In Patients With Cystic Fibrosis,05 10 2024,,Cystic_Fibrosis
"were studied. Serum 25-hydroxyvitamin D level was 35.92 ± 18.52 ng/dL. Of the 38 study patients, 23 (60.53%) had a diagnosis of CF related diabetes (CFRD). Among the Trikafta cohort, 18 (50%) had low BMD with Z-scores ≤ -2.0 and 7 (19.44%) of them had Z score ≤ -1.0 and > -2.0. Compared with the control group, LS BMD 0.93 ± 0.16 g/cm<sup>2</sup> and FN BMD 0.73± 0.13g/cm<sup>2</sup> (p >0.05) were not improved significantly. BMI of study population 23.09 ± 4.21 kg/m<sup>2</sup> (p <0.05) and FMI 6.11 ±",27_4,7522 Effects of Trikafta On Bone Mineral Density And Body Composition In Patients With Cystic Fibrosis,05 10 2024,,Cystic_Fibrosis
"± 4.21 kg/m<sup>2</sup> (p <0.05) and FMI 6.11 ± 4.25 kg/m<sup>2</sup> (p <0.05) increased significantly; however, there was a decrease in FFMI 9.60 ± 1.44 kg/m<sup>2</sup> (p <0.05). <bold>Conclusion:</bold> Treatment with Trikafta in CF patients was associated with increases in BMI and fat mass index but decrease in fat free mass index. There was no statistically significant difference in BMD at LS and FN in our study cohort. This study has limitations in terms of gender differences within the study",27_5,7522 Effects of Trikafta On Bone Mineral Density And Body Composition In Patients With Cystic Fibrosis,05 10 2024,,Cystic_Fibrosis
"in terms of gender differences within the study cohort, duration of Trikafta use in relation to bone mass, and also extent of glucocorticoid use among the study subjects. Larger prospective clinical trials are needed to study efficacy of Trikafta on CFBD.",27_6,7522 Effects of Trikafta On Bone Mineral Density And Body Composition In Patients With Cystic Fibrosis,05 10 2024,,Cystic_Fibrosis
"<italic toggle=""yes"">Presentation:</italic> 6/3/2024 Full text not available in PMC",27_7,7522 Effects of Trikafta On Bone Mineral Density And Body Composition In Patients With Cystic Fibrosis,05 10 2024,,Cystic_Fibrosis
"6500 Screening Rates in Emerging Adults With Cystic Fibrosis for Cystic Fibrosis-Related Bone Disease: A Retrospective Cohort Study 
<bold>Disclosure:</bold> C. Cobb: None. A. Stecenko: None. W.R. Hunt: None. R. Linnemann: None. T. Daley: None. V. Tangpricha: None.",28_0,6500 Screening Rates in Emerging Adults With Cystic Fibrosis for Cystic Fibrosis-Related Bone Disease: A Retrospective Cohort Study,05 10 2024,,Cystic_Fibrosis
"<bold>INTRODUCTION</bold> Cystic fibrosis bone disease (CFBD) is a common endocrinopathy in patients with cystic fibrosis (CF). Poor bone health is associated with increased risk of fractures, potentially leading to decreased pulmonary function and worse health outcomes. The transition period from adolescent to adult care is a particularly vulnerable period in terms of bone health. It is recommended that patients with CF have bone density screening starting at age 18 and every 1-2 years. The purpose of",28_1,6500 Screening Rates in Emerging Adults With Cystic Fibrosis for Cystic Fibrosis-Related Bone Disease: A Retrospective Cohort Study,05 10 2024,,Cystic_Fibrosis
at age 18 and every 1-2 years. The purpose of this study was to examine the frequency of bone density screening in adolescents and young adults with CF followed at a single accredited CF center. <bold>Methods</bold> This was a retrospective chart review of patients with CF between ages 18 and 30 who had transitioned to adult care between 2013 and 2023 at our CF clinic. Frequency of bone density screening was assessed by completion of dual-energy x-ray absorptiometry (DXA) and included the last pediatric,28_2,6500 Screening Rates in Emerging Adults With Cystic Fibrosis for Cystic Fibrosis-Related Bone Disease: A Retrospective Cohort Study,05 10 2024,,Cystic_Fibrosis
"(DXA) and included the last pediatric Z-scores, if available, and adult Z-scores up to 10 years after transition. Height adjusted Z-scores were used when appropriate for pediatric values. Transplant patients and patients who did not attend at least one year of adult clinic were excluded. <bold>Results</bold> Ninety-five patients were identified. Seven patients did not have documentation of a DXA scan, while 88 had at least one DXA scan as emerging adults. Ten out of 88 adults received a repeat DXA within 2",28_3,6500 Screening Rates in Emerging Adults With Cystic Fibrosis for Cystic Fibrosis-Related Bone Disease: A Retrospective Cohort Study,05 10 2024,,Cystic_Fibrosis
out of 88 adults received a repeat DXA within 2 years of their prior scan. 42 out of 88 (48%) of patients were at risk for CFBD with at least one Z-score ≤ -1. Of these at risk patients only 5 got a repeat DXA within two years. None of the patients undertook routine DXA exams consistently every 2 years regardless of risk. <bold>CONCLUSION</bold> Our study suggests that emerging adults with CF and decreased bone mineral density are being under screened for progression of CFBD. Evaluating the barriers to,28_4,6500 Screening Rates in Emerging Adults With Cystic Fibrosis for Cystic Fibrosis-Related Bone Disease: A Retrospective Cohort Study,05 10 2024,,Cystic_Fibrosis
"progression of CFBD. Evaluating the barriers to bone density screening will be important to optimize bone health and improve outcomes. In the era of CFTR modulator therapies, more attention to bone health is required especially with the increased life expectancy of people living with CF. Strategies focused on increased bone density screening, promotion of healthy lifestyle, optimizing nutritional status, and addressing hypogonadism appear to be critical in this transition period for young adults with CF.",28_5,6500 Screening Rates in Emerging Adults With Cystic Fibrosis for Cystic Fibrosis-Related Bone Disease: A Retrospective Cohort Study,05 10 2024,,Cystic_Fibrosis
"<italic toggle=""yes"">Presentation:</italic> 6/3/2024 Full text not available in PMC",28_6,6500 Screening Rates in Emerging Adults With Cystic Fibrosis for Cystic Fibrosis-Related Bone Disease: A Retrospective Cohort Study,05 10 2024,,Cystic_Fibrosis
"Pregnancy and fertility in people with cystic fibrosis following lung transplantation When cystic fibrosis (CF) was described as a clinical entity in the 1930 s, the diagnosis was associated with death in infancy or early childhood [<xref rid=""R1"" ref-type=""bibr"">1</xref>]. With the advances we have made in CF care and treatment, the predicted survival for a child born today in the United States (US) is 61 years of age [<xref rid=""R2"" ref-type=""bibr"">2</xref>] (Fig. <xref rid=""F1"" ref-type=""fig"">1</xref>).",29_0,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"(Fig. <xref rid=""F1"" ref-type=""fig"">1</xref>). However, that predicted survival includes the majority of people with CF in the US and other high-income countries who have access to oral CF transmembrane conductance regulator (CFTR) modulator therapy; therapy that improves lung function, nutritional status, quality of life and pulmonary exacerbations [<xref rid=""R3"" ref-type=""bibr"">3</xref>–<xref rid=""R5"" ref-type=""bibr"">5</xref>]. The health impacts conferred by CFTR modulators have been so substantial",29_1,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"by CFTR modulators have been so substantial that there are now more than ten times as many pregnancies in people with CF as lung transplants in the US [<xref rid=""R2"" ref-type=""bibr"">2</xref>] (Fig. <xref rid=""F2"" ref-type=""fig"">2</xref>). However, for those pwCF with variants not amenable to CFTR modulators and those who had very advanced disease at the time CFTR modulators were approved, lung transplantation may still be the only life-saving treatment option.  Those pwCF whose hope for a future has been",29_2,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"Those pwCF whose hope for a future has been bolstered by CFTR modulators have expressed a desire to become parents [<xref rid=""R6"" ref-type=""bibr"">6</xref>,<xref rid=""R7"" ref-type=""bibr"">7</xref>]. However, some pwCF who have undergone organ transplantation also wish to consider parenthood. Historically, pursuit of pregnancy and/or parenthood following transplant was highly discouraged, but more recently, guidelines have emerged to facilitate this choice for select posttransplant individuals [<xref",29_3,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"for select posttransplant individuals [<xref rid=""R8"" ref-type=""bibr"">8</xref><sup>▪▪</sup>]. In this review, we will discuss the available data on fertility, fertility preservation, pregnancy and partner pregnancy and parenthood in people with CF who have undergone lung transplantation. In 1968, Kaplan <italic toggle=""yes"">et al</italic>. [<xref rid=""R9"" ref-type=""bibr"">9</xref>] at the CF center in Boston sought to determine why many of the fwCF in their clinic were able to conceive, but the males with",29_4,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"clinic were able to conceive, but the males with CF (mwCF) were not. Through physical examination, semen analysis and pathological specimen analysis, they demonstrated that the majority of mwCF were infertile based on absence of the <italic toggle=""yes"">vas deferens</italic> and parts of the epididymis. Subsequently, case series of two fetuses with genotypes F508del/F508del and F508del/G542 at 12 and 18 weeks, respectively, reported intact <italic toggle=""yes"">vas deferens</italic> in both male fetuses",29_5,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"deferens</italic> in both male fetuses suggesting that as occurs in the pancreas, the pathological process caused by absent CFTR function results in in-utero loss of the vas deferens [<xref rid=""R10"" ref-type=""bibr"">10</xref>]. However, while most mwCF have CBAVD, they do produce sperm. Therefore, for those with the financial means to pursue assisted reproduction, retrieval of sperm from the testes or epididymis coupled with in-vitro fertilization and embryo implantation for the male's partner can",29_6,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"embryo implantation for the male's partner can successfully lead to pregnancy [<xref rid=""R11"" ref-type=""bibr"">11</xref>]. In contrast to mwCF, fwCF have reproductive anatomy that is similar to that of women without CF, thus the majority of fwCF can become pregnant without assisted reproduction. Factors that historically contributed to fwCF having lower fertility than those in the general population included malnutrition, delayed puberty, reduced ovarian reserve, and thick, acidic cervical mucus (caused by",29_7,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"and thick, acidic cervical mucus (caused by CFTR dysfunction in the epithelium of the uterus) [<xref rid=""R12"" ref-type=""bibr"">12</xref>,<xref rid=""R13"" ref-type=""bibr"">13</xref>]. More recently, Shteinberg <italic toggle=""yes"">et al</italic>. [<xref rid=""R14"" ref-type=""bibr"">14</xref>] reported a subfertility rate of 35% in fwCF; pancreatic insufficiency and older age at first pregnancy attempt were risk factors. Critically, the data gathered in the Shteinberg study was in the pre-CFTR modulator era. Roe",29_8,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"study was in the pre-CFTR modulator era. Roe <italic toggle=""yes"">et al</italic>. [<xref rid=""R15"" ref-type=""bibr"">15</xref>] showed that fwCF treated with the most effective approved CFTR modulator, elexacaftor-tezacaftor-ivacaftor (ETI) had cervical mucus quality comparable to that of females without CF. This improved cervical mucus quality has undoubtedly contributed to the increased pregnancy rate in fwCF in the USA (Fig. <xref rid=""F2"" ref-type=""fig"">2</xref>). Following lung transplantation,",29_9,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"Following lung transplantation, fertility may be impaired for both mwCF and fwCF based on the immunosuppressive regimen required to maintain their transplants. (See Table <xref rid=""T1"" ref-type=""table"">1</xref>). For example, for both sexes, glucocorticoid dosing in the first 2 years postlung transplantation may inhibit the hypothalamic-pituitary-gonadal axis [<xref rid=""R16"" ref-type=""bibr"">16</xref>]. In one study of more than 1000 organ transplant recipients, more than 20% of females were unable to",29_10,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"more than 20% of females were unable to achieve pregnancy [<xref rid=""R17"" ref-type=""bibr"">17</xref><sup>▪▪</sup>]. In males, use of sirolimus may lead to decreased sperm counts and dysmotility resulting in reduction in the likelihood of partner pregnancy [<xref rid=""R16"" ref-type=""bibr"">16</xref>]. Because of the potential impairment in fertility resulting from required posttransplant immunosuppression, discussions regarding future fertility should occur early in the process of transplant referral [<xref",29_11,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"in the process of transplant referral [<xref rid=""R18"" ref-type=""bibr"">18</xref>]. Discussions regarding saving or protecting eggs, sperm or reproductive tissue for use in creating future biological children, ‘fertility preservation’ is a standard part of oncology visits in people of child-bearing age requiring cancer treatment [<xref rid=""R19"" ref-type=""bibr"">19</xref>]; CF providers have cited content knowledge barriers to engaging individuals with CF under their care in similar conversations [<xref",29_12,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"under their care in similar conversations [<xref rid=""R20"" ref-type=""bibr"">20<sup>▪</sup></xref>]. To understand the perspective of pwCF, Ladores <italic toggle=""yes"">et al</italic>. [<xref rid=""R21"" ref-type=""bibr"">21</xref>] conducted a mixed methods study in fwCF to describe their knowledge, experiences and fertility preservation concerns. Although the majority (78%) reported that they wanted to have a child in the future most (74%) stated that their providers had not initiated discussions regarding",29_13,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"providers had not initiated discussions regarding fertility preservation. Similarly, mwCF were recruited for a two-phase study that was assessing fertility preservation knowledge and also testing a telehealth intervention to improve it. More than 80% stated that they want to have children, but only approximately half (44%) had received information from their CF team regarding infertility [<xref rid=""R22"" ref-type=""bibr"">22</xref><sup>▪▪</sup>]. These studies suggest that provider education is paramount to",29_14,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"suggest that provider education is paramount to improving the experience of care regarding fertility preservation prior to lung transplantation. As noted above, pregnancy in fwCF has become much more common in the era of CFTR modulators (Fig. <xref rid=""F2"" ref-type=""fig"">2</xref>), but still remains rare in fwCF after a lung transplantation. As a result, large studies on the impact of pregnancy on maternal and fetal health in the setting of postlung transplant recipients with CF are still lacking.",29_15,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"transplant recipients with CF are still lacking. Preconception counseling is essential to assess risks, optimize health and discuss family planning options. Based on currently available data (largely collected prior to widespread use of CFTR modulators), pregnancy is feasible, but maternal and fetal complications after a lung transplant are unfortunately higher than in the general population. In an analysis published in 2012 using data from the National Transplantation Pregnancy Registry, investigators",29_16,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"Transplantation Pregnancy Registry, investigators found that in 30 pregnancies (12 with CF), more than half of women had live births, with few associated life-threatening complications and no reports of permanent disability in the infants [<xref rid=""R23"" ref-type=""bibr"">23</xref>]. However, the incidence of preterm birth was 60% and there were 11 infant complications and two neonatal deaths. Relative to other transplant recipients, mean gestational age was similar but mean birth weight was lower for",29_17,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"was similar but mean birth weight was lower for babies born to fwCF (1980 g in CF vs. 2349 g in others). There was a lower rate of spontaneous abortion in fwCF (25% in CF vs. 33% in others), but there was also a higher rate of organ rejection reported during pregnancy in fwCF (25% in CF vs. 11% in others). Given reports of increased potential for graft loss, some lung transplant centers recommend that recipients avoid pregnancy all together, while others use published guidelines to consider carefully",29_18,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"use published guidelines to consider carefully select individuals who may have safe and successful pregnancies [<xref rid=""R8"" ref-type=""bibr"">8</xref><sup>▪▪</sup>]. Data from the 2022 Transplant Pregnancy Registry International show that only 58% of 50 lung transplant recipients had adequate graft function at last follow-up [<xref rid=""R17"" ref-type=""bibr"">17</xref><sup>▪▪</sup>]. Basic therapies such as calcineurin inhibitors (CNIs), cyclosporine and tacrolimus will require frequent monitoring and",29_19,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"tacrolimus will require frequent monitoring and potential dose adjustments in association with maternal weight changes or gastrointestinal issues (e.g. gastroesophageal reflux, impaired motility) that complicate the absorption of immunosuppressants and therefore increase the risk of both acute and chronic rejection (CLAD). Certain immunosuppressive agents should be avoided such as mycophenolate mofetil, which is known to be teratogenic [<xref rid=""R8"" ref-type=""bibr"">8</xref><sup>▪▪</sup>]. Medications",29_20,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"Medications such as prednisone, azathioprine and calcineurin inhibitors have limited information but are thought to be relatively well tolerated (See Table <xref rid=""T1"" ref-type=""table"">1</xref> for further medication information during pregnancy and lactation) [<xref rid=""R8"" ref-type=""bibr"">8</xref><sup>▪▪</sup>]. It is therefore important to consider timing of pregnancy after lung transplant to ideally achieve the lowest necessary doses of immunosuppressive medications during pregnancy and lactation.",29_21,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"medications during pregnancy and lactation. The higher rates of allograft rejection and more aggressive immunosuppression utilized following lung transplantation support the need for an at least 2 years posttransplant period of stability before pregnancy [<xref rid=""R8"" ref-type=""bibr"">8</xref><sup>▪▪</sup>]. As with safety of medication use in pregnancy, recent reviews and recommendations of medications frequently used in lactating fwCF are published [<xref rid=""R24"" ref-type=""bibr"">24</xref>,<xref",29_22,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"[<xref rid=""R24"" ref-type=""bibr"">24</xref>,<xref rid=""R25"" ref-type=""bibr"">25</xref>]. Two key concerns of fwCF when considering lactation are use of medications and nutritional expenditure. Lactation does require significant caloric expenditure (often an additional 500 kcal/day) and restriction of energy/calorie intake is discouraged [<xref rid=""R26"" ref-type=""bibr"">26</xref>]. Weight loss postpartum can be rapid in fwCF with some returning to their prepregnancy weight within the first 6 weeks postpartum",29_23,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"weight within the first 6 weeks postpartum and others not returning to their prepregnancy weight even after 2 years postpartum without aggressive perinatal care [<xref rid=""R27"" ref-type=""bibr"">27</xref>]. CFTR modulators have improved nutritional status in many eligible pwCF, but the impact of these therapies on weight in lung transplant recipients peri-partum is unknown. Regardless of medication regimen and nutritional status, some clinicians advise against pregnancy if there is evidence of any chronic",29_24,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"pregnancy if there is evidence of any chronic lung allograft dysfunction in the past year or if there is ongoing maternal infection that may impact the fetus such as cytomegalovirus (CMV) infection, one of the leading causes of congenital neurologic impairment [<xref rid=""R8"" ref-type=""bibr"">8</xref><sup>▪▪</sup>,<xref rid=""R28"" ref-type=""bibr"">28</xref>]. Other potential contraindications to pregnancy include uncontrolled comorbidities such as diabetes or hypertension, chronic kidney disease (eGFR <",29_25,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"or hypertension, chronic kidney disease (eGFR < 30 ml/min/1.73 m<sup>2</sup>) or the presence of donor-specific antibodies that might increase the risk of rejection [<xref rid=""R8"" ref-type=""bibr"">8</xref><sup>▪▪</sup>]. Diabetes is a particularly unique challenge for fwCF. CF-related diabetes (CFRD) is common in adults with CF with an estimated prevalence of 30% (CFFPR) and even more common during a pregnancy where 14–20% of women will receive a diagnosis of gestational diabetes (GDM) while pregnant",29_26,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"of gestational diabetes (GDM) while pregnant [<xref rid=""R29"" ref-type=""bibr"">29</xref>,<xref rid=""R30"" ref-type=""bibr"">30</xref>]. The likelihood of either CFRD or GDM is even higher for patients with severe pancreatic insufficiency and for a lung transplant recipient on chronic prednisone [<xref rid=""R31"" ref-type=""bibr"">31</xref>]. The management of diabetes shares similar goals as for females without CF and is based on risk mitigation of hyperglycemia-related adverse pregnancy outcomes. As with the",29_27,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"adverse pregnancy outcomes. As with the general population, insulin is a first-line therapy to treat diabetes during a pregnancy, but fwCF may have higher insulin requirements due to their competing need for adequate nutritional intake. Relative to other lung transplant recipients, other unique challenges in fwCF include malabsorption of fat-soluble vitamins secondary to pancreatic insufficiency, gastroesophageal reflux and gastroparesis, which are all likely to be worsened during pregnancy and may impact",29_28,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"to be worsened during pregnancy and may impact on CNI plasma levels [<xref rid=""R32"" ref-type=""bibr"">32</xref>]. Pregnancies are being followed in the Transplant Pregnancy Registry International long-term [<xref rid=""R17"" ref-type=""bibr"">17</xref><sup>▪▪</sup>]. As of the 2022 annual report, out of 50 pregnant lung transplant recipients, 53% experienced hypertension, 14% experience preeclampsia and 10% had biopsy-proven rejection. Of the 68 pregnancies in lung transplant recipients, 64% resulted in live",29_29,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"lung transplant recipients, 64% resulted in live births, 26% were born at less than 32 weeks’ gestation, 50% delivered by Cesarean section and 7% experienced neonatal death less than 30 days after birth. Maternal deaths after lung transplant were high at 36%. Importantly, more than half of these pregnancies were unplanned. These data are consistent with larger meta-analysis data reported in thoracic transplant recipients that include up to 385 pregnancies in heart or lung transplant recipients [<xref",29_30,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"in heart or lung transplant recipients [<xref rid=""R33"" ref-type=""bibr"">33</xref>]. Despite the high risk, successful pregnancies are possible in fwCF after lung transplantation, but this should be discussed in detail between providers and patients to consider timing with medications, optimize comorbidities and include needed expertise such as genetic counselors, high-risk obstetricians, CF and transplant physicians, and endocrinologists as needed. There is ongoing research into the outcomes of pregnancies",29_31,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"ongoing research into the outcomes of pregnancies in pwCF post lung transplant, focusing on maternal health, fetal development and long-term implications, but little is known in the era of CFTR modulators. Currently, a longitudinal prospective observation study called ‘Maternal and Fetal Outcomes in the Era of Modulators’ (MAYFLOWERS) sponsored by the CF Foundation and supported by the CF Therapeutics Development Network, is taking place in 41 CF centers across the USA. Over 280 FwCF pre or postlung",29_32,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"across the USA. Over 280 FwCF pre or postlung transplant and on or not on CFTR modulators will be enrolled and followed during pregnancy, delivery and up to 2 years postpregnancy to assess maternal and fetal outcomes and may provide additional information on pregnancy in fwCF with or without a lung transplant in the modern era of CF care [<xref rid=""R34"" ref-type=""bibr"">34</xref>]. An open discussion between care teams and transplant recipient is needed to discuss the risks and benefits surrounding",29_33,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"to discuss the risks and benefits surrounding pregnancy, and ideally will include more longitudinal data in the future. Although the TPRI describes the outcomes of pregnancies in women who have undergone lung transplant as noted above, there are very few men who have undergone lung transplantation who have fathered children, thus outcomes specifically for lung transplant recipients have not been reported in previous or current registry reports [<xref rid=""R17"" ref-type=""bibr"">17</xref><sup>▪▪</sup>,<xref",29_34,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"ref-type=""bibr"">17</xref><sup>▪▪</sup>,<xref rid=""R35"" ref-type=""bibr"">35</xref>]. A specific evaluation of all male solid-organ transplant recipients who had received pharmaceutical agents containing mycophenolic acid reported that the outcomes for partner pregnancies were similar to those in the general population [<xref rid=""R35"" ref-type=""bibr"">35</xref>]. There is minimal current literature describing the outcomes of parenthood in people with CF, and none specifically focused on those who have",29_35,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"and none specifically focused on those who have undergone lung transplantation. Kazmerski <italic toggle=""yes"">et al</italic>. [<xref rid=""R36"" ref-type=""bibr"">36</xref>] utilized the United Kingdom (UK) CF Registry to evaluate the short-term health outcomes of people with CF (fwCF who became pregnant and mwCF whose partner became pregnant) in the year following parenthood. Lung function and BMI declined and pulmonary exacerbations increased in the year following parenthood. The impacts of parenthood on",29_36,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"parenthood. The impacts of parenthood on lung function decline were somewhat mitigated by single or dual-combination modulator use. No parents who had a history of lung transplant were included in the study, but the results are likely still somewhat applicable to people with CF postlung transplant who continue to experience extra-pulmonary comorbidity from CF. Similarly, the on-going Health Outcomes of Parents with CF (HOPeCF) study (NCT05829694) is excluding those with lung transplantation, but will",29_37,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"those with lung transplantation, but will provide additional insights into outcomes for people with CF who become parents; these results may also have relevance for those parents with CF who have required lung transplantation. Based on her question regarding pregnancy postlung transplantation and your own knowledge of her options, you explain that you can refer her to a genetic counselor and that she could consider oocyte cryopreservation under the guidance of a fertility specialist [<xref rid=""R37""",29_38,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"of a fertility specialist [<xref rid=""R37"" ref-type=""bibr"">37</xref>]. You advise her to discuss the specific guidelines regarding pregnancy postlung transplant with her transplant team who will strongly advise her to use contraception for at least 2 years posttransplantation before attempting to become pregnant [<xref rid=""R8"" ref-type=""bibr"">8</xref><sup>▪▪</sup>]. Finally, you discuss alternative paths to parenthood [<xref rid=""R38"" ref-type=""bibr"">38</xref>] (Fig. <xref rid=""F3""",29_39,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"ref-type=""bibr"">38</xref>] (Fig. <xref rid=""F3"" ref-type=""fig"">3</xref>). Although the number of lung transplantations has decreased dramatically in the era of CFTR modulators for most people with CF in HIC, lung transplantation continues to be the only life-saving treatment option for those with end-stage disease. For fwCF and mwCF, pretransplantation discussions regarding fertility preservation counseling are essential because transplant-necessitated immunosuppression may limit or eliminate options for",29_40,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"may limit or eliminate options for unassisted conception posttransplant. Historically, pregnancy, postlung transplantation was discouraged. Today, for highly selected individuals, pregnancy after lung transplantation is a well tolerated and viable option if these requirements are met: adequate and stable graft function, no episodes of allograft rejection in the prior year, no maternal infections that may impact upon the fetus, and stable dosing of maintenance nonteratogenic immunosuppression. Because",29_41,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"nonteratogenic immunosuppression. Because although maternal and fetal outcomes posttransplant are still relatively precarious compared to those without transplant, transparent counseling is essential for the shared decisions-making process. Additional data regarding long-term morbidity and mortality for people with CF who choose to become parents posttransplantation are needed.",29_42,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
"<italic toggle=""yes"">The authors appreciate the individual with CF who was willing to include her de-identified story for this manuscript.</italic>",29_43,Pregnancy and fertility in people with cystic fibrosis following lung transplantation,11 2024,,Cystic_Fibrosis
